


NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS AND RISK BEHAVIOUR SURVEY REPORT

2004, 2007, 2010 AND 2013



Prevalence of HIV, hepatitis C, hepatitis B, sexually transmissible infections, and risk behaviours among Australian prison entrants



UNSW
AUSTRALIA



Kirby Institute



UNSW
A U S T R A L I A



Kirby Institute

www.kirby.unsw.edu.au

Postal Address:

The Kirby Institute
UNSW Australia
Wallace Wurth Building
Sydney NSW 2052

Telephone: 02 9385 0900

Facsimile: 02 9385 0920

Email: recpt@nchecr.unsw.edu.au

NATIONAL PRISON ENTRANTS' BLOODBORNE VIRUS SURVEY 2004, 2007, 2010, and 2013

Prevalence of HIV, HBV, HCV, and risk behaviours
among Australian prison entrants

NATIONAL REPORT
2004, 2007, 2010, and 2013

Report prepared by Tony Butler, Denton Callander and Melanie Simpson

The Kirby Institute for Infection and Immunity in Society (UNSW Australia)

March 2015



Suggested citation:

Butler, T, Callander, D, & Simpson, M. National Prison Entrants' Bloodborne Virus Survey Report 2004, 2007, 2010 and 2013. Kirby Institute (UNSW Australia). 2015. ISBN: 978-0-7334-3532-4.

CONTENTS

CONTENTS	1
ACKNOWLEDGEMENTS	3
FOREWORD	5
EXECUTIVE SUMMARY	6
Background	6
Methods	6
Results.....	7
Implications of the Findings	9
INTRODUCTION	12
METHODS	13
Study Sample.....	13
Sample Selection	13
Recruitment.....	13
Survey Sites	14
Screening Procedures	14
Blood Testing	15
Urine Testing.....	15
Questionnaire.....	15
Statistical Analysis	15
Interviewers.....	16
Ethics Approval.....	16
Reporting of Results	16
RESULTS	16
Response Rate	16
Summary.....	19
National	25
HIV antibody prevalence	33
HCV antibody prevalence.....	35
HBV prevalence	43
Chlamydia.....	56
Gonorrhoea.....	56
Syphilis	56
New South Wales	57
HIV antibody prevalence	65
HCV antibody prevalence.....	65
HBV prevalence	73
Chlamydia.....	85
Gonorrhoea.....	85
Syphilis	85
Northern Territory.....	86
HIV antibody prevalence	94
HCV antibody prevalence.....	94
HBV prevalence	99
Chlamydia.....	107
Gonorrhoea.....	107
Syphilis	107
Queensland.....	108
HIV antibody prevalence	116
HCV antibody prevalence.....	116
HBV prevalence	124
Chlamydia.....	136
Gonorrhoea.....	136
Syphilis	136
South Australia	137

HIV antibody prevalence	145
HCV antibody prevalence	145
HBV prevalence	150
Chlamydia	158
Gonorrhoea	158
Syphilis	158
Tasmania	159
HIV antibody prevalence	167
HCV antibody prevalence	167
HBV prevalence	175
Chlamydia	188
Gonorrhoea	188
Syphilis	188
Victoria	189
HIV antibody prevalence	197
HCV antibody prevalence	197
HBV prevalence	205
Chlamydia	217
Gonorrhoea	217
Syphilis	217
Western Australia	218
HIV antibody prevalence	226
HCV antibody prevalence	226
HBV prevalence	234
Chlamydia	246
Gonorrhoea	246
Syphilis	246
Methodological Notes	247
Appendix 1 – Blood Tests, Test Kits and Testing Laboratories	248
Appendix 2 – Questionnaire	249
References	251

ACKNOWLEDGEMENTS

We are grateful to the project steering group and the site co-ordinators:

Project steering group:

Professor Tony Butler (Kirby Institute); **ACT**: Professor Michael Levy (ACT Corrections Health); **NSW**: Denise Monkley and Ashleigh Cussen (Justice Health & Forensic Mental Health Network); **NT**: Matthew Chick (NT Correctional Services) and Dr Vinod Daniel (NT Remote Health) ; **Qld**: Laura Dyer; **SA**: Karen Harlin and Dr Michael Findlay (SA Prison Health Service); **Tas**: Dr Chris Wake and Deborah Siddall (Tasmania Correctional Primary Health Services); **Vic**: Meredith Williamson (Justice Health Victoria); and **WA**: Holly Beasley (WA Corrective Services).

State and Territory co-ordinators:

ACT: Professor Michael Levy; **NSW**: Ashleigh Cussen; **NT**: Matthew Chick; **Qld**: Laura Dyer; **SA**: Cathi Montague and Jackie Hughes; **Tas**: Deborah Siddall and Lexie Bray; **Vic**: Meredith Williamson; and **WA**: Holly Beasley.

The following individuals conducted the interviews:

ACT: Jenny Kuzek.

NSW: Stephanie Smith, Kim Campbell-Davis, Helen Pearce, Kylie-Anne Jordan-Miller, Marian Bloomfield, and Fiona Montroy.

Northern Territory: Alicia Ross.

Queensland: Shirley Sheppard, Matt Gibson, Tom Aitkin, Chris Wallis, Shannon Jeanes, Raquel How, Vanessa Brooks, and Janelle Kelly.

South Australia: Site Clinical Services Co-ordinators and BBV portfolio nurses.

Tasmania: Jenny Yeomans, David Noble and Matthew McGillvray, with support from other Correctional Primary Health Services nursing staff.

Victoria: Rebecca Dravitzki, Nikki Bartolo, Krystina Ramshaw.

Western Australia: Anita Hoy, Yvonne Morris, Mark Walters, Dr Louise Maclean, Ellen Bos, Holly Beasley, Karen O'Reilly, Tracie Boylan, Dominic Donaldson, Ann Moloney, Joseph Coles, Yvonne Udell, Lynnette Allen and Eleasha Shadbolt.

We wish to thank everyone who assisted in the development and conduct of the National Prison Entrants' Bloodborne Virus Survey, including the participants, health professionals at the survey sites, prison managers and prison officers for their cooperation in accommodating the

survey teams, laboratory staff, and nursing staff involved in providing the test results to participants. Angela Hehir and Daniel O'Connor provided support for the study in NSW.

We are grateful for the assistance of Leng Boonwaat in interpreting the hepatitis B immunity results and Dr Hammad Ali for advice on cervical cancer vaccine eligibility.

Support:

In-kind support was provided by all the jurisdictions to cover the data collection and screening. Financial support for the co-ordination and report writing was provided by Queensland, Tasmania, Northern Territory, ACT and Victoria.

FOREWORD

The first National Prison Entrants' Bloodborne Virus Survey (NPEBBVS) was conducted in 2004 and we are pleased to present the fourth iteration of this study, the 2013 national report.

The prevalence of hepatitis C is significantly higher among prisoners than the general community, highlighting the need for ongoing monitoring of bloodborne viruses and risk behaviours in this population. The NPEBBVS fulfils this important role and represents one of the few nationally collaborated prisoner health projects in Australia.

The 2013 NPEBBVS includes data from all Australian jurisdictions and is unique in the world in providing a national snapshot of the prevalence of bloodborne viruses (HIV, hepatitis B, hepatitis C) in this at-risk population. The NPEBBVS is modelled on the Australian Needle and Syringe Program (ANSP) Survey but also includes those with no histories of injecting drug use who are nonetheless at risk of exposure to bloodborne pathogens from transmission routes such as tattooing, body piercing, fighting, and other blood-to-blood contact.

The NPEBBVS has several unique attributes that add to our knowledge of bloodborne virus epidemiology in Australia, such as the inclusion of a sample of Aboriginal and Torres Strait Islander Australians who are over-represented in prisons (while only around 2% of Australia's total population, 27% of Australia's prisoners are Indigenous), and testing for hepatitis B immunity in a marginalised and hard-to-access group. The survey uses a venous blood sample, which provides a high degree of test accuracy and permits the test results to be used for diagnostic purposes.

Prisoners are known to engage in sexual risk behaviours and in 2010 the NPEBBVS was expanded to screen for three sexually transmissible infections - syphilis, gonorrhoea and chlamydia. It is reassuring that the 2013 survey findings found very few of these infections among incoming prisoners. It is also reassuring that no cases of HIV were detected in 2013.

Monitoring bloodborne viruses among prisoners is important to the overall community response to preventing the spread of infectious diseases and planning appropriate treatment and prevention strategies. The utility of this survey is highlighted by its use in the Commonwealth Government's national communicable diseases strategies, which recognise prisoners are a key population in communicable disease control in Australia.

EXECUTIVE SUMMARY

Background

Prisoner populations are characterised by engagement in risk behaviours, most notably injecting drug use. Consequently they are at an increased risk of exposure to bloodborne viruses such as hepatitis B, hepatitis C and HIV. Previous Australian research has shown that hepatitis C is between thirty to forty times higher among prisoners compared with the general community. Surveillance of this population is important to monitor trends in the prevalence of bloodborne viruses and changes over time in risk behaviours. This is the fourth NPEBBVS conducted thus far; others have been undertaken triennially since 2004.

Methods

The study represents a consecutive survey of prison entrants conducted over a two week period. In previous years the survey has been conducted over two weeks in October but the 2013 survey varied between jurisdictions (Table 1). Participants in 2013 were 793^a of the 1,235 consecutive prison entrants in all jurisdictions who were offered the survey. Twenty three reception centres across Australia participated in the survey (Table 2).

The survey screened for the following markers: HIV antibody and antigen, hepatitis B surface antibody and antigen, hepatitis B core antibodies (IgM and IgG), hepatitis B e-antigen and antibody, hepatitis C antibody, *Treponema pallidum* antibody, *Chlamydia trachomatis* DNA and *Neisseria gonorrhoea* DNA (see Appendix 1 for test details).

Test results are made available to participants and appropriate treatment pathways identified including education and advice, hepatitis B vaccination, treatment for sexually transmissible infections, and referrals for hepatitis C treatment.

Risk behaviour and demographic information were collected using a short questionnaire covering injecting drug use, illicit drug consumption, tobacco smoking, body piercing and tattooing, sexual activity, hepatitis C testing and treatment, willingness to be treated for hepatitis C, hepatitis B and cervical cancer immunisation (Appendix 2).

^a 1100 participants consented to take part in the 2013 survey of whom 307 were excluded due to missing information for the main classification variable (injecting drug user status). 793 participants' data were available for the Summary tables. 26 participants did not provide questionnaire data and have been excluded from tables requiring a classification variable.

Results

Demographic & criminographic characteristics

- The final sample consisted of 793 participants. The overall response rate to the survey was 64%.
- Thirty three percent of the sample was identified as Aboriginal or Torres Strait Islander, which is slightly higher than the national census snapshot proportion of Indigenous prisoners (27%).¹ Similarly, women represented 14% of the sample, which is higher than the proportion of women prisoners in Australia (8%).¹
- Most of those taking part in the 2013 survey (76%) lived in 'highly accessible' and 'accessible' areas prior to prison based on the Accessibility/Remoteness Index of Australia.² Living in 'highly accessible' and 'accessible' areas was more common among people who reported injecting drugs (84%) compared with those who did not (69%).
- Eight out of ten prisoners with a history of injecting drug use reported they had previously been incarcerated and 60% had been in prison in the past year.

Bloodborne viruses

- As in 2010, no cases of HIV were detected among those prisoners screened in 2013.
- In 2013, the overall prevalence of hepatitis C antibody was 31%, an increase from 22% in 2010. Among states with more than thirty prisoners tested for hepatitis C antibodies, the prevalence ranged from 52% in Queensland to 8% in the Northern Territory.
- As in previous years, hepatitis C antibody prevalence was higher among those with a history of injecting drug use than those who had not injected (58% versus 4% in 2010), and higher among women who injected than men who injected (67% versus 56% in 2010).
- Among Indigenous injecting drug users, the prevalence of hepatitis C antibody remained stable between 2010 and 2013 (54% and 52%).
- Nationally, only 11 prisoners (9% of those reporting they were hepatitis C positive) stated they had ever received treatment for hepatitis C. Two prisoners reported they were currently receiving treatment for hepatitis C.

- Nationally, 18% of those tested were positive for hepatitis B core-antibody.
- The prevalence of hepatitis B core-antibody among Indigenous injecting drug users remained stable between 2010 and 2013 at 18%, and similarly the prevalence remained stable among non-Indigenous prison entrants 19% in 2010 and 20% in 2013.
- Nationally, 44% of those screened in 2013 showed no evidence of immunity against hepatitis B either through past exposure or vaccination and are, therefore, vulnerable to infection.
- Among jurisdictions testing more than thirty prisoners, the highest proportion of prisoners who had been vaccinated against hepatitis B infection was Queensland (44%).
- Of the 149 prison entrants in 2013 who reported they had been vaccinated against hepatitis B, only 58% had hepatitis B surface-antibody levels signifying immunity. Conversely, 66 individuals reported that they had not been vaccinated against hepatitis B but the tests revealed that 30% of them had hepatitis B surface-antibody levels considered as conferring immunity.

Sexually transmissible infections

- Among female prisoners 35% reported they had not been vaccinated against cervical cancer with 18% unsure of their vaccination status.
- Rates of sexually transmissible infections were no higher than in the general population - chlamydia (5% of men, 4% of women), and gonorrhoea (only one male participant tested positive). For syphilis, around 1% of men and 1% of women had markers consistent with past or present infection. While 1% of all those tested had markers indicating possible current infection with syphilis, only 3 individuals (2 men and 1 woman) had serological markers suggesting possible current infection.

Risk behaviours

- Less than half of those screened in 2013 reported they had ever injected drugs (45%), which is similar to 2010 (44%). Of those with a history of injecting, 67% had injected in the past month.
- A history of injecting drug use was most common among prison entrants in Western Australia (60%) and least common among those in the Northern Territory (6%).

- Amphetamine was the most common drug to be last injected (68%); a 13% increase from 2010. Heroin was the second most common drug to be injected at 20%; a 20% reduction from 2010.
- Most injecting drug users had done so for more than 3 years (86%) suggesting that the prisoner population is characterised by longer term drug users.
- Nine out of ten injecting drug users reported using clean needles for 'all' or 'most' of their injections in the month prior to coming into prison.
- Tobacco smoking remains at epidemic proportions among prisoners with 90% of prisoners reporting they are current tobacco smokers. The proportion of injectors who report they are current tobacco smokers was 97%, and 87% for non-injectors, which is unchanged from 2010.
- The median age of first tobacco smoking was 13 for those with histories of injecting drug use and 15 for non-injectors.
- Approximately two-thirds of injectors (65%) and non-injectors (68%) reported cannabis use in the month prior to the survey.
- Most prisoners reported having sex in the three months prior to the survey (85%).
- A small number of prison entrants (3%) reported they had been paid for sex in the three months prior to the survey.
- Prisoners reported inconsistent condom use, regardless of whether with male or female partners.

Implications of the Findings

- Prison provides an important public health opportunity to monitor high-risk populations for exposure to bloodborne infections and, if appropriate, initiate prevention and treatment measures.
- Given the high prevalence of hepatitis C and hepatitis B in this population compared with the non-incarcerated community, it is important that this survey be regularly conducted to inform policy and health services planning for this at-risk group at local, state and national

level. The findings from the NPEBBVS are utilised by the Commonwealth Government's national communicable diseases strategies and highlight prisoners as a 'priority population.

- Prevention initiatives need to target prison entrants, particularly those with a history of injecting drugs and who are in prison for the first time to initiate prevention strategies including education, hepatitis B vaccination, and hepatitis C treatment.
- Nationally, 44% of all prison entrants were vulnerable to hepatitis B infection and had not been vaccinated or previously exposed to hepatitis B or hepatitis B carriers. This group should be vaccinated as a matter of priority given this population's engagement in risk behaviours that put them at an increased risk of infection. Accelerated vaccination schedules are effective and should be considered for this population given their mobility inside prison and, in many cases, their inability to complete the recommended six month schedule due to being released back into the community after fairly short periods in detention.
- While the prevalence of HIV has remained low in all jurisdictions across surveys (2004, 2007, 2010 and 2013), the NPEBBVS has an important role to play in monitoring this trend given the prisoner population is comprised of those who engage in practices which put them at an increased risk of HIV infection.
- In 2004, 18% of those who reported they were negative for hepatitis C tested positive for HCV antibodies, in 2007, 16% reported they were negative but tested positive, in 2010, 7% reported they were negative but tested positive and in 2013, 8% reported they were negative but tested positive. This reinforces the benefits of ongoing testing of prisoners for bloodborne pathogens such as hepatitis C to reduce the number who are unaware of their exposure to hepatitis C and prevent further transmission.
- In 2013, 11 (9%) prison entrants reported they had ever received treatment for hepatitis C (up from 5% in 2010), including five Aboriginal prison entrants. This suggests that this population has great potential to increase treatment uptake for hepatitis C.
- Amphetamine remains the most frequently reported drug last injected by prison entrants. Amphetamine substitution therapies should be investigated and service providers need to ensure that staff receive training in recognising and managing amphetamine withdrawal on entry to prison.
- Tobacco smoking is at epidemic proportions among prisoners with almost 9 out of 10 prisoners reporting they currently smoke and no apparent downward trend in the numbers who report they are current smokers. Effective smoking cessation programs that sustain

cessation in the community are needed for this population.

INTRODUCTION

Prisoner populations are characterised by engagement in health risk behaviours, most notably injecting drug use.³⁻⁵ Consequently they are at an increased risk of exposure to bloodborne viruses such as HIV and viral hepatitis.⁶⁻¹¹ Australian and overseas studies have consistently shown prisoner populations to have rates of bloodborne viruses many times that of the community. The prison setting has been shown to be a high risk environment for bloodborne virus transmission from sharing contaminated injecting equipment, tattooing, fighting and other blood-to-blood contact.¹²⁻¹⁴

Monitoring bloodborne virus infections among prisoners occurs through ad hoc prevalence surveys.^{7,8,15} Testing prisoners on reception for HIV was formerly used to monitor this infection but as screening rates dropped and approaches to screening varied between the jurisdictions, this method has become less reliable. In 2009, just under one third of Australian prison entrants were tested for HIV, which ranged from 15% in South Australia to 45% in Western Australia.¹⁶

Since 1995, the Kirby Institute of Infection and Immunity in Society has monitored bloodborne viruses in high-risk groups in the community.¹⁷ For injecting drug users (IDU) the Australian Needle and Syringe Program Survey (ANSPS) invites NSP attendees to self-complete a risk behaviour questionnaire and to provide a finger-prick sample of blood to test for HIV and hepatitis C.¹⁸ Following discussions with The Kirby Institute in 2003, the ANSPS was adapted and applied to the prison setting in an effort to provide systematic information on bloodborne virus prevalence across Australia. The NPEBBVS presents a rare opportunity for prison medical services to collaborate nationally on a research project.

This report presents the findings from the 2004, 2007, 2010 and 2013 surveys.

METHODS

Study Sample

The study is a consecutive cross-sectional sample of prison entrants over a two week period. While previous iterations of the survey have collected data in parallel over a two period in October (the same time as the community NSP survey), the timing of the current survey varied between jurisdictions (Table 1). The first state to conduct the survey was Victoria in October 2013 and the last was NSW in May 2014. Participants were 793 of the 1,235 (64%) prisoners entering Australian correctional centres who were offered the survey. However, 24 participants provided a blood and/or urine specimen but no questionnaire information, and 9 participants provided a blood and/or urine sample with some questionnaire information but were excluded due to no information on the main classification variable - injecting drug user status. Serology data from the 24 participants without a completed questionnaire have been included in this report wherever possible, which excludes tables stratified by behavioural indicators. The 2013 NPEBBVS reports the findings for the 793 participants for whom sufficient pathology and questionnaire data were available.

Table 1 Survey dates, 2013 NPEBBVS

Jurisdiction	Survey Dates
ACT	7 November to 6 December 2013*
NSW	27 May to 9 June 2014
NT	10 to 23 February 2014
Qld	10 to 23 February 2014
SA	4 to 17 November 2013
Tas	13 to 26 February 2014
Vic	22 October to 4 November 2013
WA	6 to 19 February 2014

*ACT conducted a longer collection period given low overall prison receptions during this time

Sample Selection

New receptions at 23 sentinel sites were invited to participate in the assessment (Table 1). New receptions were defined as individuals entering prison from the community and did not include remanded inmates returning from court appearances or prisoners transiting through the survey site *en route* to other prisons. In NSW, the survey was systematically offered to every third incoming inmate.

Recruitment

We aimed to minimise any disruption to the prison reception process by conducting the survey immediately after the initial health and welfare assessments which are routinely conducted on

all individuals received into prison. However, those unable to be screened at the time of reception were called up within seventy-two hours of entry into the prison and invited to participate.

Potential participants were given an outline of the project by a member of the survey team. The explanation emphasised the following: involvement was voluntary, the structure of the assessment consisted of a short questionnaire followed by blood testing, there was no obligation to answer any questions deemed intrusive or sensitive, and information would remain confidential. Participants were also informed that every effort would be made to return the blood test results, even if they were in the community, and that post-test counselling would be provided and referrals made to specialist services if necessary. Written consent was obtained from all participants. No payment was made to participants.

Confidentiality was maintained on the questionnaires and serology requests through the use of a code comprising the first two letters of each participant's surname and first name, their date of birth and a unique inmate identifier number.

Survey Sites

Twenty-three sentinel reception sites in all eight Australian jurisdictions participated in the 2013 study (Table 2). These centres receive both men and women prisoners directly from the community. In all jurisdictions, prisoners are received into the correctional system through a limited number of reception sites. By targeting these sites we could be certain that we were accessing most of the eligible prison receptions across the participating jurisdictions. For example, in Victoria all male receptions are processed through the Melbourne Assessment Prison and in New South Wales, the Metropolitan Reception and Remand Centre (MRRC) in Sydney processes approximately two-thirds of the state's prisoners.

Screening Procedures

Screening was divided into several stages to provide a consistent structure to the survey. Broadly, this involved recruiting participants and obtaining consent, administering the questionnaire, providing pre-test counselling for those who consented to blood testing, and collecting the blood specimen. Pre-test discussion included psychological assessment of the person's ability to deal with a positive result, provision of information about the possible consequences of infection with bloodborne viruses, transmission risks, confidentiality and notification requirements related to blood tests, and treatment options for those who tested positive. Those who consented to the blood test were also informed that face-to-face post-test

counselling would be provided as soon as results became available for both positive and negative test results. In some cases this involved community follow-up.

Blood Testing

Screening for bloodborne viruses included testing for the following pathological markers:

- HIV antibody and antigen
- Hepatitis B surface-antibody
- Hepatitis B surface-antigen
- Hepatitis B core-antibody
- Hepatitis C antibody
- *Treponema pallidum* (syphilis) antibody

Urine Testing

Screening for sexually transmissible infections included testing for the following pathological markers:

- *Chlamydia trachomatis* (chlamydia) DNA
- *Neisseria gonorrhoea* (gonorrhoea) DNA

Details of test kits used for the blood and urine testing by the various laboratories are provided in Appendix 1.

Questionnaire

The survey questionnaire is modelled on the NSP survey screening instrument and was designed for the community setting to collect behavioural risk factor information on body piercing, tattooing, injecting drug use, sexual activity, and immunisation status. Modifications were made to the questionnaire to adapt it to the correctional setting (Appendix 2). The questionnaire was piloted in each jurisdiction to ensure it was appropriate for the prisoner population, including Aboriginal and Torres Strait Islander detainees. In 2013, questions were added on willingness to be treated for hepatitis C and intention to be treated for hepatitis C in the near future. Sexual health questions were modified in 2010 to cover the three months prior to the survey and to differentiate between male and female sex partners.

Statistical Analysis

All data were analysed using SPSS version 22. Associations between demographic and behavioural variables and exposure to bloodborne viruses and sexually transmissible infections were assessed using Chi-squared tests.

Interviewers

Interviewers were recruited from nursing staff within each state's and territory correctional health system. Training of site co-ordinators was undertaken via a number of teleconferences with the principal investigator (TB) who in turn trained the local interviewers. Aboriginal health workers were recruited in some jurisdictions to facilitate data collection among Indigenous prisoners.

Ethics Approval

Approval for the project was obtained from the health-based human research and ethics committees in NSW, ACT, NSW, Tasmania, and Queensland. In addition to these committees, approval was obtained from corrective services' ethics committees in NSW, Queensland, Victoria, and Western Australia. In the Northern Territory, approval was granted from the Central Australia Aboriginal ethics committees. The study was also approved by the Human Research Ethics Committee of UNSW Australia.

Reporting of Results

The following sections present the findings from the survey stratified by injecting drug user status and other demographic variables, as appropriate. Summary tables include those participants who provided a blood/urine specimen but not a questionnaire. National and state/territory tables exclude those for whom the main classification variables were not available from the questionnaire.

Percentages have been rounded to the nearest whole number.

Due to the small number of prisoners screened in the ACT, findings for this jurisdiction are included in the summary section only.

RESULTS

Response Rate

A number of inmates declined to participate in the survey ('refusers') while others agreed to answer the questionnaire but opted not to provide blood. A small number initially agreed to provide a blood sample but were unable to do so due to poor venous access. Some of the reasons given by the 'refusers' included a perceived lack of personal gain from participation, needle phobia, and feeling fatigued or stressed during the reception process.^b

^b The reception process is often conducted at the end of the day and sometimes in the early hours of the morning. This is because the courts process people during the day and those receiving a custodial sentence or remanded into custody are taken to the reception prison at the end of the day. Once at the prison there is often a waiting period in a holding cell before they are seen by welfare and medical staff. The high response rate seen in this survey reflects the skill of the reception nurses in highlighting the benefits of the survey to prisoners in what is perhaps one of the most stressful and harrowing periods of the participant's life.

The response rate was calculated as follows^c:

$$\frac{\text{Total participants}}{\text{Total receptions offered survey}} \times 100$$

Table 2 Reception centre, sex of prison receptions, participants screened, and total number of receptions, 2013 NPEBBVS

State	Reception Site	Sex of prisoners	Total N° offered survey*	N° valid participants (%)
ACT	Alexander Maconochie Centre	Men & women	29	27 (93)
NSW	Cessnock CC	Men	28	11
	Metropolitan Remand & Reception Centre	Men	28	13
	Parklea CC	Men	6	3
	Silverwater Women's CC	Women	35	18
	South Coast CC	Men	28	13
	Tamworth CC	Men	11	11
	<i>Total</i>			<i>136</i>
NT	Darwin CC	Men & women	99	60
Qld	Arthur Gorrie CC	Men	100	107
	Brisbane CC	Men	141	91
	Brisbane Women's CC	Women	49	31
	Lotus Glenn CC	Men	54	53
<i>Total</i>		<i>344</i>	<i>282 (82)</i>	
SA	Adelaide Remand Centre	Men	141	38
	Adelaide Women's Prison	Women	9	1
	City Watch House	Men	15	11
<i>Total</i>		<i>165</i>	<i>50 (30)</i>	
Tas	Hobart Reception Prison	Men & women	32	8
	Launceston Reception Prison	Men	25	1
	Risdon Prison Complex	Men & women	27	26
<i>Total</i>		<i>84</i>	<i>35 (42)</i>	
Vic	Dame Phyllis Frost Centre	Women	34	29
	Melbourne Assessment Prison	Men	155	144
<i>Total</i>		<i>189</i>	<i>173 (93)</i>	
WA	Bandyup Women's Prison	Women	39	16
	Hakea Prison	Men	146	77
	Greenough Regional Prison	Men	4	4
<i>Total</i>		<i>189</i>	<i>97 (51)</i>	
Total			1235	793 (64)

* Taken from the running sheets provided by jurisdictions for the two week survey periods.

^c The response rate includes the 307 individuals who participated in the survey but were not included in the analysis due to missing data for the main classification variable - injector status.

Under half (45%) of all respondents reported current or previous injecting drug use (Table 3).

Table 3 Structure of the study sample by sex and injector status, 2013 NPEBBVS*

Sex	Ever Inject Drugs		Total
	No	Yes	
Men	382	283	665
Women	43	59	102
Total	425	342	767

* Table only includes those for whom questionnaire data was available.

Summary 2013

Table 4 Demographic characteristics of prison entrants by jurisdiction (2013)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
N° of sites	1	6	1	4	3	3	2	3	23
N° surveyed	27	69	60	282	50	35	173	97	793
N° (%) Male	21 (78)	51 (74)	57 (95)	251 (89)	49 (98)	30 (86)	144 (83)	81 (84)	684 (86)
Median age (years)	32	31	31	31	33	34	31	32	31
Age range	19 – 58	18 – 72	18 – 69	17 – 64	19 – 70	18 – 60	18 – 68	18 – 58	17 – 72
N° (%) Indigenous	8 (30)	22 (32)	49 (82)	104 (37)	20 (40)	7 (20)	18 (10)	32 (33)	260 (33)
N° (%) Aust. Born	22 (82)	58 (84)	46 (77)	253 (90)	45 (90)	32 (91)	131 (76)	81 (84)	668 (84)

Table 5 Injecting drug use, smoking status, other drug use by jurisdiction (2013)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
N° (%) with IDU* history	12 (46)	30 (47)	3 (6)	139 (50)	23 (48)	17 (52)	60 (35)	58 (60)	342 (45)
Last drug injected									
Amphetamine	3 (25)	21 (70)	1 (33)	95 (68)	16 (70)	14 (82)	31 (52)	50 (86)	231 (68)
Anabolic steroids	1 (8)	--	--	4 (3)	--	--	1 (2)	2 (3)	8 (2)
Cocaine	--	1 (3)	--	1 (1)	--	--	--	--	2 (1)
Heroin	7 (58)	5 (17)	--	24 (17)	6 (26)	--	22 (37)	4 (7)	68 (20)
Heroin + amphetamine	--	--	--	1 (1)	--	--	1 (2)	--	2 (1)
Heroin + cocaine	--	--	--	1 (1)	--	--	1 (2)	--	2 (1)
Methadone	--	2 (7)	--	1 (1)	--	--	--	--	3 (1)
Morphine	--	--	1 (33)	7 (5)	--	3 (18)	1 (2)	1 (2)	13 (4)
Others	--	1 (3)	1 (33)	2 (2)	--	--	3 (5)	1 (2)	8 (2)
Not reported	1 (8)	--	--	3 (2)	1 (4)	--	--	--	5 (2)
N° (%) injected last month									
No, did not inject	5 (42)	10 (33)	1 (33)	37 (27)	11 (48)	9 (53)	20 (33)	16 (28)	109 (32)
Yes, injected	7 (58)	20 (67)	2 (67)	100 (72)	11 (48)	8 (47)	40 (67)	42 (72)	230 (67)
Not reported	--	--	--	2 (1)	1 (4)	--	--	--	3 (1)
Places injected last month (%)**									
Prison	--	1 (5)	--	2 (2)	2 (18)	--	2 (5)	--	7 (3)
Own home	6 (86)	15 (75)	2 (100)	61 (60)	8 (73)	6 (75)	26 (67)	31 (76)	154 (68)
Friend's home	2 (29)	10 (50)	--	34 (34)	8 (73)	5 (63)	18 (46)	15 (37)	92 (40)
Dealer's home	4 (57)	4 (20)	--	15 (15)	6 (55)	--	6 (15)	9 (22)	44 (19)
Street, park, beach	2 (29)	3 (15)	--	12 (12)	5 (46)	1 (13)	5 (13)	9 (22)	37 (16)
Car	4 (57)	4 (20)	--	16 (16)	5 (46)	1 (13)	10 (26)	6 (15)	46 (20)
Public toilet	1 (14)	7 (35)	--	9 (9)	5 (46)	--	6 (15)	9 (22)	37 (16)
MSIC***	--	1 (5)	--	--	--	--	--	--	1 (<1)
Commercial shooting	--	--	--	--	--	--	--	--	--
Squat	--	--	--	--	1 (9)	--	1 (3)	1 (2)	3 (1)
Other	--	--	--	--	--	--	--	--	--
Use of sterile needles & syringes last month (%)									
All injections	4 (57)	13 (65)	2 (100)	75 (75)	6 (55)	6 (75)	26 (65)	29 (69)	161 (70)
Most of the time	3 (43)	3 (15)	--	17 (17)	3 (27)	2 (25)	8 (20)	9 (21)	45 (20)
Half of the time	--	2 (10)	--	1 (1)	2 (18)	--	2 (5)	--	7 (3)
Some of the time	--	2 (10)	--	6 (6)	--	--	3 (8)	4 (10)	15 (7)
None of the time	--	--	--	1 (1)	--	--	1 (3)	--	2 (1)
Not reported	--	--	--	--	--	--	--	--	--

*IDU=injecting drug user

** More than one option could be selected.

*** Medically Supervised Injecting Centre, Sydney.

Table 6 Injecting drug use, smoking status, other drug use by jurisdiction (2013) (cont.)

	State								Total
	ACT	NSW	NT	Qld	SA	Tas	Vic	WA	
Ever smoked a full cigarette (%)									
No	3 (12)	1 (2)	3 (6)	28 (10)	3 (6)	3 (9)	17 (10)	9 (9)	67 (9)
Yes	23 (88)	62 (96)	45 (94)	251 (90)	45 (94)	30 (91)	155 (90)	88 (91)	699 (91)
Not reported	--	1 (2)	--	--	--	--	--	--	1 (<1)
Current smoker (%)									
No	2 (9)	5 (8)	1 (2)	22 (9)	5 (11)	4 (13)	12 (8)	12 (14)	64 (9)
Yes	21 (91)	57 (92)	44 (98)	225 (90)	37 (82)	26 (87)	143 (92)	76 (86)	629 (90)
Not reported	--	--	--	4 (1)	3 (7)	--	--	--	5 (1)
Other drugs used last month*(%)									
No drugs in past 4 weeks	12 (46)	15 (23)	15 (31)	80 (29)	5 (10)	8 (24)	85 (49)	28 (29)	248 (31)
Cannabis	7 (50)	37 (79)	31 (94)	141 (71)	25 (58)	18 (72)	42 (48)	41 (59)	342 (66)
Heroin	5 (36)	6 (13)	--	33 (17)	6 (14)	--	22 (25)	7 (10)	79 (15)
Cocaine	2 (14)	5 (11)	1 (3)	12 (6)	4 (9)	--	4 (5)	2 (3)	30 (6)
Amphetamine	7 (50)	32 (68)	4 (12)	115 (58)	20 (47)	9 (36)	55 (63)	55 (80)	297 (57)
Other's methadone	--	2 (4)	1 (3)	8 (4)	--	--	6 (7)	--	17 (3)
Other opiates	3 (21)	4 (9)	2 (6)	31 (16)	7 (16)	4 (16)	7 (8)	3 (4)	61 (12)
Other's buprenorphine	--	5 (11)	--	6 (3)	2 (5)	--	7 (8)	2 (3)	22 (4)
Steroids	--	--	--	6 (3)	--	--	1 (1)	2 (3)	9 (2)
Hallucinogens	2 (14)	2 (4)	2 (6)	8 (4)	1 (2)	--	3 (3)	3 (4)	21 (4)
Benzodiazepines	3 (21)	11 (23)	--	35 (18)	7 (16)	4 (16)	33 (38)	7 (10)	100 (19)
Ecstasy/MDA	2 (14)	3 (6)	--	17 (9)	3 (7)	3 (12)	4 (5)	4 (6)	36 (7)
Inhalants (e.g. petrol)	--	1 (2)	--	1 (1)	1 (2)	--	--	--	3 (1)
Other drug	--	4 (9)	--	2 (1)	--	5 (20)	9 (10)	4 (6)	24 (5)
Not reported	--	2 (3)	--	--	--	--	--	--	2 (<1)

* More than one option could be selected.

Table 7 HIV antibody prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV
ACT	5	0 (0)	0	0 (0)	5	0 (0)
NSW	43	0 (0)	16	0 (0)	59	0 (0)
NT	49	0 (0)	2	0 (0)	51	0 (0)
Qld	74	0 (0)	20	0 (0)	94	0 (0)
SA	33	0 (0)	0	0 (0)	33	0 (0)
Tas	21	0 (0)	3	0 (0)	24	0 (0)
Vic	138	0 (0)	26	0 (0)	164	0 (0)
WA	61	0 (0)	10	0 (0)	71	0 (0)
Total	424	0 (0)	77	0 (0)	501	0 (0)

† Excludes equivocal test results and missing values.

Table 8 HIV antibody prevalence by jurisdiction, sex and injector status (2013)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HIV
	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV	N° tested	N° (%) with HIV		
ACT	2	0 (0)	3	0 (0)	0	--	0	--		--
NSW	18	0 (0)	23	0 (0)	9	0 (0)	4	0 (0)	54	0 (0)
NT	3	0 (0)	35	0 (0)	0	--	2	0 (0)	40	0 (0)
Qld	43	0 (0)	30	0 (0)	11	0 (0)	8	0 (0)	92	0 (0)
SA	15	0 (0)	16	0 (0)	0	--	0	--	31	0 (0)
Tas	10	0 (0)	10	0 (0)	0	--	2	0 (0)	22	0 (0)
Vic	43	0 (0)	94	0 (0)	13	0 (0)	13	0 (0)	163	0 (0)
WA	39	0 (0)	22	0 (0)	7	0 (0)	3	0 (0)	71	0 (0)
Total	173	0 (0)	233	0 (0)	40	0 (0)	32	0 (0)	478	0 (0)

† Excludes equivocal test results and missing values.

Table 9 Hepatitis C antibody prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV
ACT	15	5 (33)	5	2 (40)	20	7 (35)
NSW	44	12 (27)	9	2 (22)	53	14 (26)
NT	35	3 (9)	2	0 (0)	37	3 (8)
Qld	103	53 (51)	25	13 (52)	128	66 (52)
SA	33	5 (15)	1	1 (100)	34	6 (18)
Tas	22	9 (41)	3	1 (33)	25	10 (40)
Vic	140	32 (23)	26	10 (38)	166	42 (25)
WA	62	12 (19)	11	5 (45)	73	17 (23)
Total	454	131 (29)	82	34 (41)	536	165 (31)

† Excludes equivocal test results and missing values.

Table 10 Hepatitis C antibody prevalence by jurisdiction, sex and injector status (2013)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HCV
	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV	N° tested	N° (%) with HCV		
ACT	7	4 (57)	8	1 (13)	3	2 (67)	2	0 (0)	20	7 (35)
NSW	19	12 (63)	25	0 (0)	5	2 (40)	4	0 (0)	53	14 (26)
NT	2	2 (100)	33	1 (3)	0	--	2	0 (0)	37	3 (8)
Qld	71	50 (70)	32	3 (9)	17	12 (71)	8	1 (13)	128	66 (52)
SA	18	5 (28)	15	0 (0)	1	1 (100)	0	0 (0)	34	6 (18)
Tas	12	9 (75)	10	0 (0)	1	1 (100)	2	0 (0)	25	10 (40)
Vic	46	28 (61)	94	4 (4)	13	9 (69)	13	1 (8)	166	42 (25)
WA	40	11 (28)	22	1 (5)	8	5 (63)	3	0 (0)	73	17 (23)
Total	215	121 (56)	239	10 (4)	48	32 (67)	34	2 (6)	536	165 (31)

† Excludes equivocal test results and missing values.

Table 11 Hepatitis B surface-antigen prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with Hepatitis B surface-antigen	N° tested	N° (%) with Hepatitis B surface-antigen	N° tested	N° (%) with Hepatitis B surface-antigen
ACT	16	0 (0)	5	0 (0)	21	0 (0)
NSW	39	0 (0)	13	0 (0)	52	0 (0)
NT	47	1 (2)	3	0 (0)	50	1 (2)
Qld	13	3 (23)	6	0 (0)	19	3 (16)
SA	25	5 (20)	0	--	25	5 (20)
Tas	22	0 (0)	3	0 (0)	25	0 (0)
Vic	137	2 (1)	3	0 (0)	140	2 (1)
WA	61	2 (3)	9	0 (0)	70	2 (3)
Total	360	13 (4)	42	0 (0)	402	13 (3)

† Excludes equivocal test results and missing values.

Table 12 Hepatitis B core-antibody prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV
ACT	3	3 (100)	0	--	3	3 (100)
NSW	46	8 (17)	13	2 (15)	59	10 (17)
NT	47	20 (43)	3	2 (67)	50	22 (44)
Qld	74	7 (9)	17	2 (12)	91	9 (10)
SA	18	2 (11)	0	--	18	2 (11)
Tas	22	1 (5)	3	0 (0)	25	1 (4)
Vic	137	21 (15)	3	0 (0)	140	21 (15)
WA	61	13 (21)	9	1 (11)	70	14 (20)
Total	408	75 (18)	48	7 (15)	456	82 (18)

† Excludes equivocal test results and missing values.

Table 13 Hepatitis B core-antibody prevalence by jurisdiction, sex and injector status (2013)†

	Male				Female				Total	
	IDU		Non-IDU		IDU		Non-IDU		N° tested	N° (%) with HBV
	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV	N° tested	N° (%) with HBV		
ACT	2	2 (100)	1	1 (100)	0	0 (0)	0	--	3	3 (100)
NSW	19	5 (26)	25	3 (12)	6	1 (17)	4	0 (0)	54	9 (17)
NT	3	1 (33)	33	16 (48)	0	0 (0)	2	1 (50)	38	18 (47)
Qld	44	4 (9)	29	3 (10)	9	1 (11)	7	1 (14)	89	9 (10)
SA	6	2 (33)	10	0 (0)	0	--	0	--	16	2 (13)
Tas	11	1 (9)	10	0 (0)	0	--	2	0 (0)	23	1 (4)
Vic	42	10 (24)	94	11 (12)	2	0 (0)	1	0 (0)	139	21 (15)
WA	39	8 (21)	22	5 (23)	6	1 (17)	3	0 (0)	70	14 (20)
Total	166	33 (20)	224	39 (17)	23	3 (13)	19	2 (11)	432	77 (18)

† Excludes equivocal test results and missing values.

Table 14 Hepatitis B virus immune status by jurisdiction (2013)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	19	8 (42)	3 (16)	0 (0)	8 (42)
NSW	58	24 (41)	10 (17)	0 (0)	24 (41)
NT	50	16 (32)	21 (42)	1 (2)	16 (32)
Qld	91	42 (46)	6 (7)	3 (3)	40 (44)
SA	12	5 (42)	2 (17)	5 (42)	0 (0)
Tas	15	14 (93)	1 (7)	0 (0)	0 (0)
Vic	96	43 (45)	19 (20)	2 (2)	32 (33)
WA	71	33 (46)	12 (17)	2 (3)	24 (34)
Total	412	181 (44)	74 (18)	13 (3)	144 (35)

† Excludes equivocal test results and missing values.

Table 15 Hepatitis B virus immune status - Males (2013)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	15	6 (40)	3 (20)	0 (0)	6 (40)
NSW	45	21 (47)	8 (18)	0 (0)	16 (36)
NT	47	11 (23)	19 (40)	1 (2)	16 (34)
Qld	72	34 (47)	4 (6)	3 (4)	31 (43)
SA	12	5 (42)	2 (17)	5 (42)	0 (0)
Tas	12	11 (92)	1 (8)	0 (0)	0 (0)
Vic	93	43 (46)	19 (20)	2 (2)	29 (31)
WA	61	29 (48)	11 (18)	2 (3)	19 (31)
Total	357	160 (45)	67 (19)	13 (4)	117 (33)

† Excludes equivocal test results and missing values.

Table 16 Hepatitis B virus immune status - Females (2013)†

	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity
ACT	4	2 (50)	0 (0)	0 (0)	2 (50)
NSW	13	3 (23)	2 (15)	0 (0)	8 (62)
NT	3	1 (33)	2 (67)	0 (0)	0 (0)
Qld	19	8 (42)	2 (11)	0 (0)	9 (47)
SA	--	--	--	--	--
Tas	3	3 (100)	0 (0)	0 (0)	0 (0)
Vic	3	--	0 (0)	0 (0)	3 (100)
WA	10	4 (40)	1 (10)	0 (0)	5 (50)
Total	55	21 (38)	7 (13)	0 (0)	27 (49)

† Excludes equivocal test results and missing values.

Table 17 Genital chlamydia prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with chlamydia	N° tested	N° (%) with chlamydia	N° tested	N° (%) with chlamydia
ACT	3	1 (33)	0	--	3	1 (33)
NSW	25	1 (4)	18	1 (6)	43	2 (5)
NT	49	4 (8)	3	0 (0)	52	4 (8)
Qld	77	5 (6)	21	0 (0)	98	5 (5)
SA	31	4 (13)	0	--	31	4 (13)
Tas	23	0 (0)	4	0 (0)	27	0 (0)
Vic	137	3 (2)	27	2 (7)	164	5 (3)
WA	65	2 (3)	10	0 (0)	75	2 (3)
Total	410	20 (5)	83	3 (4)	493	23 (5)

† Excludes missing values.

Table 18 Genital gonorrhoea prevalence by jurisdiction and sex (2013)†

	Male		Female		Total	
	N° tested	N° (%) with gonorrhoea	N° tested	N° (%) with gonorrhoea	N° tested	N° (%) with gonorrhoea
ACT	3	0 (0)	0	--	3	0 (0)
NSW	25	0 (0)	18	0 (0)	43	0 (0)
NT	47	1 (2)	3	0 (0)	50	1 (2)
Qld	77	0 (0)	21	0 (0)	98	0 (0)
SA	31	0 (0)	0	--	31	0 (0)
Tas	23	0 (0)	4	0 (0)	27	0 (0)
Vic	137	0 (0)	27	0 (0)	164	0 (0)
WA	65	0 (0)	10	0 (0)	75	0 (0)
Total	408	1 (<1)	83	--	491	1 (<1)

† Excludes missing values.

Table 19 Syphilis markers by jurisdiction and sex (2013)†

	Male			Female			Total
	N° tested	N° (%) with syphilis antibodies	N° (%) with reactive RPR	N° tested	N° (%) with syphilis antibodies	N° (%) with reactive RPR	N° (%) with any marker for syphilis
ACT	15	0 (0)	0 (0)	5	0 (0)	0 (0)	0 (0)
NSW	43	0 (0)	0 (0)	15	0 (0)	0 (0)	0 (0)
NT	47	6 (13)	4 (57)	3	1 (33)	1 (33)	3 (6)
Qld	72	0 (0)	0 (0)	20	0 (0)	0 (0)	0 (0)
SA	31	0 (0)	0 (0)	0	--	--	--
Tas	23	0 (0)	0 (0)	4	0 (0)	0 (0)	0 (0)
Vic	138	0 (0)	0 (0)	26	0 (0)	0 (0)	0 (0)
WA	60	0 (0)	0 (0)	10	0 (0)	0 (0)	0 (0)
Total	429	6 (1)	4 (1)	83	1 (1)	1 (1)	3 (1)

† Excludes missing values.

National
2004, 2007, 2010, 2013

Table 20 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 8		N = 17		N = 27		N = 23	
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425
Sex (%)								
Male	307 (86)	228 (92)	354 (87)	315 (94)	310 (88)	424 (93)	283 (83)	382 (90)
Female	49 (14)	19 (8)	52 (13)	19 (6)	43 (12)	34 (7)	59 (17)	43 (10)
Transgender	1 (<1)	--	--	--	--	--	--	--
Sexual identity (%)								
Heterosexual	341 (96)	240 (97)	385 (95)	328 (98)	336 (95)	441 (96)	319 (93)	412 (97)
Bisexual	11 (3)	3 (1)	6 (2)	2 (<1)	8 (2)	7 (2)	12 (4)	4 (1)
Homosexual	5 (1)	3 (1)	9 (2)	1 (<1)	6 (2)	3 (1)	3 (1)	4 (1)
Unsure	--	--	2 (<1)	--	1 (<1)	2 (0)	4 (1)	2 (<1)
Not reported	--	1 (<1)	4 (<1)	3 (<1)	2 (1)	5 (1)	4 (1)	3 (1)
Age and duration of injection (years)								
Median (Med) age	30	34	32	29	33	28	32	31
Age range	17 – 58	17 – 75	18 – 54	17 – 77	18 – 79	16 – 80	17 – 68	17 – 72
Age group (%)								
<25 years	95 (27)	69 (28)	70 (17)	120 (36)	71 (20)	160 (35)	67 (20)	118 (28)
25+ years	260 (72)	178 (72)	335 (83)	214 (64)	281 (80)	298 (65)	272 (80)	305 (72)
N/A	2 (<1)	--	1 (<1)	--	1 (<1)	--	3 (1)	2 (<1)
Med age 1 st IDU	18	--	18	--	18	--	18	--
Age range	9 – 41	--	8 – 44	--	7 – 42	--	10 – 47	--
Not reported	8	--	9	--	13	--	5	--
Med IDU (years)	10	--	12	--	13	--	13	--
Range	<1 – 37	--	<1 – 36	--	<1 – 40	--	<1 – 44	--
Not reported	--	--	--	--	--	--	11	--
Duration of drug injection (%)								
<3 years	36 (10)	--	24 (6)	--	33 (9)	--	43 (13)	--
3+ years	311 (87)	--	372 (92)	--	306 (87)	--	288 (86)	--
Not reported	10 (3)	--	10 (2)	--	14 (4)	--	5 (1)	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	285 (80)	209 (85)	320 (79)	283 (85)	260 (74)	291 (64)	226 (66)	291 (68)
Yes	64 (18)	36 (15)	78 (19)	50 (15)	93 (26)	167 (36)	115 (34)	134 (32)
Not reported	8 (2)	2 (<1)	8 (2)	1 (<1)	--	--	1 (<1)	--
Residential remoteness in 12 months before prison (%)								
Highly / accessible	325 (91)	215 (87)	362 (89)	286 (86)	313 (89)	329 (72)	286 (84)	295 (69)
Mod accessible	9 (3)	6 (2)	11 (3)	14 (4)	15 (4)	22 (5)	36 (11)	58 (14)
Very / remote	13 (4)	14 (6)	11 (3)	11 (3)	14 (4)	84 (18)	8 (2)	56 (13)
Not reported	10 (3)	12 (5)	22 (5)	23 (7)	11 (3)	23 (5)	12 (4)	16 (4)
Region/Country of birth (%)								
Australia	310 (87)	182 (74)	354 (87)	263 (79)	314 (89)	372 (81)	318 (93)	348 (82)
Other Oceania	12 (3)	17 (7)	9 (2)	13 (4)	15 (4)	29 (6)	8 (2)	23 (5)
Asia	13 (4)	14 (6)	19 (5)	20 (6)	9 (3)	22 (5)	5 (1)	23 (5)
UK & Ireland	8 (2)	9 (4)	7 (2)	7 (2)	7 (2)	6 (1)	7 (2)	6 (1)
Other	13 (4)	23 (9)	15 (4)	27 (8)	7 (2)	29 (6)	4 (1)	25 (6)
Not reported	1 (<1)	2 (<1)	2 (<1)	4 (1)	1 (<1)	--	--	--
Main language spoke at home by parents (%)								
English	328 (92)	208 (84)	365 (90)	268 (80)	332 (94)	367 (80)	331 (79)	326 (77)
Non-English	28 (8)	37 (15)	40 (10)	64 (19)	17 (5)	65 (14)	11 (3)	96 (23)
Not reported	--	2 (<1)	1 (<1)	2 (<1)	4 (1)	26 (6)	--	3 (1)

Table 21 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)								
No	302 (85)	149 (60)	336 (83)	161 (48)	290 (82)	262 (57)	274 (80)	230 (54)
Yes	55 (15)	98 (40)	69 (17)	171 (51)	61 (17)	190 (41)	67 (20)	191 (45)
Not reported	--	--	1 (<1)	2 (<1)	2 (1)	6 (1)	1 (<1)	4 (1)
Lifetime Imprisonments (%)*								
One	55 (15)	98 (40)	69 (17)	171 (51)	118 (33)	285 (62)	n/a	n/a
Two to four	178 (50)	117 (47)	163 (40)	119 (36)	115 (33)	109 (24)	n/a	n/a
Five to nine	87 (24)	17 (7)	95 (23)	23 (7)	72 (20)	43 (9)	n/a	n/a
Ten or more	32 (9)	3 (1)	60 (15)	10 (3)	46 (13)	15 (3)	n/a	n/a
Not reported	5 (1)	12 (5)	19 (5)	11 (3)	2 (1)	6 (1)	n/a	n/a
Imprisonment in last year (%)								
No	129 (36)	137 (55)	113 (34)	47 (29)	160 (45)	277 (60)	90 (33)	84 (37)
Yes	220 (62)	98 (40)	214 (64)	111 (68)	180 (51)	153 (33)	164 (60)	131 (57)
Not reported	8 (2)	12 (5)	10 (3)	5 (3)	13 (4)	28 (6)	20 (7)	15 (7)
Frequency of Injection last month (%)								
Not last month	125 (35)	--	152 (37)	--	150 (42)	--	108 (32)	--
< weekly	47 (13)	--	54 (13)	--	68 (19)	--	50 (15)	--
Weekly	28 (8)	--	52 (13)	--	23 (7)	--	43 (13)	--
Daily or more	154 (43)	--	142 (35)	--	108 (31)	--	138 (40)	--
Not reported	3 (<1)	--	6 (2)	--	4 (1)	--	3 (1)	--
Ever smoked a full cigarette (%)**								
No	n/a	n/a	14 (3)	45 (14)	7 (2)	44 (10)	11 (3)	56 (13)
Yes	n/a	n/a	392 (97)	289 (87)	346 (98)	413 (90)	331 (97)	368 (87)
Not reported	n/a	n/a	--	--	--	1 (<1)	--	1 (<1)
Med age 1st smoked								
Age range	n/a	n/a	5 – 36	4 – 31	3 – 37	6 – 50	5 – 35	5 – 40
Current smoker (%)**								
No	n/a	n/a	26 (6)	85 (25)	20 (6)	99 (22)	21 (6)	42 (11)
Yes	n/a	n/a	379 (93)	249 (75)	333 (94)	357 (78)	309 (93)	320 (87)
Not reported	n/a	n/a	1 (<1)	--	--	2 (<1)	1 (<1)	6 (2)
Smoking frequency (%)**								
Weekly or less	n/a	n/a	13 (3)	22 (9)	11 (3)	12 (3)	7 (2)	16 (5)
5-10/day	n/a	n/a	98 (26)	60 (24)	106 (32)	152 (42)	102 (33)	115 (35)
11 to 20/day	n/a	n/a	154 (41)	85 (34)	144 (43)	104 (29)	127 (41)	115 (35)
>20/day	n/a	n/a	113 (30)	81 (33)	70 (21)	88 (25)	70 (23)	69 (21)
Not reported	n/a	n/a	2 (<1)	1 (<1)	2 (1)	1 (<1)	4 (1)	10 (3)
Other drugs used last month (%)***								
None	n/a	n/a	n/a	n/a	63 (19)	222 (52)	37 (11)	211 (50)
Cannabis	n/a	n/a	n/a	n/a	205 (74)	167 (80)	197 (65)	145 (68)
Heroin	n/a	n/a	n/a	n/a	78 (28)	11 (5)	72 (24)	7 (3)
Cocaine	n/a	n/a	n/a	n/a	18 (6)	11 (5)	18 (6)	12 (6)
Amphetamine	n/a	n/a	n/a	n/a	159 (57)	49 (23)	212 (70)	85 (40)
Methadone	n/a	n/a	n/a	n/a	23 (8)	--	16 (5)	1 (<1)
Other opiates	n/a	n/a	n/a	n/a	43 (16)	2 (1)	51 (17)	10 (5)
Buprenorphine	n/a	n/a	n/a	n/a	33 (12)	3 (1)	18 (6)	4 (2)
Steroids	n/a	n/a	n/a	n/a	7 (3)	2 (1)	8 (3)	1 (<1)
Hallucinogens	n/a	n/a	n/a	n/a	7 (3)	5 (2)	13 (4)	8 (4)
Benzodiazepine	n/a	n/a	n/a	n/a	62 (22)	15 (7)	77 (25)	23 (11)
Ecstasy/MDA	n/a	n/a	n/a	n/a	17 (6)	16 (8)	24 (8)	12 (6)
Inhalants	n/a	n/a	n/a	n/a	1 (<1)	1 (<1)	--	3 (1)
Other drug	n/a	n/a	n/a	n/a	2 (1)	1 (<1)	13 (4)	11 (5)
Not reported	n/a	n/a	n/a	n/a	13 (4)	28 (6)	1 (<1)	1 (<1)

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 22 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)	N = 357	N = 406	N = 353	N = 342
Amphetamine (Speed, Ice)	206 (58)	238 (59)	207 (59)	231 (68)
Anabolic steroids	1 (<1)	--	2 (1)	8 (2)
Cocaine	7 (2)	7 (2)	3 (1)	2 (1)
Heroin	115 (32)	126 (31)	88 (25)	68 (20)
Heroin + amphetamine	--	10 (2)	--	2 (1)
Heroin + cocaine	2 (<1)	1 (<1)	4 (1)	2 (1)
Methadone	7 (2)	6 (1)	5 (1)	3 (1)
Morphine	9 (3)	12 (3)	20 (6)	13 (4)
Other	8 (2)	5 (1)	19 (5)	8 (2)
Not reported	--	1 (<1)	5 (1)	5 (1)
N° Injected last month	N = 232	N = 248	N = 199	N = 231
Places injected last month (%)*				
Prison	8 (3)	7 (3)	4 (2)	7 (3)
Own home	181 (78)	199 (80)	120 (61)	155 (67)
Friend's home	117 (50)	137 (55)	78 (40)	92 (40)
Dealer's home	51 (22)	74 (30)	27 (14)	44 (19)
Street, park, beach	73 (31)	95 (38)	30 (15)	37 (16)
Car	82 (35)	112 (45)	45 (23)	46 (20)
Public toilet	56 (24)	69 (28)	31 (16)	37 (16)
Commercial injecting room	8 (3)	7 (3)	1 (<1)	--
Medically Supervised Injecting Centre, Sydney	9 (4)	10 (4)	3 (2)	1 (<1)
Squat	19 (8)	14 (6)	4 (2)	3 (1)
Other place	5 (2)	12 (5)	1 (<1)	5 (2)
Use of sterile needles & syringes last month (%)				
All injections	160 (69)	162 (65)	137 (69)	161 (70)
Most of the time	38 (16)	52 (21)	42 (21)	45 (20)
Half of the time	14 (6)	11 (4)	7 (4)	7 (3)
Some of the time	17 (7)	18 (7)	3 (2)	15 (7)
Not last month	2 (<1)	--	3 (2)	2 (1)
Not reported	1 (<1)	5 (2)	7 (4)	--
Re-used someone else's used needle & syringe last month (%)				
None	196 (84)	198 (80)	157 (79)	190 (82)
Once	6 (3)	10 (4)	11 (6)	13 (6)
Twice	14 (6)	10 (4)	9 (5)	6 (3)
3-5 times	7 (3)	7 (3)	7 (4)	9 (4)
>5 times	7 (3)	19 (8)	9 (5)	11 (5)
Not reported	2 (<1)	4 (2)	6 (3)	2 (1)
Number of people needle & syringe was re-used after last month (%)				
One	20 (9)	31 (12)	16 (8)	20 (9)
Two	7 (3)	3 (1)	6 (3)	5 (2)
Three to five	4 (2)	4 (2)	2 (1)	3 (1)
More than five	2 (<1)	--	4 (2)	7 (3)
Don't know how many	--	5 (2)	7 (4)	3 (1)
Not reported	2 (<1)	13 (5)	8 (4)	3 (1)
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	18 (8)	25 (10)	20 (10)	10 (4)
Casual sex partner	2 (<1)	2 (<1)	3 (2)	3 (1)
Close friend	7 (3)	13 (5)	7 (4)	12 (5)
Acquaintance	5 (2)	5 (2)	6 (3)	12 (5)
Other	5 (2)	5 (2)	4 (2)	6 (3)
Equipment used after someone else last month (%)*				
Spoon	49 (21)	76 (30)	50 (25)	36 (16)
Water	39 (17)	63 (25)	39 (20)	24 (11)
Filter	34 (15)	57 (23)	40 (20)	14 (6)
Tourniquet	18 (8)	31 (13)	26 (13)	17 (8)
Drug mix	33 (14)	49 (20)	36 (18)	22 (10)

* More than one option could be selected.

Table 23 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425
Any treatment/therapy for drug use (%)								
No	195 (55)	228 (92)	125 (31)	182 (54)	157 (44)	397 (87)	170 (50)	356 (84)
Yes	161 (45)	17 (7)	250 (62)	42 (13)	194 (55)	56 (12)	170 (50)	61 (14)
Not reported	1 (<1)	2 (<1)	31 (8)	110 (33)	2 (1)	4 (1)	2 (1)	8 (2)
History of methadone maintenance treatment (%)								
Currently	53 (15)	3 (1)	50 (12)	--	48 (14)	1 (<1)	30 (9)	--
Previously	76 (21)	2 (<1)	92 (23)	--	51 (14)	4 (1)	48 (14)	3 (1)
Never	226 (63)	240 (97)	225 (55)	--	250 (71)	449 (98)	262 (77)	416 (98)
Not reported	2 (<1)	2 (<1)	39 (10)	--	4 (1)	4 (1)	2 (1)	6 (1)
History of other pharmacotherapy treatment (%)								
Currently	19 (5)	3 (1)	28 (7)	--	32 (9)	4 (1)	6 (2)	2 (<1)
Previously	49 (14)	1 (<1)	95 (23)	--	44 (12)	4 (1)	49 (14)	1 (<1)
Never	284 (80)	241 (98)	268 (66)	--	276 (78)	447 (98)	285 (83)	413 (97)
Not reported	5 (1)	2 (<1)	15 (4)	--	1 (<1)	3 (1)	2 (1)	9 (2)

Table 24 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013
N° surveyed	N = 233	N = 248	N = 353	N = 342
From an NSP last month (%)				
Daily or almost daily	31 (13)	30 (12)	26 (7)	17 (5)
A couple of times each week	38 (16)	57 (22)	37 (10)	42 (12)
Less than weekly	33 (14)	38 (15)	40 (11)	42 (12)
Weekly	n/a	n/a	19 (5)	--
Once last month	39 (17)	29 (12)	12 (3)	53 (15)
Not in the last month	57 (24)	45 (18)	154 (44)	179 (52)
Not reported	35 (15)	52 (21)	65 (18)	9 (3)
From a chemist last month (%)				
Daily or almost daily	17 (7)	14 (6)	17 (5)	9 (3)
A couple of times each week	36 (16)	32 (13)	29 (8)	27 (8)
Less than weekly	51 (22)	35 (14)	38 (11)	41 (12)
Weekly	n/a	n/a	36 (10)	--
Once last month	38 (17)	32 (13)	--	45 (13)
Not in the last month	86 (37)	84 (34)	173 (49)	211 (62)
Not reported	2 (<1)	51 (21)	60 (17)	9 (3)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 25 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU N = 357	Non-IDU N = 247	IDU N = 406	Non-IDU N = 334	IDU N = 353	Non-IDU N = 458	IDU N = 342	Non-IDU N = 425
N° surveyed								
Body or ear piercings (%)								
No	184 (52)	161 (65)	179 (44)	198 (59)	205 (58)	297 (65)	197 (58)	256 (60)
Yes	172 (48)	85 (34)	224 (55)	133 (40)	147 (42)	161 (35)	144 (42)	168 (40)
Not reported	1 (<1)	1 (<1)	3 (1)	3 (1)	1 (<1)	--	1 (<1)	1 (<1)
Pierced in past 12 months (%)								
No	121 (70)	49 (58)	170 (76)	95 (72)	103 (69)	108 (66)	115 (80)	136 (81)
Yes	22 (13)	9 (10)	25 (11)	15 (11)	18 (12)	22 (13)	14 (10)	17 (10)
Not reported	29 (17)	27 (32)	29 (13)	23 (17)	28 (19)	33 (20)	15 (10)	15 (9)
Who did piercing (%)*								
Chemist/salon	5 (23)	3 (33)	3 (12)	5 (31)	2 (11)	5 (23)	2 (14)	9 (53)
Professional piercer	9 (41)	4 (44)	10 (40)	2 (13)	5 (28)	10 (45)	10 (71)	5 (29)
Tattooist/parlour	1 (5)	2 (22)	4 (16)	3 (19)	3 (17)	2 (9)	--	1 (6)
Friend	2 (9)	--	1 (4)	1 (6)	3 (17)	2 (9)	2 (14)	--
Prison inmate	1 (5)	--	1 (6)	1 (4)	1 (6)	--	--	--
Self	5 (23)	--	3 (12)	4 (25)	5 (28)	--	2 (14)	--
Family member	--	--	2 (8)	--	1 (6)	--	--	1 (6)
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	21 (95)	9 (100)	3 (12)	1 (7)	9 (50)	11 (50)	4 (29)	--
Yes	1 (5)	--	--	2 (13)	--	--	--	1 (6)
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	22 (88)	12 (80)	9 (50)	11 (50)	10 (71)	16 (94)
Tattoos (%)								
No	96 (27)	137 (55)	111 (27)	170 (51)	72 (20)	238 (52)	55 (16)	177 (42)
Yes	261 (73)	109 (44)	294 (72)	164 (49)	275 (78)	209 (46)	285 (83)	246 (58)
Not reported	--	1 (<1)	1 (<1)	--	6 (2)	11 (2)	2 (1)	1 (<1)
Tattoos in past 12 months (%)								
No	205 (79)	91 (83)	220 (75)	100 (61)	197 (72)	132 (63)	199 (70)	161 (65)
Yes	53 (20)	17 (15)	74 (25)	62 (38)	75 (27)	73 (35)	82 (29)	86 (35)
Not reported	3 (1)	1 (2)	1 (<1)	2 (1)	3 (1)	4 (2)	4 (1)	--
Who did tattooing (%)*								
Prof tattooist	32 (60)	10 (59)	41 (55)	47 (76)	40 (53)	47 (64)	37 (45)	51 (59)
Friend	11 (21)	2 (12)	21 (28)	10 (16)	24 (32)	21 (29)	28 (33)	29 (36)
Prison inmate	11 (21)	2 (12)	16 (22)	2 (3)	7 (9)	2 (3)	8 (10)	1 (1)
Self	7 (13)	2 (12)	4 (5)	4 (7)	4 (5)	4 (5)	18 (22)	4 (5)
Family member	1 (2)	1 (6)	--	1 (2)	7 (9)	--	2 (2)	5 (6)
Other	--	--	--	--	--	--	1 (1)	2 (2)

* More than one option could be selected.

Table 26 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425
Sex last month / last 3 months (%)**								
No	93 (26)	75 (30)	107 (26)	84 (25)	41 (12)	80 (17)	38 (11)	70 (16)
Yes	263 (74)	168 (68)	298 (73)	248 (74)	307 (87)	368 (80)	300 (88)	349 (82)
Not reported	1 (<1)	4 (2)	1 (<1)	2 (<1)	5 (1)	10 (2)	4 (1)	6 (2)
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 –	1 (0 – 10)	0 (0 – 15)	0 (0 – 10)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 90)	1 (0 – 26)	1 (0 – 20)	1 (0 – 40)
Condom use at last sex (%)								
No	270 (76)	175 (71)	327 (81)	239 (72)	n/a	n/a	n/a	n/a
Yes	87 (24)	69 (28)	75 (18)	94 (28)	n/a	n/a	n/a	n/a
Not reported	--	3 (1)	4 (<1)	1 (<1)	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	160 (86)	112 (81)	189 (84)	149 (74)	n/a	n/a	n/a	n/a
Sometimes	14 (7)	12 (9)	24 (11)	31 (15)	n/a	n/a	n/a	n/a
Always	13 (7)	14 (10)	12 (5)	22 (11)	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	27 (55)	9 (47)	44 (59)	11 (28)	n/a	n/a	n/a	n/a
Sometimes	8 (16)	3 (16)	14 (19)	15 (38)	n/a	n/a	n/a	n/a
Always	14 (29)	7 (37)	16 (22)	14 (35)	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	41 (49)	18 (47)	66 (69)	19 (35)	n/a	n/a	n/a	n/a
Sometimes	14 (17)	6 (16)	15 (16)	18 (33)	n/a	n/a	n/a	n/a
Always	28 (34)	14 (37)	15 (16)	17 (31)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	30 (79)	18 (64)	6 (14)	9 (35)
Sometimes	n/a	n/a	n/a	n/a	5 (13)	4 (14)	26 (62)	12 (46)
Always	n/a	n/a	n/a	n/a	3 (8)	6 (21)	10 (24)	5 (19)
Condom use last sex - casual male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	8 (57)	4 (57)	4 (29)	3 (33)
Sometimes	n/a	n/a	n/a	n/a	2 (14)	2 (29)	6 (43)	1 (11)
Always	n/a	n/a	n/a	n/a	4 (29)	1 (14)	4 (29)	5 (56)
Condom use last sex - regular female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	157 (79)	168 (62)	153 (77)	185 (70)
Sometimes	n/a	n/a	n/a	n/a	26 (13)	47 (17)	33 (17)	49 (18)
Always	n/a	n/a	n/a	n/a	16 (8)	57 (21)	13 (7)	32 (12)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	55 (53)	41 (37)	64 (58)	47 (42)
Sometimes	n/a	n/a	n/a	n/a	28 (27)	25 (22)	27 (24)	40 (35)
Always	n/a	n/a	n/a	n/a	20 (19)	46 (41)	20 (18)	26 (23)
Sex work last month (%)								
No	349 (98)	240 (97)	392 (97)	323 (97)	340 (96)	442 (97)	322 (94)	413 (97)
Yes	6 (2)	2 (<1)	10 (2)	5 (1)	10 (3)	3 (1)	17 (5)	3 (1)
Not reported	2 (<1)	5 (2)	4 (<1)	6 (2)	3 (1)	13 (3)	3 (1)	9 (2)
Condom used at last sex work last month (%)								
No	3 (43)	1 (50)	4 (40)	1 (20)	2 (20)	1 (33)	4 (24)	1 (33)
Yes	4 (57)	1 (50)	5 (50)	2 (40)	5 (50)	2 (67)	6 (35)	1 (33)
Not reported	--	--	1 (10)	2 (40)	3 (30)	--	7 (41)	1 (33)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 27 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 357	N = 247	N = 406	N = 334	N = 353	N = 458	N = 342	N = 425
Previous HIV test (%)								
Last year	168 (47)	46 (19)	182 (45)	80 (24)	160 (45)	125 (27)	149 (44)	120 (28)
>1 year ago	117 (33)	72 (29)	159 (39)	99 (30)	109 (31)	105 (23)	129 (38)	126 (30)
Never tested	71 (20)	126 (51)	61 (15)	155 (46)	82 (23)	225 (49)	60 (18)	172 (40)
Not reported	1 (<1)	3 (1)	4 (1)	--	2 (1)	3 (1)	4 (1)	7 (2)
HBV infection (%)								
No	278 (78)	226 (91)	329 (81)	311 (93)	306 (87)	411 (90)	265 (77)	339 (80)
Yes	51 (14)	5 (2)	47 (12)	6 (2)	25 (7)	8 (2)	43 (13)	8 (2)
Don't know	28 (8)	16 (6)	29 (7)	12 (4)	21 (6)	36 (8)	26 (8)	73 (17)
Not reported	--	--	1 (<1)	5 (1)	1 (<1)	3 (1)	8 (2)	5 (1)
HBV vaccination (%)*								
No	82 (27)	116 (48)	125 (31)	162 (49)	96 (27)	186 (41)	59 (17)	112 (26)
Yes	188 (61)	78 (32)	239 (59)	124 (37)	203 (58)	164 (36)	203 (59)	141 (33)
Don't know	36 (12)	44 (18)	35 (9)	45 (13)	53 (15)	103 (22)	65 (19)	161 (38)
Not reported	--	4 (2)	7 (2)	3 (1)	1 (<1)	5 (1)	15 (4)	11 (3)
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	n/a	n/a	11 (65)	7 (58)	15 (54)	11 (41)
Yes	n/a	n/a	n/a	n/a	6 (35)	4 (33)	9 (32)	10 (37)
Unsure	n/a	n/a	n/a	n/a	--	1 (8)	4 (14)	6 (22)
Not reported	n/a	n/a	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	155 (43)	42 (17)	178 (44)	75 (22)	164 (46)	111 (24)	160 (47)	120 (28)
>1 year ago	138 (39)	48 (20)	180 (44)	83 (25)	123 (35)	104 (23)	132 (39)	115 (27)
Never tested	61 (17)	154 (63)	48 (12)	174 (52)	61 (17)	241 (53)	47 (14)	186 (44)
Unsure	2 (1)	1 (<1)	--	1 (<1)	1 (<1)	--	--	--
Not reported	1 (<1)	2 (<1)	--	1 (<1)	4 (1)	2 (<1)	2 (1)	4 (1)
Any HCV treatment (%)***								
	N = 149	N = 7	N = 197	N = 11	N = 137	N = 4	N = 113	N = 4
Interferon (Int)	--	--	1 (<1)	--	4 (3)	--	2 (2)	--
Int & Ribavirin	1 (<1)	1 (14)	1 (<1)	--	3 (2)	--	7 (6)	--
Int & Ribavirin & Boceprevir	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	2 (2)	--
None	148 (99)	6 (86)	195 (99)	11 (100)	130 (99)	4 (100)	111 (90)	4 (100)
Not reported	--	--	--	--	--	--	--	--
Current HCV treatment								
Interferon (Int)	--	--	--	--	1 (<1)	--	1 (1)	--
Int & Ribavirin	1 (<1)	1 (14)	1 (<1)	--	1 (<1)	--	--	--
Other	--	--	--	--	--	--	1 (1)	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 28 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							111 (98)	4 (100)
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	50 (45)	1 (25)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	31 (28)	1 (25)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	30 (27)	2 (50)
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	13 (12)	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	1 (1)	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	5 (5)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	12 (11)	1 (25)
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	29 (26)	1 (25)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	51 (46)	2 (50)
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	28 (25)	--
No	n/a	n/a	n/a	n/a	n/a	n/a	25 (23)	1 (25)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	23 (21)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	35 (32)	3 (75)
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	46 (41)	2 (50)
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	5 (5)	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	6 (5)	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	4 (4)	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	14 (13)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	36 (32)	2 (50)

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 29 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	240	2 (<1)	23	0 (0)	263	2 (<1)
Non-IDU	172	1 (<1)	12	0 (0)	184	1 (<1)
p value		0.8		--		0.8
2007						
IDU	287	2 (<1)	37	1 (3)	324	3 (<1)
Non-IDU	246	1 (<1)	16	0 (0)	262	1 (<1)
p value		0.7		0.5		0.4
2010						
IDU	246	0 (0)	28	0 (0)	274	0 (0)
Non-IDU	358	0 (0)	29	0 (0)	387	0 (0)
p value		--		--		--
2013						
IDU	173	0 (0)	40	0 (0)	213	0 (0)
Non-IDU	233	0 (0)	32	0 (0)	265	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 30 HIV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Heterosexual	407	1 (<1)	30	0 (0)	437	1 (<1)
Bisexual	2	1 (50)	5	0 (0)	7	1 (14)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
Heterosexual	522	2 (<1)	44	1 (2)	566	3 (<1)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	6	1 (17)	1	0 (0)	7	1 (14)
Unsure	1	0 (0)	1	0 (0)	2	0 (0)
p value		<0.001		1.0		<0.001
2010						
Heterosexual	588	0 (0)	45	0 (0)	633	0 (0)
Bisexual	4	0 (0)	9	0 (0)	13	0 (0)
Homosexual	4	0 (0)	3	0 (0)	7	0 (0)
Unsure	--	--	--	--	--	--
p value		--		--		--
2013						
Heterosexual	398	0 (0)	57	0 (0)	455	0 (0)
Bisexual	2	0 (0)	10	0 (0)	12	0 (0)
Homosexual	1	0 (0)	3	0 (0)	4	0 (0)
Unsure	1	0 (0)	3	0 (0)	4	0 (0)
p value	--	--	--	--	--	--

† Excludes equivocal test results and missing values.

Table 31 HIV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Non-Indigenous	340	1 (<1)	25	0 (0)	365	1 (<1)
Indigenous	68	2 (3)	10	0 (0)	78	2 (3)
p value		0.06		--		0.08
2007						
Non-Indigenous	433	3 (<1)	35	1 (3)	468	4 (<1)
Indigenous	93	0 (0)	17	0 (0)	110	0 (0)
p value		0.4		0.5		0.3
2010						
Non-Indigenous	398	0 (0)	39	0 (0)	437	0 (0)
Indigenous	206	0 (0)	18	0 (0)	224	0 (0)
p value		--		--		--
2013						
Non-Indigenous	286	0 (0)	55	0 (0)	341	0 (0)
Indigenous	132	0 (0)	22	0 (0)	154	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 32 HIV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Highly accessible/accessible	372	3 (1)	30	0 (0)	402	3 (1)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	18	0 (0)	2	0 (0)	20	0 (0)
p value		0.9		--		0.9
2007						
Highly accessible/accessible	470	3 (1)	45	1 (2)	515	4 (1)
Moderately accessible	16	0 (0)	1	0 (0)	17	0 (0)
Remote/very remote	20	0 (0)	1	0 (0)	21	0 (0)
p value		0.9		1.0		0.9
2010						
Highly accessible/accessible	471	0 (0)	46	0 (0)	517	0 (0)
Moderately accessible	27	0 (0)	4	0 (0)	31	0 (0)
Remote/very remote	80	0 (0)	5	0 (0)	85	0 (0)
p value		--		--		--
2013						
Highly accessible/accessible	322	0 (0)	62	0 (0)	384	0 (0)
Moderately accessible	40	0 (0)	4	0 (0)	44	0 (0)
Remote/very remote	30	0 (0)	1	0 (0)	31	0 (0)
p value	392	--	67	--	459	--

† Excludes equivocal test results and missing values.

Table 33 Self-reported HIV status versus HIV serology by sex†

Self-report HIV	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
Positive	1	1 (100)	--	--	1	1 (100)
Negative	240	2 (<1)	23	0 (0)	263	2 (<1)
Not sure	19	0 (0)	4	0 (0)	23	0 (0)
p value		<0.001		--		<0.001
2007						
Positive	6	0 (0)	--	--	6	0 (0)
Negative	334	2 (<1)	36	1 (3)	370	3 (<1)
Not sure	25	0 (0)	5	0 (0)	30	0 (0)
p value		0.9		0.7		0.9
2010						
Positive	--	--	--	--	--	--
Negative	324	0 (0)	36	0 (0)	360	0 (0)
Not sure	30	0 (0)	2	0 (0)	32	0 (0)
p value		--		--		--
2013						
Positive	--	--	--	--	--	--
Negative	235	0 (0)	45	0 (0)	280	0 (0)
Not sure	26	0 (0)	5	0 (0)	31	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 34 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	242	130 (54)	23	19 (83)	265	149 (56)
Non-IDU	174	7 (4)	12	0 (0)	186	7 (4)
p value		<0.001		<0.001		<0.001
2007						
IDU	287	166 (58)	40	31 (78)	327	197 (60)
Non-IDU	247	9 (4)	15	2 (13)	262	11 (4)
p value		<0.001		<0.001		<0.001
2010						
IDU	239	118 (49)	28	19 (68)	267	137 (51)
Non-IDU	356	4 (1)	28	0 (0)	384	4 (1)
p value		<0.001		<0.001		<0.001
2013						
IDU	215	121 (56)	48	32 (67)	263	153 (58)
Non-IDU	239	10 (4)	34	2 (6)	273	12 (4)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 35 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	411	136 (33)	31	16 (52)	442	152 (34)
Bisexual	2	0 (0)	4	3 (75)	6	3 (50)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.7
2007						
Heterosexual	523	172 (33)	45	24 (53)	568	196 (35)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	6	2 (33)	2	2 (100)	8	4 (50)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.8		0.4		0.3
2010						
Heterosexual	579	120 (21)	44	12 (27)	623	132 (21)
Bisexual	4	0 (0)	9	5 (56)	13	5 (38)
Homosexual	4	2 (50)	3	2 (67)	7	4 (57)
Unsure	--	--	--	--	--	--
p value		0.2		0.1		0.03
2013						
Heterosexual	446	130 (29)	68	22 (32)	514	152 (30)
Bisexual	2	0 (0)	9	7 (78)	11	7 (64)
Homosexual	1	0 (0)	2	0 (0)	3	0 (0)
Unsure	1	0 (0)	4	4 (100)	5	4 (80)
p value		0.8		0.006		0.03

† Excludes equivocal test results and missing values.

Table 36 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	36	1 (3)	1	0 (0)	37	1 (3)
20 – 24	91	25 (27)	4	2 (50)	95	27 (28)
25 – 29	89	28 (31)	9	6 (67)	98	34 (35)
30 + years	205	84 (41)	20	9 (45)	225	93 (41)
p value		<0.001		0.5		<0.001
2007						
< 20 years	35	2 (6)	1	0 (0)	36	2 (6)
20 – 24	117	22 (19)	6	4 (67)	123	26 (21)
25 – 29	114	44 (39)	16	11 (69)	130	55 (42)
30 + years	267	107 (40)	32	18 (56)	299	125 (42)
p value		<0.001		0.5		<0.001
2010						
< 20 years	65	1 (2)	4	1 (25)	69	2 (3)
20 – 24	127	19 (15)	7	1 (14)	134	20 (15)
25 – 29	126	24 (19)	11	5 (45)	137	29 (21)
30 + years	277	78 (28)	34	12 (35)	311	90 (29)
p value		<0.001		0.6		<0.001
2013						
< 20 years	33	6 (18)	7	3 (43)	40	9 (23)
20 – 24	82	11 (13)	13	0 (0)	95	11 (12)
25 – 29	93	22 (24)	19	9 (47)	112	31 (28)
30 + years	264	94 (36)	49	23 (47)	313	117 (37)
p value		<0.001		0.02		<0.001

† Excludes equivocal test results and missing values.

Table 37 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	28	1 (4)	1	0 (0)	29	1 (3)
3 to 5 years	25	11 (44)	2	1 (50)	27	12 (44)
6 to 10 years	75	34 (45)	7	6 (86)	82	40 (49)
10 + years	111	84 (76)	12	11 (92)	123	95 (77)
p value		<0.001		0.1		<0.001
2007						
<3 years	19	4 (21)	1	1 (100)	20	5 (25)
3 to 5 years	29	12 (41)	3	2 (67)	32	14 (44)
6 to 10 years	69	28 (41)	17	12 (71)	86	40 (47)
10 + years	161	116 (72)	19	16 (84)	180	132 (73)
p value		<0.001		0.7		<0.001
2010						
<3 years	28	3 (11)	2	0 (0)	30	3 (10)
3 to 5 years	22	6 (27)	4	1 (25)	26	7 (27)
6 to 10 years	47	24 (51)	7	4 (57)	54	28 (52)
10 + years	133	81 (61)	14	13 (93)	147	94 (64)
p value		<0.001		<0.01		<0.001
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	20	4 (20)	4	3 (75)	24	7 (29)
6 to 10 years	34	14 (41)	9	5 (56)	43	19 (44)
10 + years	130	91 (70)	27	20 (74)	157	111 (71)
p value		<0.001		0.6		<0.001

† Excludes equivocal test results and missing values.

Table 38 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	22	1 (5)	129	65 (50)	151	66 (44)
Heroin	1	0 (0)	75	63 (84)	76	63 (83)
More than one	5	0 (0)	23	15 (65)	28	15 (54)
Other/not reported	1	0 (0)	5	5(100)	6	5 (83)
p value		1.0		<0.001		<0.001
2007						
Amphetamine (Speed, Ice)	17	3 (18)	178	83 (47)	195	86 (44)
Heroin	3	2 (67)	90	76 (84)	93	78 (84)
More than one	--	--	11	10 (91)	11	10 (91)
Other/not reported	--	--	19	17 (89)	19	17 (89)
p value		0.07		<0.001		<0.001
2010						
Amphetamine (Speed, Ice)	19	1 (5)	136	67 (49)	155	68 (44)
Heroin	5	1 (20)	52	39 (75)	57	40 (70)
More than one	--	--	8	1 (13)	8	1 (13)
Other/not reported	6	1 (17)	31	22 (71)	37	23 (62)
p value		0.5		<0.001		<0.001
2013						
Amphetamine (Speed, Ice)	25	7 (28)	150	82 (55)	175	89 (51)
Heroin	4	3 (75)	53	43 (81)	57	46 (81)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	2	0 (0)	24	15 (63)	26	26 (100)
p value		0.1		0.007		0.001

† Excludes equivocal test results and missing values.

Table 39 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	11	0 (0)	40	30 (75)	51	30 (59)
Daily or more	9	1 (11)	101	70 (69)	110	71 (65)
p value		0.3		0.2		0.1
2007						
Less than daily	3	1 (33)	77	45 (58)	80	46 (58)
Daily or more	5	2 (40)	110	86 (78)	115	88 (77)
p value		0.9		<0.01		<0.001
2010						
Less than daily	12	1 (8)	56	34 (61)	68	35 (51)
Daily or more	9	2 (22)	68	46 (68)	77	48 (62)
p value		0.4		0.4		0.2
2013						
Less than daily	10	2 (20)	59	33 (56)	69	35 (51)
Daily or more	13	5 (38)	96	72 (75)	109	77 (71)
p value		0.3		0.02		0.007

† Excludes equivocal test results and missing values.

Table 40 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	19	1 (5)	103	76 (74)	122	77 (63)
Yes	2	0 (0)	38	25 (66)	40	25 (63)
p value		0.1		0.7		0.8
2007						
No	8	3 (38)	143	97 (68)	151	100 (66)
Yes	--	--	36	28 (78)	36	28 (78)
p value		--		0.3		0.2
2010						
No	16	1 (6)	95	59 (62)	111	60 (54)
Yes	4	2 (50)	18	12 (67)	22	14 (64)
p value		0.03		0.7		0.4
2013						
No	--	--	--	--	--	--
Yes	5	3 (60)	29	24 (83)	34	27 (79)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 41 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	12	0 (0)	80	51 (64)	92	51 (55)
Yes	17	1 (6)	148	94 (64)	165	95 (58)
p value		0.4		1.0		0.7
2007						
No	5	1 (20)	86	53 (62)	91	54 (59)
Yes	6	3 (50)	156	114 (73)	162	117 (72)
p value		0.3		0.07		0.04
2010						
No	16	1 (6)	96	49 (51)	112	50 (45)
Yes	13	2 (15)	123	75 (61)	136	77 (57)
p value		0.4		0.1		0.06
2013						
No	6	1 (17)	65	39 (50)	71	40 (56)
Yes	12	5 (42)	118	82 (69)	130	87 (67)
p value		0.3		0.2		0.1

† Excludes equivocal test results and missing values.

Table 42 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	104	14 (13)	11	1 (9)	115	15 (13)
2 to 4	211	68 (32)	17	11 (65)	228	79 (35)
5 to 9	68	38 (56)	4	4 (100)	72	42 (58)
10 +	23	16 (70)	3	3 (100)	26	19 (73)
p value		<0.001		0.001		<0.001
2007						
1	170	9 (5)	21	9 (43)	191	18 (9)
2 to 4	210	66 (31)	20	13 (65)	230	79 (34)
5 to 9	82	54 (66)	8	7 (88)	90	61 (68)
10 +	52	39 (75)	4	3 (75)	56	42 (75)
p value		<0.001		0.1		<0.001
2010						
1	301	26 (9)	33	8 (24)	334	34 (10)
2 to 4	169	41 (24)	14	8 (57)	183	49 (27)
5 to 9	78	31 (40)	6	1 (17)	84	32 (38)
10 +	42	23 (55)	3	2 (67)	45	25 (56)
p value		<0.001		0.07		<0.001
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 43 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	345	112 (32)	24	13 (54)	369	125 (34)
Indigenous	68	24 (35)	10	5 (50)	78	29 (37)
p value		0.7		0.8		0.5
2007						
Non-Indigenous	435	136 (31)	36	19 (53)	471	155 (33)
Indigenous	92	34 (37)	18	13 (72)	110	47 (43)
p value		0.3		0.2		0.05
2010						
Non-Indigenous	392	88 (22)	39	13 (33)	431	101 (23)
Indigenous	203	34 (17)	17	6 (35)	220	40 (18)
p value		0.1		0.9		0.1
2013						
Non-Indigenous	322	90 (28)	63	25 (40)	385	115 (30)
Indigenous	145	42 (29)	25	10 (40)	170	52 (31)
p value		0.8		1.0		0.9

† Excludes equivocal test results and missing values.

Table 44 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	156	5 (3)	210	119 (57)	366	124 (34)
Indigenous	28	1 (4)	49	28 (57)	77	29 (38)
p value		0.9		0.9		0.6
2007						
Non-Indigenous	221	9 (4)	250	146 (58)	471	155 (33)
Indigenous	40	2 (5)	70	45 (64)	110	47 (43)
p value		0.8		0.4		0.05
2010						
Non-Indigenous	237	2 (1)	194	99 (51)	431	101 (23)
Indigenous	147	2 (1)	73	38 (52)	220	40 (18)
p value		0.6		0.9		0.1
2013						
Non-Indigenous	203	9 (4)	174	105 (60)	377	114 (30)
Indigenous	70	3 (4)	89	48 (54)	159	51 (32)
p value		1.0		0.3		0.9

† Excludes equivocal test results and missing values.

Table 45 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	375	128 (34)	31	18 (58)	406	146 (36)
Moderately accessible	10	2 (20)	1	0 (0)	11	2 (18)
Remote/very remote	18	2 (11)	2	0 (0)	20	2 (10)
p value		0.09		0.2		0.03
2007						
Highly accessible/accessible	471	161 (34)	47	28 (60)	518	189 (36)
Moderately accessible	16	2 (13)	1	0 (0)	17	2 (12)
Remote/very remote	20	3 (15)	1	0 (0)	21	3 (14)
p value		0.04		0.2		0.01
2010						
Highly accessible/accessible	466	107 (23)	46	18 (39)	512	125 (24)
Moderately accessible	25	6 (24)	4	1 (25)	29	7 (24)
Remote/very remote	78	5 (6)	4	0 (0)	82	5 (6)
p value		0.04		0.3		0.01
2013						
Highly accessible/accessible	366	113 (31)	74	32 (43)	440	145 (33)
Moderately accessible	41	10 (24)	4	0 (0)	45	10 (22)
Remote/very remote	33	5 (15)	1	0 (0)	34	5 (15)
p value		0.1		0.2		0.04

† Excludes equivocal test results and missing values.

Table 46 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	338	118 (35)	33	19 (58)	371	137 (37)
Other Oceania	23	2 (9)	--	--	23	2 (9)
Asia	18	10 (56)	2	0 (0)	20	10 (50)
UK & Ireland	9	2 (22)	--	--	9	2 (22)
Other	27	5 (19)	--	--	27	5 (19)
p value		<0.01		0.1		<0.01
2007						
Australia	450	149 (33)	47	28 (60)	497	177 (36)
Other Oceania	17	3 (18)	2	1 (50)	19	4 (21)
Asia	29	14 (48)	3	1 (33)	32	15 (47)
UK & Ireland	9	3 (33)	1	1 (100)	10	4 (40)
Other	27	5 (19)	2	2 (100)	29	7 (24)
p value		0.2		0.6		0.3
2010						
Australia	512	109 (21)	46	17 (37)	558	126 (23)
Other Oceania	33	8 (24)	2	0 (0)	35	8 (23)
Asia	20	2 (10)	4	0 (0)	24	2 (8)
UK & Ireland	6	0 (0)	1	1 (100)	7	1 (14)
Other	24	3 (13)	3	1 (33)	27	4 (15)
p value		0.4		0.3		0.4
2013						
Australia	383	121 (32)	68	31 (46)	451	152 (34)
Other Oceania	22	3 (14)	5	2 (40)	27	5 (19)
Asia	20	3 (15)	5	0 (0)	25	3 (12)
UK & Ireland	7	2 (29)	2	0 (0)	9	2 (22)
Other	23	2 (9)	5	1 (20)	28	3 (11)
p value		0.04		0.2		0.01

† Excludes equivocal test results and missing values.

Table 47 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	368	120 (33)	31	17 (55)	399	137 (34)
Non-English	47	17 (36)	4	2 (50)	51	19 (37)
p value		0.6		0.9		0.7
2007						
English	464	150 (32)	50	30 (60)	514	180 (35)
Non-English	69	24 (35)	5	3 (60)	74	27 (36)
p value		0.3		1.0		0.4
2010						
English	517	116 (22)	50	18 (36)	567	134 (24)
Non-English	55	6 (11)	4	1 (25)	59	7 (12)
p value		<0.01		0.5		0.04
2013						
English	382	125 (33)	72	33 (46)	454	158 (35)
Non-English	69	6 (9)	10	1 (10)	79	7 (9)
p value		<0.001		0.03		<0.001

† Excludes equivocal test results and missing values.

Table 48 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	88	87 (99)	16	16 (100)	104	103 (99)
Negative	138	25 (18)	7	1 (14)	145	26 (18)
Not sure	22	13 (59)	2	1 (50)	24	14 (58)
p value		<0.001		<0.001		<0.001
2007						
Positive	125	120 (96)	29	28 (97)	154	148 (96)
Negative	211	33 (16)	13	2 (15)	224	35 (16)
Not sure	25	10 (40)	4	2 (50)	29	12 (41)
p value		<0.001		<0.001		<0.001
2010						
Positive	79	78 (99)	19	19 (100)	98	97 (99)
Negative	231	17 (7)	21	0 (0)	252	17 (7)
Not sure	35	11 (31)	1	0 (0)	36	11 (31)
p value		<0.001		<0.001		<0.001
2013						
Positive	93	93 (100)	18	18 (100)	111	111 (100)
Negative	182	12 (7)	27	4 (15)	209	16 (8)
Not sure	31	18 (58)	15	11 (73)	46	29 (63)
p value		<0.001		<0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 49 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	244	12 (5)	24	1 (4)	268	13 (5)
Non-IDU	172	0 (0)	12	0 (0)	184	0 (0)
p value		<0.01		0.5		<0.01
2007						
IDU	288	9 (3)	38	2 (5)	326	11 (3)
Non-IDU	247	3 (1)	14	0 (0)	261	3 (1)
p value		0.1		0.4		0.08
2010						
IDU	232	3 (1)	25	0 (0)	257	3 (1)
Non-IDU	324	8 (2)	28	2 (7)	352	10 (3)
p value		0.3		0.2		0.2
2013						
IDU	139	5 (4)	19	0 (0)	158	7 (3)
Non-IDU	203	7 (3)	18	0 (0)	221	5 (3)
p value		0.9		--		1.0

† Excludes equivocal test results and missing values.

Table 50 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	239	64 (27)	23	7 (30)	264	71 (27)
Non-IDU	172	14 (8)	10	3 (30)	182	17 (9)
p value		<0.001		1.0		<0.001
2007						
IDU	272	83 (31)	39	13 (33)	311	96 (31)
Non-IDU	239	22 (9)	16	2 (13)	255	24 (9)
p value		<0.001		0.1		<0.001
2010						
IDU	214	40 (19)	9	1 (11)	223	41 (18)
Non-IDU	291	57 (20)	13	3 (23)	304	60 (20)
p value		0.8		0.5		0.7
2013						
IDU	166	33 (20)	23	3 (13)	189	36 (19)
Non-IDU	224	39 (17)	19	2 (11)	243	41 (17)
p value		0.5		0.8		0.6

† Excludes equivocal test results and missing values.

Table 51 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	406	78 (19)	29	9 (31)	435	87 (20)
Bisexual	2	0 (0)	4	1 (25)	6	1 (17)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.6		0.8		0.7
2007						
Heterosexual	501	104 (21)	45	12 (27)	546	116 (21)
Bisexual	1	0 (0)	4	0 (0)	5	0 (0)
Homosexual	5	1 (20)	2	1 (50)	7	2 (29)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.2		0.5
2010						
Heterosexual	494	93 (19)	16	4 (25)	510	97 (19)
Bisexual	4	1 (25)	4	0 (0)	8	1 (13)
Homosexual	2	1 (50)	2	0 (0)	4	1 (25)
Unsure	--	--	--	--	--	--
p value		0.5		0.4		0.9
2013						
Heterosexual	384	72 (19)	35	3 (9)	419	75 (18)
Bisexual	1	0 (0)	5	0 (0)	6	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	--	0 (0)	2	2 (100)	2	2 (100)
p value		0.7		0.002		0.01

† Excludes equivocal test results and missing values.

Table 52 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	37	1 (3)	1	0 (0)	38	1 (3)
20 – 24	89	11 (12)	5	2 (40)	94	13 (14)
25 – 29	89	17 (19)	8	2 (25)	97	19 (20)
30 + years	201	49 (24)	19	6 (32)	220	55 (25)
p value		<0.01		0.9		<0.01
2007						
< 20 years	32	2 (6)	1	0 (0)	33	2 (6)
20 – 24	115	11 (10)	6	0 (0)	121	11 (9)
25 – 29	110	24 (22)	15	2 (13)	125	26 (21)
30 + years	253	68 (27)	33	13 (39)	286	81 (28)
p value		<0.001		0.09		<0.001
2010						
< 20 years	54	3 (6)	1	0 (0)	55	3 (6)
20 – 24	107	6 (6)	4	0 (0)	111	6 (5)
25 – 29	106	19 (18)	3	1 (33)	109	20 (18)
30 + years	238	69 (29)	14	3 (21)	252	72 (29)
p value		<0.001		0.6		<0.001
2013						
< 20 years	30	1 (3)	5	0 (0)	35	1 (3)
20 – 24	71	4 (6)	10	0 (0)	81	4 (5)
25 – 29	79	14 (18)	9	2 (22)	88	16 (18)
30 + years	227	56 (25)	24	5 (21)	251	61 (24)
p value		<0.001		0.3		<0.001

† Excludes equivocal test results and missing values.

Table 53 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	29	2 (7)	1	0 (0)	30	2 (7)
3 to 5 years	23	2 (9)	3	1 (33)	26	3 (12)
6 to 10 years	76	18 (24)	7	3 (43)	83	21 (25)
10 + years	108	41 (38)	12	3 (25)	120	44 (37)
p value		<0.01		0.8		<0.01
2007						
<3 years	19	2 (11)	1	0 (0)	20	2 (10)
3 to 5 years	29	5 (17)	3	0 (0)	32	5 (16)
6 to 10 years	66	17 (26)	17	4 (24)	83	21 (25)
10 + years	149	55 (37)	18	9 (50)	167	64 (38)
p value		0.02		0.2		<0.01
2010						
<3 years	25	1 (4)	1	0 (0)	26	1 (4)
3 to 5 years	19	3 (16)	2	1 (50)	21	4 (19)
6 to 10 years	41	5 (12)	3	0 (0)	44	5 (11)
10 + years	123	29 (24)	3	0 (0)	126	29 (23)
p value		0.08		0.3		0.07
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	17	0 (0)	2	0 (0)	19	0 (0)
6 to 10 years	25	2 (8)	6	1 (17)	31	3 (10)
10 + years	99	30 (30)	11	2 (18)	110	32 (29)
p value		0.003		0.8		0.003

† Excludes equivocal test results and missing values.

Table 54 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	23	2 (9)	130	38 (22)	153	40 (26)
Heroin	1	0 (0)	70	22 (31)	71	22 (31)
More than one	5	0 (0)	23	7 (30)	28	7 (25)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.9		0.9		0.8
2007						
Amphetamine (Speed, Ice)	17	2 (12)	165	41 (25)	182	43 (24)
Heroin	3	0 (0)	87	35 (40)	90	35 (39)
More than one	--	--	11	5 (45)	11	5 (45)
Other/not reported	--	--	19	9 (47)	19	9 (47)
p value		0.5		0.02		0.01
2010						
Amphetamine (Speed, Ice)	16	0 (0)	119	22 (18)	135	22 (16)
Heroin	4	0 (0)	39	13 (33)	43	13 (30)
More than one	--	--	6	1 (17)	6	1 (17)
Other/not reported	6	1 (17)	27	2 (7)	33	3 (9)
p value		0.2		0.06		0.09
2013						
Amphetamine (Speed, Ice)	21	1 (5)	105	18 (17)	126	19 (15)
Heroin	3	0 (0)	35	12 (34)	38	12 (32)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	2	0 (0)	19	5 (26)	21	5 (24)
p value		0.9		0.2		0.1

† Excludes equivocal test results and missing values.

Table 55 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	11	1 (19)	41	20 (49)	52	21 (40)
Daily or more	10	0 (0)	99	26 (26)	109	26 (24)
p value		0.3		0.01		0.02
2007						
Less than daily	3	0 (0)	73	24 (33)	76	24 (32)
Daily or more	6	0 (0)	102	39 (38)	108	39 (36)
p value		--		0.5		0.5
2010						
Less than daily	10	0 (0)	52	11 (21)	62	11 (18)
Daily or more	8	0 (0)	54	8 (15)	62	8 (13)
p value		--		0.4		0.5
2013						
Less than daily	10	0 (0)	45	9 (20)	55	9 (16)
Daily or more	10	0 (0)	62	15 (24)	72	15 (21)
p value		--		0.6		0.5

† Excludes equivocal test results and missing values.

Table 56 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	20	1 (5)	101	33 (33)	121	34 (28)
Yes	2	0 (0)	39	13 (33)	41	13 (32)
p value		0.7		0.9		0.8
2007						
No	9	0 (0)	135	47 (35)	144	47 (33)
Yes	--	--	32	13 (41)	32	13 (41)
p value		--		0.5		0.4
2010						
No	15	0 (0)	81	15 (19)	96	15 (16)
Yes	2	0 (0)	15	1 (7)	17	1 (6)
p value		--		0.3		0.3
2013						
No	--	--	--	--	--	--
Yes	5	0 (0)	18	6 (33)	23	6 (26)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 57 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	12	0 (0)	79	29 (37)	91	29 (32)
Yes	18	2 (11)	145	37 (26)	163	39 (24)
p value		0.2		0.2		0.6
2007						
No	5	2 (40)	81	25 (31)	86	27 (31)
Yes	6	0 (0)	148	49 (33)	154	49 (32)
p value		0.9		0.7		0.9
2010						
No	14	0 (0)	84	17 (20)	98	17 (17)
Yes	11	1 (9)	100	19 (19)	111	20 (18)
p value		0.3		0.8		0.9
2013						
No	3	0 (0)	51	11 (22)	54	11 (20)
Yes	12	1 (8)	77	20 (26)	89	21 (24)
p value		0.6		0.6		0.7

† Excludes equivocal test results and missing values.

Table 58 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	103	9 (9)	9	3 (33)	112	12 (11)
2 to 4	211	40 (19)	17	4 (24)	228	44 (19)
5 to 9	67	22 (33)	4	1 (25)	71	23 (32)
10 +	22	6 (27)	3	2 (67)	25	8 (32)
p value		<0.01		0.5		<0.01
2007						
1	163	15 (9)	21	6 (29)	184	21 (11)
2 to 4	204	44 (22)	21	2 (10)	225	46 (20)
5 to 9	76	24 (32)	7	4 (57)	83	28 (34)
10 +	48	16 (33)	4	1 (25)	52	17 (33)
p value		<0.01		0.08		<0.01
2010						
1	250	31 (12)	12	3 (25)	262	34 (13)
2 to 4	145	33 (23)	7	0 (0)	152	33 (22)
5 to 9	67	21 (31)	3	1 (33)	70	22 (31)
10 +	38	12 (32)	--	--	38	12 (32)
p value		<0.001		0.3		<0.01
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 59 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	340	57 (17)	23	7 (30)	363	64 (18)
Indigenous	68	20 (29)	9	2 (22)	77	22 (29)
p value		0.02		0.6		0.03
2007						
Non-Indigenous	416	67 (16)	36	8 (22)	452	75 (17)
Indigenous	88	37 (42)	18	7 (39)	106	44 (42)
p value		<0.001		0.2		<0.001
2010						
Non-Indigenous	342	53 (15)	14	2 (14)	356	55 (15)
Indigenous	163	44 (27)	8	2 (25)	171	46 (27)
p value		<0.01		0.5		<0.01
2013						
Non-Indigenous	277	43 (16)	31	4 (13)	308	47 (15)
Indigenous	125	32 (26)	17	3 (18)	142	35 (25)
p value		0.02		0.7		0.02

† Excludes equivocal test results and missing values.

Table 60 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	154	14 (9)	206	50 (24)	360	64 (18)
Indigenous	26	3 (12)	50	19 (38)	76	22 (29)
p value		0.7		0.05		0.03
2007						
Non-Indigenous	215	12 (6)	237	63 (27)	452	75 (17)
Indigenous	39	12 (31)	67	32 (48)	106	44 (42)
p value		<0.001		0.01		<0.001
2010						
Non-Indigenous	194	25 (13)	162	30 (19)	356	55 (15)
Indigenous	110	35 (32)	61	11 (18)	171	46 (27)
p value		<0.001		0.9		<0.01
2013						
Non-Indigenous	180	22 (12)	121	24 (20)	301	46 (15)
Indigenous	63	19 (30)	68	12 (18)	131	31 (24)
p value		0.001		0.7		0.02

† Excludes equivocal test results and missing values.

Table 61 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	370	66 (18)	28	8 (29)	398	74 (19)
Moderately accessible	10	1 (10)	1	0 (0)	11	1 (9)
Remote/very remote	18	7 (39)	2	0 (0)	20	7 (35)
p value		0.06		0.6		0.1
2007						
Highly accessible/accessible	454	89 (20)	47	13 (28)	501	102 (20)
Moderately accessible	15	1 (7)	1	0 (0)	16	1 (6)
Remote/very remote	17	7 (41)	1	1 (100)	18	8 (44)
p value		0.04		0.2		0.02
2010						
Highly accessible/accessible	411	68 (17)	16	2 (13)	427	70 (16)
Moderately accessible	19	5 (26)	1	0 (0)	20	5 (25)
Remote/very remote	56	20 (36)	3	2 (67)	59	22 (37)
p value		<0.01		0.09		<0.01
2013						
Highly accessible/accessible	310	50 (16)	33	3 (9)	343	53 (15)
Moderately accessible	40	5 (13)	4	1 (25)	44	6 (14)
Remote/very remote	29	13 (45)	1	0 (0)	30	13 (43)
p value		<0.001		0.6		<0.001

† Excludes equivocal test results and missing values.

Table 62 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	337	63 (19)	31	8 (26)	368	71 (19)
Other Oceania	23	6 (26)	--	--	23	6 (26)
Asia	15	6 (40)	2	2 (100)	17	8 (47)
UK & Ireland	9	1 (11)	--	--	9	1 (11)
Other	26	2 (8)	--	--	26	2 (8)
p value		0.1		0.07		0.02
2007						
Australia	431	86 (20)	47	11 (23)	478	97 (20)
Other Oceania	17	5 (29)	2	1 (50)	19	6 (32)
Asia	29	7 (24)	3	1 (33)	32	8 (25)
UK & Ireland	8	3 (38)	1	0 (0)	9	3 (33)
Other	24	4 (17)	2	2 (100)	26	6 (23)
p value		0.6		0.2		0.7
2010						
Australia	431	74 (17)	18	2 (11)	449	76 (17)
Other Oceania	26	7 (27)	--	--	26	7 (27)
Asia	20	8 (40)	3	2 (67)	23	10 (43)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	23	8 (35)	1	0 (0)	24	8 (33)
p value		0.01		0.06		<0.01
2013						
Australia	324	51 (16)	37	5 (14)	361	56 (16)
Other Oceania	19	4 (21)	4	1 (25)	23	5 (22)
Asia	20	10 (50)	1	0 (0)	21	10 (48)
UK & Ireland	6	0 (0)	2	0 (0)	8	0 (0)
Other	21	7 (33)	1	0 (0)	22	7 (32)
p value		0.001		0.9		0.002

† Excludes equivocal test results and missing values.

Table 63 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	367	66 (18)	29	7 (24)	396	73 (18)
Non-English	43	12 (28)	4	3 (75)	47	15 (32)
p value		0.1		0.04		0.03
2007						
English	444	86 (19)	49	12 (24)	493	98 (20)
Non-English	66	18 (27)	6	3 (50)	72	21 (29)
p value		0.1		0.2		0.07
2010						
English	442	76 (17)	18	0 (0)	460	76 (17)
Non-English	53	17 (32)	2	2 (100)	55	19 (35)
p value		<0.01		<0.001		<0.01
2013						
English	319	39 (12)	39	4 (10)	358	43 (12)
Non-English	68	32 (47)	3	1 (33)	71	33 (46)
p value		<0.001		0.2		<0.001

† Excludes equivocal test results and missing values.

Table 64 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	270	117 (43)	60 (22)	13 (5)	80 (30)
Non-IDU	185	134 (72)	17 (9)	0 (0)	34 (18)
p value					<0.001
2007					
IDU	308	111 (36)	90 (29)	10 (3)	97 (31)
Non-IDU	246	166 (67)	21 (9)	3 (1)	56 (23)
p value					<0.001
2010					
IDU	236	80 (34)	38 (16)	3 (1)	115 (49)
Non-IDU	319	145 (45)	52 (16)	10 (3)	112 (35)
p value					<0.01
2013					
IDU	182	65 (36)	32 (18)	5 (3)	80 (44)
Non-IDU	208	105 (51)	37 (18)	7 (3)	58 (28)
p value					0.006

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 65 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	445	245 (55)	76 (17)	13 (3)	111 (25)
Bisexual	7	4 (57)	1 (14)	0 (0)	2 (29)
Homosexual	3	2 (67)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	534	269 (50)	108 (20)	11 (2)	146 (27)
Homosexual	5	2 (40)	--	--	3 (60)
Bisexual	7	3 (43)	1 (14)	1 (14)	2 (29)
Unsure	2	1 (50)	1 (50)	--	146 (27)
p value					0.4
2010					
Heterosexual	534	218 (41)	86 (16)	13 (2)	217 (41)
Homosexual	4	2 (50)	1 (25)	0 (0)	1 (25)
Bisexual	11	2 (18)	1 (9)	0 (0)	8 (73)
Unsure	--	--	--	--	--
p value					0.5
2013					
Heterosexual	376	167 (44)	67 (18)	12 (3)	130 (35)
Homosexual	7	1 (14)	0 (0)	0 (0)	6 (86)
Bisexual	2	1 (50)	0 (0)	0 (0)	1 (50)
Unsure	4	1 (25)	2 (50)	0 (0)	1 (25)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 66 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	38	23 (61)	0 (0)	1 (3)	14 (37)
20 – 24	96	53 (55)	10 (10)	4 (4)	29 (30)
25 – 29	100	57 (57)	16 (16)	3 (3)	24 (24)
30 + years	226	123 (54)	51 (23)	5 (2)	47 (21)
p value					0.02
2007					
< 20 years	34	21 (62)	3 (9)	0 (0)	10 (29)
20 – 24	117	59 (50)	9 (8)	2 (2)	47 (40)
25 – 29	121	54 (45)	24 (20)	3 (2)	40 (33)
30 + years	281	142 (51)	75 (27)	8 (3)	56 (20)
p value					<0.001
2010					
< 20 years	59	23 (39)	3 (5)	0 (0)	33 (56)
20 – 24	110	49 (45)	6 (5)	0 (0)	55 (50)
25 – 29	120	53 (44)	16 (13)	5 (4)	46 (38)
30 + years	266	100 (38)	65 (24)	8 (3)	93 (35)
p value					<0.001
2013					
< 20 years	31	17 (55)	1 (3)	1 (3)	12 (39)
20 – 24	73	32 (44)	3 (4)	2 (3)	36 (49)
25 – 29	83	36 (43)	14 (17)	3 (4)	30 (36)
30 + years	224	95 (42)	56 (25)	7 (3)	66 (29)
p value					0.003

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 67 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	115	85 (74)	10 (9)	2 (2)	18 (16)
2 to 4	232	124 (53)	39 (17)	8 (3)	61 (26)
5 to 9	74	25 (34)	21 (28)	1 (1)	27 (36)
10 +	25	11 (44)	6 (24)	2 (8)	6 (24)
p value					<0.001
2007					
1	182	130 (71)	19 (10)	3 (2)	30 (16)
2 to 4	215	109 (51)	42 (20)	5 (2)	59 (27)
5 to 9	83	16 (19)	27 (33)	3 (4)	37 (45)
10 +	52	13 (25)	15 (29)	2 (4)	22 (42)
p value					<0.001
2010					
1	277	143 (52)	28 (10)	6 (2)	100 (36)
2 to 4	154	51 (33)	31 (20)	3 (2)	69 (45)
5 to 9	75	22 (29)	20 (27)	2 (3)	31 (41)
10 +	44	6 (14)	11 (25)	2 (5)	25 (57)
p value					<0.001
2013**					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Lifetime imprisonment questions not asked in 2013.

Table 68 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	372	223 (60)	57 (15)	9 (2)	83 (22)
Indigenous	78	26 (33)	18 (23)	4 (5)	30 (38)
p value					<0.001
2007					
Non-Indigenous	442	242 (55)	70 (16)	8 (2)	122 (28)
Indigenous	104	32 (31)	40 (38)	5 (5)	27 (26)
p value					<0.001
2010					
Non-Indigenous	370	174 (47)	48 (13)	7 (2)	141 (38)
Indigenous	185	51 (28)	42 (23)	6 (3)	86 (46)
p value					<0.001
2013					
Non-Indigenous	269	131 (49)	42 (16)	7 (3)	89 (33)
Indigenous	139	48 (35)	32 (23)	5 (3)	54 (39)
p value					0.04

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 69 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	409	231 (56)	64 (16)	12 (3)	102 (25)
Moderately accessible	11	6 (55)	1 (9)	0 (0)	4 (36)
Remote/very remote	20	7 (35)	7 (35)	0 (0)	6 (30)
p value					0.2
2007					
Highly accessible/accessible	494	248 (50)	92 (19)	13 (3)	141 (29)
Moderately accessible	14	13 (93)	1 (7)	0 (0)	0 (0)
Remote/very remote	15	3 (20)	9 (60)	0 (0)	3 (20)
p value					<0.001
2010					
Highly accessible/accessible	447	191 (43)	64 (14)	6 (1)	186 (42)
Moderately accessible	25	9 (36)	4 (16)	2 (8)	10 (40)
Remote/very remote	64	17 (27)	18 (28)	5 (8)	24 (38)
p value					<0.001
2013					
Highly accessible/accessible	311	146 (47)	47 (15)	9 (3)	109 (35)
Moderately accessible	38	18 (47)	6 (16)	0 (0)	14 (37)
Remote/very remote	27	5 (19)	12 (44)	1 (4)	9 (33)
p value					0.006

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 70 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	403	222 (55)	65 (16)	9 (2)	107 (27)
Non-English	51	28 (55)	12 (24)	4 (8)	7 (14)
p value					0.02
2007					
English	482	248 (51)	94 (20)	8 (2)	132 (27)
Non-English	71	29 (41)	16 (23)	5 (7)	21 (30)
p value					0.02
2010					
English	485	205 (42)	72 (15)	6 (1)	202 (42)
Non-English	57	18 (32)	13 (23)	6 (11)	20 (35)
p value					<0.001
2013					
English	324	153 (47)	39 (12)	8 (2)	124 (38)
Non-English	64	18 (28)	39 (45)	4 (6)	13 (20)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 71 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	128	14 (11)	8	3 (38)	136	17 (13)
Yes	163	81 (50)	12	5 (42)	175	86 (49)
Not sure	46	9 (20)	6	2 (33)	52	11 (21)
p value		<0.001		0.9		<0.001
2007						
No	144	17 (12)	21	4 (19)	165	21 (13)
Yes	196	111 (57)	18	11 (61)	214	122 (57)
Not sure	47	9 (19)	1	0 (0)	48	9 (19)
p value		<0.001		0.02		<0.001
2010						
No	135	34 (25)	7	1 (14)	142	35 (25)
Yes	207	149 (72)	21	15 (71)	228	164 (72)
Not sure	78	27 (35)	1	0 (0)	79	27 (34)
p value		<0.001		0.4		<0.001
2013						
No	53	14 (26)	13	6 (46)	66	20 (30)
Yes	126	70 (56)	23	17 (74)	149	87 (58)
Not sure	83	27 (33)	8	3 (38)	91	30 (33)
p value		<0.001		0.1		<0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 72 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	559	27 (5)
Female	59	1 (2)
p value		0.3
2013		
Male	410	20 (5)
Female	83	3 (4)
p value		0.6

† Excludes missing values.

Gonorrhoea

Table 73 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	548	5 (1)
Female	59	0 (0)
p value		0.5
2013		
Male	408	1 (<1)
Female	83	0 (0)
p value		0.7

† Excludes missing values.

Syphilis

Table 74 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	573	37 (6)	14 (2)	37 (6)
Female	50	3 (6)	1 (2)	3 (6)
p value		0.9	0.9	0.9
2013				
Male	429	6 (1)	4 (1)	2 (<1)
Female	83	1 (1)	1 (1)	1 (1)
p value		0.9	0.9	0.9

† Excludes missing values.

**New South Wales
2004, 2007, 2010, 2013**

Table 75 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 2		N = 3		N = 7		N = 6	
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154	N = 30	N = 34
Sex (%)								
Male	152 (83)	118 (93)	101 (77)	103 (91)	92 (92)	149 (97)	20 (67)	29 (85)
Female	30 (16)	9 (7)	31 (23)	10 (9)	8 (8)	5 (3)	10 (33)	5 (15)
Transgender	1 (<1)	--	--	--	--	--	--	--
Sexual Identity (%)								
Heterosexual	171 (93)	123 (97)	120 (91)	110 (97)	99 (99)	152 (99)	27 (90)	32 (94)
Bisexual	7 (4)	1 (<1)	4 (3)	--	--	1 (<1)	2 (7)	--
Homosexual	5 (3)	2 (2)	5 (4)	--	1 (1)	--	1 (3)	1 (3)
Unsure	--	--	--	--	--	--	--	--
Not reported	--	1 (<1)	3 (2)	3 (3)	--	1 (<1)	--	1 (3)
Age and duration of injection (years)								
Median (Med) age	30	32	31	31	34	27	32	28
Age range	18 – 58	18 – 75	19 – 53	18 – 71	18 – 79	17 – 72	19 – 44	18 – 72
Age group (%)								
<25 years	47 (26)	39 (31)	22 (17)	37 (33)	9 (9)	55 (36)	5 (17)	14 (41)
25+ years	136 (74)	88 (69)	109 (83)	76 (67)	91 (91)	99 (64)	25 (83)	19 (56)
Not reported	--	--	1 (<1)	0 (0)	--	--	--	1 (3)
Med age 1st IDU	18	--	18	--	19	--	18	--
Age range	9 – 41	--	8 – 35	--	7 – 40	--	11 – 34	--
Not reported	4	--	3	--	4	--	1	--
Med IDU (years)	10	--	13	--	14	--	11	--
Range	<1 – 31	--	<1 – 36	--	<1 – 38	--	1 – 34	--
Duration of drug injection (%)								
<3 years	16 (9)	--	6 (5)	--	9 (9)	--	2 (7)	--
3+ years	163 (89)	--	122 (92)	--	87 (87)	--	27 (90)	--
Not reported	4 (2)	--	4 (3)	--	4 (4)	--	1 (3)	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	155 (85)	118 (93)	93 (70)	97 (86)	80 (80)	126 (81)	21 (70)	21 (62)
Yes	28 (15)	9 (7)	33 (25)	15 (13)	20 (20)	29 (19)	9 (30)	13 (38)
Not reported	--	--	6 (5)	1 (<1)	--	--	--	--
Residential remoteness in 12 months before prison (%)								
Highly/accessible	174 (95)	117 (92)	121 (92)	104 (92)	139 (90)	92 (92)	20 (67)	28 (82)
Mod accessible	3 (2)	2 (2)	1 (1)	1 (1)	5 (3)	6 (6)	5 (17)	3 (9)
Very/remote	3 (2)	--	--	--	4 (3)	1 (1)	1 (3)	2 (6)
Not reported	3 (2)	8 (6)	10 (8)	8 (7)	6 (4)	1 (1)	4 (13)	1 (3)
Region/Country of birth (%)								
Australia	156 (85)	87 (69)	118 (89)	73 (65)	85 (85)	110 (71)	29 (97)	29 (85)
Other Oceania	3 (2)	8 (6)	2 (2)	9 (8)	8 (8)	13 (8)	--	2 (6)
Asia	11 (6)	11 (9)	7 (5)	13 (12)	4 (4)	16 (10)	--	3 (9)
UK & Ireland	3 (2)	5 (4)	1 (<1)	2 (2)	1 (1)	1 (1)	1 (3)	--
Other	10 (5)	16 (13)	3 (2)	13 (12)	2 (2)	14 (9)	--	--
Not reported	--	--	1 (<1)	3 (3)	--	--	--	--
Main language spoke at home by parents (%)								
English	159 (87)	99 (78)	115 (87)	74 (65)	91 (91)	122 (79)	30 (100)	29 (85)
Non-English	24 (13)	28 (22)	17 (13)	39 (35)	9 (9)	31 (20)	--	5 (15)
Not reported	--	--	--	--	--	1 (1)	--	--

Table 76 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)								
No	157 (86)	59 (46)	112 (85)	63 (56)	84 (84)	86 (56)	22 (73)	21 (62)
Yes	26 (14)	68 (54)	19 (14)	50 (44)	14 (14)	64 (42)	8 (27)	13 (38)
Not reported	--	--	1 (<1)	--	2 (2)	4 (3)	--	--
Lifetime imprisonments (%)*								
One	26 (14)	68 (54)	19 (14)	50 (44)	30 (30)	96 (62)	n/a	n/a
Two to four	84 (46)	44 (35)	50 (38)	49 (43)	30 (30)	39 (25)	n/a	n/a
Five to nine	50 (27)	9 (7)	32 (24)	7 (6)	22 (22)	13 (8)	n/a	n/a
Ten or more	20 (11)	2 (2)	27 (20)	3 (3)	16 (16)	2 (1)	n/a	n/a
Not reported	3 (2)	4 (3)	4 (3)	4 (4)	2 (2)	4 (3)	n/a	n/a
Imprisonment in last year (%)								
No	84 (46)	97 (76)	35 (31)	14 (22)	50 (50)	94 (61)	6 (27)	7 (33)
Yes	99 (54)	27 (21)	76 (67)	48 (76)	48 (48)	56 (36)	16 (73)	13 (62)
Not reported	--	3 (2)	2 (2)	1 (2)	2 (2)	4 (3)	--	1 (5)
Frequency of injection last month (%)								
Not last month	55 (30)	--	44 (33)	--	46 (46)	--	10 (33)	--
< weekly	29 (16)	--	22 (17)	--	18 (18)	--	4 (13)	--
Weekly	14 (8)	--	14 (11)	--	7 (7)	--	7 (23)	--
Daily or more	83 (45)	--	49 (37)	--	28 (28)	--	9 (30)	--
Not reported	2 (1)	--	3 (2)	--	1 (1)	--	--	--
Ever smoked a full cigarette (%)**								
No	n/a	n/a	4 (3)	10 (9)	3 (3)	15 (10)	--	1 (3)
Yes	n/a	n/a	128 (97)	103 (91)	97 (97)	139 (90)	30 (100)	32 (94)
Not reported	n/a	n/a	--	--	--	--	--	1 (3)
Med age 1st smoked								
Age range	n/a	n/a	6 – 30	4 – 31	7 – 28	6 – 34	8 – 16	8 – 21
Current smoker (%)**								
No	n/a	n/a	8 (6)	27 (24)	6 (6)	37 (24)	1 (3)	4 (13)
Yes	n/a	n/a	124 (94)	86 (76)	94 (94)	117 (76)	29 (97)	28 (88)
Not reported	n/a	n/a	--	--	--	--	--	--
Smoking frequency (%)**								
Weekly or less	n/a	n/a	4 (3)	10 (12)	2 (2)	--	2 (7)	1 (3)
5 - 10/day	n/a	n/a	26 (21)	16 (19)	26 (28)	45 (38)	9 (31)	10 (34)
11 - 20/day	n/a	n/a	61 (49)	31 (36)	48 (51)	45 (38)	10 (34)	13 (45)
>20/day	n/a	n/a	32 (26)	29 (34)	18 (19)	27 (23)	8 (28)	4 (14)
Not reported	n/a	n/a	1 (<1)	--	--	--	--	1 (3)
Other drugs used last month (%)***								
None	n/a	n/a	n/a	n/a	24 (24)	90 (58)	--	15 (44)
Cannabis	n/a	n/a	n/a	n/a	52 (68)	46 (72)	25 (86)	12 (67)
Heroin	n/a	n/a	n/a	n/a	25 (33)	6 (9)	6 (21)	--
Cocaine	n/a	n/a	n/a	n/a	9 (12)	8 (13)	4 (14)	1 (6)
Amphetamine	n/a	n/a	n/a	n/a	42 (55)	25 (39)	20 (69)	12 (67)
Methadone	n/a	n/a	n/a	n/a	12 (16)	--	2 (7)	--
Other opiates	n/a	n/a	n/a	n/a	9 (12)	--	3 (10)	1 (6)
Buprenorphine	n/a	n/a	n/a	n/a	5 (7)	1 (2)	3 (10)	2 (11)
Steroids	n/a	n/a	n/a	n/a	3 (4)	1 (2)	--	--
Hallucinogens	n/a	n/a	n/a	n/a	1 (1)	1 (2)	2 (7)	--
Benzodiazepine	n/a	n/a	n/a	n/a	15 (20)	6 (9)	10 (34)	1 (6)
Ecstasy/MDA	n/a	n/a	n/a	n/a	--	8 (13)	2 (7)	1 (6)
Inhalants	n/a	n/a	n/a	n/a	--	1 (2)	--	1 (6)
Other drug	n/a	n/a	n/a	n/a	--	--	2 (7)	2 (11)
Not reported	n/a	n/a	n/a	n/a	--	--	1 (3)	1 (3)

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 77 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)	N = 183	N = 132	N = 100	N = 30
Amphetamine (Speed, Ice)	73 (40)	64 (48)	49 (49)	21 (70)
Anabolic steroids	1 (1)	--	1 (1)	--
Cocaine	7 (4)	5 (4)	2 (2)	1 (3)
Heroin	86 (47)	53 (40)	37 (37)	5 (17)
Heroin + amphetamine	--	3 (2)	--	--
Heroin + cocaine	2 (1)	1 (1)	2 (2)	--
Methadone	6 (3)	4 (3)	4 (4)	2 (7)
Morphine	1 (1)	2 (2)	2 (2)	--
Other	7 (4)	--	2 (2)	1 (3)
Not reported	--	--	1 (1)	--
N° Injected last month	N = 128	N = 88	N = 53	N = 20
Places injected last month (%)*				
Prison	3 (2)	3 (3)	--	1 (5)
Own home	99 (77)	65 (76)	34 (64)	15 (75)
Friend's home	54 (42)	46 (54)	15 (28)	10 (50)
Dealer's home	21 (16)	23 (27)	8 (15)	4 (20)
Street, park, beach	40 (31)	38 (45)	6 (11)	3 (15)
Car	37 (29)	36 (42)	9 (17)	4 (20)
Public toilet	29 (23)	25 (29)	7 (13)	7 (35)
Commercial injecting room	6 (5)	7 (8)	--	--
Medically Supervised Injecting Centre, Sydney	5 (4)	10 (12)	2 (4)	1 (5)
Squat	10 (8)	8 (9)	--	--
Other place	5 (4)	--	--	--
Use of sterile needles & syringes last month (%)				
All injections	86 (67)	49 (58)	36 (68)	13 (65)
Most of the time	20 (16)	16 (19)	10 (19)	3 (15)
Half of the time	8 (6)	7 (8)	--	2 (10)
Some of the time	12 (9)	10 (12)	1 (2)	2 (10)
Not last month	2 (2)	--	1 (2)	--
Not reported	--	3 (4)	5 (9)	--
Re-used someone else's used needle & syringe last month (%)				
None	116 (91)	68 (80)	38 (72)	17 (85)
Once	4 (3)	7 (8)	2 (4)	1 (5)
Twice	3 (2)	2 (2)	3 (6)	1 (5)
3-5 times	4 (3)	3 (4)	4 (8)	--
>5 times	1 (<1)	4 (5)	2 (4)	--
Not reported	--	1 (1)	4 (8)	1 (5)
Number of people needle & syringe was re-used after last month (%)				
One	8 (6)	12 (14)	9 (17)	1 (33)
Two	2 (2)	--	1 (2)	--
Three to five	1 (<1)	--	--	--
More than five	--	--	--	1 (33)
Don't know how many	--	--	1 (2)	--
Not reported	--	8 (9)	5 (9)	1 (33)
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	4 (3)	7 (8)	6 (11)	1 (50)
Casual sex partner	1 (<1)	--	1 (2)	--
Close friend	3 (2)	2 (2)	1 (2)	--
Acquaintance	3 (2)	2 (2)	1 (2)	--
Other	1 (<1)	1 (1)	1 (2)	1 (50)
Equipment used after someone else last month (%)*				
Spoon	28 (22)	26 (31)	11 (21)	3 (15)
Water	19 (15)	23 (27)	9 (17)	1 (5)
Filter	17 (13)	20 (24)	8 (15)	--
Tourniquet	10 (8)	11 (13)	10 (19)	--
Drug mix	18 (14)	17 (20)	8 (15)	--

* More than one option could be selected.

Table 78 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154	N = 30	N = 34
Any treatment/therapy for drug use (%)								
No	89 (49)	118 (93)	24 (18)	76 (67)	29 (29)	128 (83)	4 (13)	21 (62)
Yes	93 (51)	9 (7)	100 (76)	15 (13)	70 (70)	26 (17)	25 (83)	9 (26)
Not reported	1 (<1)	--	8 (6)	22 (19)	1 (1)	--	1 (3)	4 (12)
History of methadone maintenance treatment (%)								
Currently	44 (24)	--	25 (19)	--	25 (25)	1 (1)	5 (17)	--
Previously	50 (27)	2 (2)	39 (30)	--	17 (17)	3 (2)	6 (20)	1 (3)
Never	88 (48)	125 (98)	57 (43)	--	55 (55)	150 (97)	19 (63)	30 (88)
Not reported	1 (<1)	--	11 (8)	--	3 (3)	--	--	3 (9)
History of other pharmacotherapy treatment (%)								
Currently	9 (5)	--	4 (3)	--	18 (18)	2 (1)	--	--
Previously	31 (17)	1 (<1)	35 (27)	--	13 (13)	3 (2)	6 (20)	--
Never	139 (77)	126 (98)	89 (67)	--	69 (69)	149 (97)	23 (77)	30 (88)
Not reported	1 (<1)	--	4 (3)	--	--	--	1 (3)	4 (12)

Table 79 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013
N° surveyed	N = 129	N = 85	N = 53	N = 30
From an NSP last month (%)				
Daily or almost daily	17 (6)	11 (13)	8 (15)	2 (7)
A couple of times each week	21 (7)	18 (21)	11 (21)	4 (13)
Less than weekly	14 (5)	13 (15)	11 (21)	7 (23)
Weekly	n/a	n/a	--	--
Once last month	24 (8)	15 (18)	13 (25)	3 (10)
Not in the last month	28 (9)	12 (14)	10 (19)	11 (37)
Not reported	25 (8)	16 (19)	--	3 (10)
From a chemist last month (%)				
Daily or almost daily	5 (2)	5 (6)	3 (6)	--
A couple of times each week	17 (6)	8 (9)	5 (9)	1 (3)
Less than weekly	30 (10)	9 (11)	7 (13)	5 (17)
Weekly	n/a	n/a	8 (15)	--
Once last month	19 (6)	11 (13)	--	2 (7)
Not in the last month	54 (17)	37 (44)	30 (57)	18 (60)
Not reported	4 (3)	15 (18)	--	4 (13)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 80 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU N = 183	Non-IDU N = 127	IDU N = 132	Non-IDU N = 113	IDU N = 100	Non-IDU N = 154	IDU N = 30	Non-IDU N = 34
N ^o surveyed								
Body or ear piercings (%)								
No	74 (82)	30 (71)	73 (82)	43 (82)	41 (100)	47 (78)	8 (27)	19 (56)
Yes	11 (12)	5 (12)	13 (15)	6 (12)	--	12 (20)	22 (73)	14 (41)
Not reported	5 (6)	7 (17)	2 (3)	3 (6)	--	1 (2)	--	1 (3)
Pierced in past 12 months (%)								
No	74 (82)	30 (71)	73 (82)	43 (82)	41 (100)	47 (78)	13 (59)	10 (71)
Yes	11 (12)	5 (12)	13 (15)	6 (12)	--	12 (20)	3 (14)	1 (7)
Not reported	5 (6)	7 (17)	2 (3)	3 (6)	--	1 (2)	6 (27)	3 (21)
Who did piercing (%)*								
Chemist/salon	2 (18)	3 (60)	1 (8)	1 (17)	--	1 (8)	--	--
Professional piercer	7 (64)	1 (20)	4 (31)	1 (17)	--	6 (50)	2 (67)	1 (100)
Tattooist/parlour	--	--	4 (31)	1 (17)	--	1 (8)	--	--
Friend	--	--	--	1 (17)	--	2 (17)	1 (33)	--
Prison inmate	--	--	1 (8)	--	--	--	--	--
Self	1 (9)	--	--	2 (33)	--	--	1 (33)	--
Family member	--	--	2 (15)	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	2 (18)	--	--	--	--	10 (83)	2 (67)	--
Yes	--	--	--	2 (33)	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	9 (82)	5 (100)	13 (100)	4 (67)	--	2 (17)	1 (33)	1 (100)
Tattoos (%)								
No	48 (26)	67 (53)	25 (19)	44 (39)	20 (20)	64 (42)	7 (23)	12 (35)
Yes	135 (74)	59 (46)	107 (81)	69 (61)	80 (80)	90 (58)	23 (77)	21 (62)
Not reported	--	1 (1)	--	--	--	--	--	1 (3)
Tattoos in past 12 months (%)								
No	114 (84)	48 (80)	81 (76)	44 (64)	64 (80)	55 (61)	16 (70)	11 (52)
Yes	21 (16)	10 (17)	26 (24)	24 (35)	16 (20)	35 (39)	7 (30)	10 (48)
Not reported	--	1 (3)	--	1 (1)	--	--	--	--
Who did tattooing (%)*								
Prof tattooist	12 (57)	4 (40)	14 (54)	18 (75)	9 (56)	23 (80)	3 (43)	7 (70)
Friend	5 (24)	1 (10)	7 (27)	4 (17)	6 (38)	6 (17)	2 (29)	3 (30)
Prison inmate	5 (24)	2 (20)	6 (23)	--	41 (6)	--	--	--
Self	3 (14)	1 (10)	1 (4)	2 (8)	--	1 (3)	2 (29)	--
Family member	1 (5)	--	--	1 (4)	--	--	--	--
Other	--	--	--	--	--	--	1 (14)	--

* More than one option could be selected.

Table 81 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154	N = 30	N = 34
Sex last month / last 3 months (%)**								
No	47 (26)	38 (30)	39 (30)	28 (25)	17 (17)	28 (18)	3 (10)	7 (21)
Yes	136 (74)	86 (68)	93 (70)	84 (74)	83 (83)	123 (80)	27 (90)	26 (76)
Not reported	--	--	--	1 (<1)	--	--	--	1 (3)
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 23)	1 (0 – 20)	0 (0 – 2)	0 (0 – 2)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 1)	1 (0 – 10)	1 (0 – 5)	1 (0–10)
Condom use at last sex (%)								
No	136 (74)	85 (67)	114 (86)	90 (80)	n/a	n/a	n/a	n/a
Yes	47 (26)	39 (31)	15 (11)	22 (19)	n/a	n/a	n/a	n/a
Not reported	--	--	3 (2)	1 (<1)	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	83 (84)	57 (81)	69 (88)	57 (77)	n/a	n/a	n/a	n/a
Sometimes	8 (8)	7 (10)	8 (10)	9 (12)	n/a	n/a	n/a	n/a
Always	8 (8)	6 (9)	1 (<1)	8 (11)	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	6 (27)	2 (22)	17 (63)	5 (36)	n/a	n/a	n/a	n/a
Sometimes	6 (27)	1 (11)	5 (19)	5 (36)	n/a	n/a	n/a	n/a
Always	10 (45)	6 (67)	5 (19)	4 (29)	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	17 (40)	8 (40)	17 (74)	6 (43)	n/a	n/a	n/a	n/a
Sometimes	9 (21)	4 (20)	4 (17)	5 (36)	n/a	n/a	n/a	n/a
Always	17 (40)	8 (40)	2 (9)	3 (21)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	6 (86)	3 (60)	2 (67)	2 (67)
Sometimes	n/a	n/a	n/a	n/a	1 (14)	1 (20)	--	--
Always	n/a	n/a	n/a	n/a	--	1 (20)	1 (33)	1 (33)
Condom use last sex - casual male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	6 (86)	3 (60)	2 (40)	--
Sometimes	n/a	n/a	n/a	n/a	1 (14)	1 (20)	1 (20)	--
Always	n/a	n/a	n/a	n/a	--	1 (20)	2 (40)	1 (100)
Condom use last sex - regular female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	47 (78)	57 (62)	10 (67)	9 (53)
Sometimes	n/a	n/a	n/a	n/a	7 (12)	12 (13)	2 (13)	3 (18)
Always	n/a	n/a	n/a	n/a	6 (10)	23 (25)	3 (20)	5 (29)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	7 (28)	15 (36)	7 (58)	3 (27)
Sometimes	n/a	n/a	n/a	n/a	11 (44)	10 (24)	--	4 (36)
Always	n/a	n/a	n/a	n/a	7 (28)	17 (40)	5 (42)	4 (36)
Sex work last month (%)								
No	178 (97)	122 (96)	126 (95)	103 (91)	97 (97)	151 (98)	29 (97)	28 (82)
Yes	5 (3)	--	3 (2)	5 (4)	2 (2)	--	1 (3)	--
Not reported	--	5 (4)	3 (2)	5 (4)	1 (1)	3 (2)	--	6 (18)
Condom used at last sex work last month (%)								
No	2 (50)	--	--	1 (20)	--	--	--	--
Yes	3 (60)	--	2 (67)	2 (40)	--	--	1 (100)	--
Not reported	--	--	1 (33)	2 (40)	2 (100)	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 82 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 183	N = 127	N = 132	N = 113	N = 100	N = 154	N = 30	N = 34
Previous HIV test (%)								
Last year	96 (52)	23 (18)	52 (39)	25 (22)	41 (41)	31 (20)	14 (47)	3 (9)
>1 year ago	59 (32)	31 (25)	62 (47)	34 (30)	40 (40)	35 (23)	13 (43)	15 (44)
Never tested	27 (15)	72 (57)	17 (13)	54 (48)	19 (19)	88 (57)	3 (10)	14 (41)
Not reported	1 (<1)	--	1 (<1)	--	--	--	--	2 (6)
HBV infection (%)								
No	131 (72)	115 (91)	97 (73)	106 (94)	82 (82)	140 (91)	24 (80)	32 (94)
Yes	34 (19)	3 (2)	26 (20)	4 (4)	11 (11)	1 (1)	6 (20)	--
Don't know	18 (10)	9 (7)	8 (6)	3 (3)	7 (7)	13 (8)	--	1 (3)
Not reported	--	--	1 (<1)	--	--	--	--	1 (3)
HBV vaccination (%)*								
No	65 (36)	58 (46)	43 (33)	60 (53)	27 (27)	50 (32)	4 (13)	8 (24)
Yes	87 (48)	33 (26)	70 (53)	36 (32)	52 (52)	50 (32)	21 (70)	12 (35)
Don't know	30 (16)	33 (26)	13 (10)	15 (13)	21 (21)	51 (33)	4 (13)	13 (38)
Not reported	--	3 (2)	6 (5)	2 (2)	--	3 (2)	1 (3)	1 (3)
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	n/a	n/a	--	--	3 (60)	1 (33)
Yes	n/a	n/a	n/a	n/a	--	--	2 (40)	2 (67)
Unsure	n/a	n/a	n/a	n/a	--	--	--	--
Not reported	n/a	n/a	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	23 (13)	84 (67)	43 (33)	22 (19)	14 (14)	100 (65)	15 (50)	3 (9)
>1 year ago	85 (46)	23 (18)	77 (58)	30 (27)	41 (41)	24 (16)	13 (43)	13 (38)
Never tested	72 (39)	17 (13)	12 (9)	59 (52)	44 (44)	30 (19)	2 (7)	16 (47)
Unsure	--	--	--	1 (<1)	--	--	--	--
Not reported	2 (1)	1 (<1)	--	1 (<1)	1 (1)	--	--	2 (6)
Any HCV treatment (%)***								
	N = 85	N = 2	N = 80	N = 3	N = 46	N = 2	N = 12	N = 0
Interferon (Int)	--	--	--	--	3 (7)	--	--	--
Int & Ribavirin	1 (1)	--	--	--	2 (4)	--	2 (17)	--
Int & Ribavirin & Boceprevir	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
None	84 (99)	2 (100)	80 (100)	3 (100)	46 (100)	2 (100)	10 (83)	--
Not reported	--	--	--	--	--	--	--	--
Current HCV treatment								
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 83 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							N = 12	N = 0
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	7 (58)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	2 (17)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	3 (25)	--
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	1 (8)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	4 (33)	--
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	1 (8)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	6 (50)	--
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	4 (33)	--
No	n/a	n/a	n/a	n/a	n/a	n/a	2 (17)	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	3 (25)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	3 (25)	--
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	2 (17)	--
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	4 (33)	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (8)	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	5 (42)	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 84 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	104	2 (2)	16	0 (0)	120	2 (2)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.2		--		0.2
2007						
IDU	84	1 (1)	27	1 (4)	111	2 (2)
Non-IDU	75	1 (1)	10	0 (0)	85	1 (1)
p value		0.9		0.5		0.7
2010						
IDU	72	0 (0)	3	0 (0)	75	0 (0)
Non-IDU	123	0 (0)	4	0 (0)	127	0 (0)
p value		--		--		--
2013						
IDU	18	0 (0)	9	0 (0)	27	0 (0)
Non-IDU	23	0 (0)	4	0 (0)	27	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 85 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	108	72 (67)	16	13 (81)	124	85 (69)
Non-IDU	75	2 (3)	5	0 (0)	80	2 (3)
p value		<0.001		<0.01		<0.001
2007						
IDU	84	57 (68)	28	23 (82)	112	80 (71)
Non-IDU	76	2 (3)	9	1 (11)	85	3 (3)
p value		<0.001		<0.001		<0.001
2010						
IDU	71	44 (62)	3	2 (67)	74	46 (62)
Non-IDU	124	2 (2)	4	0 (0)	128	2 (2)
p value		<0.001		0.05		<0.001
2013						
IDU	19	12 (63)	5	2 (40)	24	14 (58)
Non-IDU	25	0 (0)	4	0 (0)	29	0 (0)
p value		<0.001		0.2		<0.001

† Excludes equivocal test results and missing values.

Table 86 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	180	73 (41)	18	11 (61)	198	84 (42)
Bisexual	--	--	3	2 (67)	3	2 (67)
Homosexual	3	1 (33)	--	--	3	1 (33)
Unsure	--	--	--	--	--	--
p value		0.8		0.9		0.7
2007						
Heterosexual	155	59 (38)	29	16 (55)	184	75 (41)
Bisexual	1	0 (0)	3	3 (100)	4	3 (75)
Homosexual	2	0 (0)	2	2 (100)	4	2 (50)
Unsure	--	--	--	--	--	--
p value		0.4		0.2		0.4
2010						
Heterosexual	194	46 (24)	7	2 (29)	201	48 (24)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value	0.3			--		0.6
2013						
Heterosexual	44	12 (27)	10	2 (20)	54	14 (26)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	1	0 (0)	1	0 (0)
Unsure	--	--	--	--	--	--
p value		--		0.8		0.6

† Excludes equivocal test results and missing values.

Table 87 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	44	16 (36)	3	2 (67)	47	18 (38)
25 – 29	40	14 (35)	4	3 (75)	44	17 (39)
30 + years	86	44 (51)	13	8 (62)	99	52 (53)
p value		0.003		0.6		0.002
2007						
< 20 years	8	1 (13)	1	0 (0)	9	1 (11)
20 – 24	32	5 (16)	6	4 (67)	38	9 (24)
25 – 29	31	11 (35)	11	9 (82)	42	20 (48)
30 + years	88	42 (48)	19	11 (58)	107	53 (50)
p value		0.005		0.3		0.03
2010						
< 20 years	22	0 (0)	--	--	22	0 (0)
20 – 24	34	2 (6)	--	--	34	2 (6)
25 – 29	42	9 (21)	--	--	42	9 (21)
30 + years	97	35 (36)	7	2 (29)	104	37 (36)
p value		<0.001		--		<0.001
2013						
< 20 years	4	1 (25)	1	0 (0)	5	1 (20)
20 – 24	8	1 (13)	3	0 (0)	11	1 (9)
25 – 29	8	3 (38)	1	0 (0)	9	3 (33)
30 + years	26	8 (31)	7	2 (29)	33	10 (30)
p value		0.7		0.6		0.5

† Excludes equivocal test results and missing values.

Table 88 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	11	1 (9)	1	0 (0)	12	1 (8)
3 to 5 years	11	7 (64)	2	1 (50)	13	8 (62)
6 to 10 years	35	20 (57)	5	4 (80)	40	24 (60)
10 + years	50	44 (88)	8	8 (100)	58	52 (90)
p value		<0.001		0.06		<0.001
2007						
<3 years	4	3 (75)	1	1 (100)	5	4 (80)
3 to 5 years	5	3 (60)	2	1 (50)	7	4 (57)
6 to 10 years	17	7 (41)	14	11 (79)	31	18 (58)
10 + years	55	43 (78)	11	10 (91)	66	53 (80)
p value		0.04		0.5		0.1
2010						
<3 years	6	1 (17)	1	0 (0)	7	1 (14)
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	11	7 (64)	--	--	11	7 (64)
10 + years	47	35 (74)	2	2 (100)	49	37 (76)
p value		<0.01		0.08		<0.001
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	3	1 (33)	2	1 (50)	5	2 (40)
6 to 10 years	4	1 (25)	--	--	4	1 (25)
10 + years	11	9 (82)	2	1 (50)	13	10 (77)
p value		0.08		1.0		0.1

† Excludes equivocal test results and missing values.

Table 89 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	6	1 (17)	42	26 (62)	48	27 (56)
Heroin	1	0 (0)	55	47 (85)	56	47 (84)
More than one	--	--	9	6 (67)	6	5 (83)
Other/not reported	1	0 (0)	5	5 (100)	15	8 (53)
p value		0.6		0.03		0.008
2007						
Amphetamine (Speed, Ice)	3	3 (100)	49	28 (57)	52	31 (60)
Heroin	2	1 (50)	43	36 (84)	45	37 (82)
More than one	--	--	4	4 (100)	4	4 (100)
Other/not reported	--	--	8	7 (88)	8	7 (88)
p value		0.2		0.01		0.003
2010						
Amphetamine (Speed, Ice)	2	0 (0)	37	22 (59)	39	22 (56)
Heroin	4	1 (25)	17	13 (76)	21	14 (67)
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	1	0 (0)	9	8 (89)	10	8 (80)
p value		0.7		0.3		0.5
2013						
Amphetamine (Speed, Ice)	2	1 (50)	15	8 (53)	17	9 (53)
Heroin	--	--	4	2 (50)	4	2 (50)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	3 (100)	3	3 (100)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 90 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	6	0 (0)	21	17 (81)	27	17 (63)
Daily or more	2	1 (50)	52	39 (75)	54	40 (74)
p value		0.08		0.8		0.2
2007						
Less than daily	2	1 (50)	24	17 (71)	26	18 (69)
Daily or more	1	1 (100)	42	33 (79)	43	34 (79)
p value		0.4		0.5		0.5
2010						
Less than daily	2	0 (0)	17	16 (94)	19	16 (84)
Daily or more	3	1 (33)	14	10 (71)	17	11 (65)
p value		0.4		0.09		0.2
2013						
Less than daily	--	--	10	5 (50)	10	5 (50)
Daily or more	1	0 (0)	6	5 (83)	7	5 (71)
p value		--		0.2		0.9

† Excludes equivocal test results and missing values.

Table 91 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	8	1 (13)	53	44 (83)	61	45 (74)
Yes	1	0 (0)	20	12 (60)	21	12 (57)
p value		0.7		0.01		0.02
2007						
No	3	2 (67)	50	39 (78)	53	41 (77)
Yes	--	--	12	8 (67)	12	8 (67)
p value		--		0.4		0.4
2010						
No	3	0 (0)	21	17 (81)	24	17 (71)
Yes	2	1 (50)	6	6 (100)	8	7 (88)
p value		0.2		0.3		0.4
2013						
No	--	--	--	--	--	--
Yes	--	--	1	1 (100)	1	1 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 92 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	53	39 (74)	59	39 (66)
Yes	6	1 (17)	58	45 (78)	64	46 (72)
p value		0.3		0.6		0.5
2007						
No	1	1 (100)	30	22 (73)	31	23 (74)
Yes	2	2 (100)	58	45 (78)	60	47 (78)
p value		--		0.7		0.7
2010						
No	5	0 (0)	29	17 (59)	34	17 (50)
Yes	2	1 (50)	34	26 (76)	36	27 (75)
p value		0.1		0.1		0.03
2013						
No	--	--	5	2 (40)	5	2 (40)
Yes	1	1 (100)	12	9 (75)	13	10 (77)
p value		--		0.09		0.4

† Excludes equivocal test results and missing values.

Table 93 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	61	9 (15)	6	1 (17)	67	10 (15)
2 to 4	72	33 (46)	10	7 (70)	82	40 (49)
5 to 9	32	19 (59)	3	3 (100)	35	22 (63)
10 +	15	12 (80)	2	2 (100)	17	14 (82)
p value		<0.001		0.04		<0.001
2007						
1	40	5 (13)	13	5 (38)	53	10 (19)
2 to 4	67	19 (28)	14	10 (71)	81	29 (36)
5 to 9	25	18 (72)	5	5 (100)	30	23 (77)
10 +	22	16 (73)	4	3 (75)	26	19 (73)
p value		<0.001		0.07		<0.001
2010						
1	103	8 (8)	6	2 (33)	109	10 (9)
2 to 4	52	14 (27)	1	0 (0)	53	14 (26)
5 to 9	23	12 (52)	--	--	23	12 (52)
10 +	13	11 (85)	--	--	13	11 (85)
p value		<0.001		0.5		<0.001
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 94 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	163	63 (39)	17	10 (59)	180	73 (41)
Indigenous	20	11 (55)	4	3 (75)	24	14 (58)
p value		0.2		0.6		0.1
2007						
Non-Indigenous	124	38 (31)	24	12 (50)	148	50 (34)
Indigenous	30	16 (53)	12	11 (92)	42	27 (64)
p value		0.02		0.01		<0.001
2010						
Non-Indigenous	159	38 (24)	3	0 (0)	162	38 (23)
Indigenous	36	8 (22)	4	2 (50)	40	10 (25)
p value		0.8		0.2		0.8
2013						
Non-Indigenous	29	9 (31)	10	2 (20)	39	11 (28)
Indigenous	15	3 (20)	2	0 (0)	17	3 (18)
p value		0.4		0.5		0.4

† Excludes equivocal test results and missing values.

Table 95 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	77	2 (3)	103	71 (69)	180	73 (41)
Indigenous	3	0 (0)	21	14 (67)	24	14 (58)
p value		0.8		0.8		0.1
2007						
Non-Indigenous	74	2 (3)	74	48 (65)	148	50 (34)
Indigenous	10	1 (10)	32	26 (81)	42	27 (64)
p value		0.2		0.09		<0.001
2010						
Non-Indigenous	103	1 (1)	59	37 (63)	162	38 (23)
Indigenous	25	1 (4)	15	9 (60)	40	10 (25)
p value		0.3		0.9		0.8
2013						
Non-Indigenous	19	0 (0)	17	11 (65)	36	11 (31)
Indigenous	10	0 (0)	7	3 (43)	17	3 (18)
p value		--		0.3		0.4

† Excludes equivocal test results and missing values.

Table 96 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	171	70 (41)	21	13 (62)	192	83 (43)
Moderately accessible	3	1 (33)	--	--	3	1 (33)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	151	55 (36)	30	19 (63)	181	74 (41)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.5		0.2		0.2
2010						
Highly accessible/accessible	181	41 (23)	5	2 (40)	186	43 (23)
Moderately accessible	8	4 (50)	1	0 (0)	9	4 (44)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.2		0.4		0.3
2013						
Highly accessible/accessible	33	9 (27)	7	1 (14)	40	10 (25)
Moderately accessible	8	3 (38)	--	--	8	3 (38)
Remote/very remote	3	0 (0)	--	--	3	0 (0)
p value		0.5		--		0.4

† Excludes equivocal test results and missing values.

Table 97 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	138	60 (43)	19	13 (68)	157	73 (46)
Other Oceania	7	0 (0)	--	--	7	0 (0)
Asia	14	8 (57)	2	0 (0)	16	8 (50)
UK & Ireland	5	2 (40)	--	--	5	2 (40)
Other	19	4 (21)	--	--	19	4 (21)
p value		0.04		0.06		0.04
2007						
Australia	127	52 (41)	32	21 (66)	159	73 (46)
Other Oceania	8	1 (13)	1	1 (100)	9	2 (22)
Asia	14	5 (36)	2	0 (0)	16	5 (31)
UK & Ireland	--	--	--	--	--	--
Other	9	0 (0)	2	2 (100)	11	2 (18)
p value		0.08		0.1		0.1
2010						
Australia	151	38 (25)	5	2 (40)	156	40 (26)
Other Oceania	16	5 (31)	--	--	16	5 (31)
Asia	15	1 (7)	1	0 (0)	16	1 (6)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	11	2 (18)	1	0 (0)	12	2 (17)
p value		0.4		0.6		0.4
2013						
Australia	38	12 (32)	9	2 (22)	47	14 (30)
Other Oceania	2	0 (0)	1	0 (0)	3	0 (0)
Asia	3	0 (0)	--	--	3	0 (0)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	--	--	1	0 (0)	1	0 (0)
p value		0.5		0.9		0.5

† Excludes equivocal test results and missing values.

Table 98 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	146	59 (40)	18	12 (67)	164	71 (43)
Non-English	37	15 (41)	3	1 (33)	40	16 (40)
p value		1.0		0.3		0.7
2007						
English	121	48 (40)	33	22 (67)	154	70 (45)
Non-English	39	11 (28)	4	2 (50)	43	13 (30)
p value		0.2		0.5		0.07
2010						
English	162	41 (25)	7	2 (29)	169	43 (25)
Non-English	32	5 (16)	--	--	32	5 (16)
p value		0.4		--		0.2
2013						
English	39	12 (31)	9	2 (22)	48	14 (29)
Non-English	5	0 (0)	--	--	5	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 99 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	45	44 (98)	12	12 (100)	57	56 (98)
Negative	45	12 (27)	4	1 (25)	49	13 (27)
Not sure	14	9 (64)	1	0 (0)	15	9 (60)
p value		<0.001		0.002		<0.001
2007						
Positive	44	42 (95)	20	19 (95)	64	61 (95)
Negative	55	8 (15)	9	2 (22)	64	10 (16)
Not sure	5	4 (80)	4	2 (50)	9	6 (67)
p value		<0.001		<0.001		<0.001
2010						
Positive	36	36 (100)	2	2 (100)	38	38 (100)
Negative	55	6 (11)	4	0 (0)	59	6 (10)
Not sure	5	1 (20)	--	--	5	1 (20)
p value		<0.001		0.014		<0.001
2013						
Positive	6	6 (100)	2	2 (100)	8	8 (100)
Negative	21	3 (14)	6	0 (0)	27	3 (11)
Not sure	3	1 (33)	--	--	3	1 (33)
p value		<0.001		0.005		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 100 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	108	6 (6)	16	0 (0)	124	6 (5)
Non-IDU	75	0 (0)	5	0 (0)	80	0 (0)
p value		0.04		--		0.05
2007						
IDU	85	1 (1)	27	2 (7)	112	3 (3)
Non-IDU	76	3 (4)	10	0 (0)	86	3 (3)
p value		0.3		0.4		0.7
2010						
IDU	72	2 (3)	3	0 (0)	75	2 (3)
Non-IDU	125	4 (3)	4	0 (0)	129	4 (3)
p value		0.9		--		0.9
2013						
IDU	15	0 (0)	6	0 (0)	21	0 (0)
Non-IDU	22	0 (0)	4	0 (0)	26	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 101 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	105	35 (33)	16	3 (19)	121	38 (31)
Non-IDU	74	6 (8)	5	3 (60)	79	9 (11)
p value		<0.001		0.08		0.001
2007						
IDU	85	33 (39)	28	9 (32)	113	42 (37)
Non-IDU	76	11 (14)	10	1 (10)	86	12 (14)
p value		0.001		0.2		0.0
2010						
IDU	72	17 (24)	--	--	72	17 (24)
Non-IDU	126	21 (17)	4	0 (0)	130	21 (16)
p value		0.2		--		0.2
2013						
IDU	19	5 (26)	6	1 (17)	25	6 (24)
Non-IDU	25	3 (12)	4	0 (0)	29	3 (10)
p value		0.2		0.4		0.2

† Excludes equivocal test results and missing values.

Table 102 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	176	41 (23)	18	5 (28)	194	46 (24)
Bisexual	--	--	3	1 (33)	3	1 (33)
Homosexual	3	0 (0)	--	--	3	0 (0)
Unsure	--	--	--	--	--	--
p value		0.3		0.8		0.6
2007						
Heterosexual	156	44 (28)	30	8 (27)	186	52 (28)
Bisexual	1	0 (0)	3	0 (0)	4	0 (0)
Homosexual	2	0 (0)	2	1 (50)	4	1 (25)
Unsure	--	--	--	--	--	--
p value		0.6		0.4		0.5
2010						
Heterosexual	197	38 (19)	4	0 (0)	201	38 (19)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6
2013						
Heterosexual	44	8 (18)	10	1 (10)	54	9 (17)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	--	--	1	0 (0)	1	0 (0)
Unsure	--	--	--	--	--	--
p value		--		0.1		0.8

† Excludes equivocal test results and missing values.

Table 103 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	43	9 (21)	3	1 (33)	46	10 (22)
25 – 29	40	8 (20)	4	0 (0)	44	8 (18)
30 + years	83	24 (29)	13	5 (38)	96	29 (30)
p value		0.1		0.5		0.06
2007						
< 20 years	8	0 (0)	1	0 (0)	9	0 (0)
20 – 24	32	5 (16)	6	0 (0)	38	5 (13)
25 – 29	31	7 (23)	11	2 (18)	42	9 (21)
30 + years	89	32 (36)	20	8 (40)	109	40 (37)
p value		0.03		0.2		0.01
2010						
< 20 years	13	0 (0)	1	0 (0)	14	0 (0)
20 – 24	43	9 (21)	3	1 (33)	46	10 (22)
25 – 29	40	8 (20)	4	0 (0)	44	8 (18)
30 + years	83	24 (29)	13	5 (38)	96	29 (30)
p value		0.1		0.5		0.06
2013						
< 20 years	4	0 (0)	1	0 (0)	5	0 (0)
20 – 24	8	0 (0)	4	0 (0)	12	0 (0)
25 – 29	8	0 (0)	1	0 (0)	9	0 (0)
30 + years	26	8 (31)	7	2 (29)	33	10 (30)
p value		0.06		0.6		0.02

† Excludes equivocal test results and missing values.

Table 104 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	11	0 (0)	1	0 (0)	12	0 (0)
3 to 5 years	9	2 (22)	2	0 (0)	11	2 (18)
6 to 10 years	35	12 (34)	5	1 (20)	40	13 (33)
10 + years	49	21 (43)	8	2 (25)	57	23 (40)
p value		0.05		0.8		0.04
2007						
<3 years	4	0 (0)	1	0 (0)	5	0 (0)
3 to 5 years	5	1 (20)	2	0 (0)	7	1 (14)
6 to 10 years	17	6 (35)	14	3 (21)	31	9 (29)
10 + years	56	25 (45)	11	6 (55)	67	31 (46)
p value		0.2		0.2		0.05
2010						
<3 years	6	0 (0)	--	--	6	0 (0)
3 to 5 years	5	2 (40)	--	--	5	2 (40)
6 to 10 years	11	2 (18)	--	--	11	2 (18)
10 + years	48	12 (25)	--	--	48	12 (25)
p value		0.4		--		0.4
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	3	0 (0)	2	0 (0)	5	0 (0)
6 to 10 years	4	0 (0)	1	0 (0)	5	0 (0)
10 + years	11	5 (45)	2	1 (50)	13	6 (46)
p value		0.1		0.4		0.04

† Excludes equivocal test results and missing values.

Table 105 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	6	0 (0)	42	16 (38)	48	16 (33)
Heroin	1	0 (0)	52	18 (35)	53	18 (34)
More than one	4	0 (0)	9	3 (33)	13	3 (23)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.9		0.7
2007						
Amphetamine (Speed, Ice)	3	0 (0)	50	16 (32)	53	16 (30)
Heroin	2	0 (0)	43	18 (42)	45	18 (40)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	8	5 (63)	8	5 (63)
p value		--		0.4		0.3
2010						
Amphetamine (Speed, Ice)	2	0 (0)	38	8 (21)	40	8 (20)
Heroin	3	0 (0)	16	7 (44)	19	7 (37)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	9	1 (11)	10	1 (10)
p value		--		0.2		0.3
2013						
Amphetamine (Speed, Ice)	2	0 (0)	15	3 (20)	17	3 (18)
Heroin	--	--	5	2 (40)	5	2 (40)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	1 (33)	3	1 (33)
p value		--		0.7		0.5

† Excludes equivocal test results and missing values.

Table 106 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	6	0 (0)	21	10 (48)	27	10 (37)
Daily or more	2	0 (0)	50	14 (28)	52	14 (27)
p value		--		0.1		0.4
2007						
Less than daily	2	0 (0)	25	6 (24)	27	6 (22)
Daily or more	1	0 (0)	42	18 (43)	43	18 (42)
p value		--		0.2		0.1
2010						
Less than daily	2	0 (0)	17	4 (24)	19	4 (21)
Daily or more	2	0 (0)	14	2 (14)	16	2 (13)
p value		--		0.5		0.5
2013						
Less than daily	--	--	10	2 (20)	10	2 (20)
Daily or more	1	0 (0)	7	1 (14)	8	1 (13)
p value		--		0.8		0.7

† Excludes equivocal test results and missing values.

Table 107 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	8	0 (0)	51	16 (31)	59	16 (27)
Yes	1	0 (0)	20	8 (40)	21	8 (38)
p value		--		0.5		0.3
2007						
No	3	0 (0)	51	18 (35)	54	18 (33)
Yes	--	--	12	5 (42)	12	5 (42)
p value		--		0.7		0.6
2010						
No	3	0 (0)	21	4 (19)	24	4 (17)
Yes	1	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.9		0.9
2013						
No	--	--	--	--	--	--
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 108 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	52	20 (38)	58	20 (34)
Yes	6	0 (0)	56	18 (32)	62	18 (29)
p value		--		0.5		0.6
2007						
No	1	0 (0)	30	11 (37)	31	11 (35)
Yes	2	0 (0)	59	26 (44)	61	26 (43)
p value		--		0.5		0.5
2010						
No	4	0 (0)	27	8 (30)	31	8 (26)
Yes	2	0 (0)	35	8 (23)	37	8 (22)
p value		--		0.6		0.7
2013						
No	--	--	5	1 (20)	5	1 (20)
Yes	1	0 (0)	13	4 (31)	14	4 (29)
p value		--		0.7		0.7

† Excludes equivocal test results and missing values.

Table 109 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	60	4 (7)	6	3 (50)	66	7 (11)
2 to 4	72	19 (26)	10	1 (10)	82	20 (24)
5 to 9	31	13 (42)	3	1 (33)	34	14 (41)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		0.001		0.3		0.003
2007						
1	40	3 (8)	13	4 (31)	53	7 (13)
2 to 4	67	20 (30)	15	1 (7)	82	21 (26)
5 to 9	26	10 (38)	5	3 (60)	31	13 (42)
10 +	22	10 (45)	4	1 (25)	26	11 (42)
p value		0.004		0.01		0.008
2010						
1	103	13 (13)	3	0 (0)	106	13 (12)
2 to 4	55	14 (25)	1	0 (0)	56	14 (25)
5 to 9	23	5 (22)	--	--	23	5 (22)
10 +	13	6 (46)	--	--	13	6 (46)
p value		0.02		--		0.01
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 110 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	158	33 (21)	17	5 (29)	175	38 (22)
Indigenous	21	8 (38)	4	1 (25)	25	9 (36)
p value		0.08		0.9		0.1
2007						
Non-Indigenous	125	29 (23)	25	6 (24)	150	35 (23)
Indigenous	30	15 (50)	12	4 (33)	42	19 (45)
p value		0.003		0.5		0.005
2010						
Non-Indigenous	162	30 (19)	2	0 (0)	164	30 (18)
Indigenous	36	8 (22)	2	0 (0)	38	8 (21)
p value		0.6		--		0.7
2013						
Non-Indigenous	29	7 (24)	10	2 (20)	39	9 (23)
Indigenous	15	1 (7)	3	0 (0)	18	1 (6)
p value		0.2		0.4		0.1

† Excludes equivocal test results and missing values.

Table 111 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	76	9 (12)	99	29 (29)	175	38 (22)
Indigenous	3	0 (0)	22	9 (41)	25	9 (36)
p value		0.5		0.3		0.1
2007						
Non-Indigenous	75	8 (11)	75	27 (36)	150	35 (23)
Indigenous	10	4 (40)	32	15 (47)	42	19 (45)
p value		0.01		0.3		0.005
2010						
Non-Indigenous	105	16 (15)	59	14 (24)	164	30 (18)
Indigenous	25	5 (20)	13	3 (23)	38	8 (21)
p value		0.6		1.0		0.7
2013						
Non-Indigenous	19	3 (16)	17	5 (29)	36	8 (22)
Indigenous	10	0 (0)	8	1 (13)	18	1 (6)
p value		0.2		0.4		0.1

† Excludes equivocal test results and missing values.

Table 112 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	167	39 (23)	21	6 (29)	188	45 (24)
Moderately accessible	3	0 (0)	--	--	3	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.5		--		0.5
2007						
Highly accessible/accessible	152	40 (26)	31	9 (29)	183	49 (27)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.6		0.5		0.4
2010						
Highly accessible/accessible	183	33 (18)	2	0 (0)	185	33 (18)
Moderately accessible	8	3 (38)	1	0 (0)	9	3 (33)
Remote/very remote	4	1 (25)	--	--	4	1 (25)
p value		0.4		--		0.5
2013						
Highly accessible/accessible	33	8 (24)	7	1 (14)	40	9 (23)
Moderately accessible	8	0 (0)	--	--	8	0 (0)
Remote/very remote	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 113 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	138	32 (23)	19	4 (21)	157	36 (23)
Other Oceania	7	3 (43)	--	--	7	3 (43)
Asia	11	4 (36)	2	2 (100)	13	6 (46)
UK & Ireland	5	1 (20)	--	--	5	1 (20)
Other	18	1 (6)	--	--	18	1 (6)
p value		0.2		0.02		0.08
2007						
Australia	128	35 (27)	33	6 (18)	161	41 (25)
Other Oceania	8	3 (38)	1	1 (100)	9	4 (44)
Asia	14	3 (21)	2	1 (50)	16	4 (25)
UK & Ireland	--	--	--	--	--	--
Other	9	3 (33)	2	2 (100)	11	5 (45)
p value		0.8		0.02		0.4
2010						
Australia	153	23 (15)	2	0 (0)	155	23 (15)
Other Oceania	16	4 (25)	--	--	16	4 (25)
Asia	15	7 (47)	1	0 (0)	16	7 (44)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	12	4 (33)	1	0 (0)	13	4 (31)
p value		0.02		--		0.04
2013						
Australia	38	6 (16)	10	1 (10)	48	7 (15)
Other Oceania	2	0 (0)	1	1 (100)	3	1 (33)
Asia	3	2 (67)	--	0 (0)	3	2 (67)
UK & Ireland	1	0 (0)	1	0 (0)	2	0 (0)
Other	--	--	1	0 (0)	1	0 (0)
p value		0.1		0.1		0.2

† Excludes equivocal test results and missing values.

Table 114 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	146	32 (22)	18	4 (22)	164	36 (22)
Non-English	33	9 (27)	3	2 (67)	36	11 (31)
p value		0.5		0.1		0.3
2007						
English	122	34 (28)	33	7 (21)	155	41 (26)
Non-English	39	10 (26)	5	3 (60)	44	13 (30)
p value		0.8		0.07		0.7
2010						
English	164	12 (36)	4	0 (0)	168	26 (15)
Non-English	33	26 (16)	--	--	33	26 (36)
p value		0.006		--		0.005
2013						
English	39	6 (15)	10	1 (10)	49	7 (14)
Non-English	5	2 (40)	--	--	5	2 (40)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

Table 115 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	124	60 (40)	33 (27)	6 (5)	25 (20)
Non-IDU	80	62 (78)	9 (11)	0 (0)	9 (11)
p value					<0.001
2007					
IDU	112	36 (32)	39 (35)	3 (3)	34 (30)
Non-IDU	86	53 (62)	9 (10)	3 (3)	21 (24)
p value					<0.001
2010					
IDU	72	27 (38)	15 (21)	2 (3)	28 (39)
Non-IDU	130	74 (57)	17 (13)	4 (3)	35 (27)
p value					0.06
2013					
IDU	25	6 (24)	6 (24)	0 (0)	13 (52)
Non-IDU	28	14 (50)	3 (11)	0 (0)	11 (39)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 116 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	198	119 (60)	41 (21)	6 (3)	32 (16)
Bisexual	3	1 (33)	1 (33)	0 (0)	1 (33)
Homosexual	3	2 (37)	0 (0)	0 (0)	1 (33)
Unsure	--	--	--	--	--
p value					0.9
2007					
Heterosexual	185	85 (46)	47 (25)	5 (3)	48 (26)
Homosexual	4	1 (25)	0 (0)	1 (25)	2 (50)
Bisexual	4	1 (25)	0 (0)	0 (0)	3 (75)
Unsure	--	--	--	--	--
p value					0.4
2010					
Heterosexual	201	101 (50)	32 (16)	6 (3)	62 (31)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.5
2013					
Heterosexual	53	21 (40)	9 (17)	0 (0)	23 (43)
Homosexual	1	1 (100)	0 (0)	0 (0)	1 (100)
Bisexual	1	0 (0)	1 (100)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 117 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	14	11 (79)	0 (0)	0 (0)	3 (21)
20 – 24	46	27 (59)	8 (17)	2 (4)	9 (20)
25 – 29	44	29 (66)	7 (16)	1 (2)	7 (16)
30 + years	100	55 (55)	27 (27)	3 (3)	15 (15)
p value					0.5
2007					
< 20 years	9	7 (78)	0 (0)	0 (0)	2 (22)
20 – 24	38	21 (55)	4 (11)	1 (3)	12 (32)
25 – 29	41	14 (34)	8 (20)	1 (2)	18 (44)
30 + years	109	46 (42)	36 (33)	4 (4)	23 (21)
p value					0.02
2010					
< 20 years	22	7 (32)	2 (9)	0 (0)	13 (59)
20 – 24	34	23 (68)	2 (6)	0 (0)	9 (26)
25 – 29	43	20 (47)	8 (19)	1 (2)	14 (33)
30 + years	103	51 (50)	20 (19)	5 (5)	27 (26)
p value					0.05
2013					
< 20 years	5	2 (40)	0 (0)	0 (0)	3 (60)
20 – 24	12	6 (50)	0 (0)	0 (0)	6 (50)
25 – 29	9	5 (56)	0 (0)	0 (0)	4 (44)
30 + years	32	11 (34)	10 (31)	0 (0)	11 (34)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 118 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	67	52 (78)	6 (9)	1 (1)	8 (12)
2 to 4	83	46 (55)	17 (20)	4 (4)	16 (19)
5 to 9	35	14 (40)	14 (40)	0 (0)	7 (20)
10 +	16	8 (50)	5 (31)	1 (6)	2 (13)
p value					<0.01
2007					
1	53	37 (70)	6 (11)	1 (2)	9 (17)
2 to 4	81	41 (51)	18 (22)	3 (4)	19 (23)
5 to 9	31	2 (6)	11 (35)	2 (6)	16 (52)
10 +	26	6 (23)	11 (42)	0 (0)	9 (35)
p value					<0.001
2010					
1	106	69 (65)	10 (9)	3 (3)	24 (23)
2 to 4	56	20 (36)	12 (21)	2 (4)	22 (39)
5 to 9	23	8 (35)	5 (22)	0 (0)	10 (43)
10 +	13	1 (8)	5 (38)	1 (8)	6 (46)
p value					0.001
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 119 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	179	112 (63)	35 (20)	4 (2)	28 (16)
Indigenous	25	10 (40)	7 (28)	2 (8)	6 (24)
p value					0.1
2007					
Non-Indigenous	149	76 (51)	32 (21)	3 (2)	38 (26)
Indigenous	42	10 (24)	16 (38)	3 (7)	13 (31)
p value					<0.01
2010					
Non-Indigenous	164	86 (52)	25 (15)	5 (3)	48 (29)
Indigenous	38	15 (39)	7 (18)	1 (3)	15 (39)
p value					0.5
2013					
Non-Indigenous	38	14 (37)	9 (24)	0 (0)	15 (39)
Indigenous	18	8 (44)	1 (6)	0 (0)	9 (50)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 120 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	192	115 (60)	40 (21)	6 (3)	31 (16)
Moderately accessible	3	2 (67)	0 (0)	0 (0)	1 (33)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.4
2007					
Highly accessible/accessible	182	84 (46)	43 (24)	6 (3)	49 (27)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.5
2010					
Highly accessible/accessible	185	95 (51)	28 (15)	5 (3)	57 (31)
Moderately accessible	9	3 (33)	2 (22)	1 (11)	3 (33)
Remote/very remote	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.6
2013					
Highly accessible/accessible	39	14 (46)	9 (23)	0 (0)	16 (41)
Moderately accessible	8	5 (63)	0 (0)	0 (0)	3 (38)
Remote/very remote	3	1 (33)	0 (0)	0 (0)	2 (67)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 121 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	164	98 (60)	33 (20)	3 (2)	30 (18)
Non-English	40	24 (60)	9 (23)	3 (8)	4 (10)
p value					0.2
2007					
English	154	74 (48)	38 (25)	3 (2)	39 (25)
Non-English	44	15 (34)	10 (23)	3 (7)	16 (36)
p value					0.1
2010					
English	168	89 (53)	24 (14)	2 (1)	53 (32)
Non-English	33	12 (36)	8 (24)	4 (12)	9 (27)
p value					0.002
2013					
English	49	19 (39)	7 (14)	0 (0)	23 (47)
Non-English	4	1 (25)	2 (50)	0 (0)	1 (25)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 122 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	56	5 (9)	3	1 (33)	59	6 (10)
Yes	50	19 (38)	10	4 (40)	60	23 (38)
Not sure	34	4 (12)	2	1 (50)	36	5 (14)
p value		<0.001		0.9		<0.001
2007						
No	49	8 (16)	13	3 (23)	62	11 (18)
Yes	54	30 (56)	13	9 (69)	67	39 (58)
Not sure	12	4 (33)	--	--	12	4 (33)
p value		<0.001		0.02		<0.001
2010						
No	47	6 (13)	2	0 (0)	49	6 (12)
Yes	65	41 (63)	1	1 (100)	66	42 (64)
Not sure	47	15 (32)	1	0 (0)	48	15 (31)
p value		<0.001		0.1		<0.001
2013						
No	5	2 (50)	2	2 (100)	7	4 (57)
Yes	18	12 (67)	5	5 (100)	23	17 (74)
Not sure	11	2 (18)	2	1 (50)	13	3 (23)
p value		0.04		0.1		0.01

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 123 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	185	10 (5)
Female	5	0 (0)
p value		0.6
2013		
Male	25	1 (4)
Female	18	1 (6)
p value		0.8

† Excludes missing values.

Gonorrhoea

Table 124 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	184	0 (0)
Female	5	0 (0)
p value		--
2013		
Male	25	0 (0)
Female	18	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 125 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	195	4 (2)	0 (0)	4 (2)
Female	7	0 (0)	0 (0)	0 (0)
p value		0.7	--	0.7
2013				
Male	43	0 (0)	0 (0)	0 (0)
Female	15	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Northern Territory 2010, 2013

Table 126 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 2		N = 1	
N° surveyed	N = 9	N = 66	N = 3	N = 45
Sex (%)				
Male	8 (89)	64 (97)	3 (100)	43 (96)
Female	1 (11)	2 (3)	--	2 (4)
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	9 (100)	62 (94)	3 (100)	45 (100)
Bisexual	--	2 (3)	--	--
Homosexual	--	1 (2)	--	--
Unsure	--	1 (2)	--	--
Not reported	--	--	--	--
Age and duration of injection (years)				
Median age	34	30	30	32
Age range	25 – 21	18 – 56	27 – 36	18 -56
Age group (%)				
<25 years	--	19 (29)	--	14 (31)
25+ years	9 (100)	47 (71)	3 (100)	31 (69)
Not reported	--	--	--	--
Median age 1 st IDU	25	--	18	--
Age range	14 – 42	--	12 -21	--
Not reported	1	--	--	--
Median IDU (years)	11	--	10	--
Range	1 – 32	--	9 – 24	--
Duration of drug injection (%)				
<3 years	1 (11)	--	--	--
3+ years	7 (78)	--	3 (100)	--
Not reported	1 (11)	--	--	--
Aboriginal and/or Torres Strait Islander origin (%)				
No	4 (44)	5 (8)	1 (33)	8 (18)
Yes	5 (56)	61 (92)	2 (67)	37 (82)
Not reported	--	--	--	--
Residential remoteness in 12 months before prison (%)				
Highly / accessible	5 (56)	11 (17)	--	2 (4)
Mod accessible	--	1 (2)	2 (67)	15 (33)
Very / remote	4 (44)	47 (71)	1 (33)	27 (60)
Not reported	--	7 (11)	--	1 (2)
Region/Country of birth (%)				
Australia	7 (78)	64 (97)	3 (100)	43 (96)
Other Oceania	1 (11)	--	--	1 (2)
Asia	1 (11)	2 (3)	--	--
UK & Ireland	--	--	--	--
Other	--	--	--	1 (2)
Not reported	--	--	--	--
Main language spoke at home by parents (%)				
English	6 (67)	34 (52)	3 (100)	10 (22)
Non-English	1 (11)	10 (15)	--	32 (71)
Not reported	2 (22)	22 (33)	--	3 (7)

Table 127 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)				
No	7 (78)	52 (79)	2 (67)	30 (67)
Yes	2 (22)	14 (21)	1 (33)	13 (29)
Not reported	--	--	--	2 (4)
Lifetime imprisonments (%)*				
One	3 (33)	29 (44)	n/a	n/a
Two to four	3 (33)	20 (30)	n/a	n/a
Five to nine	3 (33)	14 (21)	n/a	n/a
Ten or more	--	3 (5)	n/a	n/a
Not reported	--	--	n/a	n/a
Imprisonment in last year (%)				
No	4 (44)	27 (41)	2 (100)	7 (23)
Yes	5 (56)	29 (44)	--	23 (77)
Not reported	--	10 (15)	--	--
Frequency of injection last month (%)				
Not last month	4 (44)	--	1 (33)	--
< weekly	1 (11)	--	1 (33)	--
Weekly	--	--	1 (33)	--
Daily or more	3 (33)	--	--	--
Not reported	1 (11)	--	--	--
Ever smoked a full cigarette (%)**				
No	--	6 (9)	--	3 (7)
Yes	9 (100)	60 (91)	3 (100)	42 (93)
Not reported	--	--	--	--
Med age 1st smoked				
Age range	5 – 17	10 – 27	13 – 15	8 – 31
Current smoker (%)**				
No	--	7 (11)	--	1 (2)
Yes	9 (100)	59 (89)	3 (100)	41 (98)
Not reported	--	--	--	--
Smoking frequency (%)**				
Weekly or less	--	3 (5)	--	2 (5)
5-10/day	4 (44)	19 (32)	--	16 (39)
11 to 20/day	1 (11)	7 (12)	2 (67)	16 (39)
>20/day	4 (44)	30 (51)	1 (33)	7 (17)
Not reported	--	--	--	--
Other drugs used last month (%)***				
None	--	46 (71)	--	15 (33)
Cannabis	6 (67)	19 (100)	2 (67)	29 (97)
Heroin	1 (11)	--	--	--
Cocaine	1 (11)	--	--	1 (3)
Amphetamine	2 (22)	--	--	4 (13)
Methadone	3 (33)	--	1 (33)	--
Other opiates	3 (33)	--	2 (67)	--
Buprenorphine	--	--	--	--
Steroids	1 (11)	--	--	--
Hallucinogens	--	--	--	2 (7)
Benzodiazepine	1 (11)	1 (5)	--	--
Ecstasy/MDA	1 (11)	--	--	--
Inhalants	--	--	--	--
Other drug	1 (11)	--	--	--
Not reported	--	1 (2)	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 128 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010	2013
Last drug injected (%)	N = 9	N = 3
Amphetamine (Speed, Ice)	3 (33)	1 (33)
Anabolic steroids	--	--
Cocaine	--	--
Heroin	--	--
Heroin + amphetamine	--	--
Heroin + cocaine	--	--
Methadone	--	--
Morphine	2 (22)	1 (33)
Other	3 (33)	1 (33)
Not reported	1 (11)	--
N° Injected last month	N = 4	N = 2
Places injected last month (%)*		
Prison	--	--
Own home	3 (75)	2 (100)
Friend's home	2 (50)	--
Dealer's home	--	--
Street, park, beach	1 (25)	--
Car	--	--
Public toilet	--	--
Commercial injecting room	--	--
Medically Supervised Injecting Centre, Sydney	--	--
Squat	--	--
Other place	--	1 (50)
Use of sterile needles & syringes last month (%)		
All injections	4 (100)	2 (100)
Most of the time	--	--
Half of the time	--	--
Some of the time	--	--
Not last month	--	--
Not reported	--	--
Re-used someone else's used needle & syringe last month (%)		
None	4 (100)	2 (100)
Once	--	--
Twice	--	--
3-5 times	--	--
>5 times	--	--
Not reported	--	--
Number of people needle & syringe was re-used after last month (%)		
One	--	--
Two	--	--
Three to five	--	--
More than five	--	--
Don't know how many	--	--
Not reported	--	--
Relationship to people needle & syringe was re-used after last month (%)*		
Regular sex partner	--	--
Casual sex partner	--	--
Close friend	--	--
Acquaintance	--	--
Other	--	--
Equipment used after someone else last month (%)*		
Spoon	--	1 (50)
Water	--	--
Filter	--	1 (50)
Tourniquet	--	--
Drug mix	--	--

* More than one option could be selected.

Table 129 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 9	N = 66	N = 3	N = 45
Any treatment/therapy for drug use (%)				
No	3 (33)	64 (97)	2 (67)	45 (100)
Yes	6 (67)	2 (3)	1 (33)	--
Not reported	--	--	--	--
History of methadone maintenance treatment (%)				
Currently	1 (11)	--	--	--
Previously	3 (33)	--	--	--
Never	5 (56)	66 (100)	3 (100)	45 (100)
Not reported	--	--	--	--
History of other pharmacotherapy treatment (%)				
Currently	--	--	1 (33)	--
Previously	2 (22)	--	--	--
Never	7 (78)	66 (100)	2 (67)	45 (100)
Not reported	--	--	--	--

Table 130 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2010	2013
N ^o surveyed	N = 8	N = 3
From an NSP last month (%)		
Daily or almost daily	--	--
A couple of times each week	1 (13)	--
Less than weekly	1 (13)	--
Weekly	--	--
Once last month	1 (13)	1 (33)
Not in the last month	4 (50)	2 (67)
Not reported	1 (13)	--
From a chemist last month (%)		
Daily or almost daily	--	--
A couple of times each week	1 (11)	--
Less than weekly	--	--
Weekly	--	--
Once last month	--	--
Not in the last month	6 (67)	3 (100)
Not reported	1 (11)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 131 Number (%) of respondents by body piercing and tattoos

Demographics	2010		2013	
	IDU N = 9	Non-IDU N = 66	IDU N = 3	Non-IDU N = 45
N° surveyed				
Body or ear piercings (%)				
No	6 (67)	56 (85)	2 (67)	20 (44)
Yes	3 (33)	10 (15)	1 (33)	25 (56)
Not reported	--	--	--	--
Pierced in past 12 months (%)				
No	1 (33)	7 (70)	1 (100)	23 (92)
Yes	--	2 (20)	--	1 (4)
Not reported	2 (67)	1 (10)	--	1 (4)
Who did piercing (%)*				
Chemist/salon	--	1 (50)	--	--
Professional piercer	--	--	--	--
Tattooist/parlour	--	--	--	--
Friend	--	--	--	--
Prison inmate	--	--	--	--
Self	--	--	--	--
Family member	--	--	--	1 (100)
Other	--	--	--	--
Needle used by other (%)				
No	--	--	--	--
Yes	--	--	--	1 (100)
Unsure	--	--	--	--
Not reported	--	2 (100)	--	--
Tattoos (%)				
No	2 (22)	55 (83)	1 (33)	32 (71)
Yes	7 (78)	10 (15)	2 (67)	13 (29)
Not reported	--	1 (2)	--	--
Tattoos in past 12 months (%)				
No	6 (86)	5 (50)	2 (100)	10 (77)
Yes	1 (14)	4 (40)	--	3 (23)
Not reported	--	1 (10)	--	--
Who did tattooing (%)*				
Prof tattooist	1 (100)	3 (75)	--	1 (33)
Friend	--	--	--	2 (67)
Prison inmate	--	1 (25)	--	--
Self	--	--	--	--
Family member	--	--	--	--
Other	--	--	--	--

* More than one option could be selected.

Table 132 Number (%) of respondents by sexual behaviour in the 3 months prior to survey by injector status and survey year

Sex behaviour	2010		2013	
	IDU N = 9	Non-IDU N = 66	IDU N = 3	Non-IDU N = 45
Sex last 3 months (%)				
No	1 (11)	8 (12)	--	4 (9)
Yes	8 (89)	57 (86)	3 (100)	41 (91)
Not reported	--	1 (2)	--	--
Male sex partners in last 3 months				
Median (Range)	--	0 (0 – 1)	--	2 (0 – 5)
Female sex partners in last 3 months				
Median (Range)	1 (0 – 90)	1 (0 – 7)	--	1 (0 – 8)
Condom use last sex - regular male partners - last 3 months (%)				
Never	1 (100)	2 (100)	--	--
Sometimes	--	--	--	2 (67)
Always	--	--	--	1 (33)
Condom use last sex - casual male partners - last 3 months (%)				
Never	--	1 (33)	--	--
Sometimes	--	1 (33)	--	--
Always	--	1 (33)	--	--
Condom use last sex - regular female partners - last 3 months (%)				
Never	4 (80)	25 (61)	3 (100)	25 (93)
Sometimes	--	4 (10)	--	1 (4)
Always	1 (20)	12 (29)	--	1 (4)
Condom use last sex - casual female partners - last 3 months (%)				
Never	2 (100)	7 (37)	--	6 (55)
Sometimes	--	3 (16)	--	5 (45)
Always	--	9 (47)	--	--
Sex work last month (%)				
No	8 (89)	63 (95)	3 (100)	45 (100)
Yes	1 (11)	2 (3)	--	--
Not reported	--	1 (2)	--	--
Condom used at last sex work last month (%)				
No	1 (100)	1 (50)	--	--
Yes	--	1 (50)	--	--
Not reported	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 133 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 9	N = 66	N = 3	N = 45
Previous HIV test (%)				
Last year	4 (44)	10 (15)	2 (67)	24 (53)
>1 year ago	1 (11)	14 (21)	1 (33)	13 (29)
Never tested	4 (44)	42 (64)	--	8 (18)
Not reported	--	--	--	--
HBV infection (%)				
No	8 (89)	61 (92)	--	2 (4)
Yes	--	--	1 (33)	--
Don't know	1 (11)	4 (6)	2 (67)	43 (96)
Not reported	--	1 (2)	--	--
HBV vaccination (%)*				
No	4 (44)	48 (73)	--	--
Yes	5 (56)	12 (18)	1 (33)	3 (7)
Don't know	--	5 (8)	2 (67)	41 (91)
Not reported	--	1 (2)	--	1 (2)
Ever had cervical cancer vaccine (women only)** (%)				
No	--	--	--	1 (50)
Yes	--	--	--	--
Unsure	--	--	--	1 (50)
Previous HCV test (%)				
Last year	4 (44)	6 (9)	2 (67)	20 (44)
>1 year ago	1 (11)	18 (27)	1 (33)	11 (24)
Never tested	3 (33)	42 (64)	--	14 (31)
Unsure	--	--	--	--
Not reported	1 (11)	--	--	--
Any HCV treatment (%)***				
	N = 3	N = 0	N = 0	N = 0
Interferon (Int)	--	--	--	--
Int & Ribavirin	--	--	--	--
Int & Ribavirin & Boceprevir	--	--	--	--
Other	--	--	--	--
None		3 (100)	--	--
Not reported	--	--	--	--
Current HCV treatment				
Interferon (Int)	--	--	--	--
Int & Ribavirin	--	--	--	--
Other	--	--	--	--
Unsure	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 134 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N ^o reporting previous positive HCV test not currently on treatment				
			N = 0	N = 0
Ever sought out HCV treatment?				
No	n/a	n/a	--	--
Yes	n/a	n/a	--	--
Not reported	n/a	n/a	--	--
Willingness to receive treatment for HCV				
Very unwilling	n/a	n/a	--	--
Unwilling	n/a	n/a	--	--
Neutral	n/a	n/a	--	--
Willing	n/a	n/a	--	--
Very willing	n/a	n/a	--	--
Not reported	n/a	n/a	--	--
More willing to receive HCV treatment in prison than community				
Yes	n/a	n/a	--	--
No	n/a	n/a	--	--
Unsure	n/a	n/a	--	--
Not reported	n/a	n/a	--	--
Future treatment plans				
Within 1 year	n/a	n/a	--	--
Next 1-2 years	n/a	n/a	--	--
Next 2-5 years	n/a	n/a	--	--
>5 years	n/a	n/a	--	--
No plans	n/a	n/a	--	--
Not reported	n/a	n/a	--	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 135 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	7	0 (0)	1	0 (0)	59	0 (0)
Non-IDU	57	0 (0)	2	0 (0)	8	0 (0)
p value		--		--		--
2013						
IDU	3	0 (0)	--	--	3	0 (0)
Non-IDU	35	0 (0)	2	0 (0)	37	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 136 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
IDU	7	3 (43)	1	0 (0)	8	3 (38)
Non-IDU	57	0 (0)	2	0 (0)	59	0 (0)
p value		<0.001		--		<0.001
2013						
IDU	2	2 (100)	--	--	2	2 (100)
Non-IDU	33	1 (3)	2	0 (0)	35	1 (3)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 137 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	61	3 (5)	3	0 (0)	64	3 (5)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	--	--	--	--	--	--
p value		0.1		--		0.9
2013						
Heterosexual	35	3 (9)	2	0 (0)	37	3 (8)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 138 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	6	0 (0)	--	--	6	0 (0)
20 – 24	12	0 (0)	--	--	12	0 (0)
25 – 29	13	0 (0)	--	--	13	0 (0)
30 + years	33	3 (9)	--	--	36	3 (8)
p value		0.4		--		0.4
2013						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	10	0 (0)	1	0 (0)	11	0 (0)
25 – 29	8	1 (13)	1	0 (0)	9	1 (11)
30 + years	23	2 (9)	1	0 (0)	24	2 (8)
p value		0.6		--		0.7

† Excludes equivocal test results and missing values.

Table 139 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	1	0 (0)	1	0 (0)
6 to 10 years	--	--	--	--	--	--
10 + years	5	3 (60)	--	--	5	3 (60)
p value		0.3		--		0.4
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	1	1 (100)	--	--	1	1 (100)
10 + years	1	1 (100)	--	--	1	1 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 140 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	--	--	3	2 (67)	3	2 (67)
Heroin	--	--	--	--	--	--
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3
2013						
Amphetamine (Speed, Ice)	--	--	1	1 (100)	1	1 (100)
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	1	1 (100)	1	1 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 141 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	--	--	1	1 (100)	1	1 (100)
Daily or more	--	--	3	1 (33)	3	1 (33)
p value		--		0.3		0.3
2013						
Less than daily	--	--	1	1 (100)	1	1 (100)
Daily or more	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 142 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	4	2 (50)	4	2 (50)
Yes	--	--	--	--	--	--
p value		--		--		--
2013						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 143 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	3	2 (67)	3	2 (67)
Yes	1	0 (0)	3	1 (33)	4	1 (25)
p value		--		0.4		0.3
2013						
No	--	--	2	2 (100)	--	--
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 144 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	26	1 (4)	2	0 (0)	28	1 (4)
2 to 4	21	1 (5)	--	--	21	1 (5)
5 to 9	14	1 (7)	1	1 (100)	15	1 (7)
10 +	3	0 (0)	--	--	3	0 (0)
p value		1.0		--		1.0
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 145 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	7	2 (29)	1	0 (0)	8	2 (25)
Indigenous	57	1 (2)	2	0 (0)	59	1 (2)
p value		0.002		--		0.003
2013						
Non-Indigenous	7	2 (29)	--	--	7	2 (29)
Indigenous	38	1 (3)	3	0 (0)	41	1 (2)
p value		0.01		--		0.008

† Excludes equivocal test results and missing values.

Table 146 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	55	0 (0)	4	1 (25)	59	1 (2)
p value		--		0.5		0.003
2013						
Non-Indigenous	5	1 (20)	1	1 (100)	6	2 (33)
Indigenous	30	0 (0)	1	1 (100)	31	1 (3)
p value		0.01		--		0.008

† Excludes equivocal test results and missing values.

Table 147 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	14	1 (7)	1	0 (0)	15	1 (7)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	43	2 (5)	2	0 (0)	45	2 (4)
p value		0.7		--		0.7
2013						
Highly accessible/accessible	1	0 (0)	--	--	1	0 (0)
Moderately accessible	11	1 (9)	1	0 (0)	12	1 (8)
Remote/very remote	22	2 (9)	1	0 (0)	23	2 (9)
p value		1.0		--		1.0

† Excludes equivocal test results and missing values.

Table 148 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	61	2 (3)	2	0 (0)	63	2 (3)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	2	0 (0)	1	0 (0)	3	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		<0.001		--		<0.001
2013						
Australia	34	3 (9)	2	0 (0)	36	3 (8)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 149 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
English	37	3 (8)	--	--	37	3 (8)
Non-English	8	0 (0)	1	0 (0)	9	0 (0)
p value		0.3		--		0.4
2013						
English	7	3 (43)	--	--	7	3 (43)
Non-English	25	0 (0)	2	0 (0)	27	0 (0)
p value		0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 150 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	2	2 (100)	--	--	2	2 (100)
Negative	24	0 (0)	--	--	24	0 (0)
Not sure	--	--	1	0 (0)	1	0 (0)
p value		<0.001				<0.001
2013						
Positive	--	--	--	--	--	--
Negative	20	0 (0)	--	--	20	0 (0)
Not sure	3	3 (100)	--	--	3	3 (100)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 151 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	72	2 (3)	3	0 (0)	75	2 (3)
Non-IDU	125	4 (3)	4	0 (0)	129	4 (3)
p value		0.9		--		0.9
2013						
IDU	3	0 (0)	--	--	3	0 (0)
Non-IDU	33	1 (3)	2	0 (0)	35	1 (3)
p value		0.8		--		0.8

† Excludes equivocal test results and missing values.

Table 152 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	7	0 (0)	1	0 (0)	8	0 (0)
Non-IDU	44	2 (5)	2	1 (50)	46	3 (7)
p value		0.6		0.4		0.5
2013						
IDU	3	1 (33)	--	--	3	1 (33)
Non-IDU	33	16 (48)	2	1 (50)	35	17 (49)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 153 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	49	17 (35)	3	0 (0)	52	20 (38)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.5		--		0.4
2013						
Heterosexual	36	17 (47)	2	1 (50)	38	18 (47)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 154 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
< 20 years	6	1 (17)	--	--	6	1 (17)
< 20 years	10	1 (10)	--	--	10	1 (10)
20 – 24	9	3 (33)	--	--	9	3 (33)
25 – 29	26	13 (50)	3	3 (100)	29	16 (55)
30 + years		0.1		--		0.04
p value						
2013						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	9	2 (22)	1	0 (0)	10	2 (20)
25 – 29	8	3 (38)	1	1 (100)	9	4 (44)
30 + years	25	15 (60)	1	1 (100)	26	16 (62)
p value		0.04		0.2		0.02

† Excludes equivocal test results and missing values.

Table 155 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	1	1 (100)	--	--	1	1 (100)
3 to 5 years	--	--	1	1 (100)	1	1 (100)
6 to 10 years	1	0 (0)	--	--	1	0 (0)
10 + years	5	1 (20)	--	--	5	1 (20)
p value		0.2		--		0.2
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	2	0 (0)	--	--	2	0 (0)
10 + years	1	1 (100)	--	--	1	1 (100)
p value		0.08		--		0.08

† Excludes equivocal test results and missing values.

Table 156 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Amphetamine (Speed, Ice)	--	--	3	1 (33)	3	1 (33)
Heroin	--	--	--	--	--	--
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	1	1 (100)	2	0 (0)	3	1 (33)
p value		--		0.5		0.9
2013						
Amphetamine (Speed, Ice)	--	--	1	1 (100)	1	1 (100)
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	2	0 (0)	2	0 (0)
p value		--		0.08		0.08

† Excludes equivocal test results and missing values.

Table 157 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	--	--	1	1 (100)	1	1 (100)
Daily or more	--	--	3	1 (33)	3	1 (33)
p value		--		0.3		0.3
2013						
Less than daily	--	--	2	1 (50)	2	1 (50)
Daily or more	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 158 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	4	2 (50)	4	2 (50)
Yes	--	--	--	--	--	--
p value		--		--		--
2013						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 159 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	3	0 (0)	3	0 (0)
Yes	1	1 (100)	4	2 (50)	5	3 (60)
p value		--		0.2		0.1
2013						
No	--	--	2	1 (50)	2	1 (50)
Yes	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 160 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	21	5 (24)	2	2 (100)	23	7 (30)
2 to 4	15	5 (33)	--	--	15	5 (33)
5 to 9	12	6 (50)	1	1 (100)	13	7 (54)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.3		--		0.4
2013						
1	n/a	n/a		n/a		n/a
2 to 4	n/a	n/a		n/a		n/a
5 to 9	n/a	n/a		n/a		n/a
10 +	n/a	n/a		n/a		n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 161 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	7	1 (14)	1	1 (100)	8	2 (25)
Indigenous	44	17 (39)	2	2 (100)	46	19 (41)
p value		0.2		--		0.4
2013						
Non-Indigenous	8	3 (38)	--	--	8	3 (38)
Indigenous	38	17 (45)	3	2 (67)	41	19 (46)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 162 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	4	0 (0)	4	2 (50)	8	2 (25)
Indigenous	42	18 (43)	4	1 (25)	46	19 (41)
p value		0.09		0.5		0.4
2013						
Non-Indigenous	6	2 (33)	1	1 (100)	7	3 (43)
Indigenous	29	15 (52)	2	0 (0)	31	15 (48)
p value		0.4		0.08		0.7

† Excludes equivocal test results and missing values.

Table 163 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	15	6 (40)	1	1 (100)	16	7 (44)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	32	12 (38)	2	2 (100)	34	14 (41)
p value		0.9		--		0.9
2013						
Highly accessible/accessible	1	0 (0)	--	--	1	0 (0)
Moderately accessible	13	4 (31)	1	1 (100)	14	5 (46)
Remote/very remote	22	13 (59)	1	0 (0)	23	13 (57)
p value		0.2		0.2		0.3

† Excludes equivocal test results and missing values.

Table 164 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	48	17 (35)	2	2 (100)	50	19 (38)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	2	0 (0)	1	1 (100)	3	1 (33)
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.2		--		0.4
2013						
Australia	35	16 (46)	2	1 (50)	37	17 (46)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.3		--		0.4

† Excludes equivocal test results and missing values.

Table 165 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
English	36	11 (31)	--	--	36	11 (31)
Non-English	7	3 (43)	1	1 (100)	8	4 (50)
p value		0.5		--		0.3
2013						
English	8	2 (25)	--	--	8	2 (25)
Non-English	25	14 (56)	2	1 (50)	27	16 (56)
p value		0.1		--		0.1

† Excludes equivocal test results and missing values.

Table 166 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	8	1 (13)	3 (38)	0 (0)	4 (50)
Non-IDU	46	17 (37)	15 (33)	3 (7)	11 (24)
p value					0.3
2013					
IDU	3	1 (33)	1 (33)	0 (0)	1 (33)
Non-IDU	35	7 (20)	16 (46)	1 (3)	11 (31)
p value					0.9

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 167 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Heterosexual	52	18 (35)	17 (33)	3 (6)	14 (27)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.5
2013					
Heterosexual	38	8 (21)	17 (45)	1 (3)	12 (32)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 168 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
< 20 years	6	4 (67)	1 (17)	0 (0)	1 (17)
20 – 24	10	3 (30)	1 (10)	0 (0)	6 (60)
25 – 29	9	3 (33)	1 (11)	2 (22)	3 (33)
30 + years	29	8 (28)	15 (52)	1 (3)	5 (17)
p value					0.02
2013					
< 20 years	5	3 (60)	0 (0)	0 (0)	2 (40)
20 – 24	11	3 (27)	1 (9)	1 (9)	6 (55)
25 – 29	9	5 (56)	4 (44)	0 (0)	0 (0)
30 + years	25	1 (4)	16 (64)	0 (0)	8 (32)
p value					0.002

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 169 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
1	23	10 (43)	5 (22)	2 (9)	6 (26)
2 to 4	15	6 (40)	5 (33)	0 (0)	4 (27)
5 to 9	13	2 (15)	6 (46)	1 (8)	4 (31)
10 +	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.6
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 170 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Non-Indigenous	8	4 (50)	2 (25)	0 (0)	2 (25)
Indigenous	46	14 (33)	16 (35)	3 (7)	13 (28)
p value					0.7
2013					
Non-Indigenous	8	3 (38)	3 (38)	0 (0)	2 (25)
Indigenous	41	9 (22)	18 (44)	1 (2)	9 (22)
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 171 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	16	3 (19)	7 (44)	0 (0)	6 (38)
Moderately accessible	--	--	--	--	--
Remote/very remote	34	11 (32)	11 (32)	3 (9)	9 (26)
p value					0.4
2013					
Highly accessible/accessible	1	1 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	14	4 (49)	5 (36)	0 (0)	5 (36)
Remote/very remote	22	3 (14)	12 (55)	1 (5)	6 (27)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 172 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
English	36	15 (42)	10 (28)	1 (3)	10 (28)
Non-English	8	1 (13)	3 (38)	1 (13)	3 (38)
p value					0.3
2013					
English	9	3 (33)	2 (22)	0 (0)	4 (44)
Non-English	27	5 (19)	14 (52)	1 (4)	7 (26)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 173 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	23	9 (39)	--	--	23	9 (39)
Yes	8	5 (63)	--	--	8	5 (63)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		1.0		--		0.3
2013						
No	--	--	--	--	--	--
Yes	2	2 (100)	--	--	2	2 (100)
Not sure	16	10 (63)	1	0 (0)	17	10 (59)
p value		0.3		--		0.3

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 174 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	63	1 (2)
Female	3	0 (0)
p value		0.8
2013		
Male	49	4 (8)
Female	3	0 (0)
p value		0.6

† Excludes missing values.

Gonorrhoea

Table 175 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	63	2 (3)
Female	3	0 (0)
p value		0.8
2013		
Male	47	1 (2)
Female	3	0 (0)
p value		0.8

† Excludes missing values.

Syphilis

Table 176 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	64	13 (20)	5 (8)	13 (20)
Female	3	1 (33)	0 (0)	1 (33)
p value		0.6	0.4	0.6
2013				
Male	47	6 (13)	4 (8)	2 (4)
Female	3	1 (33)	1 (33)	1 (33)
p value		0.3	0.4	0.2

† Excludes missing values.

Queensland
2004, 2007, 2010, 2013

Table 177 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 1		N = 1		N = 5		N = 4	
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N=139	N=140
Sex (%)								
Male	80 (100)	58 (100)	91 (100)	66 (100)	70 (82)	110 (87)	121 (87)	129 (92)
Female	--	--	--	--	15 (18)	16 (13)	18 (13)	11 (8)
Transgender	--	--	--	--	--	--	--	--
Sexual Identity (%)								
Heterosexual	81 (99)	56 (97)	90 (99)	66 (100)	76 (89)	123 (98)	135 (97)	135 (96)
Bisexual	1 (1)	2 (3)	--	--	5 (6)	1 (1)	3 (2)	2 (1)
Homosexual	--	--	--	--	2 (2)	--	--	1 (1)
Unsure	--	--	--	--	--	1 (1)	1 (1)	2 (1)
Not reported	--	--	1 (1)	--	2 (2)	1 (1)	--	--
Age and duration of Injection (years)								
Median (Med) age	29	36	29	27	30	30	32	31
Age range	17 – 53	17 – 67	18 – 47	17 – 63	18 – 52	17 – 66	17 – 55	17 – 64
Age group (%)								
<25 years	28 (34)	12 (21)	21 (23)	29 (44)	26 (31)	43 (34)	28 (20)	41 (29)
25+ years	54 (64)	46 (79)	70 (77)	37 (56)	59 (69)	83 (66)	109 (78)	98 (70)
Not reported	--	--	--	--	--	--	2 (1)	1 (1)
Med age 1st IDU	17	--	17	--	17	--	18	--
Age range	11 – 38	--	11 – 34	--	8 – 35	--	10 – 47	--
Not reported	--	--	5	--	4	--	4	--
Med IDU (years)	9	--	10	--	13	--	14	--
Range	<1 – 28	--	<1 – 33	--	<1 – 34	--	<1 – 44	--
Duration of drug injection (%)								
<3 years	9 (11)	--	6 (7)	--	5 (6)	--	18 (13)	--
3+ years	73 (89)	--	80 (88)	--	76 (89)	--	114 (84)	--
Not reported	--	--	5 (5)	--	4 (5)	--	4 (3)	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	74 (90)	52 (90)	77 (85)	57 (86)	63 (74)	76 (60)	87 (63)	88 (63)
Yes	8 (10)	6 (10)	14 (15)	9 (14)	22 (26)	50 (40)	51 (37)	52 (37)
Not reported	--	--	--	--	--	--	1 (1)	--
Residential remoteness in 12 months before prison (%)								
Highly/accessible	80 (98)	52 (90)	82 (90)	60 (91)	72 (85)	89 (71)	119 (86)	90 (64)
Mod accessible	--	1 (2)	1 (1)	2 (3)	4 (5)	9 (7)	14 (10)	24 (17)
Very / remote	2 (2)	2 (3)	2 (2)	1 (2)	3 (4)	22 (17)	5 (4)	22 (16)
Not reported	--	3 (5)	6 (7)	3 (5)	6 (7)	6 (5)	1 (1)	4 (3)
Region/Country of birth (%)								
Australia	71 (87)	40 (69)	83 (91)	61 (92)	76 (89)	106 (84)	128 (92)	124 (89)
Other Oceania	8 (10)	8 (14)	1 (1)	1 (2)	4 (5)	11 (9)	5 (4)	8 (6)
Asia	2 (2)	2 (3)	6 (7)	1 (2)	1 (1)	--	1 (1)	2 (1)
UK & Ireland	1 (1)	3 (5)	--	--	3 (4)	2 (2)	4 (3)	2 (1)
Other	--	5 (9)	--	3 (5)	1 (1)	7 (6)	1 (1)	4 (3)
Not reported	--	--	1 (1)	--	--	--	--	--
Main language spoke at home by parents (%)								
English	79 (96)	52 (90)	86 (95)	63 (95)	82 (96)	118 (94)	136 (98)	118 (84)
Non-English	3 (4)	6 (10)	5 (5)	3 (5)	2 (2)	7 (6)	3 (2)	22 (16)
Not reported	--	--	--	--	1 (1)	1 (1)	--	--

Table 178 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-	IDU	Non-	IDU	Non-	IDU	Non-
First time in prison (%)								
No	81 (99)	53 (91)	80 (88)	33 (50)	73 (86)	68 (54)	118 (85)	82 (59)
Yes	1 (1)	5 (9)	11 (12)	32 (48)	12 (14)	56 (44)	20 (14)	57 (41)
Not reported	--	--	--	1 (2)	--	2 (2)	1 (1)	1 (1)
Lifetime imprisonments (%)*								
One	1 (1)	5 (9)	11 (12)	32 (48)	25 (29)	78 (62)	n/a	n/a
Two to four	57 (70)	47 (81)	48 (53)	25 (38)	28 (33)	30 (24)	n/a	n/a
Five to nine	19 (23)	4 (7)	20 (22)	3 (5)	21 (25)	8 (6)	n/a	n/a
Ten or more	5 (6)	1 (2)	10 (11)	4 (6)	11 (13)	8 (6)	n/a	n/a
Not reported	--	1 (2)	2 (2)	2 (3)	--	2 (2)	n/a	n/a
Imprisonment in last year (%)								
No	2 (2)	5 (9)	32 (40)	11 (32)	27 (32)	80 (63)	33 (28)	22 (57)
Yes	80 (98)	53 (91)	46 (58)	22 (65)	55 (65)	41 (33)	77 (65)	53 (65)
Not reported	--	--	2 (3)	1 (3)	3 (4)	5 (4)	8 (7)	7 (9)
Frequency of injection last month (%)								
Not last month	32 (39)	--	44 (48)	--	38 (45)	--	36 (26)	--
< weekly	6 (7)	--	10 (11)	--	8 (9)	--	24 (17)	--
Weekly	7 (9)	--	6 (7)	--	5 (6)	--	14 (10)	--
Daily or more	37 (45)	--	28 (31)	--	33 (39)	--	63 (45)	--
Not reported	--	--	3 (3)	--	1 (1)	--	2 (1)	--
Ever smoked a full cigarette (%)**								
No	n/a	n/a	5 (5)	14 (21)	2 (2)	11 (9)	8 (6)	20 (14)
Yes	n/a	n/a	86 (95)	52 (79)	83 (98)	115 (91)	131 (94)	120 (86)
Not reported	n/a	n/a	--	--	--	--	--	--
Med Age 1st smoked								
Age range	n/a	n/a	6 – 25	6 – 22	7 – 37	6 – 50	6 – 35	6 – 40
Current smoker (%)**								
No	n/a	n/a	5 (6)	14 (21)	8 (9)	30 (24)	9 (7)	13 (11)
Yes	n/a	n/a	86 (95)	52 (79)	77 (91)	96 (76)	122 (93)	103 (86)
Not reported	--	--	--	--	--	--	--	4 (3)
Smoking frequency (%)**								
Weekly or less	n/a	n/a	5 (6)	4 (8)	1 (1)	6 (6)	--	--
5 - 10/day	n/a	n/a	19 (22)	11 (21)	18 (23)	46 (48)	46 (38)	41 (39)
11 - 20/day	n/a	n/a	28 (33)	15 (29)	40 (52)	24 (25)	48 (39)	40 (38)
>20/day	n/a	n/a	34 (40)	21 (40)	17 (22)	19 (20)	26 (21)	20 (19)
Not reported	n/a	n/a	--	1 (2)	1 (1)	1 (1)	2 (2)	5 (5)
Other drugs used last month (%)***								
None	n/a	n/a	n/a	n/a	17 (21)	53 (47)	16 (12)	64 (46)
Cannabis	n/a	n/a	n/a	n/a	45 (69)	48 (81)	84 (68)	57 (75)
Heroin	n/a	n/a	n/a	n/a	23 (35)	1 (2)	31 (25)	2 (3)
Cocaine	n/a	n/a	n/a	n/a	1 (2)	1 (2)	7 (6)	5 (7)
Amphetamine	n/a	n/a	n/a	n/a	33 (51)	7 (12)	89 (72)	26 (34)
Methadone	n/a	n/a	n/a	n/a	4 (6)	--	7 (6)	1 (1)
Other opiates	n/a	n/a	n/a	n/a	6 (9)	1 (2)	28 (23)	3 (4)
Buprenorphine	n/a	n/a	n/a	n/a	10 (15)	1 (2)	6 (5)	--
Steroids	n/a	n/a	n/a	n/a	--	1 (2)	6 (5)	--
Hallucinogens	n/a	n/a	n/a	n/a	1 (2)	--	4 (3)	4 (5)
Benzodiazepine	n/a	n/a	n/a	n/a	15 (23)	4 (7)	28 (23)	7 (9)
Ecstasy/MDA	n/a	n/a	n/a	n/a	2 (3)	2 (3)	11 (9)	6 (8)
Inhalants	n/a	n/a	n/a	n/a	--	--	--	1 (1)
Other drug	n/a	n/a	n/a	n/a	--	1 (2)	2 (2)	--
Not reported	n/a	n/a	n/a	n/a	3 (4)	14 (11)	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 179 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)	N = 82	N = 91	N = 85	N = 139
Amphetamine (Speed, Ice)	59 (72)	57 (63)	49 (58)	95 (68)
Anabolic steroids	--	--	--	4 (3)
Cocaine	--	1 (1)	1 (1)	1 (1)
Heroin	20 (24)	20 (22)	21 (25)	24 (17)
Heroin + amphetamine	--	2 (2)	--	1 (1)
Heroin + cocaine	--	--	--	1 (1)
Methadone	1 (1)	2 (2)	--	1 (1)
Morphine	2 (2)	4 (4)	5 (6)	7 (5)
Other	--	4 (4)	7 (8)	2 (1)
Not reported	--	1 (1)	2 (2)	3 (2)
N° Injected last month	N = 50	N = 44	N = 46	N = 102
Places injected last month (%)*				
Prison	3 (6)	1 (2)	2 (4)	2 (2)
Own home	45 (90)	39 (89)	28 (61)	61 (60)
Friend's home	37 (74)	27 (61)	20 (43)	34 (33)
Dealer's home	23 (46)	19 (43)	8 (17)	15 (15)
Street, park, beach	25 (50)	20 (45)	8 (17)	12 (12)
Car	31 (62)	21 (48)	12 (26)	16 (16)
Public toilet	21 (42)	16 (36)	11 (24)	9 (9)
Commercial injecting room	2 (4)	--	1 (2)	--
Medically Supervised Injecting Centre, Sydney	4 (8)	--	1 (2)	--
Squat	9 (18)	1 (2)	1 (2)	--
Other place	--	1 (2)	1 (2)	1 (1)
Use of sterile needles & syringes last month (%)				
All injections	37 (74)	28 (64)	38 (83)	75 (74)
Most of the time	8 (16)	9 (20)	4 (9)	17 (17)
Half of the time	4 (8)	4 (9)	2 (4)	1 (1)
Some of the time	1 (2)	3 (7)	--	6 (6)
Not last month	--	--	1 (2)	1 (1)
Not reported	--	--	1 (2)	2 (2)
Re-used someone else's used needle & syringe last month (%)				
None	39 (78)	33 (75)	36 (78)	81 (79)
Once	1 (2)	2 (5)	2 (4)	4 (4)
Twice	4 (8)	3 (7)	3 (7)	3 (3)
3-5 times	2 (4)	3 (7)	2 (4)	5 (5)
>5 times	4 (8)	3 (7)	2 (4)	7 (7)
Not reported	--	--	1 (2)	2 (2)
Number of people needle & syringe was re-used after last month (%)				
One	8 (16)	5 (11)	2 (4)	7 (33)
Two	2 (4)	1 (2)	2 (4)	4 (19)
Three to five	1 (2)	2 (5)	1 (2)	3 (14)
More than five	--	--	2 (4)	3 (14)
Don't know how many	--	3 (7)	1 (2)	1 (5)
Not reported	--	--	1 (2)	3 (14)
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	8 (16)	6 (14)	3 (7)	3 (14)
Casual sex partner	1 (2)	1 (2)	2 (4)	2 (10)
Close friend	2 (4)	5 (11)	2 (4)	8 (38)
Acquaintance	1 (2)	1 (2)	3 (7)	7 (33)
Other	1 (2)	--	1 (2)	1 (5)
Equipment used after someone else last month (%)*				
Spoon	11 (22)	20 (46)	15 (33)	8 (38)
Water	42 (84)	18 (41)	12 (26)	8 (38)
Filter	42 (84)	19 (43)	12 (26)	4 (19)
Tourniquet	2 (4)	10 (23)	9 (20)	4 (19)
Drug mix	7 (14)	18 (41)	10 (22)	9 (43)

* More than one option could be selected.

Table 180 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140
Any treatment/therapy for drug use (%)								
No	50 (61)	55 (95)	48 (53)	9 (14)	48 (56)	115 (91)	81 (58)	121 (86)
Yes	32 (38)	2 (3)	24 (26)	--	37 (44)	8 (6)	58 (42)	17 (12)
Not reported	--	1 (2)	19 (21)	57 (86)	--	3 (2)	--	2 (1)
History of methadone maintenance treatment (%)								
Currently	3 (4)	2 (3)	2 (2)	--	4 (5)	--	3 (2)	--
Previously	17 (21)	--	9 (10)	--	12 (14)	--	16 (12)	--
Never	62 (76)	56 (97)	62 (68)	--	69 (81)	123 (98)	138 (99)	120 (86)
Not reported	--	--	18 (20)	--	--	3 (2)	--	2 (1)
History of other pharmacotherapy treatment (%)								
Currently	66 (80)	56 (97)	7 (8)	--	5 (6)	1 (1)	--	--
Previously	4 (5)	2 (3)	9 (10)	--	11 (13)	--	12 (9)	--
Never	12 (15)	--	64 (70)	--	69 (81)	123 (98)	126 (91)	137 (98)
Not reported	--	--	11 (12)	--	--	2 (2)	1 (1)	3 (2)

Table 181 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013
N° surveyed	N = 50	N = 44	N = 85	N = 139
From an NSP last month (%)				
Daily or almost daily	11 (22)	4 (9)	6 (7)	5 (4)
A couple of times each week	10 (20)	7 (16)	17 (20)	15 (11)
Less than weekly	n/a	n/a	6 (7)	21 (15)
Weekly	8 (16)	8 (18)	12 (14)	--
Once last month	10 (20)	3 (7)	--	28 (20)
Not in the last month	11 (22)	6 (14)	37 (44)	65 (47)
Not reported	--	16 (36)	6 (7)	5 (4)
From a chemist last month (%)				
Daily or almost daily	4 (8)	5 (11)	1 (1)	2 (1)
A couple of times each week	12 (24)	2 (5)	10 (12)	6 (4)
Less than weekly	12 (24)	12 (27)	7 (8)	15 (11)
Weekly	n/a	n/a	7 (8)	--
Once last month	7 (14)	5 (11)	--	21 (15)
Not in the last month	15 (30)	4 (9)	54 (64)	90 (65)
Not reported	--	16 (36)	4 (5)	5 (4)

* The option of 'weekly' was not asked in the 2004 and 2007 surveys

Table 182 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU N = 82	Non-IDU N = 58	IDU N = 91	Non-IDU N = 66	IDU N = 85	Non- N = 126	IDU N = 139	Non-IDU N = 140
N^o surveyed								
Body or ear piercings (%)								
No	50 (61)	40 (69)	55 (60)	44 (67)	46 (54)	76 (60)	88 (63)	95 (68)
Yes	31 (38)	18 (31)	35 (38)	22 (33)	39 (46)	50 (40)	51 (37)	45 (32)
Not reported	1 (1)	--	1 (1)	--	--	--	--	--
Pierced in past 12 months (%)								
No	10 (32)	5 (28)	14 (40)	9 (40)	26 (65)	26 (50)	43 (84)	36 (80)
Yes	5 (16)	--	4 (11)	1 (5)	4 (10)	3 (6)	4 (8)	6 (13)
Not reported	16 (52)	13 (72)	17 (49)	12 (55)	10 (25)	23 (44)	4 (8)	3 (7)
Who did piercing (%)*								
Chemist/salon	--	--	--	--	--	--	1 (25)	2 (33)
Professional piercer	1 (20)	--	3 (75)	1 (100)	--	2 (67)	2 (50)	2 (33)
Tattooist/parlour	--	--	--	--	1 (25)	1 (33)	--	1 (17)
Friend	1 (20)	--	--	--	1 (25)	--	1 (25)	--
Prison inmate	1 (20)	--	--	--	--	--	--	--
Self	3 (60)	--	1 (25)	--	2 (50)	--	1 (25)	--
Family member	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	5 (100)	--	1 (25)	--	3 (75)	--	2 (100)	--
Yes	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	3 (75)	1 (100)	1 (25)	3 (100)	--	--
Tattoos (%)								
No	23 (28)	30 (52)	25 (27)	36 (55)	9 (11)	53 (42)	15 (11)	50 (36)
Yes	59 (72)	28 (48)	66 (73)	30 (45)	71 (84)	64 (51)	124 (89)	90 (64)
Not reported	--	--	--	--	5 (6)	9 (7)	--	--
Tattoos in past 12 months (%)								
No	42 (71)	24 (86)	51 (77)	13 (43)	49 (69)	44 (69)	82 (66)	62 (69)
Yes	15 (25)	4 (14)	15 (23)	17 (57)	21 (30)	17 (27)	39 (31)	28 (31)
Not reported	2 (3)	--	--	--	1 (1)	3 (5)	3 (2)	--
Who did tattooing (%)*								
Prof tattooist	9 (60)	2 (50)	3 (20)	12 (71)	10 (48)	6 (35)	13 (33)	13 (46)
Friend	2 (13)	--	7 (47)	4 (24)	7 (33)	9 (53)	16 (41)	11 (39)
Prison inmate	3 (20)	--	3 (20)	1 (6)	3 (14)	1 (6)	5 (13)	--
Self	2 (13)	1 (25)	1 (7)	--	1 (5)	2 (12)	7 (18)	3 (11)
Family member	--	1 (25)	--	--	3 (14)	--	1 (3)	2 (7)
Other	--	--	--	--	--	--	--	2 (7)

* More than one option could be selected.

Table 183 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU N = 82	Non- N = 58	IDU N = 91	Non- N = 66	IDU N = 85	Non- N = 126	IDU N = 139	Non- N = 140
Sex last month / last 3 months (%)**								
No	13 (16)	15 (26)	26 (29)	20 (30)	9 (11)	26 (21)	21 (15)	21 (15)
Yes	69 (84)	43 (74)	64 (70)	46 (70)	73 (86)	97 (77)	117 (84)	117 (84)
Not reported	--	--	1 (1)	--	3 (4)	3 (2)	1 (1)	2 (1)
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 1)	1 (0 – 2)	0 (0 – 10)	0 (0 – 15)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 12)	1 (0 – 26)	1 (0 – 20)	1 (0 – 40)
Condom use at last sex (%)								
No	66 (80)	44 (76)	69 (76)	45 (68)	n/a	n/a	n/a	n/a
Yes	16 (20)	14 (24)	21 (23)	21 (32)	n/a	n/a	n/a	n/a
Not reported	--	--	1 (1)	--	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	47 (94)	29 (81)	33 (75)	29 (85)	n/a	n/a	n/a	n/a
Sometimes	3 (6)	2 (6)	4 (9)	4 (12)	n/a	n/a	n/a	n/a
Always	--	5 (14)	7 (16)	1 (3)	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	8 (100)	2 (100)	1 (100)	--	n/a	n/a	n/a	n/a
Sometimes	--	--	--	1 (50)	n/a	n/a	n/a	n/a
Always	--	--	--	1 (50)	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	17 (40)	8 (40)	17 (74)	6 (43)	n/a	n/a	n/a	n/a
Sometimes	9 (21)	4 (20)	4 (17)	5 (36)	n/a	n/a	n/a	n/a
Always	17 (40)	8 (40)	2 (9)	3 (21)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	8 (73)	9 (64)	1 (7)	3 (38)
Sometimes	n/a	n/a	n/a	n/a	1 (9)	2 (14)	10 (71)	3 (38)
Always	n/a	n/a	n/a	n/a	2 (18)	3 (21)	3 (21)	2 (25)
Condom use last sex - casual male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	3 (60)	1 (100)	1 (50)	1 (25)
Sometimes	n/a	n/a	n/a	n/a	--	--	1 (50)	1 (25)
Always	n/a	n/a	n/a	n/a	2 (40)	--	--	2 (50)
Condom use last sex - regular female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	37 (84)	40 (62)	62 (82)	59 (66)
Sometimes	n/a	n/a	n/a	n/a	4 (9)	12 (18)	10 (13)	18 (20)
Always	n/a	n/a	n/a	n/a	3 (7)	13 (20)	4 (5)	13 (14)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	16 (70)	8 (24)	25 (57)	14 (45)
Sometimes	n/a	n/a	n/a	n/a	4 (17)	9 (27)	12 (27)	9 (29)
Always	n/a	n/a	n/a	n/a	3 (13)	16 (48)	7 (16)	8 (26)
Sex work last month (%)								
No	81 (99)	57 (98)	90 (99)	66 (100)	82 (96)	122 (97)	134 (96)	138 (99)
Yes	--	1 (2)	--	--	3 (4)	--	5 (4)	2 (1)
Not reported	1 (1)	--	1 (1)	--	--	4 (3)	--	--
Condom used at last sex work last month (%)								
No	--	--	--	--	--	--	3 (60)	1 (50)
Yes	--	1 (100)	--	--	2 (67)	--	1 (20)	1 (50)
Not reported	--	--	--	--	1 (33)	--	1 (20)	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 184 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 82	N = 58	N = 91	N = 66	N = 85	N = 126	N = 139	N = 140
Previous HIV test (%)								
Last year	33 (40)	10 (17)	59 (65)	26 (39)	52 (61)	53 (42)	84 (60)	66 (47)
>1 year ago	33 (40)	26 (45)	24 (26)	25 (38)	23 (27)	33 (26)	39 (28)	34 (24)
Never tested	16 (20)	22 (38)	7 (8)	15 (23)	9 (11)	40 (32)	13 (9)	38 (27)
Not reported	--	--	1 (1)	--	1 (1)	--	3 (2)	2 (1)
HBV infection (%)								
No	76 (93)	56 (97)	88 (97)	61 (92)	75 (88)	113 (90)	203 (73)	106 (76)
Yes	6 (7)	1 (2)	2 (2)	--	1 (1)	3 (2)	32 (11)	8 (6)
Don't know	--	1 (2)	1 (1)	1 (2)	9 (11)	10 (8)	34 (12)	23 (16)
Not reported	--	--	--	4 (6)	--	--	7 (5)	3 (2)
HBV vaccination (%)*								
No	13 (16)	27 (47)	14 (15)	17 (26)	11 (13)	34 (27)	11 (8)	26 (19)
Yes	69 (84)	31 (53)	72 (79)	42 (64)	68 (80)	68 (54)	89 (64)	65 (46)
Don't know	--	--	5 (5)	7 (11)	6 (7)	24 (19)	26 (19)	43 (31)
Not reported	--	--	--	--	--	--	13 (9)	6 (4)
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	n/a	n/a	6 (75)	2 (50)	5 (71)	4 (50)
Yes	n/a	n/a	n/a	n/a	2 (25)	1 (25)	1 (14)	3 (38)
Unsure	n/a	n/a	n/a	n/a	--	1 (25)	1 (14)	1 (13)
Not reported	n/a	n/a	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	30 (37)	9 (16)	6 (7)	15 (23)	54 (64)	51 (40)	87 (63)	65 (46)
>1 year ago	43 (52)	21 (36)	60 (66)	28 (42)	24 (28)	34 (27)	39 (28)	33 (24)
Never tested	9 (11)	28 (48)	25 (27)	23 (35)	6 (7)	41 (33)	13 (9)	41 (29)
Unsure	--	--	--	--	1 (1)	--	--	--
Not reported	--	--	--	--	--	--	--	1 (1)
Any HCV treatment (%)***								
	N = 36	N = 2	N = 41	N = 2	N = 41	N = 0	N = 53	N = 2
Interferon (Int)	--	--	1 (2)	--	1 (2)	--	1 (2)	--
Int & Ribavirin	--	--	--	--	--	--	1 (2)	--
Int & Ribavirin & Boceprevir	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	2 (4)	--
None	36 (100)	2 (100)	40 (98)	2 (100)	40 (98)	--	--	--
Not reported	--	--	--	--	--	--	--	2 (100)
Current HCV treatment								
Interferon (Int)	--	--	--	--	1 (2)	--	1 (2)	--
Int & Ribavirin	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	1 (2)	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 185 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							N = 51	N = 2
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	25 (49)	1 (50)
Yes	n/a	n/a	n/a	n/a	n/a	n/a	25 (49)	1 (50)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	--
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	10 (20)	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	4 (8)	1 (50)
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	18 (35)	1 (50)
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	17 (33)	--
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	15 (29)	--
No	n/a	n/a	n/a	n/a	n/a	n/a	15 (29)	1 (50)
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	13 (25)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	8 (16)	1 (50)
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	35 (69)	2 (100)
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	4 (8)	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (2)	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	6 (12)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	4 (8)	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 186 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	77	0 (0)	--	--	77	0 (0)
Non-IDU	53	1 (2)	--	--	53	1 (2)
p value		0.2		--		0.2
2007						
IDU	77	1 (1)	--	--	77	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	59	0 (0)	14	0 (0)	73	0 (0)
Non-IDU	103	0 (0)	15	0 (0)	118	0 (0)
p value		--		--		--
2013						
IDU	43	0 (0)	11	0 (0)	54	0 (0)
Non-IDU	30	0 (0)	8	0 (0)	38	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 187 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	75	36 (48)	--	--	75	36 (48)
Non-IDU	54	2 (4)	--	--	54	2 (4)
p value		<0.001		--		<0.001
2007						
IDU	77	41 (53)	--	--	77	41 (53)
Non-IDU	58	2 (3)	--	--	58	2 (3)
p value		<0.001		--		<0.001
2010						
IDU	58	29 (50)	14	12 (86)	72	41 (57)
Non-IDU	102	0 (0)	14	0 (0)	116	0 (0)
p value		<0.001		<0.001		<0.001
2013						
IDU	71	50 (70)	17	12 (71)	88	62 (70)
Non-IDU	32	3 (9)	8	1 (13)	40	4 (10)
p value						<0.001

† Excludes equivocal test results and missing values.

Table 188 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	127	38 (30)	--	--	127	38 (30)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.4				0.4
2007						
Heterosexual	134	42 (31)	--	--	134	42 (31)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	154	28 (18)	23	8 (35)	177	36 (20)
Bisexual	1	0 (0)	4	3 (75)	5	3 (60)
Homosexual	1	1 (100)	1	1 (100)	2	2 (100)
Unsure	--	--	--	--	--	--
p value		0.1		0.2		<0.01
2013						
Heterosexual	103	53 (51)	20	9 (45)	123	62 (50)
Bisexual	--	0 (0)	3	3 (100)	3	2 (67)
Homosexual	--	0 (0)	--	0 (0)	--	0 (0)
Unsure	--	0 (0)	2	2 (100)	2	2 (100)
p value		--		0.3		0.6

† Excludes equivocal test results and missing values.

Table 189 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	27	6 (22)	--	--	27	6 (22)
25 – 29	24	11 (46)	--	--	24	11 (46)
30 + years	67	21 (31)	--	--	67	21 (31)
p value		0.04		--		0.04
2007						
< 20 years	13	1 (8)	--	--	13	1 (8)
20 – 24	32	10 (31)	--	--	32	10 (31)
25 – 29	36	13 (36)	--	--	36	13 (36)
30 + years	54	19 (35)	--	--	54	19 (35)
p value		0.3		--		0.3
2010						
< 20 years	23	0 (0)	3	1 (33)	26	1 (4)
20 – 24	36	8 (22)	3	1 (33)	39	9 (23)
25 – 29	28	5 (18)	6	4 (67)	34	9 (27)
30 + years	73	16 (22)	16	6 (38)	89	22 (25)
p value		0.1		0.6		0.1
2013						
< 20 years	9	3 (33)	2	0 (0)	11	3 (27)
20 – 24	18	5 (28)	2	0 (0)	20	5 (25)
25 – 29	19	9 (47)	5	3 (60)	24	12 (50)
30 + years	58	37 (64)	17	11 (65)	75	48 (64)
p value		0.031		0.1		0.005

† Excludes equivocal test results and missing values.

Table 190 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	8	0 (0)	--	--	8	0 (0)
3 to 5 years	9	1 (11)	--	--	9	1 (11)
6 to 10 years	22	10 (45)	--	--	22	10 (45)
10 + years	36	25 (69)	--	--	36	25 (69)
p value		<0.001		--		<0.001
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	5 (50)	--	--	10	5 (50)
6 to 10 years	23	9 (39)	--	--	23	9 (39)
10 + years	34	22 (65)	--	--	34	22 (65)
p value		0.1		--		0.1
2010						
<3 years	4	1 (25)	--	--	4	1 (25)
3 to 5 years	5	1 (20)	2	1 (50)	7	2 (29)
6 to 10 years	13	6 (46)	3	3 (100)	16	9 (56)
10 + years	33	20 (61)	8	7 (88)	41	27 (66)
p value		0.2		0.3		0.2
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	6	1 (17)	--	--	6	1 (17)
6 to 10 years	10	8 (80)	3	2 (67)	13	10 (77)
10 + years	45	37 (82)	11	9 (82)	56	46 (82)
p value		0.002		0.6		0.002

† Excludes equivocal test results and missing values.

Table 191 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	46	20 (43)	54	20 (37)
Heroin	--	--	19	15 (79)	19	15 (79)
More than one	--	--	2	1 (50)	2	1 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.03		0.007
2007						
Amphetamine (Speed, Ice)	4	0 (0)	46	19 (41)	50	19 (38)
Heroin	1	1 (100)	13	10 (77)	14	1 (79)
More than one	--	--	2	2 (100)	2	2 (100)
Other/not reported	--	--	6	5 (83)	6	5 (83)
p value		0.03		0.02		0.002
2010						
Amphetamine (Speed, Ice)	4	1 (25)	36	17 (47)	40	18 (45)
Heroin	--	--	18	15 (83)	18	15 (83)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	--	--	9	6 (67)	9	6 (67)
p value		--		0.04		0.03
2013						
Amphetamine (Speed, Ice)	7	1 (14)	54	39 (72)	61	40 (66)
Heroin	1	0 (0)	17	15 (88)	18	15 (83)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	7	6 (86)	8	6 (75)
p value		0.9		0.3		0.3

† Excludes equivocal test results and missing values.

Table 192 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	2	0 (0)	9	7 (78)	11	7 (64)
Daily or more	3	0 (0)	30	18 (60)	33	18 (55)
p value		--		0.09		0.6
2007						
Less than daily	1	0 (0)	13	6 (46)	14	6 (43)
Daily or more	1	1 (100)	21	15 (71)	22	16 (73)
p value		0.2		0.1		0.07
2010						
Less than daily	2	1 (50)	9	4 (44)	11	5 (45)
Daily or more	--	--	24	19 (79)	24	19 (79)
p value		--		0.05		0.05
2013						
Less than daily	4	0 (0)	18	12 (67)	22	1 (55)
Daily or more	4	1 (25)	44	40 (91)	48	41 (85)
p value		0.3		0.02		0.05

† Excludes equivocal test results and missing values.

Table 193 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	5	0 (0)	28	16 (57)	33	16 (48)
Yes	0	0 (0)	11	9 (82)	11	9 (82)
p value		--		0.1		0.05
2007						
No	2	1 (50)	25	12 (48)	27	13 (48)
Yes	--	--	7	7 (100)	7	7 (100)
p value		--		0.01		0.005
2010						
No	1	0 (0)	27	19 (70)	28	19 (68)
Yes	1	1 (100)	5	3 (60)	6	4 (67)
p value		0.2		0.7		1.0
2013						
No	--	--	--	--	--	--
Yes	3	1 (33)	12	12 (100)	15	13 (87)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 194 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	1	1 (100)	1	1 (100)
Yes	8	0 (0)	66	35 (53)	74	35 (47)
p value		--		0.4		0.3
2007						
No	2	0 (0)	24	9 (38)	26	9 (35)
Yes	2	1 (50)	33	26 (79)	35	27 (77)
p value		0.2		0.002		0.001
2010						
No	1	0 (0)	20	9 (45)	21	9 (43)
Yes	3	1 (33)	42	27 (64)	45	28 (62)
p value		0.5		0.2		0.1
2013						
No	2	0 (0)	17	12 (71)	19	12 (63)
Yes	3	0 (0)	51	42 (82)	54	42 (78)
p value		--		0.3		0.005

† Excludes equivocal test results and missing values.

Table 195 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	5	1 (20)	--	--	5	1 (20)
2 to 4	97	24 (25)	--	--	97	24 (25)
5 to 9	20	10 (50)	--	--	20	10 (50)
10 +	6	3 (50)	--	--	6	3 (50)
p value		0.09		--		0.09
2007						
1	40	0 (0)	--	--	40	0 (0)
2 to 4	64	22 (34)	--	--	64	22 (34)
5 to 9	17	11 (65)	--	--	17	11 (65)
10 +	12	9 (75)	--	--	12	9 (75)
p value		<0.001		--		<0.001
2010						
1	78	4 (5)	17	5 (29)	95	9 (10)
2 to 4	50	11 (22)	6	5 (83)	56	16 (29)
5 to 9	17	9 (53)	3	1 (33)	20	10 (50)
10 +	14	5 (36)	2	1 (50)	16	6 (38)
p value		<0.001		0.1		<0.001
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 196 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	115	34 (30)	--	--	115	34 (30)
Indigenous	14	4 (29)	--	--	14	4 (29)
p value		0.9		--		0.9
2007						
Non-Indigenous	116	36 (31)	--	--	116	36 (31)
Indigenous	19	7 (37)	--	--	19	7 (37)
p value		0.6		--		0.6
2010						
Non-Indigenous	99	19 (19)	21	8 (38)	120	27 (23)
Indigenous	61	10 (16)	7	4 (57)	68	14 (21)
p value		0.7		0.4		0.8
2013						
Non-Indigenous	76	34 (45)	17	9 (53)	93	43 (46)
Indigenous	28	20 (71)	9	5 (56)	37	25 (68)
p value		0.016		0.9		0.03

† Excludes equivocal test results and missing values.

Table 197 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	48	2 (4)	67	32 (48)	115	34 (30)
Indigenous	6	0 (0)	8	4 (50)	14	4 (29)
p value		0.6		0.9		0.9
2007						
Non-Indigenous	50	1 (2)	66	35 (53)	116	36 (31)
Indigenous	8	1 (13)	11	6 (55)	19	7 (37)
p value		0.1		0.9		0.6
2010						
Non-Indigenous	68	0 (0)	52	27 (52)	120	27 (23)
Indigenous	48	0 (0)	20	14 (70)	68	14 (21)
p value		--		0.2		0.8
2013						
Non-Indigenous	36	3 (8)	56	39 (70)	92	42 (46)
Indigenous	4	1 (25)	32	23 (72)	36	24 (67)
p value		0.3		0.8		0.03

† Excludes equivocal test results and missing values.

Table 198 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	123	37 (30)	--	--	123	37 (30)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Highly accessible/accessible	123	40 (33)	--	--	123	40 (33)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	0 (0)	--	--	3	0 (0)
p value		0.6		--		0.6
2010						
Highly accessible/accessible	118	26 (22)	24	11 (46)	142	37 (26)
Moderately accessible	8	0 (0)	3	1 (33)	11	1 (9)
Remote/very remote	23	0 (0)	1	0 (0)	24	0 (0)
p value		0.02		0.6		0.01
2013						
Highly accessible/accessible	96	48 (50)	23	12 (52)	119	60 (50)
Moderately accessible	3	2 (67)	1	0 (0)	4	2 (50)
Remote/very remote	4	3 (75)	--	--	4	3 (75)
p value		0.5		0.3		0.6

† Excludes equivocal test results and missing values.

Table 199 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	104	34 (33)	--	--	104	34 (33)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.1		--		0.1
2007						
Australia	124	38 (31)	--	--	124	38 (31)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	4 (67)	--	--	6	4 (67)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	143	26 (18)	23	10 (43)	166	36 (22)
Other Oceania	11	2 (18)	2	0 (0)	13	2 (15)
Asia	1	1 (100)	--	--	1	1 (100)
UK & Ireland	1	0 (0)	1	1 (100)	2	1 (50)
Other	4	0 (0)	2	1 (50)	6	1 (17)
p value		0.2		0.4		0.3
2013						
Australia	86	49 (57)	20	12 (60)	106	61 (58)
Other Oceania	9	2 (22)	3	1 (33)	12	3 (25)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	3	1 (33)	1	0 (0)	4	1 (25)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.05		0.4		0.04

† Excludes equivocal test results and missing values.

Table 200 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	121	36 (30)	--	--	121	36 (30)
Non-English	8	2 (25)	--	--	8	2 (25)
p value		0.8		--		0.8
2007						
English	128	40 (31)	--	--	128	40 (31)
Non-English	7	3 (43)	--	--	7	3 (43)
p value		0.5		--		0.5
2010						
English	153	28 (18)	26	11 (42)	179	39 (22)
Non-English	5	1 (20)	2	1 (50)	7	2 (29)
p value		0.8		0.8		0.7
2013						
English	98	52 (53)	--	--	123	65 (53)
Non-English	5	1 (20)	25	13 (52)	5	1 (20)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 201 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	29	29 (100)	--	--	29	29 (100)
Negative	61	5 (8)	--	--	61	5 (8)
Not sure	4	2 (50)	--	--	4	2 (50)
p value		<0.001		--		<0.001
2007						
Positive	30	27 (90)	--	--	30	27 (90)
Negative	80	11 (14)	--	--	80	11 (14)
Not sure	7	4 (57)	--	--	7	4 (57)
p value		<0.001		--		<0.001
2010						
Positive	16	16 (100)	12	12 (100)	28	28 (100)
Negative	87	6 (7)	9	0 (0)	96	6 (6)
Not sure	18	6 (33)	--	--	18	6 (33)
p value		<0.001		<0.001		<0.001
2013						
Positive	47	47 (100)	6	6 (100)	53	53 (100)
Negative	37	2 (5)	6	0 (0)	43	2 (5)
Not sure	6	4 (67)	9	7 (78)	15	11 (73)
p value		<0.001		0.001		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 202 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	77	3 (4)	--	--	77	3 (4)
Non-IDU	54	0 (0)	--	--	54	0 (0)
p value		0.1		--		0.1
2007						
IDU	78	1 (1)	--	--	78	1 (1)
Non-IDU	59	0 (0)	--	--	59	0 (0)
p value		0.4		--		0.4
2010						
IDU	58	0 (0)	14	0 (0)	72	0 (0)
Non-IDU	93	2 (2)	14	0 (0)	107	2 (2)
p value		0.3		--		0.2
2013						
IDU	8	2 (25)	2	0 (0)	10	2 (20)
Non-IDU	5	1 (20)	4	0 (0)	9	1 (11)
p value		0.8		--		0.6

† Excludes equivocal test results and missing values.

Table 203 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	74	12 (16)	--	--	74	12 (16)
Non-IDU	54	5 (9)	--	--	54	5 (9)
p value		0.3		--		0.3
2007						
IDU	78	8 (10)	--	--	78	8 (10)
Non-IDU	59	4 (7)	--	--	59	4 (7)
p value		0.5		--		0.5
2010						
IDU	32	6 (19)	1	0 (0)	33	6 (18)
Non-IDU	48	8 (17)	1	0 (0)	49	8 (16)
p value		0.8		--		0.8
2013						
IDU	44	4 (9)	9	1 (11)	53	4 (11)
Non-IDU	29	3 (10)	7	1 (14)	36	5 (9)
p value		0.9		0.9		0.8

† Excludes equivocal test results and missing values.

Table 204 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	126	17 (13)	--	--	126	17 (13)
Bisexual	2	0 (0)	--	--	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6
2007						
Heterosexual	136	12 (9)	--	--	136	12 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	78	14 (18)	2	0 (0)	80	14 (18)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.6		--		0.7
2013						
Heterosexual	73	7 (10)	12	0 (0)	85	7 (8)
Bisexual	--	--	2	0 (0)	2	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	2	2 (100)	2	2 (100)
p value		--		<0.001		<0.001

† Excludes equivocal test results and missing values.

Table 205 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	12	1 (8)	--	--	12	1 (8)
20 – 24	26	1 (4)	--	--	26	1 (4)
25 – 29	24	3 (13)	--	--	24	3 (13)
30 + years	66	12 (18)	--	--	66	12 (18)
p value		0.3		--		0.3
2007						
< 20 years	13	2 (15)	--	--	13	2 (15)
20 – 24	33	1 (3)	--	--	33	1 (3)
25 – 29	36	4 (11)	--	--	36	4 (11)
30 + years	55	5 (9)	--	--	55	5 (9)
p value		0.5		--		0.5
2010						
< 20 years	13	0 (0)	--	--	13	0 (0)
20 – 24	19	1 (5)	--	--	19	1 (5)
25 – 29	12	2 (17)	--	--	12	2 (17)
30 + years	36	11 (31)	2	0 (0)	38	11 (29)
p value		0.03		--		0.04
2013						
< 20 years	8	0 (0)	2	0 (0)	10	0 (0)
20 – 24	14	0 (0)	2	0 (0)	16	0 (0)
25 – 29	15	3 (20)	3	1 (33)	18	4 (22)
30 + years	37	4 (11)	10	1 (10)	47	5 (11)
p value		0.2		0.6		0.1

† Excludes equivocal test results and missing values.

Table 206 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	9	0 (0)	--	--	9	0 (0)
6 to 10 years	22	2 (9)	--	--	22	2 (9)
10 + years	34	9 (26)	--	--	34	9 (26)
p value		0.1		--		0.1
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	10	0 (0)	--	--	10	0 (0)
6 to 10 years	23	2 (9)	--	--	23	2 (9)
10 + years	35	3 (9)	--	--	35	3 (9)
p value		0.6		--		0.6
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	4	0 (0)	--	--	4	0 (0)
6 to 10 years	7	1 (14)	--	--	7	1 (14)
10 + years	19	5 (26)	1	0 (0)	20	5 (25)
p value		0.6		--		0.6
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	5	0 (0)	--	--	--	--
6 to 10 years	4	0 (0)	--	--	5	0 (0)
10 + years	27	4 (15)	1	0 (0)	5	0 (0)
p value		0.5		0.7		0.4

† Excludes equivocal test results and missing values.

Table 207 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	9	1 (11)	46	7 (15)	55	8 (15)
Heroin	--	--	17	4 (24)	17	4 (24)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	--	--	--	--
p value		--		0.6		0.6
2007						
Amphetamine (Speed, Ice)	4	1 (25)	47	4 (9)	51	5 (10)
Heroin	1	0 (0)	13	0 (0)	14	0 (0)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	6	1 (17)	6	1 (17)
p value		0.6		0.6		0.5
2010						
Amphetamine (Speed, Ice)	1	0 (0)	19	2 (11)	20	2 (10)
Heroin	--	--	8	4 (50)	8	4 (50)
More than one	--	--	--	--	--	--
Other/not reported	--	--	4	0 (0)	4	0 (0)
p value		--		0.04		0.03
2013						
Amphetamine (Speed, Ice)	7	0 (0)	30	3 (10)	37	3 (8)
Heroin	2	0 (0)	10	2 (20)	12	2 (17)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	3	0 (0)	4	0 (0)
p value		--		0.6		0.5

† Excludes equivocal test results and missing values.

Table 208 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	2	0 (0)	9	5 (56)	11	5 (45)
Daily or more	4	0 (0)	29	4 (14)	33	4 (12)
p value		--		0.01		0.01
2007						
Less than daily	1	0 (0)	13	2 (15)	14	2 (14)
Daily or more	1	0 (0)	21	1 (5)	22	1 (5)
p value		--		0.3		0.3
2010						
Less than daily	--	--	6	0 (0)	6	0 (0)
Daily or more	--	--	12	4 (33)	12	4 (33)
p value		--		0.1		0.1
2013						
Less than daily	5	0 (0)	11	0 (0)	16	0 (0)
Daily or more	4	0 (0)	19	4 (21)	23	4 (17)
p value		--		0.1		0.08

† Excludes equivocal test results and missing values.

Table 209 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	27	6 (22)	33	6 (18)
Yes	0	0 (0)	11	3 (27)	11	3 (27)
p value		--		0.7		0.5
2007						
No	2	0 (0)	25	3 (12)	27	3 (11)
Yes	--	--	7	0 (0)	7	0 (0)
p value		--		0.3		0.4
2010						
No	--	--	15	3 (20)	15	3 (20)
Yes	--	--	2	0 (0)	2	0 (0)
p value		--		0.5		0.5
2013						
No	--	--	--	--	--	--
Yes	3	0 (0)	5	2 (40)	8	2 (25)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 210 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	1	1 (100)	1	1 (100)
Yes	9	1 (11)	64	11 (17)	73	12 (16)
p value		--		0.7		0.4
2007						
No	2	1 (50)	25	3 (12)	27	4 (15)
Yes	2	0 (0)	33	2 (6)	35	2 (6)
p value		0.3		0.4		0.2
2010						
No	--	--	11	4 (36)	11	4 (36)
Yes	1	0 (0)	19	2 (11)	20	2 (10)
p value		--		0.1		0.1
2013						
No	2	0 (0)	11	0 (0)	13	0 (0)
Yes	4	0 (0)	27	5 (19)	31	5 (16)
p value		--		0.1		0.1

† Excludes equivocal test results and missing values.

Table 211 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	5	0 (0)	--	--	5	0 (0)
2 to 4	96	12 (13)	--	--	96	12 (13)
5 to 9	20	4 (20)	--	--	20	4 (20)
10 +	6	1 (17)	--	--	6	1 (17)
p value		0.7		--		0.7
2007						
1	40	2 (5)	--	--	40	2 (5)
2 to 4	66	10 (15)	--	--	66	10 (15)
5 to 9	17	0 (0)	--	--	17	0 (0)
10 +	12	0 (0)	--	--	12	0 (0)
p value		0.08		--		0.08
2010						
1	32	2 (6)	1	0 (0)	33	2 (6)
2 to 4	31	6 (19)	1	0 (0)	32	6 (19)
5 to 9	8	4 (50)	--	--	8	4 (50)
10 +	8	2 (25)	--	--	8	2 (25)
p value		0.03		--		0.03
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 212 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	114	15 (13)	--	--	114	15 (13)
Indigenous	14	2 (14)	--	--	14	2 (14)
p value		0.9		--		0.9
2007						
Non-Indigenous	117	7 (6)	--	--	117	7 (6)
Indigenous	20	5 (25)	--	--	20	5 (25)
p value		0.005		--		0.005
2010						
Non-Indigenous	47	4 (9)	1	0 (0)	48	4 (8)
Indigenous	33	10 (30)	1	0 (0)	34	10 (29)
p value		0.01		--		0.01
2013						
Non-Indigenous	55	5 (9)	11	1 (9)	66	6 (9)
Indigenous	19	2 (11)	6	1 (17)	25	3 (12)
p value		0.9		0.6		0.7

† Excludes equivocal test results and missing values.

Table 213 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	48	5 (10)	66	10 (15)	114	15 (13)
Indigenous	6	0 (0)	8	2 (25)	14	2 (14)
p value		0.7		0.5		0.9
2007						
Non-Indigenous	50	1 (2)	67	6 (9)	117	7 (6)
Indigenous	9	3 (33)	11	2 (18)	20	5 (25)
p value		0.001		0.4		0.005
2010						
Non-Indigenous	24	0 (0)	24	4 (17)	48	4 (8)
Indigenous	25	8 (32)	9	2 (22)	34	10 (29)
p value		0.002		0.7		0.01
2013						
Non-Indigenous	33	3 (9)	32	3 (9)	65	6 (9)
Indigenous	3	1 (33)	21	2 (10)	24	3 (13)
p value		0.2		1.0		0.7

† Excludes equivocal test results and missing values.

Table 214 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	122	15 (12)	--	--	122	15 (12)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	3	2 (67)	--	--	3	2 (67)
p value		0.02		--		0.02
2007						
Highly accessible/accessible	125	9 (7)	--	--	125	9 (7)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	3	1 (33)	--	--	3	1 (33)
p value		0.2		--		0.2
2010						
Highly accessible/accessible	60	7 (12)	2	0 (0)	62	7 (11)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	11	5 (45)	--	--	11	5 (46)
p value		0.02		--		0.01
2013						
Highly accessible/accessible	71	7 (10)	14	1 (7)	85	8 (9)
Moderately accessible	1	0 (0)	1	0 (0)	2	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.9		0.8		0.9

† Excludes equivocal test results and missing values.

Table 215 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	No tested	No with HBV (%)	No tested	No with HBV (%)	No tested	No with HBV (%)
2004						
Australia	103	12 (12)	--	--	103	12 (12)
Other Oceania	15	2 (13)	--	--	15	2 (13)
Asia	3	2 (67)	--	--	3	2 (67)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.07		--		0.07
2007						
Australia	126	11 (9)	--	--	126	11 (9)
Other Oceania	2	1 (50)	--	--	2	1 (50)
Asia	6	0 (0)	--	--	6	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2
2010						
Australia	72	13 (18)	2	0 (0)	74	13 (18)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	1(100)	--	--	1	1(100)
UK & Ireland	--	--	--	--	--	--
Other	3	0 (0)	--	--	3	0 (0)
p value		0.1		--		0.1
2013						
Australia	58	4 (7)	12	2 (17)	70	6 (9)
Other Oceania	8	1 (13)	2	0 (0)	10	1 (10)
Asia	1	1 (100)	1	0 (0)	2	1 (50)
UK & Ireland	2	0 (0)	1	0 (0)	3	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.02		0.9		0.4

† Excludes equivocal test results and missing values.

Table 216 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	120	14 (12)	--	--	120	14 (12)
Non-English	8	3 (38)	--	--	8	3 (38)
p value		0.04		--		0.04
2007						
English	130	11 (8)	--	--	130	11 (8)
Non-English	7	1 (14)	--	--	7	1 (14)
p value		0.6		--		0.6
2010						
English	77	14 (18)	2	0 (0)	79	14 (18)
Non-English	3	0 (0)	--	--	3	0 (0)
p value		0.4		--		0.4
2013						
English	68	5 (7)	16	2 (13)	84	7 (8)
Non-English	5	2 (40)	--	--	5	2 (40)
p value		0.02		--		0.02

† Excludes equivocal test results and missing values.

Table 217 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	77	29 (38)	10 (13)	3 (4)	35 (45)
Non-IDU	54	35 (65)	5 (9)	0 (0)	14 (26)
p value					0.02
2007					
IDU	78	30 (38)	8 (10)	1 (1)	39 (50)
Non-IDU	59	38 (64)	4 (7)	0 (0)	17 (29)
p value					0.02
2010					
IDU	43	6 (14)	6 (14)	0 (0)	31 (72)
Non-IDU	64	10 (16)	8 (13)	2 (3)	44 (69)
p value					0.7
2013					
IDU	54	19 (35)	3 (6)	2 (4)	30 (56)
Non-IDU	35	22 (63)	3 (9)	1 (3)	9 (26)
p value					0.04

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 218 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	129	62 (48)	15 (12)	3 (2)	49 (38)
Bisexual	2	2 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	136	68 (50)	12 (9)	0 (0)	56 (41)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2010					
Heterosexual	102	13 (13)	14 (14)	2 (2)	73 (72)
Homosexual	--	--	--	--	--
Bisexual	3	1 (33)	0 (0)	0 (0)	2 (67)
Unsure	--	--	--	--	--
p value					0.7
2013					
Heterosexual	85	41 (48)	4 (5)	3 (4)	37 (44)
Homosexual	2	0 (0)	0 (0)	0 (0)	2 (100)
Bisexual	--	--	--	--	--
Unsure	2	0 (0)	0 (0)	0 (0)	0 (0)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 219 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	12	5 (42)	0 (0)	1 (8)	6 (50)
20 – 24	28	12 (43)	2 (7)	0 (0)	14 (50)
25 – 29	24	9 (38)	2 (8)	1 (4)	12 (50)
30 + years	67	38 (57)	11 (16)	1 (1)	17 (25)
p value					0.1
2007					
< 20 years	13	8 (62)	2 (15)	0 (0)	3 (23)
20 – 24	33	11 (33)	1 (3)	0 (0)	21 (64)
25 – 29	36	18 (50)	4 (11)	0 (0)	14 (39)
30 + years	55	31 (53)	5 (9)	1 (2)	18 (33)
p value					0.2
2010					
< 20 years	17	5 (29)	0 (0)	0 (0)	12 (71)
20 – 24	19	2 (11)	1 (5)	0 (0)	16 (84)
25 – 29	21	3 (14)	2 (10)	1 (5)	15 (71)
30 + years	50	6 (12)	11 (22)	1 (2)	32 (64)
p value					0.2
2013					
< 20 years	10	6 (60)	0 (0)	0 (0)	4 (40)
20 – 24	16	10 (63)	0 (0)	0 (0)	6 (38)
25 – 29	18	5 (28)	2 (11)	2 (11)	9 (50)
30 + years	47	21 (45)	4 (9)	1 (2)	21 (45)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 220 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	5	4 (80)	0 (0)	0 (0)	1 (20)
2 to 4	98	50 (51)	12 (12)	2 (2)	34 (35)
5 to 9	21	6 (29)	3 (14)	0 (0)	12 (57)
10 +	6	3 (50)	0 (0)	1 (17)	2 (33)
p value					0.2
2007					
1	40	31 (78)	2 (5)	0 (0)	7 (18)
2 to 4	66	26 (39)	10 (15)	1 (2)	29 (44)
5 to 9	17	7 (41)	0 (0)	0 (0)	10 (59)
10 +	12	3 (25)	0 (0)	0 (0)	9 (75)
p value					<0.01
2010					
1	46	10 (22)	2 (4)	0 (0)	34 (74)
2 to 4	35	4 (11)	6 (17)	1 (3)	24 (69)
5 to 9	12	2 (17)	4 (33)	0 (0)	6 (50)
10 +	13	0 (0)	2 (15)	1 (8)	10 (77)
p value					0.1
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 221 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	117	60 (51)	13 (11)	3 (3)	41 (35)
Indigenous	14	4 (29)	2 (14)	0 (0)	8 (57)
p value					0.3
2007					
Non-Indigenous	117	61 (52)	7 (6)	0 (0)	49 (42)
Indigenous	20	7 (35)	5 (25)	1 (5)	7 (35)
p value					<0.01
2010					
Non-Indigenous	59	11 (19)	4 (7)	0 (0)	44 (75)
Indigenous	48	5 (10)	10 (21)	2 (4)	31 (65)
p value					<0.01
2013					
Non-Indigenous	65	33 (51)	4 (6)	2 (3)	26 (40)
Indigenous	26	9 (35)	2 (8)	1 (4)	14 (54)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 222 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	125	62 (50)	13 (10)	3 (2)	47 (38)
Moderately accessible	1	1(100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	0 (0)	2 (67)	0 (0)	1 (33)
p value					0.1
2007					
Highly accessible/accessible	125	61 (49)	9 (7)	1 (1)	54 (43)
Moderately accessible	2	2(100)	0 (0)	0 (0)	0 (0)
Remote/very remote	3	1 (33)	1 (33)	0 (0)	1 (33)
p value					0.6
2010					
Highly accessible/accessible	78	12 (15)	7 (9)	0 (0)	59 (76)
Moderately accessible	7	2 (29)	0 (0)	1(14)	4 (57)
Remote/very remote	22	8 (36)	1 (5)	1 (5)	12 (55)
p value					<0.01
2013					
Highly accessible/accessible	85	40 (47)	5 (6)	3 (4)	37 (44)
Moderately accessible	2	1 (50)	0 (0)	0 (0)	1 (50)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					1.0

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 223 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	123	62 (50)	13 (11)	2 (2)	46 (37)
Non-English	8	2 (25)	2 (25)	1 (13)	3 (38)
p value					0.1
2007					
English	130	65 (50)	11 (8)	1 (1)	53 (42)
Non-English	7	3 (43)	1 (14)	0 (0)	3 (43)
p value					0.4
2010					
English	102	16 (16)	14 (14)	2 (2)	70 (69)
Non-English	4	0 (0)	0 (0)	0 (0)	4(100)
p value					0.6
2013					
English	84	38 (45)	5 (6)	2 (2)	39 (46)
Non-English	5	3 (60)	1 (20)	1 (20)	0 (0)
p value					0.04

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 224 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	32	4 (13)	--	--	32	4 (13)
Yes	81	45 (56)	--	--	81	45 (56)
Not sure	--	--	--	--	--	--
p value		<0.001		--		<0.001
2007						
No	26	3 (12)	--	--	26	3 (12)
Yes	88	52 (59)	--	--	88	52 (59)
Not sure	10	1 (10)	--	--	10	1 (10)
p value		<0.001		--		<0.001
2010						
No	6	1 (17)	1	0 (0)	7	1 (14)
Yes	69	65 (94)	11	6 (55)	80	71 (89)
Not sure	4	3 (75)	--	--	4	3 (75)
p value		<0.001		0.3		<0.001
2013						
No	5	0 (0)	6	3 (50)	11	3 (27)
Yes	48	28 (58)	7	4 (57)	55	32 (58)
Not sure	11	2 (27)	3	1 (33)	14	4 (29)
p value		0.01		0.8		0.04

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 225 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	158	10 (6)
Female	31	0 (0)
p value		0.2
2013		
Male	77	5 (6)
Female	21	0 (0)
p value		0.2

† Excludes missing values.

Gonorrhoea

Table 226 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	158	2 (1)
Female	31	0 (0)
p value		0.5
2013		
Male	77	0 (0)
Female	21	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 227 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	161	15 (9)	7 (4)	15 (9)
Female	29	2 (7)	1 (3)	2 (7)
p value		0.7	0.9	0.7
2013				
Male	72	0 (0)	0 (0)	0 (0)
Female	20	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

South Australia 2010, 2013

Table 228 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° sites		N = 4		N = 3
N° surveyed	N = 27	N = 29	N = 23	N = 25
Sex (%)				
Male	19 (70)	24 (83)	22 (96)	25 (100)
Female	8 (30)	5 (17)	1 (4)	--
Transgender	--	--	--	--
Sexual identity (%)				
Heterosexual	24 (89)	27 (93)	21 (91)	23 (92)
Bisexual	2 (7)	1 (3)	1 (4)	--
Homosexual	1 (4)	--	--	1 (4)
Unsure	--	--	1 (4)	--
Not reported	--	1 (3)	--	1 (4)
Age and duration of injection (years)				
Median (Med) age	32	37	35	33
Age range	20 – 45	19 – 80	20 – 59	19 – 70
Age group (%)				
<25 years	5 (19)	10 (34)	4 (17)	7 (28)
25+ years	22 (81)	19 (66)	19 (83)	18 (72)
Not reported	--	--	--	--
Med age 1st IDU	16	--	19	--
Age range	10 – 35	--	12 – 36	--
Not reported	2	--	--	--
Med IDU (years)	13	--	12	--
Range	<1 – 30	--	2 – 40	--
Duration of drug injection (%)				
<3 years	1 (4)	--	3 (13)	--
3+ years	24 (89)	--	20 (87)	--
Not reported	2 (7)	--	--	--
Aboriginal and/or Torres Strait Islander origin (%)				
No	19 (70)	17 (59)	13 (57)	15 (60)
Yes	8 (30)	12 (41)	10 (43)	10 (40)
Not reported	--	--	--	--
Residential remoteness in 12 months before prison (%)				
Highly /accessible	24 (89)	22 (76)	19 (83)	16 (64)
Mod accessible	--	2 (7)	1 (4)	--
Very / remote	1 (4)	4 (14)	--	3 (12)
Not reported	2 (7)	1 (3)	3 (13)	6 (24)
Region/Country of birth (%)				
Australia	25 (93)	28 (97)	22 (96)	23 (92)
Other Oceania	--	1 (3)	--	--
Asia	2 (7)	--	1 (4)	--
UK & Ireland	--	--	--	1 (4)
Other	--	--	--	1 (4)
Not reported	--	--	--	--
Main language spoke at home by parents (%)				
English	26 (96)	25 (86)	23 (100)	23 (92)
Non-English	1 (4)	2 (7)	--	2 (8)
Not reported	--	2 (7)	--	--

Table 229 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)				
No	24 (89)	21 (72)	21 (91)	12 (48)
Yes	3 (11)	8 (28)	2 (9)	12 (48)
Not reported	--	--	--	1 (4)
Lifetime imprisonments (%)*				
One	7 (26)	19 (66)	n/a	n/a
Two to four	11 (41)	5 (17)	n/a	n/a
Five to nine	5 (19)	4 (14)	n/a	n/a
Ten or more	4 (15)	1 (3)	n/a	n/a
Not reported	--	--	n/a	n/a
Imprisonment in last year (%)				
No	13 (48)	12 (41)	8 (38)	4 (33)
Yes	12 (44)	11 (38)	9 (43)	6 (50)
Not reported	2 (7)	6 (21)	4 (19)	2 (17)
Frequency of injection last month (%)				
Not last month	16 (59)	--	11 (48)	--
< weekly	4 (15)	--	--	--
Weekly	2 (7)	--	2 (9)	--
Daily or more	5 (19)	--	9 (39)	--
Not reported	--	--	1 (4)	--
Ever smoked a full cigarette (%)**				
No	1 (4)	1 (3)	1 (4)	2 (8)
Yes	26 (96)	28 (97)	22 (96)	23 (92)
Not reported	--	--	--	--
Med age 1st				
Age range	8–20	6–20	9–23	8–18
Current smoker (%)**				
No	1 (4)	4 (14)	3 (14)	2 (9)
Yes	26 (96)	24 (83)	18 (82)	19 (83)
Not reported	--	1 (3)	1 (5)	2 (9)
Smoking frequency (%)**				
Weekly or less	1 (4)	2 (8)	--	--
5-10/day	7 (27)	8 (33)	3 (16)	4 (19)
11 to 20/day	10 (38)	11 (46)	8 (42)	6 (29)
>20/day	8 (31)	3 (13)	6 (32)	7 (33)
Not reported	--	--	2 (11)	4 (19)
Other drugs used last month (%)***				
None	5 (19)	7 (29)	3 (13)	2 (8)
Cannabis	18 (82)	14 (78)	10 (50)	15 (65)
Heroin	4 (18)	1 (6)	5 (25)	1 (4)
Cocaine	3 (14)	--	3 (15)	1 (4)
Amphetamine	14 (64)	5 (28)	10 (50)	10 (43)
Methadone	--	--	--	--
Other opiates	2 (9)	--	3 (15)	4 (17)
Buprenorphine	4 (18)	--	2 (10)	--
Steroids	1 (5)	--	--	--
Hallucinogens	1 (5)	2 (11)	1 (5)	--
Benzodiazepine	4 (18)	3 (17)	4 (20)	3 (13)
Ecstasy/MDA	3 (14)	2 (11)	2 (10)	1 (4)
Inhalants	1 (5)	--	--	1 (4)
Other drug	--	--	--	--
Not reported	--	5 (17)	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 230 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2010	2013
Last drug injected (%)	N = 27	N = 23
Amphetamine (Speed, Ice)	19 (70)	16 (70)
Anabolic steroids	1 (4)	--
Cocaine	--	--
Heroin	6 (22)	6 (26)
Heroin + amphetamine	--	--
Heroin + cocaine	--	--
Methadone	1 (4)	--
Morphine	--	--
Other	--	--
Not reported	--	1 (4)
N° Injected last month	N = 11	N = 11
Places Injected last month (%)*		
Prison	--	2 (18)
Own home	7 (64)	8 (73)
Friend's home	3 (27)	8 (73)
Dealer's home	1 (9)	6 (55)
Street, park, beach	1 (9)	5 (46)
Car	3 (27)	5 (46)
Public toilet	1 (9)	5 (46)
Commercial injecting room	--	--
Medically Supervised Injecting Centre, Sydney	--	--
Squat	--	1 (9)
Other place	--	--
Use of sterile needles & syringes last month (%)		
All injections	10 (91)	6 (55)
Most of the time	1 (9)	3 (27)
Half of the time	--	2 (18)
Some of the time	--	--
Not last month	--	--
Not reported	--	--
Re-used someone else's used needle & syringe last month (%)		
None	10 (91)	9 (82)
Once	1 (9)	1 (9)
Twice	--	--
3-5 times	--	--
>5 times	--	1 (9)
Not reported	--	--
Number of people needle & syringe was re-used after last month (%)		
One	--	1 (50)
Two	1 (9)	--
Three to five	--	--
More than five	--	1 (50)
Don't know how many	--	--
Not reported	--	--
Relationship to people needle & syringe was re-used after last month (%)*		
Regular sex partner	--	--
Casual sex partner	--	--
Close friend	1 (9)	1 (50)
Acquaintance	--	1 (50)
Other	--	--
Equipment used after someone else last month (%)*		
Spoon	1 (9)	4 (9)
Water	--	2 (4)
Filter	--	--
Tourniquet	1 (9)	1 (2)
Drug mix	--	1 (2)

* More than one option could be selected.

Table 231 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25
Any treatment/therapy for drug use (%)				
No	14 (52)	24 (83)	13 (57)	19 (76)
Yes	13 (48)	4 (14)	9 (39)	5 (20)
Not reported	--	1 (3)	1 (4)	1 (4)
History of methadone maintenance treatment (%)				
Currently	4 (15)	--	1 (4)	--
Previously	7 (26)	1 (3)	4 (17)	--
Never	16 (59)	27 (93)	16 (70)	24 (96)
Not reported	--	1 (3)	2 (9)	1 (4)
History of other pharmacotherapy treatment (%)				
Currently	2 (7)	--	1 (4)	--
Previously	5 (19)	--	3 (13)	--
Never	20 (74)	28 (97)	19 (83)	24 (96)
Not reported	--	1 (3)	--	1 (4)

Table 232 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2010	2013
N° surveyed	N = 27	N = 23
From an NSP last month (%)		
Daily or almost daily	2 (7)	2 (9)
A couple of times each week	1 (4)	3 (13)
Less than weekly	2 (7)	2 (9)
Weekly	3 (11)	--
Once last month	--	3 (13)
Not in the last month	18 (67)	13 (57)
Not reported	1 (4)	--
From a chemist last month (%)		
Daily or almost daily	1 (4)	--
A couple of times each week	1 (4)	3 (13)
Less than weekly	3 (11)	1 (4)
Weekly	1 (4)	--
Once last month	--	3 (13)
Not in the last month	20 (74)	16 (70)
Not reported	1 (4)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 233 Number (%) of respondents by body piercing and tattoos

Demographics	2010		2013	
	IDU N = 27	Non-IDU N = 29	IDU N = 23	Non-IDU N = 25
N ^o surveyed				
Body or ear piercings (%)				
No	13 (48)	18 (62)	15 (65)	18 (72)
Yes	13 (48)	11 (38)	8 (35)	7 (28)
Not reported	1 (4)	--	--	--
Pierced in past 12 months (%)				
No	8 (57)	10 (91)	6 (75)	3 (43)
Yes	2 (14)	--	2 (25)	--
Not reported	4 (29)	1 (9)	--	4 (57)
Who did piercing (%)*				
Chemist/salon	1 (50)	--	--	--
Professional	1 (50)	--	2 (100)	--
Tattooist/parlour	--	--	--	--
Friend	--	--	--	--
Prison inmate	--	--	--	--
Self	--	--	--	--
Family member	--	--	--	--
Other	--	--	--	--
Needle used by other (%)				
No	--	--	--	--
Yes	--	--	--	--
Unsure	--	--	--	--
Not reported	--	2 (100)	--	--
Tattoos (%)				
No	8 (30)	17 (59)	1 (4)	10 (40)
Yes	18 (67)	12 (41)	22 (96)	15 (60)
Not reported	1 (4)	--	--	--
Tattoos in past 12 months (%)				
No	14 (78)	10 (83)	12 (55)	7 (47)
Yes	3 (17)	2 (17)	10 (45)	8 (53)
Not reported	1 (5)	--	--	--
Who did tattooing (%)*				
Prof tattooist	3 (100)	2 (100)	7 (70)	5 (63)
Friend	--	--	2 (20)	3 (38)
Prison inmate	--	--	2 (20)	--
Self	--	--	1 (10)	--
Family member	--	--	--	--
Other	--	--	--	--

* More than one option could be selected.

Table 234 Number (%) of respondents by sexual behaviour in the 3 months prior to survey by injector status and survey year

Sex behaviour	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25
Sex last 3 months (%)				
No	3 (11)	3 (10)	3 (13)	2 (8)
Yes	24 (89)	24 (83)	20 (87)	22 (88)
Not reported	--	2 (7)	--	--
Male sex partners in last 3 months				
Median (Range)	1 (0–2)	0 (0–1)	0 (0–1)	--
Female sex partners in last 3 months				
Median (Range)	1 (0–11)	1 (0–6)	1 (0–6)	1 (0–3)
Condom use at last sex - regular male partners – last 3 months				
Never	5 (83)	2 (67)	--	--
Sometimes	--	--	2 (67)	--
Always	1 (17)	1 (33)	1 (33)	--
Condom use last sex - casual male partners - last 3 months (%)				
Never	2 (100)	--	--	--
Sometimes	--	--	--	--
Always	--	--	--	--
Condom use last sex - regular female partners - last 3 months(%)				
Never	12 (75)	16 (84)	12 (71)	15 (75)
Sometimes	4 (25)	3 (16)	3 (18)	3 (15)
Always	--	--	2 (12)	2 (10)
Condom use last sex - casual female partners - last 3 months (%)				
Never	2 (67)	6 (100)	6 (67)	5 (50)
Sometimes	--	--	1 (11)	4 (40)
Always	1 (33)	--	2 (22)	1 (10)
Sex work last month (%)				
No	26 (96)	26 (90)	20 (87)	23 (92)
Yes	1 (4)	--	3 (13)	1 (4)
Not reported	--	3 (10)	--	1 (4)
Condom used at last sex work last month (%)				
No	--	--	--	--
Yes	1 (100)	--	--	--
Not reported	--	--	3 (100)	1 (100)

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

Table 235 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 27	N = 29	N = 23	N = 25
Previous HIV test (%)				
Last year	14 (52)	6 (21)	6 (26)	2 (8)
>1 year ago	5 (19)	7 (24)	12 (52)	5 (20)
Never tested	8 (30)	14 (48)	5 (22)	15 (60)
Not reported	--	--	--	3 (12)
HBV infection (%)				
No	25 (93)	23 (79)	18 (78)	21 (84)
Yes	2 (7)	--	2 (9)	--
Don't know	--	5 (17)	2 (9)	3 (12)
Not reported	--	1 (3)	1 (4)	1 (4)
HBV vaccination (%)*				
No	8 (30)	11 (38)	4 (17)	11 (44)
Yes	17 (63)	11 (38)	17 (74)	6 (24)
Don't know	2 (7)	6 (21)	2 (9)	6 (24)
Not reported	--	1 (3)	--	2 (8)
Ever had cervical cancer vaccine (women only)** (%)				
No	2 (25)	1 (20)	--	--
Yes	3 (38)	2 (40)	--	--
Unsure	--	--	--	--
Not reported	3 (38)	2 (40)	--	--
Previous HCV test (%)				
Last year	13 (48)	7 (24)	11 (48)	4 (16)
>1 year ago	7 (26)	4 (14)	9 (39)	6 (24)
Never tested	6 (22)	16 (55)	3 (13)	14 (56)
Unsure	--	--	--	--
Not reported	1 (4)	2 (7)	--	1 (4)
Any HCV treatment (%)***				
	N = 6	N = 1	N = 4	N = 0
Interferon (Int)	--	--	--	--
Int & Ribavirin	--	--	2 (50)	--
Int & Ribavirin & Boceprevir	--	--	--	--
Other	--	--	--	--
None	6 (100)	1 (100)	--	--
Not reported	--	--	2 (50)	--
Current HCV treatment				
Interferon (Int)	--	--	--	--
Int & Ribavirin	--	--	--	--
Other	--	--	--	--
Unsure	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those testing positive for hepatitis C antibodies.

Table 236 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2010		2013	
	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment				
			N = 2	N = 0
Ever sought out HCV treatment?				
No	n/a	n/a	--	--
Yes	n/a	n/a	1 (50)	--
Not reported	n/a	n/a	1 (50)	--
Willingness to receive treatment for HCV				
Very unwilling	n/a	n/a	--	--
Unwilling	n/a	n/a	--	--
Neutral	n/a	n/a	--	--
Willing	n/a	n/a	--	--
Very willing	n/a	n/a	--	--
Not reported	n/a	n/a	2 (100)	--
More willing to receive HCV treatment in prison than community				
Yes	n/a	n/a	1 (50)	--
No	n/a	n/a	--	--
Unsure	n/a	n/a	--	--
Not reported	n/a	n/a	1 (50)	--
Future treatment plans				
Within 1 year	n/a	n/a	1 (50)	--
Next 1-2 years	n/a	n/a	--	--
Next 2-5 years	n/a	n/a	--	--
>5 years	n/a	n/a	--	--
No plans	n/a	n/a	--	--
Not reported	n/a	n/a	1 (50)	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 237 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2010						
IDU	11	0 (0)	4	0 (0)	15	0 (0)
Non-IDU	18	0 (0)	3	0 (0)	21	0 (0)
p value		--		--		--
2013						
IDU	15	0 (0)	--	--	15	0 (0)
Non-IDU	16	0 (0)	--	--	16	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 238 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
IDU	10	4 (40)	4	2 (50)	14	6 (43)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.03		0.2		<0.01
2013						
IDU	18	5 (28)	1	1 (100)	19	6 (32)
Non-IDU	15	--	--	--	15	--
p value		0.03		--		0.02

† Excludes equivocal test results and missing values.

Table 239 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Heterosexual	25	5 (20)	3	0 (0)	28	5 (18)
Bisexual	--	--	3	1 (33)	3	1 (33)
Homosexual	--	--	1	1 (100)	1	1 (100)
Unsure	--	--	--	--	--	--
p value		--		0.2		0.1
2013						
Heterosexual	30	5 (17)	1	1 (100)	31	6 (19)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	1	0 (0)	--	--	1	0 (0)
p value		0.9		--		0.6

† Excludes equivocal test results and missing values.

Table 240 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	6	0 (0)	1	0 (0)	7	0 (0)
25 – 29	5	1 (20)	2	0 (0)	7	1 (14)
30 + years	14	4 (29)	4	2 (50)	18	6 (33)
p value		0.5		0.4		0.3
2013						
< 20 years	2	0 (0)	--	--	2	0 (0)
20 – 24	8	1 (13)	--	--	8	1 (13)
25 – 29	6	0 (0)	--	--	6	0 (0)
30 + years	19	4 (21)	1	1 (100)	20	5 (25)
p value		0.6		--		0.4

† Excludes equivocal test results and missing values.

Table 241 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	1	0 (0)	1	0 (0)	2	0 (0)
6 to 10 years	1	0 (0)	1	0 (0)	2	0 (0)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.5		0.1		0.2
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	2	0 (0)	--	--	2	0 (0)
6 to 10 years	6	1 (17)	--	--	6	1 (17)
10 + years	8	4 (50)	1	1 (100)	9	5 (56)
p value		0.3		--		0.2

† Excludes equivocal test results and missing values.

Table 242 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Amphetamine (Speed, Ice)	--	--	8	4 (50)	8	4 (50)
Heroin	--	--	3	0 (0)	3	0 (0)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	1	1 (100)	2	1 (50)
p value		--		0.2		0.3
2013						
Amphetamine (Speed, Ice)	2	0 (0)	11	2 (18)	13	2 (15)
Heroin	--	--	5	4 (80)	5	4 (80)
More than one	--	--	--	--	--	--
Other/not reported	--	--	1	0 (0)	1	0 (0)
p value		--		0.04		0.02

† Excludes equivocal test results and missing values.

Table 243 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Less than daily	--	--	3	1 (33)	3	1 (33)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value		--		0.4		0.4
2013						
Less than daily	--	--	2	1 (50)	2	1 (50)
Daily or more	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		0.8		0.2

† Excludes equivocal test results and missing values.

Table 244 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		0.6		0.6
2013						
No	--	--	--	--	--	--
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 245 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
No	--	--	5	2 (40)	5	2 (40)
Yes	1	0 (0)	5	2 (40)	6	2 (33)
p value		--		1.0		0.8
2013						
No	2	0 (0)	5	1 (20)	7	1 (14)
Yes	--	--	7	3 (43)	7	3 (43)
p value		--		0.4		0.7

† Excludes equivocal test results and missing values.

Table 246 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
1	16	2 (13)	3	1 (33)	19	3 (16)
2 to 4	4	1 (25)	2	1 (50)	6	2 (33)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.6		0.5		0.6
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 247 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	18	3 (17)	7	2 (29)	25	5 (20)
Indigenous	8	2 (25)	--	--	8	2 (25)
p value		0.6		--		0.8
2013						
Non-Indigenous	18	2 (11)	--	--	18	2 (11)
Indigenous	15	3 (20)	1	1 (100)	16	4 (25)
p value		0.5		--		0.3

† Excludes equivocal test results and missing values.

Table 248 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Non-Indigenous	14	0 (0)	11	5 (45)	25	5 (20)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.1		0.7		0.8
2013						
Non-Indigenous	8	0 (0)	10	2 (20)	18	2 (11)
Indigenous	7	0 (0)	9	4 (44)	16	4 (25)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 249 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Highly accessible/accessible	23	4 (17)	6	2 (33)	29	6 (21)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	1	1 (100)	--	--	1	1 (100)
p value		0.1		--		0.2
2013						
Highly accessible/accessible	25	4 (16)	1	1 (100)	26	5 (19)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 250 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Australia	25	5 (20)	7	2 (29)	32	7 (22)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.6		--		0.6
2013						
Australia	32	5 (16)	1	1 (100)	33	6 (18)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6

† Excludes equivocal test results and missing values.

Table 251 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
English	25	5 (20)	7	2 (29)	32	7 (22)
Non-English	--	--	--	--	--	--
p value		--		--		--
2013						
English	31	5 (16)	1	1 (100)	32	6 (19)
Non-English	2	0 (0)	--	--	2	0 (0)
p value		0.5		--		0.5

† Excludes equivocal test results and missing values.

Table 252 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2010						
Positive	3	3 (100)	2	2 (100)	5	5 (100)
Negative	7	1 (14)	3	0 (0)	10	1 (10)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		0.03		0.03		0.002
2013						
Positive	17	2 (12)	1	1 (100)	18	3 (17)
Negative	1	1 (100)	--	--	1	1 (100)
Not sure	2	2 (100)	--	--	2	2 (100)
p value		0.005		--		0.13

† Excludes equivocal test results and missing values.

HBV prevalence

Table 253 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	2	1 (50)	1	0 (0)	3	1 (33)
Non-IDU	3	0 (0)	3	0 (0)	6	0 (0)
p value		0.2				0.1
2013						
IDU	13	1 (8)	--	--	13	1 (8)
Non-IDU	10	3 (30)	--	--	10	3 (30)
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 254 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
IDU	11	2 (18)	4	0 (0)	15	2 (13)
Non-IDU	16	1 (6)	3	0 (0)	19	1 (5)
p value		0.3		--		0.4
2013						
IDU	6	2 (33)	--	--	6	2 (33)
Non-IDU	10	0 (0)	--	--	10	0 (0)
p value		0.05		--		0.05

† Excludes equivocal test results and missing values.

Table 255 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Heterosexual	26	3 (12)	3	0 (0)	29	3 (10)
Bisexual	--	--	3	0 (0)	3	0 (0)
Homosexual	--	--	1	0 (0)	1	0 (0)
Unsure	--	--	--	--	--	--
p value		--		--		0.8
2013						
Heterosexual	15	2 (13)	--	--	15	2 (13)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 256 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
< 20 years	6	0 (0)	1	0 (0)	7	0 (0)
20 – 24	5	0 (0)	2	0 (0)	7	0 (0)
25 – 29	15	3 (20)	4	0 (0)	19	3 (16)
30 + years		0.4		--		0.5
p value						
2013						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	5	0 (0)	--	--	5	0 (0)
25 – 29	2	0 (0)	--	--	2	0 (0)
30 + years	10	2 (20)	--	--	10	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 257 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
<3 years	6	0 (0)	--	--	6	0 (0)
3 to 5 years	5	2 (40)	--	--	5	2 (40)
6 to 10 years	11	2 (18)	--	--	11	2 (18)
10 + years	48	12 (25)	--	--	48	12 (25)
p value		0.4		--		0.4
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	3	0 (0)	--	--	3	0 (0)
10 + years	3	2 (67)	--	--	3	2 (67)
p value		0.08		--		0.08

† Excludes equivocal test results and missing values.

Table 258 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Amphetamine (Speed, Ice)	--	--	9	2 (22)	9	2 (22)
Heroin	--	--	3	0 (0)	3	0 (0)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	1	0 (0)	2	0 (0)
p value		--		0.6		0.5
2013						
Amphetamine (Speed, Ice)	--	--	4	1 (25)	4	1 (25)
Heroin	--	--	1	0 (0)	1	0 (0)
More than one	--	--	--	--	--	--
Other/not reported	--	--	1	1 (100)	1	1 (100)
p value		--		0.3		0.3

† Excludes equivocal test results and missing values.

Table 259 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Less than daily	--	--	3	1 (33)	3	1 (33)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value		--		0.4		0.4
2013						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	3	1 (33)	3	1 (33)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 260 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	3	0 (0)	21	4 (19)	24	4 (17)
Yes	1	0 (0)	6	1 (17)	7	1 (14)
p value		--		0.9		0.9
2013						
No	--	--	--	--	--	--
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 261 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
No	--	--	6	0 (0)	6	0 (0)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		--		0.3		0.3
2013						
No	--	--	3	1 (33)	3	1 (33)
Yes	--	--	2	1 (50)	2	1 (50)
p value		--		0.7		0.7

† Excludes equivocal test results and missing values.

Table 262 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
1	16	1 (6)	3	0 (0)	19	1 (5)
2 to 4	5	0 (0)	2	0 (0)	7	0 (0)
5 to 9	4	1 (25)	2	0 (0)	6	1 (17)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.2		--		0.1
2013						
1	n/a	n/a		n/a		n/a
2 to 4	n/a	n/a		n/a		n/a
5 to 9	n/a	n/a		n/a		n/a
10 +	n/a	n/a		n/a		n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 263 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	19	1 (5)	7	0 (0)	26	1 (4)
Indigenous	8	2 (25)	--	--	8	2 (25)
p value		0.1		--		0.07
2013						
Non-Indigenous	7	1 (14)	--	--	7	1 (14)
Indigenous	9	1 (11)	--	--	9	1 (11)
p value		0.9		--		0.9

† Excludes equivocal test results and missing values.

Table 264 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Non-Indigenous	14	0 (0)	12	1 (8)	26	1 (4)
Indigenous	5	1 (20)	3	1 (33)	8	2 (25)
p value		0.09		0.3		0.07
2013						
Non-Indigenous	5	0 (0)	2	1 (50)	7	1 (14)
Indigenous	5	0 (0)	4	1 (25)	9	1 (11)
p value		--		0.5		0.9

† Excludes equivocal test results and missing values.

Table 265 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Highly accessible/accessible	24	2 (8)	6	0 (0)	30	2 (7)
Moderately accessible	1	0 (0)	--	--	1	0 (0)
Remote/very remote	1	1 (100)	--	--	1	1 (100)
p value		0.02		--		0.01
2013						
Highly accessible/accessible	11	2 (18)	--	--	11	2 (18)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	1	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 266 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
Australia	26	3 (12)	7	0 (0)	33	3 (9)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.7		--		0.8
2013						
Australia	15	2 (13)	--	--	15	2 (13)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.8

† Excludes equivocal test results and missing values.

Table 267 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2010						
English	26	3 (12)	7	0 (0)	33	3 (9)
Non-English	--	--	--	--	--	--
p value		--		--		--
2013						
English	14	2 (14)	--	--	14	2 (14)
Non-English	2	0 (0)	--	--	2	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 268 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
IDU	15	1 (7)	1 (7)	1 (7)	12 (80)
Non-IDU	18	7 (39)	1 (6)	0 (0)	10 (56)
p value					0.1
2013					
IDU	9	5 (56)	2 (22)	--	2 (22)
Non-IDU	9	3 (33)	--	--	6 (67)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 269 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Heterosexual	28	7 (25)	2 (7)	1 (4)	18 (64)
Homosexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Bisexual	3	0 (0)	0 (0)	0 (0)	3 (100)
Unsure	--	--	--	--	--
p value					0.9
2013					
Heterosexual	17	8 (47)	2 (12)	--	7 (41)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 270 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	7	0 (0)	0 (0)	0 (0)	7 (100)
25 – 29	7	1 (14)	0 (0)	0 (0)	6 (86)
30 + years	18	6 (33)	2 (11)	1 (6)	9 (50)
p value					0.3
2013					
< 20 years	2	1 (50)	--	--	1 (50)
20 – 24	6	3 (50)	--	--	3 (50)
25 – 29	4	1 (25)	--	--	3 (75)
30 + years	7	3 (43)	2 (29)	--	2 (29)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 271 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
1	18	6 (33)	1 (6)	0 (0)	11 (61)
2 to 4	7	1 (14)	0 (0)	0 (0)	6 (86)
5 to 9	6	1 (17)	0 (0)	1 (17)	4 (67)
10 +	2	0 (0)	1 (50)	0 (0)	1 (50)
p value					0.1
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 272 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Non-Indigenous	25	5 (20)	0 (0)	1 (4)	19 (76)
Indigenous	8	3 (38)	2 (25)	0 (0)	3 (38)
p value					0.03
2013					
Non-Indigenous	10	6 (60)	1 (10)	--	3 (30)
Indigenous	8	2 (25)	1 (13)	--	5 (63)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 273 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
Highly accessible/accessible	29	7 (24)	2 (7)	0 (0)	20 (69)
Moderately accessible	1	0 (0)	0 (0)	0 (0)	1 (100)
Remote/very remote	1	0 (0)	0 (0)	1 (100)	0 (0)
p value					<0.001
2013					
Highly accessible/accessible	13	6 (46)	2 (15)	--	5 (38)
Moderately accessible	--	--	--	--	--
Remote/very remote	2	1 (50)	--	--	1 (50)
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 274 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2010					
English	32	8 (25)	2 (6)	1 (3)	21 (66)
Non-English	--	--	--	--	--
p value					--
2013					
English	17	8 (47)	2 (12)	--	7 (41)
Non-English	1	--	--	--	1 (100)
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 275 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2010						
No	8	4 (50)	1	0 (0)	9	4 (44)
Yes	11	10 (91)	5	5 (100)	16	15 (94)
Not sure	4	3 (75)	--	--	4	3 (75)
p value		0.1		0.01		0.02
2013						
No	7	3 (43)	--	--	7	3 (43)
Yes	4	2 (50)	--	--	4	2 (50)
Not sure	4	2 (50)	--	--	4	2 (50)
p value		1.0		--		1.0

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 276 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--
2013		
Male	31	4 (13)
Female	--	--
p value		--

† Excludes missing values.

Gonorrhoea

Table 277 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	29	0 (0)
Female	8	0 (0)
p value		--
2013		
Male	31	0 (0)
Female	--	--
p value		--

† Excludes missing values.

Syphilis

Table 278 Syphilis markers by sex and survey year†

Sex	N° tested	No with syphilis antibodies (%)	No with syphilis RPR (%)	No with any marker for syphilis (%)
2010				
Male	25	2 (8)	0 (0)	2 (8)
Female	--	--	--	--
p value		--	--	--
2013				
Male	31	0 (0)	0 (0)	0 (0)
Female	--	--	--	--
p value		--	--	--

† Excludes missing values.

Tasmania
2004, 2007, 2010, 2013

Table 279 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 2		N = 3		N = 4		N = 3	
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16
Sex (%)								
Male	22 (85)	14 (93)	19 (86)	21 (88)	18 (95)	13 (100)	16 (94)	13 (81)
Female	4 (15)	1 (7)	3 (14)	3 (13)	1 (5)	--	1 (6)	3 (19)
Transgender	--	--	--	--	--	--	--	--
Sexual Identity (%)								
Heterosexual	25 (96)	15 (100)	21 (95)	23 (96)	19 (100)	12 (92)	14 (82)	15 (94)
Bisexual	1 (4)	--	--	1 (4)	--	1 (8)	--	--
Homosexual	--	--	1 (5)	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	--	--	--	--	3 (18)	1 (6)
Age and duration of injection (years)								
Median (Med) age	25	42	32	26	27	26	31	34
Age range	21 – 48	17 – 64	21 – 45	19 – 58	19 – 50	19 – 59	18 – 43	19 – 60
Age group (%)								
<25 years	2 (8)	3 (20)	1 (5)	11 (46)	6 (32)	5 (38)	3 (18)	4 (25)
25+ years	24 (92)	12 (80)	21 (95)	13 (54)	13 (68)	8 (62)	14 (82)	12 (75)
N/A	--	--	--	--	--	--	--	--
Med age 1 st IDU	20	--	19	--	18	--	19	--
Age range	14 – 30	--	12 – 40	--	12 – 35	--	14 – 32	--
Not reported	--	--	--	--	--	--	--	--
Med IDU (years)	10	--	10	--	9	--	14	--
Range	1 – 32	--	<1 – 27	--	<1 – 25	--	<1 – 22	--
Duration of drug injection (%)								
<3 years	1 (4)	--	1 (5)	--	4 (21)	--	2 (12)	--
3+ years	23 (88)	--	21 (95)	--	15 (79)	--	13 (76)	--
Not reported	2 (8)	--	--	--	--	--	2 (12)	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	16 (62)	9 (60)	18 (82)	20 (83)	17 (89)	10 (77)	11 (65)	15 (94)
Yes	2 (8)	4 (27)	4 (18)	4 (17)	2 (11)	3 (23)	6 (35)	1 (6)
Not reported	8 (31)	2 (13)	--	--	--	--	--	--
Residential remoteness in 12 months before prison (%)								
Highly/accessible	20 (77)	11 (73)	13 (59)	18 (75)	16 (84)	8 (62)	7 (41)	8 (50)
Mod accessible	2 (8)	1 (7)	6 (27)	4 (17)	1 (5)	4 (31)	8 (47)	7 (44)
Very/remote	--	2 (13)	3 (14)	2 (8)	1 (5)	--	1 (6)	1 (6)
Not reported	4 (15)	1 (7)	--	--	1 (5)	1 (8)	1 (6)	--
Region/Country of birth (%)								
Australia	26 (100)	13 (87)	22 (100)	23 (96)	19 (100)	13 (100)	17 (100)	15 (94)
Other Oceania	--	--	--	--	--	--	--	1 (6)
Asia	--	--	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--	--	--
Other	--	--	--	1 (4)	--	--	--	--
Not reported	--	2 (13)	--	--	--	--	--	--
Main language spoke at home by parents (%)								
English	26 (100)	13 (87)	22 (100)	23 (96)	19 (100)	12 (92)	17 (100)	16 (100)
Non-English	--	--	--	1 (4)	--	1 (8)	--	--
Not reported	--	2 (13)	--	--	--	--	--	--

Table 280 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-	IDU	Non-	IDU	Non-	IDU	Non-
First time in prison (%)								
No	17 (65)	10 (67)	19 (86)	12 (50)	15 (79)	10 (77)	12 (71)	4 (25)
Yes	9 (35)	5 (33)	3 (14)	12 (50)	4 (21)	3 (23)	5 (29)	12 (75)
Not reported	--	--	--	--	--	--	--	--
Lifetime imprisonments (%)*								
One	9 (35)	5 (33)	3 (14)	12 (50)	5 (26)	6 (46)	n/a	n/a
Two to four	8 (31)	5 (33)	10 (45)	9 (38)	8 (42)	6 (46)	n/a	n/a
Five to nine	6 (23)	1 (7)	6 (27)	3 (13)	4 (21)	--	n/a	n/a
Ten or more	2 (8)	--	2 (9)	--	2 (11)	1 (8)	n/a	n/a
Not reported	1 (4)	4 (27)	1 (5)	--	--	--	n/a	n/a
Imprisonment in last year (%)								
No	12 (46)	7 (47)	5 (26)	5 (42)	11 (58)	8 (62)	5 (42)	2 (50)
Yes	11 (42)	4 (27)	13 (68)	7 (58)	8 (42)	5 (38)	4 (33)	2 (50)
Not reported	3 (12)	4 (27)	1 (5)	--	--	--	3 (25)	--
Frequency of injection last month (%)								
Not last month	12 (46)	--	6 (27)	--	10 (53)	--	9 (53)	--
< weekly	2 (8)	--	4 (18)	--	5 (26)	--	2 (12)	--
Weekly	6 (23)	--	4 (18)	--	2 (11)	--	2 (12)	--
Daily or more	5 (19)	--	8 (36)	--	2 (11)	--	4 (24)	--
Not reported	1 (4)	--	--	--	--	--	--	--
Ever smoked a full cigarette (%)**								
No	n/a	n/a	--	1 (4)	--	1 (8)	--	3 (19)
Yes	n/a	n/a	22 (100)	23 (96)	19 (100)	12 (92)	17 (100)	13 (81)
Not reported	n/a	n/a	--	--	--	--	--	--
Med age 1st smoked								
Age range	n/a	n/a	7 – 36	6 – 17	8 – 15	10 – 20	5 – 21	7 – 28
Current smoker (%)**								
No	n/a	n/a	1 (5)	4 (17)	1 (5)	4 (31)	2 (12)	2 (15)
Yes	n/a	n/a	21 (95)	20 (83)	18 (85)	9 (69)	15 (88)	11 (85)
Not reported	n/a	n/a	--	--	--	--	--	--
Smoking frequency (%)**								
Weekly or less	n/a	n/a	--	1 (5)	--	--	--	--
5 - 10/day	n/a	n/a	4 (19)	3 (15)	12 (67)	6 (67)	--	--
11 - 20/day	n/a	n/a	8 (38)	9 (45)	3 (17)	3 (33)	9 (60)	4 (40)
>20/day	n/a	n/a	9 (43)	7 (35)	3 (17)	--	6 (40)	6 (60)
Not reported	n/a	n/a	--	--	--	--	--	--
Other drugs used last month (%)***								
None	n/a	n/a	n/a	n/a	5 (26)	4 (31)	1 (6)	7 (44)
Cannabis	n/a	n/a	n/a	n/a	10 (71)	8 (89)	13 (81)	5 (56)
Heroin	n/a	n/a	n/a	n/a	1 (7)	--	--	--
Cocaine	n/a	n/a	n/a	n/a	2 (14)	--	--	--
Amphetamine	n/a	n/a	n/a	n/a	7 (50)	--	9 (56)	--
Methadone	n/a	n/a	n/a	n/a	--	--	--	--
Other opiates	n/a	n/a	n/a	n/a	2 (14)	--	2 (13)	2 (22)
Buprenorphine	n/a	n/a	n/a	n/a	2 (14)	1 (11)	--	--
Steroids	n/a	n/a	n/a	n/a	--	--	--	--
Hallucinogens	n/a	n/a	n/a	n/a	--	--	--	--
Benzodiazepine	n/a	n/a	n/a	n/a	6 (43)	--	4 (25)	--
Ecstasy/MDA	n/a	n/a	n/a	n/a	1 (7)	--	3 (19)	--
Inhalants	n/a	n/a	n/a	n/a	--	--	--	--
Other drug	n/a	n/a	n/a	n/a	--	--	2 (13)	3 (33)
Not reported	n/a	n/a	n/a	n/a	--	--	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 281 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)	N = 26	N = 22	N = 19	N = 17
Amphetamine (Speed, Ice)	20 (77)	16 (73)	12 (63)	14 (82)
Anabolic steroids	--	--	--	--
Cocaine	--	--	--	--
Heroin	2 (8)	1 (5)	--	--
Heroin + amphetamine	--	--	--	--
Heroin + cocaine	--	--	--	--
Methadone	--	--	--	--
Morphine	3 (12)	4 (18)	5 (26)	3 (18)
Other	1 (4)	1 (5)	2 (11)	--
Not reported	--	--	--	--
N° Injected last month	N = 14	N = 16	N = 9	N = 8
Places injected last month (%)*				
Prison	1 (8)	1 (6)	--	--
Own home	11 (79)	15 (94)	4 (44)	6 (75)
Friend's home	7 (50)	13 (81)	4 (44)	5 (63)
Dealer's home	2 (14)	4 (25)	1 (11)	--
Street, park, beach	2 (14)	3 (19)	2 (22)	1 (13)
Car	7 (50)	10 (63)	5 (56)	1 (13)
Public toilet	4 (29)	4 (25)	2 (22)	--
Commercial injecting room	--	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--	--
Squat	--	--	--	--
Other place	--	--	--	--
Use of sterile needles & syringes last month (%)				
All injections	12 (86)	13 (81)	7 (28)	6 (75)
Most of the time	1 (7)	2 (13)	2 (22)	2 (25)
Half of the time	1 (7)	--	--	--
Some of the time	--	--	--	--
Not last month	--	--	--	--
Not reported	--	1 (6)	--	--
Re-used someone else's used needle & syringe last month (%)				
None	12 (86)	14 (88)	8 (89)	7 (88)
Once	1 (7)	1 (6)	--	1 (13)
Twice	1 (7)	--	--	--
3-5 times	--	1 (6)	1 (11)	--
>5 times	--	--	--	--
Not reported	--	--	--	--
Number of people needle & syringe was re-used after last month (%)				
One	1 (7)	1 (6)	--	1 (13)
Two	--	--	--	--
Three to five	--	--	--	--
More than five	--	--	--	--
Don't know how many	--	1 (6)	1 (11)	--
Not reported	1 (7)	--	--	--
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	1 (7)	2 (13)	1 (11)	1 (13)
Casual sex partner	--	--	--	--
Close friend	--	--	1 (11)	--
Acquaintance	1 (7)	--	--	--
Other	--	--	--	--
Equipment used after someone else last month (%)*				
Spoon	1 (7)	3 (19)	1 (11)	--
Water	4 (29)	2 (13)	1 (11)	--
Filter	2 (14)	1 (6)	1 (11)	--
Tourniquet	1 (7)	--	1 (11)	--
Drug mix	1 (7)	2 (13)	1 (11)	--

* More than one option could be selected.

Table 282 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16
Any treatment/therapy for drug use (%)								
No	10 (38)	14 (93)	9 (41)	16 (67)	7 (37)	12 (92)	12 (71)	14 (88)
Yes	16 (62)	--	13 (59)	4 (17)	12 (63)	1 (8)	5 (29)	1 (6)
Not reported	--	1 (7)	--	4 (17)	--	--	--	1 (6)
History of methadone maintenance treatment (%)								
Currently	3 (12)	--	3 (14)	--	1 (5)	--	--	--
Previously	6 (23)	--	2 (9)	--	2 (11)	--	2 (12)	--
Never	16 (62)	14 (93)	17 (77)	--	16 (84)	13 (100)	15 (88)	16 (100)
Not reported	1 (4)	1 (7)	--	--	--	--	--	--
History of other pharmacotherapy treatment (%)								
Currently	2 (8)	--	--	--	2 (11)	1 (8)	--	--
Previously	2 (8)	--	5 (23)	--	3 (16)	--	2 (12)	--
Never	21 (81)	14 (93)	17 (77)	--	14 (74)	12 (92)	15 (88)	15 (94)
Not reported	1 (4)	1 (7)	--	--	--	--	--	1 (6)

Table 283 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013
N° surveyed	N = 14	N = 16	N = 19	N = 17
From an NSP last month (%)				
Daily or almost daily	--	1 (6)	--	--
A couple of times each week	2 (14)	5 (31)	3 (16)	1 (6)
Less than weekly	4 (29)	1 (6)	1 (5)	2 (12)
Weekly	n/a	n/a	4 (21)	--
Once last month	--	1 (6)	--	3 (18)
Not in the last month	--	1 (6)	11 (58)	11 (65)
Not reported	8 (57)	7 (44)	--	--
From a chemist last month (%)				
Daily or almost daily	2 (14)	--	--	--
A couple of times each week	1 (7)	3 (19)	--	--
Less than weekly	1 (7)	3 (19)	1 (5)	2 (12)
Weekly	n/a	n/a	3 (16)	--
Once last month	6 (43)	--	--	1 (6)
Not in the last month	4 (29)	2 (13)	15 (79)	14 (82)
Not reported	--	8 (50)	--	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 284 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU	Non-	IDU	Non-	IDU	Non-	IDU	Non-
N ^o surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16
Body or ear piercings (%)								
No	11 (42)	8 (53)	8 (36)	15 (63)	12 (63)	10 (77)	9 (53)	8 (50)
Yes	15 (58)	7 (47)	14 (64)	9 (38)	7 (37)	3 (23)	7 (41)	8 (50)
Not reported	--	--	--	--	--	--	1 (6)	--
Pierced in past 12 months (%)								
No	12 (80)	5 (71)	13 (93)	9 (100)	3 (43)	2 (67)	5 (71)	6 (75)
Yes	1 (7)	1 (14)	--	--	4 (57)	1 (33)	1 (14)	2 (25)
Not reported	2 (13)	1 (14)	1 (7)	--	--	--	1 (14)	--
Who did piercing (%)*								
Chemist/salon	--	--	--	--	--	1 (100)	--	2 (100)
Professional piercer	--	1 (100)	--	--	--	--	1 (100)	--
Tattooist/parlour	--	--	--	--	--	--	--	--
Friend	--	--	--	--	1 (25)	--	--	--
Prison inmate	--	--	--	--	1 (25)	--	--	--
Self	--	--	--	--	2 (50)	--	--	--
Family member	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	--	--	--	--	4 (100)	--	--	--
Yes	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	3 (100)	1 (100)	--	--	--	1 (100)	1 (100)	2 (100)
Tattoos (%)								
No	48 (26)	67 (53)	25 (19)	44 (39)	20 (20)	64 (42)	1 (6)	3 (19)
Yes	135 (74)	59 (46)	107 (81)	69 (61)	80 (80)	90 (58)	16 (94)	13 (81)
Not reported	--	1 (1)	--	--	--	--	--	--
Tattoos in past 12 months (%)								
No	2 (8)	9 (60)	6 (27)	11 (46)	1 (5)	7 (54)	10 (63)	11 (85)
Yes	24 (92)	6 (40)	16 (73)	13 (54)	18 (95)	5 (38)	6 (38)	2 (15)
Not reported	--	--	--	--	--	1 (8)	--	--
Who did tattooing (%)*								
Prof tattooist	3 (43)	1 (100)	1 (33)	2 (67)	6 (67)	3 (100)	3 (50)	2 (100)
Friend	1 (14)	--	2 (67)	1 (33)	3 (33)	--	2 (33)	--
Prison inmate	1 (14)	--	2 (67)	--	--	--	--	--
Self	1 (14)	--	--	--	--	--	2 (33)	--
Family member	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--

* More than one option could be selected.

Table 285 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU N = 26	Non- N = 15	IDU N = 22	Non- N = 24	IDU N = 19	Non- N = 13	IDU N = 17	Non- N = 16
Sex last month / last 3 months (%)**								
No	9 (35)	8 (53)	6 (27)	3 (13)	4 (13)	2 (15)	--	3 (19)
Yes	17 (65)	7 (47)	16 (73)	21 (88)	28 (88)	11 (85)	14 (82)	12 (75)
Not reported	--	--	--	--	--	--	3 (18)	1 (6)
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 1)	--	0 (0 – 1)	0 (0 – 1)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 4)	1 (0 – 2)	1 (1-10)	1 (0 – 3)
Condom use at last sex (%)								
No	22 (85)	10 (67)	19 (86)	23 (96)	n/a	n/a	n/a	n/a
Yes	4 (15)	5 (33)	3 (14)	1 (4)	n/a	n/a	n/a	n/a
Not reported	--	--	--	--	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	9 (90)	4 (57)	10 (91)	13 (76)	n/a	n/a	n/a	n/a
Sometimes	1 (10)	1 (14)	1 (9)	4 (24)	n/a	n/a	n/a	n/a
Always	--	2 (29)	--	--	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	1 (50)	--	2 (100)	1 (100)	n/a	n/a	n/a	n/a
Sometimes	1 (50)	--	--	--	n/a	n/a	n/a	n/a
Always	--	--	--	--	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	5 (71)	--	4 (100)	3 (60)	n/a	n/a	n/a	n/a
Sometimes	2 (29)	--	--	--	n/a	n/a	n/a	n/a
Always	--	--	--	2 (40)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	--	--	--	--
Sometimes	n/a	n/a	n/a	n/a	1 (100)	--	--	1 (100)
Always	n/a	n/a	n/a	n/a	--	--	1 (100)	--
Condom use last sex - casual male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	--	3 (60)	--	--
Sometimes	n/a	n/a	n/a	n/a	1 (100)	1 (20)	--	--
Always	n/a	n/a	n/a	n/a	--	1 (20)	--	--
Condom use last sex - regular female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	7 (70)	7 (70)	6 (100)	7 (78)
Sometimes	n/a	n/a	n/a	n/a	2 (20)	2 (20)	--	--
Always	n/a	n/a	n/a	n/a	1 (10)	1 (10)	--	2 (22)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	5 (71)	--	6 (86)	1 (50)
Sometimes	n/a	n/a	n/a	n/a	2 (29)	--	1 (14)	--
Always	n/a	n/a	n/a	n/a	--	1 (100)	--	1 (50)
Sex work last month (%)								
No	25 (96)	15 (100)	21 (95)	24 (100)	19 (100)	13 (100)	14 (82)	15 (94)
Yes	1 (4)	--	1 (5)	--	--	--	--	--
Not reported	--	--	--	--	--	--	3 (18)	1 (6)
Condom used at last sex work last month (%)								
No	--	--	1 (100)	--	--	--	--	--
Yes	1 (100)	--	--	--	--	--	--	--
Not reported	--	--	--	--	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 286 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N ^o surveyed	N = 26	N = 15	N = 22	N = 24	N = 19	N = 13	N = 17	N = 16
Previous HIV test (%)								
Last year	13 (50)	5 (22)	3 (14)	11 (46)	7 (37)	5 (38)	6 (35)	2 (13)
>1 year ago	8 (31)	4 (27)	7 (32)	5 (21)	6 (32)	1 (8)	6 (35)	4 (25)
Never tested	5 (19)	5 (33)	12 (55)	8 (33)	6 (32)	7 (54)	4 (24)	10 (63)
Not reported	--	1 (7)	--	--	--	--	1 (6)	--
HBV infection (%)								
No	19 (73)	14 (93)	20 (91)	23 (96)	17 (89)	12 (92)	15 (88)	16 (100)
Yes	6 (23)	--	--	1 (4)	2 (11)	1 (8)	1 (6)	--
Don't know	1 (4)	1 (7)	2 (9)	--	--	--	1 (6)	--
Not reported	--	--	--	--	--	--	--	--
HBV vaccination (%)*								
No	12 (46)	11 (73)	9 (41)	10 (42)	5 (26)	5 (38)	3 (18)	4 (25)
Yes	11 (42)	4 (27)	12 (55)	10 (42)	10 (53)	5 (38)	13 (76)	5 (31)
Don't know	6 (23)	--	1 (5)	4 (17)	3 (16)	3 (23)	1 (6)	7 (44)
Not reported	--	--	--	--	1 (5)	--	--	--
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	n/a	n/a	1 (100)	--	--	--
Yes	n/a	n/a	n/a	n/a	--	--	--	--
Unsure	n/a	n/a	n/a	n/a	--	--	1 (100)	--
Not reported	n/a	n/a	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	9 (35)	4 (27)	5 (23)	11 (46)	5 (26)	5 (38)	5 (31)	2 (13)
>1 year ago	11 (42)	3 (20)	7 (32)	7 (29)	7 (37)	1 (8)	8 (50)	4 (25)
Never tested	6 (23)	8 (53)	10 (45)	6 (25)	6 (32)	7 (54)	2 (13)	10 (63)
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	--	--	1 (5)	--	1 (6)	--
Any HCV treatment (%)***								
	N = 12	N = 1	N = 7	N = 1	N = 8	N = 0	N = 8	N = 0
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	1 (100)	--	--	1 (13)	--	--	--
Int & Ribavirin & Boceprevir	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
None	12 (100)	--	7 (100)	1 (100)	7 (88)	--	8 (100)	--
Not reported	--	--	--	--	--	--	--	--
Current HCV treatment								
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	1 (13)	--	--	--
Other	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 287 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							N = 8	N = 0
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	8 (100)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	7 (88)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	--	--
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	3 (38)	--
No	n/a	n/a	n/a	n/a	n/a	n/a	4 (50)	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	2 (25)	--
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (13)	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	3 (38)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	--	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 288 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	15	0 (0)	2	0 (0)	17	0 (0)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		--
2007						
IDU	16	0 (0)	--	--	16	0 (0)
Non-IDU	17	0 (0)	--	--	17	0 (0)
p value		--		--		--
2010						
IDU	18	0 (0)	1	0 (0)	19	0 (0)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		--		--		--
2013						
IDU	10	0 (0)	--	--	10	0 (0)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 289 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	No with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	16	10 (63)	2	2 (100)	18	12 (67)
Non-IDU	9	1 (11)	--	--	9	1 (11)
p value		0.01		--		<0.01
2007						
IDU	15	7 (47)	--	--	15	7 (47)
Non-IDU	17	1 (6)	--	--	17	1 (6)
p value		0.008		--		0.008
2010						
IDU	17	8 (47)	1	0 (0)	18	8 (44)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		<0.01		--		<0.01
2013						
IDU	12	0 (0)	1	0 (0)	13	10 (77)
Non-IDU	10	9 (75)	2	1 (100)	12	0 (0)
p value		<0.001		0.08		<0.001

† Excludes equivocal test results and missing values.

Table 290 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
Heterosexual	25	11 (44)	1	1 (100)	26	12 (46)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		0.3
2007						
Heterosexual	32	8 (25)	--	--	32	8 (25)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	28	8 (29)	1	0 (0)	29	8 (28)
Bisexual	1	0 (0)	--	--	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.5		--		0.5
2013						
Heterosexual	19	8 (42)	3	1 (33)	22	9 (41)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 291 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	1 (50)	--	--	2	1 (50)
25 – 29	8	2 (25)	3	2 (67)	11	4 (36)
30 + years	16	9 (56)	--	--	16	9 (56)
p value		0.4		--		0.6
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	1 (13)	--	--	8	1 (13)
25 – 29	6	1 (17)	--	--	6	1 (17)
30 + years	17	6 (35)	--	--	17	6 (35)
p value		0.5		--		0.5
2010						
< 20 years	3	1 (33)	--	--	3	1 (33)
20 – 24	7	1 (14)	1	0 (0)	8	1 (13)
25 – 29	6	2 (33)	--	--	6	2 (33)
30 + years	13	4 (31)	--	--	13	4 (31)
p value		0.8		--		0.8
2013						
< 20 years	4	0 (0)	1	1 (100)	5	1 (20)
20 – 24	--	--	--	--	--	--
25 – 29	5	2 (40)	--	--	5	2 (40)
30 + years	14	7 (50)	3	0 (0)	17	7 (41)
p value		0.2		0.05		0.7

† Excludes equivocal test results and missing values.

Table 292 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	No with HCV (%)	No tested	No with HCV (%)	No tested	No with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	6	2 (33)	1	1 (100)	7	3 (43)
10 + years	9	8 (89)	1	1 (100)	10	9 (90)
p value		0.03		--		0.04
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	1 (25)	--	--	4	1 (25)
10 + years	10	6 (60)	--	--	10	6 (60)
p value		0.3		--		0.3
2010						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	3	1 (33)	--	--	3	1 (33)
6 to 10 years	2	2 (100)	1	0 (0)	3	2 (67)
10 + years	8	5 (63)	--	--	8	5 (63)
p value		0.08		--		0.2
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	1	0 (0)	--	--	1	0 (0)
10 + years	8	7 (88)	--	--	8	7 (88)
p value		0.05		--		0.05

† Excludes equivocal test results and missing values.

Table 293 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	9	6 (67)	9	6 (67)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	7	5 (71)	7	5 (71)
Other/not reported	--	--	--	--	--	--
p value		--		0.7		0.7
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	3 (30)	11	3 (27)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	3 (100)	3	3 (100)
p value		--		0.06		0.04
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	3 (38)	11	3 (27)
Heroin	--	--	--	--	--	--
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	5 (100)	6	5 (83)
p value		--		0.04		0.06
2013						
Amphetamine (Speed, Ice)	1	1 (100)	7	6 (86)	8	7 (88)
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	2 (67)	3	2 (67)
p value		--		0.5		0.4

† Excludes equivocal test results and missing values.

Table 294 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	5	3 (60)	5	3 (60)
Daily or more	--	--	4	4 (100)	4	4 (100)
p value		--		0.3		0.3
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.2		0.3
2010						
Less than daily	2	0 (0)	5	3 (60)	7	3 (43)
Daily or more	--	--	2	2 (100)	2	2 (100)
p value		--		0.3		0.2
2013						
Less than daily	--	--	2	2 (100)	2	2 (100)
Daily or more	--	--	3	3 (100)	3	3 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 295 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		0.4		0.4
2007						
No	1	0 (0)	10	4 (40)	11	4 (36)
Yes	--	--	--	--	--	--
p value		--		--		--
2010						
No	2	0 (0)	6	4 (67)	8	4 (50)
Yes	--	--	--	--	--	--
p value		--		--		--
2013						
No	--	--	--	--	--	--
Yes	--	--	1	1 (100)	1	1 (100)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 296 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	8	6 (75)	8	6 (75)
Yes	--	--	2	2 (100)	6	2 (100)
p value		--		0.7		0.7
2007						
No	--	--	4	3 (75)	4	3 (75)
Yes	--	--	10	4 (40)	10	4 (40)
p value		--		0.2		0.2
2010						
No	3	0 (0)	7	3 (43)	10	3 (30)
Yes	1	0 (0)	7	5 (71)	8	5 (63)
p value		--		0.3		0.2
2013						
No	--	--	4	4 (100)	4	4 (100)
Yes	--	--	3	2 (67)	3	2 (67)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 297 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	10	4 (40)	--	--	10	4 (40)
2 to 4	9	4 (44)	--	--	9	4 (44)
5 to 9	4	3 (75)	1	1 (100)	5	4 (80)
10 +	--	--	1	1 (100)	1	1 (100)
p value		0.5		--		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	3 (20)	--	--	15	3 (20)
5 to 9	9	4 (44)	--	--	9	4 (44)
10 +	1	1 (100)	--	--	1	1 (100)
p value		0.06		--		0.06
2010						
1	9	0 (0)	--	--	9	0 (0)
2 to 4	13	2 (15)	1	0 (0)	14	2 (14)
5 to 9	4	4 (100)	--	--	4	4 (100)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.001		--		<0.001
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 298 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	16	9 (56)	1	1 (100)	17	10 (59)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.5		--		0.4
2007						
Non-Indigenous	28	6 (21)	--	--	28	6 (21)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.2		--		0.2
2010						
Non-Indigenous	24	6 (25)	1	0 (0)	25	6 (24)
Indigenous	5	2 (40)	--	--	5	2 (40)
p value		0.5		--		0.5
2013						
Non-Indigenous	17	7 (41)	3	0 (0)	20	7 (35)
Indigenous	5	2 (40)	1	1 (100)	6	3 (50)
p value		1.0		0.05		0.5

† Excludes equivocal test results and missing values.

Table 299 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	5	0 (0)	11	9 (82)	16	9 (56)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.6		0.6
2007						
Non-Indigenous	16	1 (6)	12	5 (42)	28	6 (21)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		0.8		0.4		0.2
2010						
Non-Indigenous	9	0 (0)	16	6 (38)	25	6 (24)
Indigenous	3	0 (0)	2	2 (100)	5	2 (40)
p value		--		0.1		0.5
2013						
Non-Indigenous	11	0 (0)	8	7 (88)	19	7 (37)
Indigenous	1	0 (0)	5	3 (60)	6	3 (50)
p value		--		0.3		0.5

† Excludes equivocal test results and missing values.

Table 300 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	19	8 (42)	2	2 (100)	21	10 (48)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.6
2007						
Highly accessible/accessible	24	7 (29)	--	--	24	7 (29)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	7 (33)	1	0 (0)	22	7 (32)
Moderately accessible	5	0 (0)	--	--	5	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.3		--		0.3
2013						
Highly accessible/accessible	11	4 (36)	2	1 (50)	13	5 (38)
Moderately accessible	8	4 (50)	1	0 (0)	9	4 (44)
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.4		0.4		0.5

† Excludes equivocal test results and missing values.

Table 301 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	25	11 (44)	2	2 (100)	27	13 (48)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	8 (26)	--	--	31	8 (26)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.6
2010						
Australia	29	8 (28)	1	0 (0)	30	8 (27)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2013						
Australia	21	9 (43)	3	1 (33)	24	10 (42)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 302 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	25	11 (44)	2	2 (100)	27	13 (48)
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	31	8 (26)	--	--	31	8 (26)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.6
2010						
English	28	8 (29)	1	0 (0)	29	8 (28)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.5		--		0.5
2013						
English	22	9 (41)	3	1 (33)	25	10 (40)
Non-English	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 303 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	7	2 (29)	--	--	7	2 (29)
Not sure	2	1 (50)	--	--	2	1 (50)
p value		0.01		--		0.006
2007						
Positive	4	4 (100)	--	--	4	4 (100)
Negative	11	1 (9)	--	--	11	1 (9)
Not sure	4	1 (25)	--	--	4	1 (25)
p value		0.003		--		0.003
2010						
Positive	7	6 (86)	--	--	7	6 (86)
Negative	11	1 (9)	1	0 (0)	12	1 (8)
Not sure	--	--	--	--	--	--
p value		0.001		--		0.001
2013						
Positive	7	7 (100)	1	1 (100)	8	8 (100)
Negative	8	0 (0)	--	--	8	0 (0)
Not sure	2	2 (100)	--	--	2	2 (100)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 304 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	15	0 (0)	3	1 (33)	18	1 (6)
Non-IDU	8	0 (0)	--	--	8	0 (0)
p value		--		--		0.5
2007						
IDU	14	1 (7)	--	--	14	1 (7)
Non-IDU	16	0 (0)	--	--	16	0 (0)
p value		0.3		--		0.3
2010						
IDU	17	0 (0)	1	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	--	--	12	0 (0)
p value		--		--		--
2013						
IDU	11	0 (0)	--	--	11	0 (0)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 305 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	16	6 (38)	3	2 (67)	19	8 (42)
Non-IDU	9	0 (0)	--	--	9	0 (0)
p value		0.04		--		0.02
2007						
IDU	15	3 (20)	--	--	15	3 (20)
Non-IDU	17	0 (0)	--	--	17	0 (0)
p value		0.05		--		0.05
2010						
IDU	17	2 (12)	1	0 (0)	18	2 (11)
Non-IDU	12	3 (25)	--	--	12	3 (25)
p value		0.4		--		0.3
2013						
IDU	11	1 (9)	--	--	11	1 (9)
Non-IDU	10	0 (0)	2	0 (0)	12	0 (0)
p value		0.3		--		0.3

† Excludes equivocal test results and missing values.

Table 306 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	25	6 (24)	2	2 (100)	27	8 (30)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		0.08		0.5
2007						
Heterosexual	32	3 (9)	--	--	32	3 (9)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2010						
Heterosexual	28	4 (14)	1	0 (0)	29	4 (14)
Bisexual	1	1 (100)	--	--	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		0.03		--		0.02
2013						
Heterosexual	18	1 (6)	2	0 (0)	20	1 (5)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 307 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	2	0 (0)	1	1 (100)	3	1 (33)
25 – 29	8	3 (38)	3	1 (33)	11	4 (36)
30 + years	16	3 (19)	--	-	16	3 (19)
p value		0.6		0.3		0.7
2007						
< 20 years	1	0 (0)	--	--	1	0 (0)
20 – 24	8	0 (0)	--	--	8	0 (0)
25 – 29	6	0 (0)	--	--	6	0 (0)
30 + years	17	3 (18)	--	--	17	3 (18)
p value		0.4		--		0.4
2010						
< 20 years	3	0 (0)	--	--	3	0 (0)
20 – 24	7	0 (0)	1	0 (0)	8	0 (0)
25 – 29	6	1 (17)	--	--	6	1 (17)
30 + years	13	4 (31)	--	--	13	4 (31)
p value		0.3		--		0.3
2013						
< 20 years	4	0 (0)	--	--	4	0 (0)
20 – 24	--	--	--	--	--	--
25 – 29	5	1 (20)	--	--	5	1 (20)
30 + years	13	0 (0)	3	0 (0)	16	0 (0)
p value		0.2		--		0.1

† Excludes equivocal test results and missing values.

Table 308 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	1	1 (100)	1	1 (100)
6 to 10 years	6	1 (17)	1	1 (100)	7	2 (29)
10 + years	9	4 (44)	1	0 (0)	10	4 (40)
p value		0.3		0.2		0.4
2007						
<3 years	1	0 (0)	--	--	1	0 (0)
3 to 5 years	--	--	--	--	--	--
6 to 10 years	4	0 (0)	--	--	4	0 (0)
10 + years	10	3 (30)	--	--	10	3 (30)
p value		0.4		--		0.4
2010						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	3	0 (0)	--	--	3	0 (0)
6 to 10 years	2	0 (0)	1	0 (0)	3	0 (0)
10 + years	8	2 (25)	--	--	8	2 (25)
p value		0.5		--		0.4
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	1	0 (0)	--	--	1	0 (0)
10 + years	8	1 (13)	--	--	8	1 (13)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 309 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	10	5 (50)	10	5 (50)
Heroin	--	--	1	0 (0)	1	0 (0)
More than one	--	--	7	2 (29)	7	2 (29)
Other/not reported	--	--	--	--	--	--
p value				0.4		0.4
2007						
Amphetamine (Speed, Ice)	1	0 (0)	10	1 (10)	11	1 (9)
Heroin	--	--	1	1 (100)	1	1 (100)
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	1 (33)	3	1 (33)
p value				0.1		0.08
2010						
Amphetamine (Speed, Ice)	3	0 (0)	8	1 (13)	11	1 (9)
Heroin	--	--	--	--	--	--
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	1	0 (0)	5	1 (20)	6	1 (17)
p value				0.9		0.8
2013						
Amphetamine (Speed, Ice)	--	--	6	0 (0)	6	0 (0)
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	3	1 (33)	3	1 (33)
p value				0.1		0.1

† Excludes equivocal test results and missing values.

Table 310 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	6	1 (17)	6	1 (17)
Daily or more	--	--	4	3 (75)	4	3 (75)
p value				0.07		0.07
2007						
Less than daily	--	--	5	1 (20)	5	1 (20)
Daily or more	1	0 (0)	5	1 (20)	6	1 (17)
p value				1.0		0.9
2010						
Less than daily	2	0 (0)	5	1 (20)	7	1 (14)
Daily or more	--	--	2	0 (0)	2	0 (0)
p value				0.5		0.6
2013						
Less than daily	--	--	1	0 (0)	1	0 (0)
Daily or more	--	--	3	1 (33)	3	1 (33)
p value				0.5		0.5

† Excludes equivocal test results and missing values.

Table 311 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	3	1 (33)	3	1 (33)
p value		--		0.9		0.9
2007						
No	1	0 (0)	10	2 (20)	11	2 (18)
Yes	--	--	--	--	--	--
p value		--		--		--
2010						
No	2	0 (0)	6	1 (17)	8	1 (13)
Yes	--	--	--	--	--	--
p value		--		--		--
2013						
No	--	--	--	--	--	--
Yes	--	--	1	0 (0)	1	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 312 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	8	3 (38)	8	3 (38)
Yes	--	--	7	2 (29)	7	2 (29)
p value		--		0.5		0.5
2007						
No	--	--	4	1 (25)	4	1 (25)
Yes	--	--	10	2 (20)	10	2 (20)
p value		--		0.8		0.8
2010						
No	3	0 (0)	7	0 (0)	10	0 (0)
Yes	1	0 (0)	7	2 (29)	8	2 (25)
p value		--		0.1		0.1
2013						
No	--	--	4	0 (0)	4	0 (0)
Yes	--	--	3	1 (33)	3	1 (33)
p value		--		0.2		0.2

† Excludes equivocal test results and missing values.

Table 313 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	10	3 (30)	--	--	10	3 (30)
2 to 4	9	1 (11)	1	1 (100)	10	2 (20)
5 to 9	4	1 (25)	1	0 (0)	5	1 (20)
10 +	--	--	1	1 (100)	1	1 (100)
p value		0.6		0.2		0.4
2007						
1	7	0 (0)	--	--	7	0 (0)
2 to 4	15	1 (7)	--	--	15	1 (7)
5 to 9	9	2 (22)	--	--	9	2 (22)
10 +	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.4
2010						
1	9	2 (22)	--	--	9	2 (22)
2 to 4	13	1 (8)	1	0 (0)	14	1 (7)
5 to 9	4	2 (50)	--	--	4	2 (50)
10 +	3	0 (0)	--	--	3	0 (0)
p value		0.2		--		0.2
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 314 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	16	4 (25)	2	1 (50)	18	5 (28)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		0.8
2007						
Non-Indigenous	28	1 (4)	--	--	28	1 (4)
Indigenous	4	2 (50)	--	--	4	2 (50)
p value		0.003		--		0.003
2010						
Non-Indigenous	24	5 (21)	1	0 (0)	25	5 (20)
Indigenous	5	0 (0)	--	--	5	0 (0)
p value		0.3		--		0.3
2013						
Non-Indigenous	16	1 (6)	3	0 (0)	19	1 (5)
Indigenous	5	0 (0)	--	--	5	0 (0)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 315 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	5	0 (0)	12	5 (42)	17	5 (29)
Indigenous	2	0 (0)	1	1 (100)	3	1 (33)
p value		--		0.3		0.9
2007						
Non-Indigenous	16	0 (0)	12	1 (8)	28	1 (4)
Indigenous	1	0 (0)	3	2 (67)	4	2 (50)
p value		--		0.02		0.003
2010						
Non-Indigenous	9	3 (33)	16	2 (13)	25	5 (20)
Indigenous	3	0 (0)	2	0 (0)	5	0 (0)
p value		0.3		0.6		0.3
2013						
Non-Indigenous	11	0 (0)	7	1 (14)	18	1 (6)
Indigenous	1	0 (0)	4	0 (0)	5	0 (0)
p value		--		0.4		0.6

† Excludes equivocal test results and missing values.

Table 316 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	19	3 (16)	2	1 (50)	21	4 (19)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.5
2007						
Highly accessible/accessible	24	2 (8)	--	--	24	2 (8)
Moderately accessible	4	1 (25)	--	--	4	1 (25)
Remote/very remote	4	0 (0)	--	--	4	0 (0)
p value		0.5		--		0.5
2010						
Highly accessible/accessible	21	3 (14)	1	0 (0)	22	3 (14)
Moderately accessible	5	2 (40)	--	--	5	2 (40)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.4		--		0.3
2013						
Highly accessible/accessible	11	0 (0)	1	0 (0)	12	0 (0)
Moderately accessible	7	0 (0)	1	0 (0)	8	0 (0)
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 317 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	25	6 (24)	3	2 (67)	28	8 (29)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	31	3 (10)	--	--	31	3 (10)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7
2010						
Australia	29	5 (17)	1	0 (0)	30	5 (17)
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2013						
Australia	20	1 (5)	2	0 (0)	22	1 (5)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		0.8		--		0.9

† Excludes equivocal test results and missing values.

Table 318 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	25	6 (24)	3	2 (67)	28	8 (29)
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	31	3 (10)	--	--	31	3 (10)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.7		--		0.7
2010						
English	28	5 (18)	1	0 (0)	29	5 (17)
Non-English	1	0 (0)	--	--	1	0 (0)
p value		0.6		--		0.7
2013						
English	21	1 (5)	2	0 (0)	23	1 (4)
Non-English	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 319 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	No (%) vaccine conferred immunity*
2004					
IDU	20	7 (35)	7 (35)	1 (5)	5 (25)
Non-IDU	9	8 (89)	0 (0)	0 (0)	1 (11)
p value					0.05
2007					
IDU	7	2 (29)	3 (43)	0 (0)	2 (29)
Non-IDU	7	0 (0)	0 (0)	0 (0)	7 (100)
p value					0.02
2010					
IDU	17	10 (59)	2 (12)	0 (0)	5 (29)
Non-IDU	11	6 (55)	3 (27)	0 (0)	2 (18)
p value					0.5
2013					
IDU	7	6 (86)	1 (14)	0 (0)	0 (0)
Non-IDU	7	7 (100)	0 (0)	0 (0)	0 (0)
p value					0.3

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 320 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	No (%) vaccine conferred immunity*
2004					
Heterosexual	28	14 (50)	7 (25)	1 (4)	6 (21)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.8
2007					
Heterosexual	14	2 (14)	3 (21)	0 (0)	9 (64)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2010					
Heterosexual	27	16 (59)	4 (15)	0 (0)	7 (26)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	1 (100)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.09
2013					
Heterosexual	12	11 (92)	1 (8)	0 (0)	0 (0)
Homosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 321 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	3	1 (33)	0 (0)	1 (33)	1 (33)
25 – 29	12	7 (58)	4 (33)	0 (0)	1 (8)
30 + years	16	9 (56)	3 (19)	0 (0)	4 (25)
p value					0.1
2007					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	4	0 (0)	0 (0)	0 (0)	4 (100)
25 – 29	1	0 (0)	0 (0)	0 (0)	1 (100)
30 + years	8	2 (25)	3 (38)	0 (0)	3 (38)
p value					0.4
2010					
< 20 years	2	1 (50)	0 (0)	0 (0)	1 (50)
20 – 24	7	4 (57)	0 (0)	0 (0)	3 (43)
25 – 29	6	5 (83)	1 (17)	0 (0)	0 (0)
30 + years	13	6 (46)	4 (31)	0 (0)	3 (23)
p value					0.4
2013					
< 20 years	1	1 (100)	0 (0)	0 (0)	0 (0)
20 – 24	--	--	--	--	--
25 – 29	5	4 (80)	1 (20)	0 (0)	0 (0)
30 + years	9	9 (100)	0 (0)	0 (0)	0 (0)
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 322 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	10	5 (50)	3 (30)	0 (0)	2 (20)
2 to 4	10	8 (80)	1 (10)	1 (10)	0 (0)
5 to 9	6	1 (17)	1 (17)	0 (0)	4 (67)
10 +	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.05
2007					
1	4	0 (0)	0 (0)	0 (0)	4 (100)
2 to 4	4	1 (25)	1 (25)	0 (0)	2 (50)
5 to 9	5	0 (0)	2 (40)	0 (0)	3 (60)
10 +	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.1
2010					
1	9	4 (44)	2 (22)	0 (0)	3 (33)
2 to 4	12	9 (75)	1 (8)	0 (0)	2 (17)
5 to 9	4	2 (50)	2 (50)	0 (0)	0 (0)
10 +	3	1 (33)	0 (0)	0 (0)	2 (67)
p value					0.2
2013					
1	--	--	--	--	--
2 to 4	--	--	--	--	--
5 to 9	--	--	--	--	--
10 +	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 323 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	18	9 (50)	4 (22)	1 (6)	4 (22)
Indigenous	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.8
2007					
Non-Indigenous	12	2 (17)	1 (8)	0 (0)	9 (75)
Indigenous	2	0 (0)	2 (100)	0 (0)	0 (0)
p value					0.01
2010					
Non-Indigenous	24	12 (50)	5 (21)	0 (0)	7 (29)
Indigenous	4	4 (100)	0 (0)	0 (0)	0 (0)
p value					0.2
2013					
Non-Indigenous	11	10 (91)	0 (0)	0 (0)	0 (0)
Indigenous	4	4 (100)	1 (9)	0 (0)	0 (0)
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 324 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	No (%) immune through past exposure	No (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	22	12 (55)	4 (18)	0 (0)	6 (27)
Moderately accessible	2	1 (50)	1 (50)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7
2007					
Highly accessible/accessible	13	2 (15)	2 (15)	0 (0)	9 (69)
Moderately accessible	1	0 (0)	1 (100)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.1
2010					
Highly accessible/accessible	21	12 (57)	3 (14)	0 (0)	6 (29)
Moderately accessible	5	3 (60)	2 (40)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	0 (0)	0 (0)	1 (100)
p value					0.2
2013					
Highly accessible/accessible	8	8 (100)	0 (0)	0 (0)	0 (0)
Moderately accessible	4	4 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 325 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	29	15 (52)	7 (24)	1 (3)	6 (21)
Non-English	--	--	--	--	--
p value					--
2007					
English	14	2 (14)	3 (21)	0 (0)	9 (64)
Non-English	--	--	--	--	--
p value					--
2010					
English	27	15 (56)	5 (19)	0 (0)	7 (26)
Non-English	1	1 (100)	0 (0)	0 (0)	0 (0)
p value					0.7
2013					
English	14	13 (93)	1 (7)	0 (0)	0 (0)
Non-English	--	--	--	--	--
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 326 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	9	0 (0)	--	--	9	0 (0)
Yes	10	6 (60)	1	0 (0)	11	6 (55)
Not sure	1	0 (0)	--	--	1	0 (0)
p value		0.01		--		0.02
2007						
No	1	0 (0)	--	--	1	0 (0)
Yes	9	8 (89)	--	--	9	8 (89)
Not sure	1	1 (100)	--	--	1	1 (100)
p value		0.08		--		0.08
2010						
No	5	0 (0)	1	1 (100)	6	1 (17)
Yes	14	6 (43)	--	--	14	6 (43)
Not sure	3	0 (0)	--	--	3	0 (0)
p value		0.1		--		0.2
2013						
No	3	0 (0)	1	0 (0)	4	0 (0)
Yes	5	0 (0)	1	0 (0)	6	0 (0)
Not sure	3	0 (0)	0	--	3	0 (0)
p value		--		--		--

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 327 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	10	0 (0)
Female	--	--
p value		--
2013		
Male	23	0 (0)
Female	4	0 (0)
p value		--

† Excludes missing values.

Gonorrhoea

Table 328 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	--	--
Female	--	--
p value		--
2013		
Male	23	0 (0)
Female	4	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 329 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	5	0 (0)	0 (0)	0 (0)
Female		--	--	--
p value		--	--	--
2013				
Male	23	0 (0)	0 (0)	0 (0)
Female	4	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Victoria
2007, 2010, 2013

Table 330 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites								
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112
Sex (%)								
Male	--	--	78 (90)	71 (95)	27 (87)	15 (88)	46 (77)	97 (87)
Female	--	--	9 (10)	4 (5)	4 (13)	2 (12)	14 (23)	15 (13)
Transgender	--	--	--	--	--	--	--	--
Sexual identity (%)								
Heterosexual	--	--	84 (97)	73 (97)	29 (94)	15 (88)	53 (88)	109 (97)
Bisexual	--	--	1 (1)	1 (1)	1 (3)	--	5 (8)	2 (2)
Homosexual	--	--	--	1 (1)	1 (3)	1 (6)	1 (2)	1 (1)
Unsure	--	--	2 (2)	--	--	--	1 (2)	--
Not reported	--	--	--	--	--	1 (6)	--	--
Age and duration of injection (years)								
Median (Med) age	--	--	32	32	30	32	31	31
Age range	--	--	18 – 54	18 – 77	21 – 55	20 – 75	18 – 68	18 – 64
Age group (%)								
<25 years	--	--	12 (14)	22 (29)	6 (19)	3 (18)	12 (20)	24 (21)
25+ years	--	--	75 (86)	53 (71)	25 (81)	14 (82)	48 (80)	88 (79)
Not reported	--	--	--	--	--	--	--	--
Med age 1 st IDU	--	--	18	--	17	--	18	--
Age range	--	--	10 – 35	--	13 – 39	--	10 – 37	--
Not reported	--	--	--	--	--	--	--	--
Med IDU (years)	--	--	12	--	11	--	13	--
Range	--	--	<1 – 29	--	2 – 35	--	<1 – 39	--
Duration of drug injection (%)								
<3 years	--	--	4 (5)	--	2 (6)	--	7 (12)	--
3+ years	--	--	83 (95)	--	29 (94)	--	53 (88)	--
Not reported	--	--	--	--	--	--	--	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	--	--	80 (92)	73 (97)	27 (87)	16 (94)	51 (85)	103 (92)
Yes	--	--	7 (8)	2 (3)	4 (13)	1 (6)	9 (15)	9 (8)
Not reported	--	--	--	--	--	--	--	--
Residential remoteness in 12 months before prison (%)								
Highly/accessible	--	--	83 (95)	66 (88)	31 (100)	12 (71)	55 (92)	107 (96)
Mod accessible	--	--	2 (2)	5 (7)	--	--	5 (8)	5 (4)
Very/remote	--	--	1 (1)	--	--	3 (18)	--	--
Not reported	--	--	1 (1)	4 (5)	--	2 (12)	--	--
Region/Country of birth (%)								
Australia	--	--	67 (77)	62 (83)	28 (90)	12 (71)	53 (88)	78 (70)
Other Oceania	--	--	3 (3)	2 (3)	--	1 (6)	--	5 (4)
Asia	--	--	6 (7)	4 (5)	--	3 (18)	3 (5)	16 (14)
UK & Ireland	--	--	4 (5)	1 (1)	1 (3)	--	1 (2)	--
Other	--	--	7 (8)	5 (7)	1 (3)	1 (6)	3 (5)	13 (12)
Not reported	--	--	--	1 (1)	1 (3)	--	--	--
Main language spoke at home by parents (%)								
English	--	--	72 (83)	59 (79)	30 (97)	12 (71)	53 (88)	82 (73)
Non-English	--	--	14 (16)	14 (19)	1 (3)	5 (29)	7 (12)	30 (27)
Not reported	--	--	1 (1)	2 (3)	--	--	--	--

Table 331 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)								
No	--	--	69 (79)	25 (33)	25 (81)	8 (47)	45 (75)	50 (45)
Yes	--	--	18 (21)	50 (67)	6 (19)	9 (53)	15 (25)	62 (55)
Not reported	--	--	--	--	--	--	--	--
Lifetime imprisonments (%)*								
One	--	--	18 (21)	50 (67)	11 (35)	13 (76)	n/a	n/a
Two to four	--	--	33 (38)	17 (23)	11 (35)	3 (18)	n/a	n/a
Five to nine	--	--	24 (28)	6 (8)	5 (16)	1 (6)	n/a	n/a
Ten or more	--	--	12 (14)	2 (3)	4 (13)	--	n/a	n/a
Not reported	--	--	--	--	--	--	n/a	n/a
Imprisonment in last year (%)								
No	--	--	22 (32)	6 (24)	16 (52)	13 (76)	13 (29)	28 (56)
Yes	--	--	47 (68)	19 (76)	13 (42)	2 (12)	32 (71)	21 (42)
Not reported	--	--	--	--	2 (6)	2 (12)	--	1 (2)
Frequency of Injection last month (%)								
Not last month	--	--	27 (31)	--	8 (26)	--	20 (33)	--
< weekly	--	--	7 (8)	--	9 (29)	--	6 (10)	--
Weekly	--	--	17 (20)	--	1 (3)	--	5 (8)	--
Daily or more	--	--	36 (41)	--	13 (42)	--	29 (48)	--
Not reported	--	--	--	--	--	--	--	--
Ever smoked a full cigarette (%)**								
No	--	--	1 (1)	12 (16)	--	2 (12)	1 (2)	16 (14)
Yes	--	--	86 (99)	63 (84)	31 (100)	14 (82)	59 (98)	96 (86)
Not reported	--	--	--	--	--	1 (6)	--	--
Med age 1st smoked								
Age range	--	--	5 – 25	9 – 30	7 – 35	10 – 21	5 – 18	8 – 30
Current smoker (%)**								
No	--	--	4 (5)	24 (32)	1 (3)	4 (24)	2 (3)	10 (10)
Yes	--	--	83 (95)	51 (68)	30 (97)	12 (71)	57 (97)	86 (90)
Not reported	--	--	--	--	--	1 (6)	--	--
Smoking frequency (%)**								
Weekly or less	--	--	1 (1)	2 (4)	--	--	2 (4)	8 (9)
5 - 10/day	--	--	30 (36)	19 (37)	9 (30)	6 (50)	20 (35)	35 (41)
11 - 20/day	--	--	32 (39)	16 (31)	14 (47)	3 (25)	23 (40)	26 (30)
>20/day	--	--	20 (24)	14 (27)	7 (23)	3 (25)	12 (21)	17 (20)
Not reported	--	--	--	--	--	--	--	--
Other drugs used last month (%)***								
None	--	--	n/a	n/a	3 (14)	5 (42)	11 (18)	74 (66)
Cannabis	--	--	n/a	n/a	14 (74)	6 (86)	24 (49)	18 (47)
Heroin	--	--	n/a	n/a	9 (47)	1 (14)	19 (39)	3 (8)
Cocaine	--	--	n/a	n/a	1 (5)	1 (14)	2 (4)	2 (5)
Amphetamine	--	--	n/a	n/a	11 (58)	3 (43)	32 (65)	23 (61)
Methadone	--	--	n/a	n/a	3 (16)	--	6 (12)	--
Other opiates	--	--	n/a	n/a	6 (32)	1 (14)	7 (14)	--
Buprenorphine	--	--	n/a	n/a	5 (26)	--	5 (10)	2 (5)
Steroids	--	--	n/a	n/a	2 (11)	--	--	1 (3)
Hallucinogens	--	--	n/a	n/a	3 (16)	--	2 (4)	1 (3)
Benzodiazepine	--	--	n/a	n/a	10 (53)	--	23 (47)	10 (26)
Ecstasy/MDA	--	--	n/a	n/a	2 (11)	--	1 (2)	3 (8)
Inhalants	--	--	n/a	n/a	--	--	--	--
Other drug	--	--	n/a	n/a	--	--	5 (10)	4 (11)
Not reported	--	--	n/a	n/a	9 (29)	5 (29)	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 332 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)		N = 87	N = 31	N = 60
Amphetamine (Speed, Ice)	--	37 (43)	12 (39)	31 (52)
Anabolic steroids	--	--	--	1 (2)
Cocaine	--	1 (1)	--	--
Heroin	--	43 (49)	14 (45)	22 (37)
Heroin + amphetamine	--	4 (5)	--	1 (2)
Heroin + cocaine	--	--	2 (6)	1 (2)
Methadone	--	--	--	--
Morphine	--	2 (2)	2 (6)	1 (2)
Other	--	--	1 (3)	3 (5)
Not reported	--	--	--	--
N° Injected last month	--	N = 60	N = 23	N = 40
Places injected last month (%)*				
Prison	--	1 (2)	1 (4)	2 (5)
Own home	--	47 (78)	15 (65)	26 (65)
Friend's home	--	32 (53)	8 (35)	18 (45)
Dealer's home	--	15 (25)	3 (13)	6 (15)
Street, park, beach	--	21 (35)	7 (30)	5 (13)
Car	--	34 (57)	9 (39)	10 (25)
Public toilet	--	16 (27)	6 (26)	6 (15)
Commercial injecting room	--	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--	--
Squat	--	3 (5)	2 (9)	1 (1)
Other place	--	6 (10)	--	2 (5)
Use of sterile needles & syringes last month (%)				
All injections	--	44 (73)	11 (48)	26 (65)
Most of the time	--	13 (22)	9 (39)	8 (20)
Half of the time	--	--	2 (9)	2 (5)
Some of the time	--	2 (3)	1 (4)	3 (8)
Not last month	--	--	--	1 (3)
Not reported	--	1 (2)	--	--
Re-used someone else's used needle & syringe last month (%)				
None	--	50 (83)	18 (78)	33 (83)
Once	--	3 (5)	3 (13)	2 (5)
Twice	--	2 (3)	--	--
3-5 times	--	1 (2)	--	3 (8)
>5 times	--	1 (2)	2 (9)	2 (5)
Not reported	--	3 (5)	--	--
Number of people needle & syringe was re-used after last month (%)				
One	--	3 (5)	2 (9)	5 (14)
Two	--	2 (3)	--	--
Three to five	--	1 (2)	1 (4)	--
More than five	--	1 (2)	--	1 (14)
Don't know how many	--	--	2 (9)	1 (14)
Not reported	--	3 (5)	--	--
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	--	6 (10)	4 (17)	2 (29)
Casual sex partner	--	--	--	--
Close friend	--	3 (5)	--	1 (14)
Acquaintance	--	--	2 (9)	3 (43)
Other	--	1 (2)	1 (4)	1 (14)
Equipment used after someone else last month (%)*				
Spoon	--	22 (37)	10 (43)	14 (35)
Water	--	10 (17)	7 (30)	10 (25)
Filter	--	11 (18)	6 (26)	7 (18)
Tourniquet	--	4 (7)	3 (13)	6 (15)
Drug mix	--	6 (10)	5 (22)	8 (20)

* More than one option could be selected.

Table 333 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112
Any treatment/therapy for drug use (%)								
No	--	--	14 (16)	42 (56)	6 (19)	14 (82)	15 (25)	89 (79)
Yes	--	--	71 (82)	13 (17)	24 (77)	3 (18)	45 (75)	23 (21)
Not reported	--	--	2 (2)	20 (27)	1 (3)	--	--	--
History of methadone maintenance treatment (%)								
Currently	--	--	37 (43)	--	9 (29)	--	14 (23)	--
Previously	--	--	16 (18)	--	4 (13)	--	14 (23)	2 (2)
Never	--	--	32 (37)	--	17 (55)	17 (100)	32 (53)	110 (98)
Not reported	--	--	2 (2)	--	1 (3)	--	--	--
History of other pharmacotherapy treatment (%)								
Currently	--	--	40 (46)	--	4 (13)	--	4 (7)	2 (2)
Previously	--	--	12 (14)	--	7 (23)	--	20 (33)	1 (1)
Never	--	--	35 (40)	--	19 (61)	17 (100)	36 (60)	109 (97)
Not reported	--	--	--	--	1 (3)	--	--	--

Table 334 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition*	2004	2007	2010	2013
N° surveyed	--	N = 60	N = 31	N = 60
From an NSP last month (%)				
Daily or almost daily	--	13 (22)	7 (23)	6 (10)
A couple of times each week	--	23 (38)	2 (6)	9 (15)
Less than weekly	--	8 (13)	6 (19)	6 (10)
Weekly	--	n/a	2 (6)	--
Once last month	--	7 (12)	1 (3)	10 (17)
Not in the last month	--	9 (15)	12 (39)	29 (48)
Not reported	--	--	1 (3)	--
From a chemist last month (%)				
Daily or almost daily	--	1 (2)	2 (6)	1 (2)
A couple of times each week	--	11 (18)	4 (13)	3 (5)
Less than weekly	--	5 (8)	2 (6)	7 (12)
Weekly	--	n/a	5 (16)	--
Once last month	--	10 (17)	--	7 (12)
Not in the last month	--	33 (55)	17 (55)	42 (70)
Not reported	--	--	1 (3)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 335 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-	IDU	Non-IDU
N ^o surveyed	--	--	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112
Body or ear piercings (%)								
No	--	--	35 (40)	53 (71)	14 (45)	12 (71)	33 (55)	62 (55)
Yes	--	--	52 (60)	22 (29)	17 (55)	5 (59)	27 (45)	50 (45)
Not reported	--	--	--	--	--	--	--	--
Pierced in past 12 months (%)								
No	--	--	42 (81)	16 (73)	8 (47)	1 (20)	25 (93)	45 (90)
Yes	--	--	6 (12)	4 (18)	2 (12)	--	2 (7)	5 (10)
Not reported	--	--	4 (8)	2 (9)	7 (41)	4 (80)	--	--
Who did piercing (%)*								
Chemist/salon	--	--	1 (17)	2 (50)	--	--	1 (50)	3 (60)
Professional piercer	--	--	2 (33)	--	--	--	1 (50)	2 (40)
Tattooist/parlour	--	--	--	2 (50)	1 (50)	--	--	--
Friend	--	--	1 (17)	--	1 (50)	--	--	--
Prison inmate	--	--	--	--	--	--	--	--
Self	--	--	1 (17)	--	1 (50)	--	--	--
Family member	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	--	--	1 (20)	--	2 (100)	--	--	--
Yes	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	4 (80)	4 (100)	--	--	2 (100)	5 (100)
Tattoos (%)								
No	--	--	26 (30)	45 (60)	8 (26)	10 (59)	12 (20)	48 (43)
Yes	--	--	61 (70)	30 (40)	23 (74)	7 (41)	47 (78)	64 (57)
Not reported	--	--	--	--	--	--	1 (2)	--
Tattoos in past 12 months (%)								
No	--	--	41 (67)	17 (57)	16 (65)	3 (43)	38 (81)	40 (63)
Yes	--	--	20 (33)	13 (43)	7 (30)	4 (57)	9 (19)	24 (38)
Not reported	--	--	--	--	1 (4)	--	--	--
Who did tattooing (%)*								
Prof tattooist	--	--	15 (75)	10 (77)	4 (57)	3 (75)	6 (67)	14 (58)
Friend	--	--	4 (20)	1 (8)	1 (14)	3 (75)	2 (22)	9 (38)
Prison inmate	--	--	4 (20)	1 (8)	--	--	--	--
Self	--	--	1 (5)	2 (15)	--	--	3 (33)	1 (4)
Family member	--	--	--	--	--	--	--	2 (8)
Other	--	--	--	--	--	--	--	--

* More than one option could be selected.

Table 336 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112
Sex last month / last 3 months (%)**								
No	--	--	19 (22)	20 (27)	1 (11)	8 (12)	6 (10)	21 (19)
Yes	--	--	68 (78)	55 (73)	8 (89)	57 (86)	54 (90)	91 (81)
Not reported	--	--	--	--	--	1 (2)	--	--
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (1 – 4)	1 (0 – 2)	0 (0-15)	0 (0 – 2)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 20)	1 (0 – 5)	1 (0 – 7)	1 (0-20)
Condom use at last sex (%)								
No	--	--	69 (79)	48 (64)	n/a	n/a	n/a	n/a
Yes	--	--	18 (21)	27 (36)	n/a	n/a	n/a	n/a
Not reported	--	--	--	--	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	--	--	41 (85)	33 (70)	n/a	n/a	n/a	n/a
Sometimes	--	--	7 (15)	7 (15)	n/a	n/a	n/a	n/a
Always	--	--	--	7 (15)	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	--	--	10 (56)	1 (13)	n/a	n/a	n/a	n/a
Sometimes	--	--	3 (17)	3 (38)	n/a	n/a	n/a	n/a
Always	--	--	5 (28)	4 (50)	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	--	--	15 (58)	3 (33)	n/a	n/a	n/a	n/a
Sometimes	--	--	4 (15)	3 (33)	n/a	n/a	n/a	n/a
Always	--	--	7 (27)	3 (33)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	--	--	n/a	n/a	5 (83)	--	1 (11)	2 (22)
Sometimes	--	--	n/a	n/a	1 (17)	1 (100)	5 (56)	6 (67)
Always	--	--	n/a	n/a	--	--	3 (33)	1 (11)
Condom use last sex - casual male partners - last 3 months (%)**								
Never	--	--	n/a	n/a	2 (50)	--	--	--
Sometimes	--	--	n/a	n/a	1 (25)	1 (100)	2 (50)	--
Always	--	--	n/a	n/a	1 (25)	--	2 (50)	1 (100)
Condom use last sex - regular female partners - last 3 months (%)**								
Never	--	--	n/a	n/a	14 (78)	6 (46)	17 (57)	44 (62)
Sometimes	--	--	n/a	n/a	4 (22)	4 (31)	11 (37)	21 (30)
Always	--	--	n/a	n/a	--	3 (23)	2 (7)	6 (8)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	--	--	n/a	n/a	5 (42)	1 (100)	12 (40)	15 (41)
Sometimes	--	--	n/a	n/a	4 (33)	--	12 (40)	15 (41)
Always	--	--	n/a	n/a	3 (25)	--	6 (20)	7 (19)
Sex work last month (%)								
No	--	--	85 (98)	74 (99)	27 (87)	15 (88)	56 (93)	111 (99)
Yes	--	--	2 (2)	--	2 (6)	1 (6)	4 (7)	--
Not reported	--	--	--	1 (1)	2 (6)	1 (6)	--	1 (1)
Condom used at last sex work last month (%)								
No	--	--	--	--	1 (50)	--	1 (25)	--
Yes	--	--	2 (100)	--	1 (50)	1 (100)	2 (50)	--
Not reported	--	--	--	--	--	--	1 (25)	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 337 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	--	--	N = 87	N = 75	N = 31	N = 17	N = 60	N = 112
Previous HIV test (%)								
Last year	--	--	43 (49)	13 (17)	13 (42)	5 (29)	19 (32)	15 (13)
>1 year ago	--	--	28 (32)	19 (25)	13 (42)	5 (29)	26 (43)	36 (32)
Never tested	--	--	16 (18)	43 (57)	4 (13)	6 (35)	15 (25)	61 (54)
Not reported	--	--	--	--	1 (3)	1 (6)	--	--
HBV infection (%)								
No	--	--	67 (77)	72 (96)	25 (81)	13 (76)	51 (85)	111 (99)
Yes	--	--	9 (10)	--	4 (13)	2 (12)	3 (5)	--
Don't know	--	--	11 (13)	2 (3)	2 (6)	2 (12)	6 (10)	1 (1)
Not reported	--	--	--	1 (1)	--	--	--	--
HBV vaccination (%)*								
No	--	--	25 (29)	43 (57)	5 (16)	6 (35)	16 (27)	41 (37)
Yes	--	--	51 (59)	20 (27)	15 (48)	6 (35)	33 (55)	40 (36)
Don't know	--	--	10 (11)	11 (15)	11 (35)	5 (29)	10 (17)	31 (28)
Not reported	--	--	1 (1)	1 (1)	--	--	1 (2)	--
Ever had cervical cancer vaccine (women only)** (%)								
No	--	--	n/a	n/a	2 (100)	1 (50)	3 (33)	4 (40)
Yes	--	--	n/a	n/a	--	1 (50)	5 (56)	2 (20)
Unsure	--	--	n/a	n/a	--	--	1 (11)	4 (40)
Not reported	--	--	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	--	--	11 (13)	53 (71)	18 (58)	5 (29)	22 (37)	14 (13)
>1 year ago	--	--	41 (47)	10 (13)	12 (39)	6 (35)	29 (48)	35 (31)
Never tested	--	--	35 (40)	12 (16)	1 (3)	6 (35)	9 (15)	63 (56)
Unsure	--	--	--	--	--	--	--	--
Not reported	--	--	--	--	--	--	--	--
Any HCV treatment (%)***								
			N = 46	N = 3	N = 9	N = 1	N = 24	N = 2
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	--	--	1 (4)	1 (50)
Int & Ribavirin & Boceprevir	--	--	--	1 (2)	--	--	--	--
Other	--	--	--	--	--	--	--	--
None	--	--	45 (98)	3 (100)	9 (100)	1 (100)	23 (96)	--
Not reported	--	--	--	--	--	--	--	1 (50)
Current HCV treatment								
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	--	--	--	--
Other	--	--	1 (2)	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 338 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							N = 24	N = 2
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	24 (100)	2 (100)
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	24 (100)	2 (100)
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	--	--
No	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	24 (100)	2 (100)
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	24 (100)	2 (100)

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 339 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	No with HIV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	0 (0)	5	0 (0)	64	0 (0)
Non-IDU	49	0 (0)	4	0 (0)	53	0 (0)
p value		--		--		--
2010						
IDU	17	0 (0)	3	0 (0)	20	0 (0)
Non-IDU	9	0 (0)	2	0 (0)	11	0 (0)
p value		--		--		--
2013						
IDU	43	0 (0)	13	0 (0)	56	0 (0)
Non-IDU	94	0 (0)	13	0 (0)	107	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 340 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	40 (68)	7	6 (86)	66	46 (70)
Non-IDU	49	2 (4)	4	1 (25)	53	3 (6)
p value		<0.001		0.04		<0.001
2010						
IDU	15	6 (40)	3	3 (100)	18	9 (50)
Non-IDU	10	1 (10)	2	0 (0)	12	1 (8)
p value		0.1		0.03		0.02
2013						
IDU	46	28 (61)	13	9 (69)	59	37 (63)
Non-IDU	94	4 (4)	13	1 (8)	107	5 (5)
p value		<0.001		0.001		<0.001

† Excludes equivocal test results and missing values.

Table 341 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	106	42 (40)	9	6 (67)	115	48 (42)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.5		0.3		0.5
2010						
Heterosexual	23	6 (26)	4	2 (50)	27	8 (30)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	1	1 (100)	--	--	1	1 (100)
Unsure	--	--	--	--	--	--
p value		0.1		0.4		0.1
2013						
Heterosexual	138	32 (23)	19	5 (26)	157	37 (24)
Bisexual	1	0 (0)	5	4 (80)	6	4 (67)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	--	--	1	1 (100)	1	1 (100)
p value		0.7		0.07		0.04

† Excludes equivocal test results and missing values.

Table 342 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	6	0 (0)	--	--	6	0 (0)
20 – 24	21	4 (19)	--	--	21	4 (19)
25 – 29	25	17 (68)	3	2 (67)	28	19 (68)
30 + years	56	21 (38)	8	5 (63)	64	26 (41)
p value		0.001		0.9		0.001
2010						
< 20 years	--	--	--	--	--	--
20 – 24	8	3 (38)	--	--	8	3 (38)
25 – 29	5	1 (20)	3	1 (33)	8	2 (25)
30 + years	12	3 (25)	2	2 (100)	14	5 (36)
p value		0.8		0.1		0.8
2013						
< 20 years	2	0 (0)	2	2 (100)	4	2 (50)
20 – 24	24	2 (8)	6	0 (0)	30	2 (7)
25 – 29	29	6 (21)	7	4 (57)	36	10 (28)
30 + years	86	24 (28)	11	4 (36)	97	28 (29)
p value		0.2		0.05		0.06

† Excludes equivocal test results and missing values.

Table 343 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug Injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	3	0 (0)	--	--	3	0 (0)
3 to 5 years	7	4 (57)	1	1 (100)	8	5 (63)
6 to 10 years	17	9 (53)	2	1 (50)	19	10 (53)
10 + years	32	27 (84)	4	4 (100)	36	31 (86)
p value		0.006		0.2		0.003
2010						
<3 years	2	0 (0)	--	--	2	0 (0)
3 to 5 years	4	2 (50)	--	--	4	2 (50)
6 to 10 years	3	1 (33)	1	1 (100)	4	2 (50)
10 + years	6	3 (50)	2	2 (100)	8	5 (63)
p value		0.6		--		0.5
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	5	2 (40)	2	2 (100)	7	4 (57)
6 to 10 years	7	2 (29)	3	2 (67)	10	4 (40)
10 + years	29	22 (76)	6	4 (67)	35	26 (74)
p value		0.03		0.6		0.1

† Excludes equivocal test results and missing values.

Table 344 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	3	0 (0)	27	15 (56)	30	15 (50)
Heroin	--	--	30	26 (87)	30	26 (87)
More than one	--	--	4	3 (75)	4	3 (75)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.05		0.02
2010						
Amphetamine (Speed, Ice)	1	0 (0)	5	3 (60)	6	3 (50)
Heroin	1	0 (0)	7	5 (71)	8	5 (63)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	2	1 (50)	2	1 (50)
p value		--		0.4		0.5
2013						
Amphetamine (Speed, Ice)	6	2 (33)	25	13 (52)	31	15 (48)
Heroin	1	1 (100)	20	17 (85)	21	18 (86)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	6	3 (50)	6	3 (50)
p value		0.2		0.09		0.04

† Excludes equivocal test results and missing values.

Table 345 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	20	16 (80)	20	16 (80)
Daily or more	--	--	26	23 (88)	26	23 (88)
p value		--		0.4		0.4
2010						
Less than daily	--	--	5	2 (40)	5	2 (40)
Daily or more	2	0 (0)	8	6 (75)	10	6 (60)
p value		--		0.2		0.5
2013						
Less than daily	1	0 (0)	10	5 (50)	11	5 (45)
Daily or more	4	2 (50)	24	17 (71)	28	19 (68)
p value		0.4		0.3		0.8

† Excludes equivocal test results and missing values.

Table 346 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	36	30 (83)	36	30 (83)
Yes	--	--	9	8 (89)	9	8 (89)
p value		--		0.7		0.7
2010						
No	2	0 (0)	9	5 (56)	11	5 (45)
Yes	--	--	2	2 (100)	2	2 (100)
p value		--		0.2		0.2
2013						
No	--	--	--	--	--	--
Yes	--	--	7	6 (86)	7	6 (86)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 347 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	13	10 (77)	13	10 (77)
Yes	1	0 (0)	35	32 (91)	36	32 (89)
p value		--		0.2		0.3
2010						
No	1	0 (0)	8	5 (63)	9	5 (56)
Yes	--	--	8	4 (50)	8	4 (50)
p value		--		0.6		0.8
2013						
No	--	--	13	10 (77)	13	10 (77)
Yes	5	2 (40)	26	18 (69)	31	20 (65)
p value		--		0.6		0.2

† Excludes equivocal test results and missing values.

Table 348 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	2 (4)	6	3 (50)	54	5 (9)
2 to 4	33	17 (52)	3	2 (67)	36	19 (53)
5 to 9	17	15 (88)	2	2 (100)	19	17 (89)
10 +	10	8 (80)	--	--	10	8 (80)
p value		<0.001		0.4		<0.001
2010						
1	13	4 (31)	2	0 (0)	15	4 (27)
2 to 4	8	2 (25)	2	2 (100)	10	4 (40)
5 to 9	3	1 (33)	--	--	3	1 (33)
10 +	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.9		0.08		0.9
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 349 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	100	37 (37)	10	6 (60)	110	43 (39)
Indigenous	8	5 (63)	1	1 (100)	9	6 (67)
p value		0.2		0.4		0.1
2010						
Non-Indigenous	22	6 (27)	5	3 (60)	27	9 (33)
Indigenous	3	1 (33)	--	--	3	1 (33)
p value		0.8		--		1.0
2013						
Non-Indigenous	128	27 (21)	22	8 (36)	150	35 (23)
Indigenous	13	5 (38)	4	2 (50)	17	7 (41)
p value		0.2		0.6		0.1

† Excludes equivocal test results and missing values.

Table 350 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	3 (6)	59	40 (68)	110	43 (39)
Indigenous	2	0 (0)	7	6 (86)	9	6 (67)
p value		0.7		0.3		0.1
2010						
Non-Indigenous	11	1 (9)	16	8 (50)	27	9 (33)
Indigenous	1	0 (0)	2	1 (50)	3	1 (33)
p value		0.8		1.0		1.0
2013						
Non-Indigenous	99	4 (4)	50	31 (62)	149	35 (23)
Indigenous	8	1 (13)	9	6 (67)	17	7 (41)
p value		0.3		0.8		0.1

† Excludes equivocal test results and missing values.

Table 351 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	98	42 (43)	11	7 (64)	109	49 (45)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	1	0 (0)	--	--	1	0 (0)
p value		0.08		--		0.07
2010						
Highly accessible/accessible	21	7 (33)	5	3 (60)	26	10 (39)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.3		--		0.3
2013						
Highly accessible/accessible	131	32 (24)	25	10 (40)	156	42 (27)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.09		0.4		0.06

† Excludes equivocal test results and missing values.

Table 352 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	88	31 (35)	8	5 (63)	96	36 (38)
Other Oceania	3	1 (33)	1	0 (0)	4	1 (25)
Asia	8	5 (63)	1	1 (100)	9	6 (67)
UK & Ireland	3	3 (100)	1	1 (100)	4	4 (100)
Other	6	2 (33)	--	--	6	2 (33)
p value		0.1		0.4		0.6
2010						
Australia	22	6 (27)	3	3 (100)	25	9 (36)
Other Oceania	--	--	--	--	--	--
Asia	1	0 (0)	2	0 (0)	3	0 (0)
UK & Ireland	--	--	--	--	--	--
Other	2	1 (50)	--	--	2	1 (50)
p value		0.7		0.03		0.4
2013						
Australia	108	27 (25)	19	9 (47)	127	36 (28)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	15	2 (13)	4	0 (0)	19	2 (11)
UK & Ireland	1	1 (100)	--	--	1	1 (100)
Other	12	2 (17)	3	1 (33)	15	3 (20)
p value		0.2		0.2		0.1

† Excludes equivocal test results and missing values.

Table 353 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	--	--	--	--	--	--
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	93	34 (37)	10	6 (60)	103	40 (39)
Non-English	14	7 (50)	1	1 (100)	15	8 (53)
p value		0.3		0.4		0.3
2010						
English	23	7 (30)	4	3 (75)	27	10 (37)
Non-English	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.4		0.2		0.2
2013						
English	110	27 (25)	20	9 (45)	130	36 (28)
Non-English	30	5 (17)	6	1 (17)	36	6 (17)
p value		0.4		0.2		0.2

† Excludes equivocal test results and missing values.

Table 354 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	--	--	--	--	--	--
Negative	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
Positive	35	35 (100)	7	7 (100)	42	42 (100)
Negative	24	4 (17)	2	0 (0)	26	4 (15)
Not sure	2	0 (0)	--	--	2	0 (0)
p value		<0.001		0.003		<0.001
2010						
Positive	4	4 (100)	3	3 (100)	7	7 (100)
Negative	14	1 (7)	1	0 (0)	15	1 (7)
Not sure	3	1 (33)	--	--	3	1 (33)
p value		0.001		0.05		<0.001
2013						
Positive	48	3 (6)	7	2 (29)	55	5 (9)
Negative	21	21 (100)	5	5 (100)	26	26 (100)
Not sure	13	6 (46)	3	2 (67)	16	8 (50)
p value		<0.001		0.05		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 355 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	59	4 (7)	6	0 (0)	65	4 (6)
Non-IDU	49	0 (0)	2	0 (0)	51	0 (0)
p value		0.06		--		0.07
2010						
IDU	15	0 (0)	3	0 (0)	18	0 (0)
Non-IDU	12	0 (0)	2	1 (50)	14	1 (7)
p value		--		0.2		0.3
2013						
IDU	43	1 (2)	2	0 (0)	45	1 (2)
Non-IDU	93	1 (1)	1	0 (0)	94	1 (1)
p value		0.6		--		0.6

† Excludes equivocal test results and missing values.

Table 356 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	--	--	--	--	--	--
Non-IDU	--	--	--	--	--	--
p value		--		--		--
2007						
IDU	56	23 (41)	6	2 (33)	62	25 (40)
Non-IDU	49	2 (4)	4	0 (0)	53	2 (4)
p value		<0.001		0.2		<0.001
2010						
IDU	15	2 (13)	--	--	15	2 (13)
Non-IDU	12	1 (8)	1	1 (100)	13	2 (15)
p value		0.7		--		0.9
2013						
IDU	42	10 (24)	2	0 (0)	44	10 (23)
Non-IDU	94	11 (12)	1	0 (0)	95	11 (12)
p value		0.07		--		0.09

† Excludes equivocal test results and missing values.

Table 357 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	--	--	--	--	--	--
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	103	25 (24)	8	1 (13)	111	26 (23)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	1	0 (0)	1	1 (100)	2	1 (50)
p value		0.7		0.1		0.7
2010						
Heterosexual	25	2 (8)	1	1 (100)	26	3 (12)
Bisexual	--	--	--	--	--	--
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	--	--	--	--	--	--
p value		0.8		--		0.7
2013						
Heterosexual	134	21 (16)	1	0 (0)	135	21 (16)
Bisexual	1	0 (0)	2	0 (0)	3	0 (0)
Homosexual	1	0 (0)	--	--	1	0 (0)
Unsure	--	--	--	--	--	--
p value		0.8		--		0.7

† Excludes equivocal test results and missing values.

Table 358 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	--	--	--	--	--	--
20 – 24	--	--	--	--	--	--
25 – 29	--	--	--	--	--	--
30 + years	--	--	--	--	--	--
p value		--		--		--
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	21	3 (14)	--	--	21	3 (14)
25 – 29	25	9 (36)	2	0 (0)	27	9 (33)
30 + years	54	13 (24)	8	2 (25)	62	15 (24)
p value		0.2		0.4		0.3
2010						
< 20 years	--	--	--	--	--	--
20 – 24	9	0 (0)	--	--	9	0 (0)
25 – 29	4	0 (0)	1	1 (100)	5	1 (20)
30 + years	14	3 (21)	--	--	14	3 (21)
p value		0.2		--		0.3
2013						
< 20 years	2	0 (0)	1	0 (0)	3	0 (0)
20 – 24	24	2 (8)	2	0 (0)	26	2 (8)
25 – 29	28	3 (11)	--	--	28	3 (11)
30 + years	83	16 (19)	--	--	83	16 (19)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 359 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	--	--	--	--	--	--
3 to 5 years	--	--	--	--	--	--
6 to 10 years	--	--	--	--	--	--
10 + years	--	--	--	--	--	--
p value		--		--		--
2007						
<3 years	4	0 (0)	--	--	4	0 (0)
3 to 5 years	7	3 (43)	1	0 (0)	8	3 (38)
6 to 10 years	16	7 (44)	2	1 (50)	18	8 (44)
10 + years	29	13 (45)	3	1 (33)	32	14 (44)
p value		0.4		0.7		0.4
2010						
<3 years	2	0 (0)	--	--	2	0 (0)
3 to 5 years	2	0 (0)	--	--	2	0 (0)
6 to 10 years	3	0 (0)	--	--	3	0 (0)
10 + years	8	2 (25)	--	--	8	2 (25)
p value		0.6		--		0.6
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	7	2 (29)	1	0 (0)	8	2 (25)
10 + years	25	7 (28)	--	--	25	7 (28)
p value		0.4		--		0.4

† Excludes equivocal test results and missing values.

Table 360 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	--	--	--	--	--	--
Heroin	--	--	--	--	--	--
More than one	--	--	--	--	--	--
Other/not reported	--	--	--	--	--	--
p value		--		--		--
2007						
Amphetamine (Speed, Ice)	4	0 (0)	24	6 (25)	28	6 (21)
Heroin	--	--	28	15 (54)	28	15 (54)
More than one	--	--	4	2 (50)	4	2 (50)
Other/not reported	--	--	2	2 (100)	2	2 (100)
p value		--		0.07		0.03
2010						
Amphetamine (Speed, Ice)	1	0 (0)	4	1 (25)	5	1 (20)
Heroin	1	0 (0)	5	1 (20)	6	1 (17)
More than one	--	--	2	0 (0)	2	0 (0)
Other/not reported	--	--	2	0 (0)	2	0 (0)
p value		--		0.8		0.8
2013						
Amphetamine (Speed, Ice)	5	1 (20)	19	3 (16)	24	4 (17)
Heroin	1	0 (0)	13	4 (31)	14	4 (29)
More than one	--	--	1	0 (0)	1	0 (0)
Other/not reported	--	--	5	2 (40)	5	2 (40)
p value		0.6		0.6		0.6

† Excludes equivocal test results and missing values.

Table 361 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	--	--	--	--	--	--
Daily or more	--	--	--	--	--	--
p value		--		--		--
2007						
Less than daily	--	--	19	11 (58)	19	11 (58)
Daily or more	1	0 (0)	23	12 (52)	24	12 (50)
p value		--		0.7		0.6
2010						
Less than daily	--	--	4	0 (0)	4	0 (0)
Daily or more	2	0 (0)	7	1 (14)	9	1 (11)
p value		--		0.4		0.5
2013						
Less than daily	1	0 (0)	8	2 (25)	9	2 (22)
Daily or more	3	0 (0)	17	4 (24)	20	4 (20)
p value		--		0.9		0.9

† Excludes equivocal test results and missing values.

Table 362 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	1	0 (0)	35	18 (51)	36	18 (50)
Yes	--	--	6	4 (67)	6	4 (67)
p value		--		0.5		0.5
2010						
No	2	0 (0)	7	1 (14)	9	1 (11)
Yes	--	--	2	0 (0)	2	0 (0)
p value		--		0.6		0.6
2013						
No	--	--	--	--	--	--
Yes	--	--	4	1 (25)	4	1 (25)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 363 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
p value		--		--		--
2007						
No	--	--	11	4 (36)	11	4 (36)
Yes	1	0 (0)	33	16 (48)	34	16 (47)
p value		--		0.5		0.5
2010						
No	1	0 (0)	5	2 (40)	6	2 (33)
Yes	--	--	8	0 (0)	8	0 (0)
p value		--		0.05		0.08
2013						
No	--	--	10	3 (30)	10	3 (30)
Yes	5	1 (20)	18	5 (28)	23	6 (26)
p value		--		0.9		0.8

† Excludes equivocal test results and missing values.

Table 364 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	--	--	--	--	--	--
2 to 4	--	--	--	--	--	--
5 to 9	--	--	--	--	--	--
10 +	--	--	--	--	--	--
p value		--		--		--
2007						
1	48	5 (10)	6	1 (17)	54	6 (11)
2 to 4	33	9 (27)	3	0 (0)	36	9 (25)
5 to 9	14	7 (50)	1	1 (100)	15	8 (53)
10 +	10	4 (40)	--	--	10	4 (40)
p value		0.008		0.09		0.003
2010						
1	14	1 (7)	1	0 (0)	15	2 (13)
2 to 4	7	1 (14)	--	--	7	1 (14)
5 to 9	3	0 (0)	--	--	3	0 (0)
10 +	3	1 (33)	--	--	3	1 (33)
p value		0.5		--		0.7
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 365 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	97	20 (21)	9	2 (22)	106	22 (21)
Indigenous	8	5 (63)	1	0 (0)	9	5 (56)
p value		0.008		0.6		0.02
2010						
Non-Indigenous	23	2 (9)	1	1 (100)	24	3 (13)
Indigenous	4	1 (25)	--	--	4	1 (25)
p value		0.3		--		0.5
2013						
Non-Indigenous	124	19 (15)	2	0 (0)	126	19 (15)
Indigenous	13	2 (15)	1	0 (0)	14	2 (14)
p value		1.0		--		0.9

† Excludes equivocal test results and missing values.

Table 366 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	--	--	--	--	--	--
Indigenous	--	--	--	--	--	--
p value		--		--		--
2007						
Non-Indigenous	51	2 (4)	55	20 (36)	106	22 (21)
Indigenous	2	0 (0)	7	5 (71)	9	5 (56)
p value		0.8		0.08		0.02
2010						
Non-Indigenous	12	2 (17)	12	1 (8)	24	3 (13)
Indigenous	1	0 (0)	3	1 (33)	4	1 (25)
p value		0.7		0.3		0.5
2013						
Non-Indigenous	88	11 (13)	37	8 (22)	125	19 (15)
Indigenous	7	0 (0)	7	2 (29)	14	2 (14)
p value		0.3		0.7		0.9

† Excludes equivocal test results and missing values.

Table 367 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	--	--	--	--	--	--
Moderately accessible	--	--	--	--	--	--
Remote/very remote	--	--	--	--	--	--
p value		--		--		--
2007						
Highly accessible/accessible	96	25 (26)	10	2 (20)	106	27 (25)
Moderately accessible	6	0 (0)	--	--	6	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.2		--		0.2
2010						
Highly accessible/accessible	23	2 (9)	1	1 (100)	24	3 (13)
Moderately accessible	--	--	--	--	--	--
Remote/very remote	2	0 (0)	--	--	2	0 (0)
p value		0.7		--		0.6
2013						
Highly accessible/accessible	127	21 (17)	2	0 (0)	129	21 (16)
Moderately accessible	9	0 (0)	1	0 (0)	10	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 368 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	--	--	--	--	--	--
Other Oceania	--	--	--	--	--	--
Asia	--	--	--	--	--	--
UK & Ireland	--	--	--	--	--	--
Other	--	--	--	--	--	--
p value		--		--		--
2007						
Australia	85	17 (20)	7	2 (29)	92	19 (21)
Other Oceania	3	0 (0)	1	0 (0)	4	0 (0)
Asia	8	4 (50)	1	0 (0)	9	4 (44)
UK & Ireland	3	3 (100)	1	0 (0)	4	3 (75)
Other	6	1 (17)	--	--	6	1 (17)
p value		0.006		0.8		0.04
2010						
Australia	24	2 (8)	--	--	24	2 (8)
Other Oceania	--	--	--	--	--	--
Asia	1	0 (0)	1	1 (100)	2	1 (50)
UK & Ireland	--	--	--	--	--	--
Other	2	1 (50)	--	--	2	1 (50)
p value		0.2		--		0.09
2013						
Australia	105	9 (9)	3	0 (0)	108	9 (8)
Other Oceania	4	2 (50)	--	--	4	2 (50)
Asia	15	7 (47)	--	--	15	7 (47)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	11	3 (27)	--	--	11	3 (27)
p value		<0.001		--		0.001

† Excludes equivocal test results and missing values.

Table 369 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	--	--	--	--	--	--
Non-English	--	--	--	--	--	--
p value		--		--		--
2007						
English	90	19 (21)	9	2 (22)	99	21 (21)
Non-English	14	5 (36)	1	0 (0)	15	5 (33)
p value		0.3		0.6		0.3
2010						
English	24	2 (8)	--	--	24	2 (8)
Non-English	3	1 (33)	1	1 (100)	4	2 (50)
p value		0.2		--		0.03
2013						
English	107	7 (7)	3	0 (0)	110	7 (6)
Non-English	29	14 (48)	--	--	29	14 (48)
p value		<0.001		--		<0.001

† Excludes equivocal test results and missing values.

Table 370 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	--	--	--	--	--
Non-IDU	--	--	--	--	--
p value					--
2007					
IDU	67	26 (39)	24 (36)	4 (6)	13 (9)
Non-IDU	53	45 (85)	2 (4)	0 (0)	6 (11)
p value					<0.001
2010					
IDU	19	7 (37)	2 (11)	0 (0)	10 (53)
Non-IDU	14	8 (57)	1 (7)	1 (7)	4 (29)
p value					0.3
2013					
IDU	32	36 (56)	9 (28)	1 (3)	9 (28)
Non-IDU	64	7 (22)	10 (16)	1 (2)	10 (16)
p value					0.02

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 371 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	--	--	--	--	--
Bisexual	--	--	--	--	--
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					--
2007					
Heterosexual	116	68 (59)	25 (22)	4 (3)	19 (16)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Unsure	2	1 (50)	1 (50)	0 (0)	0 (0)
p value					1.0
2010					
Heterosexual	30	14 (47)	2 (7)	1 (3)	13 (43)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.8
2013					
Heterosexual	92	42 (46)	19 (21)	2 (2)	29 (32)
Homosexual	3	0 (0)	0 (0)	0 (0)	1 (100)
Bisexual	1	1 (33)	0 (0)	0 (0)	2 (67)
Unsure	--	--	--	--	--
p value					0.7

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 372 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
< 20 years	--	--	--	--	--
20 – 24	--	--	--	--	--
25 – 29	--	--	--	--	--
30 + years	--	--	--	--	--
p value					--
2007					
< 20 years	6	3 (50)	1 (17)	0 (0)	2 (33)
20 – 24	21	11 (52)	2 (10)	1 (5)	7 (33)
25 – 29	29	14 (48)	9 (31)	1 (3)	5 (17)
30 + years	64	43 (67)	14 (22)	2 (3)	5 (8)
p value					0.2
2010					
< 20 years	--	--	--	--	--
20 – 24	9	4 (44)	0 (0)	0 (0)	5 (56)
25 – 29	7	3 (43)	0 (0)	1 (14)	3 (43)
30 + years	17	8 (47)	3 (18)	0 (0)	6 (35)
p value					0.3
2013					
< 20 years	1	0 (0)	0 (0)	0 (0)	1 (100)
20 – 24	17	5 (29)	2 (12)	0 (0)	10 (59)
25 – 29	20	8 (40)	3 (15)	0 (0)	9 (45)
30 + years	58	30 (52)	14 (24)	0 (0)	12 (21)
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 373 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	--	--	--	--	--
2 to 4	--	--	--	--	--
5 to 9	--	--	--	--	--
10 +	--	--	--	--	--
p value					--
2007					
1	55	42 (76)	6 (11)	1 (2)	6 (11)
2 to 4	36	24 (67)	8 (22)	1 (3)	3 (8)
5 to 9	19	3 (16)	10 (53)	0 (0)	6 (32)
10 +	10	2 (20)	2 (20)	2 (20)	4 (40)
p value					<0.001
2010					
1	17	10 (59)	1 (6)	1 (6)	5 (29)
2 to 4	8	3 (38)	1 (13)	0 (0)	4 (50)
5 to 9	4	1 (25)	0 (0)	0 (0)	3 (75)
10 +	4	1 (25)	1 (25)	0 (0)	2 (50)
p value					0.7
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 374 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	N° tested	N° (%) with no evidence of HBV immunity	Hepatitis B Virus Immune Status		
			N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	--	--	--	--	--
Indigenous	--	--	--	--	--
p value					--
2007					
Non-Indigenous	111	69 (62)	21 (19)	4 (4)	17 (15)
Indigenous	9	2 (22)	5 (56)	0 (0)	2 (22)
p value					0.05
2010					
Non-Indigenous	28	15 (54)	2 (7)	1 (4)	10 (36)
Indigenous	5	0 (0)	1 (20)	0 (0)	4 (80)
p value					0.1
2013					
Non-Indigenous	86	39 (45)	17 (20)	2 (2)	28 (33)
Indigenous	10	4 (40)	2 (20)	0 (0)	4 (40)
p value					0.9

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 375 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	N° tested	N° (%) with no evidence of HBV immunity	Hepatitis B Virus Immune Status		
			No (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	--	--	--	--	--
Moderately accessible	--	--	--	--	--
Remote/very remote	--	--	--	--	--
p value					--
2007					
Highly accessible/accessible	110	62 (56)	25 (23)	4 (4)	19 (17)
Moderately accessible	6	6 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	1	0 (0)	1 (100)	0 (0)	0 (0)
p value					0.2
2010					
Highly accessible/accessible	29	14 (48)	2 (7)	1 (3)	12 (41)
Moderately accessible	--	--	--	--	--
Remote/very remote	2	1 (50)	0 (0)	0 (0)	1 (50)
p value					0.9
2013					
Highly accessible/accessible	88	40 (45)	19 (22)	2 (2)	27 (31)
Moderately accessible	8	3 (38)	0 (0)	0 (0)	5 (63)
Remote/very remote	--	--	--	--	--
p value					0.2

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 376 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	--	--	--	--	--
Non-English	--	--	--	--	--
p value					--
2007					
English	104	62 (60)	22 (21)	2 (2)	18 (17)
Non-English	15	9 (60)	3 (20)	2 (13)	1 (7)
p value					0.1
2010					
English	28	13 (46)	2 (7)	0 (0)	13 (46)
Non-English	5	2 (40)	1 (20)	1 (20)	1 (20)
p value					0.07
2013					
English	72	35 (49)	7 (10)	0 (0)	30 (42)
Non-English	24	8 (33)	12 (50)	2 (8)	2 (8)
p value					<0.001

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 377 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	--	--	--	--	--	--
Yes	--	--	--	--	--	--
Not sure	--	--	--	--	--	--
p value		--		--		--
2007						
No	38	3 (8)	4	0 (0)	42	3 (7)
Yes	26	12 (46)	5	2 (40)	31	14 (45)
Not sure	16	2 (13)	1	0 (0)	17	2 (12)
p value		0.001		0.3		<0.001
2010						
No	5	1 (20)	0	0 (0)	5	1 (20)
Yes	12	8 (67)	2	2 (100)	14	10 (71)
Not sure	10	3 (30)	--	--	10	3 (30)
p value		0.4		--		0.05
2013						
No	20	6 (30)	1	1 (100)	21	7 (33)
Yes	34	21 (62)	2	2 (100)	26	23 (64)
Not sure	18	2 (11)	--	--	18	2 (11)
p value		0.001		--		0.001

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 378 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	19	1 (5)
Female	6	0 (0)
p value		0.6
2013		
Male	137	3 (2)
Female	27	2 (7)
p value		0.2

† Excludes missing values.

Gonorrhoea

Table 379 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	19	0 (0)
Female	6	0 (0)
p value		--
2013		
Male	137	0 (0)
Female	27	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 380 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	27	1 (4)	0 (0)	1 (4)
Female	6	0 (0)	0 (0)	0 (0)
p value		0.6	--	0.6
2013				
Male	138	0 (0)	0 (0)	0 (0)
Female	26	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

**Western Australia
2004, 2007, 2010, 2013**

Table 381 Number (%) of respondents by demographic characteristics, injector status and survey year

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° sites	N = 3		N = 4		N = 2		N = 3	
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45	N = 58	N = 39
Sex (%)								
Male	51 (77)	38 (81)	47 (85)	41 (95)	72 (94)	42 (93)	47 (81)	34 (87)
Female	15 (23)	9 (19)	8 (15)	2 (5)	5 (6)	3 (7)	11 (19)	5 (13)
Transgender	--	--	--	--	--	--	--	--
Sexual identity (%)								
Heterosexual	64 (97)	46 (98)	53 (96)	43 (100)	75 (97)	43 (96)	55 (95)	39 (100)
Bisexual	2 (3)	--	--	--	--	1 (2)	1 (2)	--
Homosexual	--	1 (2)	2 (4)	--	1 (1)	1 (2)	1 (2)	--
Unsure	--	--	--	--	1 (1)	--	--	--
Not reported	--	--	--	--	--	--	1 (2)	--
Age and duration of Injection (years)								
Median (Med) age	30	30	33	27	29	26	32	31
Age range	27 – 35	18 – 60	19 – 53	19 – 65	18 – 57	18 – 74	18 – 53	18 – 58
Age group (%)								
<25 years	18 (27)	15 (32)	14 (25)	14 (33)	18 (23)	20 (44)	14 (24)	8 (21)
25+ years	43 (65)	32 (68)	41 (75)	29 (67)	58 (75)	25 (56)	43 (74)	31 (79)
Not reported	5 (8)	--	--	--	1 (1)	--	1 (2)	--
Med age 1 st IDU	19	--	19	--	18	--	17	--
Age range	10 – 39	--	14 – 44	--	8 – 36	--	10 – 45	--
Not reported	2	--	1	--	2	--	--	--
Med IDU (years)	8	--	12	--	10	--	14	--
Range	<1 – 26	--	<1 – 35	--	<1 – 28	--	<1 – 41	--
Duration of drug injection (%)								
<3 years	10 (15)	--	6 (11)	--	11 (14)	--	9 (15)	--
3+ years	52 (79)	--	48 (87)	--	63 (82)	--	48 (83)	--
Not reported	4 (6)	--	1 (2)	--	3 (4)	--	1 (2)	--
Aboriginal and/or Torres Strait Islander origin (%)								
No	40 (61)	30 (64)	36 (65)	26 (60)	46 (60)	35 (78)	35 (60)	30 (77)
Yes	26 (39)	17 (36)	17 (31)	17 (40)	31 (40)	10 (22)	23 (40)	9 (23)
Not reported	--	--	2 (4)	--	--	--	--	--
Residential remoteness in 12 months before prison (%)								
Highly/accessible	51 (77)	35 (74)	47 (85)	29 (67)	69 (90)	40 (89)	54 (93)	31 (79)
Mod accessible	4 (6)	2 (4)	1 (2)	1 (2)	4 (5)	1 (2)	1 (2)	3 (8)
Very/remote	8 (12)	10 (21)	4 (7)	6 (14)	3 (4)	4 (9)	--	1 (3)
Not reported	3 (5)	--	3 (5)	7 (16)	1 (1)	--	3 (5)	4 (10)
Region/Country of birth (%)								
Australia	57 (86)	42 (90)	47 (85)	34 (79)	71 (92)	32 (71)	54 (93)	27 (69)
Other Oceania	1 (2)	1 (2)	3 (5)	1 (2)	1 (1)	3 (7)	3 (5)	3 (8)
Asia	--	1 (2)	--	2 (5)	1 (1)	1 (2)	--	2 (5)
UK & Ireland	4 (5)	1 (2)	1 (2)	4 (9)	2 (3)	3 (7)	1 (2)	3 (8)
Other	3 (5)	2 (4)	4 (7)	2 (5)	2 (3)	6 (13)	--	4 (10)
Not reported	1 (2)	--	--	--	--	--	--	--
Main language spoke at home by parents (%)								
English	64 (98)	44 (94)	53 (96)	40 (93)	73 (95)	37 (82)	57 (98)	36 (92)
Non-English	1 (2)	3 (6)	2 (4)	3 (7)	3 (4)	8 (18)	1 (2)	3 (8)
Not reported	--	--	--	--	1 (1)	--	--	--

Table 382 Number (%) of respondents by demographic characteristics, injector status and survey year (cont.)

Demographics	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
First time in prison (%)								
No	47 (71)	27 (57)	40 (73)	21 (49)	57 (74)	14 (31)	44 (76)	22 (56)
Yes	19 (29)	20 (43)	15 (27)	21 (49)	20 (26)	31 (69)	14 (24)	17 (44)
Not reported	--	--	--	1 (2)	--	--	--	--
Lifetime imprisonments (%)*								
One	19 (29)	20 (43)	15 (27)	21 (49)	36 (47)	39 (87)	n/a	n/a
Two to four	29 (44)	21 (45)	17 (31)	14 (33)	22 (29)	4 (9)	n/a	n/a
Five to nine	12 (18)	3 (6)	9 (16)	2 (5)	11 (14)	2 (4)	n/a	n/a
Ten or more	5 (8)	--	2 (4)	1 (2)	8 (10)	--	n/a	n/a
Not reported	1 (2)	3 (6)	12 (22)	5 (12)	--	--	n/a	n/a
Imprisonment in last year (%)								
No	31 (47)	28 (60)	14 (35)	9 (41)	39 (51)	38 (84)	19 (43)	9 (41)
Yes	30 (45)	14 (30)	21 (53)	10 (45)	34 (44)	6 (13)	21 (48)	9 (41)
Not reported	5 (8)	5 (11)	5 (13)	3 (14)	4 (5)	1 (2)	4 (9)	4 (18)
Frequency of injection last month (%)								
Not last month	26 (39)	--	25 (45)	--	26 (34)	--	16 (28)	--
< weekly	10 (15)	--	9 (16)	--	22 (29)	--	13 (22)	--
Weekly	1 (2)	--	6 (11)	--	6 (8)	--	8 (14)	--
Daily or more	29 (44)	--	15 (27)	--	22 (29)	--	21 (36)	--
Not reported	--	--	--	--	1 (1)	--	--	--
Ever smoked a full cigarette (%)**								
No	n/a	n/a	4 (7)	4 (9)	1 (1)	8 (18)	--	9 (23)
Yes	n/a	n/a	51 (93)	39 (91)	76 (99)	37 (82)	58 (100)	30 (77)
Not reported	n/a	n/a	--	--	--	--	--	--
Med age 1st smoked								
Age range	n/a	n/a	7 – 20	6 – 24	3 – 22	11 – 33	6 – 28	8 – 19
Current smoker (%)**								
No	n/a	n/a	7 (13)	11 (26)	3 (4)	13 (29)	4 (7)	8 (27)
Yes	n/a	n/a	47 (85)	32 (74)	74 (96)	32 (71)	54 (93)	22 (73)
Not reported	n/a	n/a	1 (2)	--	--	--	--	--
Smoking frequency (%)**								
Weekly or less	n/a	n/a	3 (6)	5 (16)	7 (9)	1 (3)	3 (6)	3 (14)
5 - 10/day	n/a	n/a	15 (31)	10 (31)	28 (38)	17 (53)	24 (44)	7 (32)
11 - 20/day	n/a	n/a	16 (33)	13 (41)	26 (35)	9 (28)	22 (41)	6 (27)
>20/day	n/a	n/a	13 (27)	4 (13)	12 (16)	5 (16)	5 (9)	6 (27)
Not reported	n/a	n/a	1 (2)	--	1 (1)	--	--	--
Other drugs used last month (%)***								
None	n/a	n/a	n/a	n/a	9 (12)	16 (36)	5 (9)	23 (59)
Cannabis	n/a	n/a	n/a	n/a	57 (85)	22 (79)	33 (62)	8 (50)
Heroin	n/a	n/a	n/a	n/a	14 (21)	1 (4)	6 (11)	1 (6)
Cocaine	n/a	n/a	n/a	n/a	1 (1)	1 (4)	1 (2)	1 (6)
Amphetamine	n/a	n/a	n/a	n/a	47 (70)	8 (29)	45 (85)	10 (63)
Methadone	n/a	n/a	n/a	n/a	1 (1)	--	--	--
Other opiates	n/a	n/a	n/a	n/a	15 (22)	--	3 (6)	--
Buprenorphine	n/a	n/a	n/a	n/a	6 (9)	--	2 (4)	--
Steroids	n/a	n/a	n/a	n/a	--	--	2 (4)	--
Hallucinogens	n/a	n/a	n/a	n/a	1 (1)	1 (4)	2 (4)	1 (6)
Benzodiazepine	n/a	n/a	n/a	n/a	10 (15)	1 (4)	6 (11)	1 (6)
Ecstasy/MDA	n/a	n/a	n/a	n/a	8 (12)	4 (14)	3 (6)	1 (6)
Inhalants	n/a	n/a	n/a	n/a	--	--	--	--
Other drug	n/a	n/a	n/a	n/a	1 (1)	--	2 (4)	2 (13)
Not reported	n/a	n/a	n/a	n/a	1 (1)	1 (2)	--	--

* Number of imprisonments over lifetime not asked in 2013.

** Smoking questions not asked in 2004.

*** Other drugs used in the past month not asked in 2004 and 2007. More than one option could be selected.

Table 383 Number (%) of respondents by last drug injected, injecting behaviour in the month prior to survey and survey year

Injecting behaviour	2004	2007	2010	2013
Last drug injected (%)	N = 66	N = 55	N = 77	N = 58
Amphetamine (Speed, Ice)	54 (82)	47 (85)	58 (75)	50 (86)
Anabolic steroids	--	--	--	2 (3)
Cocaine	--	--	--	--
Heroin	7 (11)	7 (13)	10 (13)	4 (7)
Heroin + amphetamine	--	1 (2)	--	--
Heroin + cocaine	--	--	--	--
Methadone	3 (5)	--	--	--
Morphine	2 (3)	--	4 (5)	1 (2)
Other	--	--	4 (5)	1 (2)
Not reported	--	--	1 (1)	--
N° Injected last month	N = 40	N = 30	N = 50	N = 42
Places injected last month (%)*				
Prison	1 (3)	1 (3)	1 (2)	--
Own home	26 (65)	23 (77)	27 (55)	31 (74)
Friend's home	19 (48)	11 (37)	23 (47)	15 (36)
Dealer's home	5 (13)	8 (27)	5 (10)	9 (21)
Street, park, beach	6 (15)	9 (30)	3 (6)	9 (21)
Car	7 (18)	5 (17)	5 (10)	6 (14)
Public toilet	2 (5)	4 (13)	3 (6)	9 (21)
Commercial injecting room	--	--	--	--
Medically Supervised Injecting Centre, Sydney	--	--	--	--
Squat	--	1 (3)	1 (2)	1 (2)
Other place	--	3 (10)	--	--
Use of sterile needles & syringes last month (%)				
All injections	26 (65)	16 (53)	30 (60)	29 (69)
Most of the time	9 (23)	11 (37)	15 (30)	9 (21)
Half of the time	1 (3)	--	2 (4)	--
Some of the time	4 (10)	3 (10)	1 (2)	4 (10)
Not last month	--	--	1 (2)	--
Not reported	1 (3)	--	1 (2)	--
Re-used someone else's used needle & syringe last month (%)				
None	29 (73)	21 (70)	41 (82)	34 (81)
Once	--	6 (20)	3 (6)	4 (10)
Twice	6 (15)	--	2 (4)	2 (5)
3-5 times	1 (3)	1 (3)	--	1 (2)
>5 times	2 (5)	2 (7)	3 (6)	1 (2)
Not reported	2 (5)	--	1 (2)	--
Number of people needle & syringe was re-used after last month (%)				
One	3 (8)	6 (20)	3 (6)	5 (12)
Two	3 (8)	--	2 (4)	1 (2)
Three to five	1 (3)	1 (3)	--	--
More than five	2 (5)	--	2 (4)	1 (2)
Don't know how many	--	1 (3)	2 (4)	1 (2)
Not reported	2 (5)	1 (3)	1 (2)	--
Relationship to people needle & syringe was re-used after last month (%)*				
Regular sex partner	5 (13)	3 (10)	6 (12)	3 (7)
Casual sex partner	--	1 (3)	--	1 (2)
Close friend	2 (5)	2 (7)	2 (4)	2 (5)
Acquaintance	--	2 (7)	--	1 (2)
Other	4 (10)	2 (7)	1 (2)	2 (5)
Equipment used after someone else last month (%)*				
Spoon	9 (23)	4 (13)	10 (20)	6 (14)
Water	8 (20)	8 (27)	8 (16)	3 (7)
Filter	7 (18)	4 (13)	11 (22)	3 (7)
Tourniquet	5 (13)	3 (10)	1 (2)	1 (2)
Drug mix	7 (18)	5 (17)	11 (22)	4 (10)

* More than one option could be selected.

Table 384 Number (%) of respondents by treatment for drug use, injector status and survey year

Treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45	N = 58	N = 39
Any treatment/therapy for drug use (%)								
No	41 (62)	41 (87)	23 (42)	31 (72)	50 (65)	36 (80)	39 (67)	33 (85)
Yes	25 (38)	6 (13)	30 (55)	8 (19)	27 (35)	9 (20)	19 (33)	6 (15)
Not reported			2 (4)	4 (9)	--	--	--	--
History of methadone maintenance treatment (%)								
Currently	3 (5)	1 (2)	2 (4)	--	1 (1)	--	2 (3)	--
Previously	3 (5)	--	7 (13)	--	5 (6)	--	4 (7)	--
Never	60 (90)	45 (96)	38 (69)	--	71 (92)	45 (100)	52 (90)	39 (100)
Not reported	--	1 (2)	8 (15)	--	--	--	--	--
History of other pharmacotherapy treatment (%)								
Currently	4 (6)	1 (2)	5 (9)	--	--	--	--	--
Previously	4 (6)	--	7 (13)	--	3 (4)	1 (2)	5 (9)	--
Never	58 (88)	45 (96)	43 (78)	--	74 (96)	44 (98)	53 (91)	39 (100)
Not reported	--	1 (2)	--	--	--	--	--	--

Table 385 Number (%) of respondents by site of needle and syringe acquisition last month and survey year

Needle & Syringe acquisition	2004	2007	2010	2013
N° surveyed	N = 40	N = 30	N = 76	N = 58
From an NSP last month (%)*				
Daily or almost daily	3 (8)	1 (3)	2 (3)	1 (2)
A couple of times each week	5 (13)	2 (7)	2 (3)	6 (10)
Less than weekly	7 (18)	3 (10)	7 (9)	3 (5)
Weekly	n/a	n/a	3 (4)	--
Once last month	5 (13)	3 (10)	--	5 (9)
Not in the last month	18 (45)	17 (57)	55 (72)	42 (72)
Not reported	2 (5)	4 (13)	7 (9)	1 (2)
From a chemist last month (%)*				
Daily or almost daily	6 (15)	3 (10)	9 (12)	6 (10)
A couple of times each week	6 (15)	8 (27)	8 (10)	11 (19)
Less than weekly	8 (20)	5 (17)	18 (23)	9 (16)
Weekly	n/a	n/a	11 (14)	--
Once last month	6 (15)	5 (17)	--	10 (17)
Not in the last month	13 (33)	6 (20)	27 (35)	--
Not reported	1 (3)	3 (10)	3 (4)	--

* The option of 'weekly' was not asked in the 2004 and 2007 surveys.

Table 386 Number (%) of respondents by body piercing and tattoos

Demographics	2004		2007		2010		2013	
	IDU N = 66	Non-IDU N = 47	IDU N = 55	Non-IDU N = 43	IDU N = 77	Non- N = 45	IDU N = 58	Non-IDU N = 39
N° surveyed								
Body or ear piercings (%)								
No	30 (45)	29 (62)	25 (45)	22 (51)	53 (69)	27 (60)	32 (55)	25 (64)
Yes	36 (55)	18 (38)	29 (53)	21 (49)	24 (31)	18 (40)	26 (45)	14 (36)
Not reported	--	--	1 (2)	--	--	--	--	--
Pierced in past 12 months (%)								
No	25 (69)	9 (50)	23 (79)	17 (81)	15 (63)	13 (72)	21 (81)	10 (71)
Yes	5 (14)	3 (17)	1 (3)	1 (5)	5 (21)	3 (17)	2 (8)	2 (14)
Not reported	6 (17)	6 (33)	5 (17)	3 (14)	4 (17)	2 (11)	3 (12)	2 (14)
Who did piercing (%)*								
Chemist/salon	3 (60)	--	1 (100)	--	1 (20)	2 (67)	--	2 (100)
Professional piercer	1 (20)	2 (67)	1 (100)	--	4 (80)	1 (33)	2 (100)	--
Tattooist/parlour	1 (20)	2 (67)	--	--	--	--	--	--
Friend	1 (20)	--	--	--	--	--	--	--
Prison inmate	--	--	--	--	--	--	--	--
Self	1 (20)	--	--	1 (100)	--	--	--	--
Family member	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Needle used by other (%)								
No	--	1 (33)	--	1 (100)	--	1 (33)	--	--
Yes	1 (20)	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--
Not reported	4 (80)	2 (67)	1 (100)	--	5 (100)	2 (67)	2 (100)	2 (100)
Tattoos (%)								
No	23 (25)	31 (66)	21 (38)	27 (63)	22 (29)	26 (58)	10 (17)	16 (41)
Yes	43 (65)	16 (34)	34 (62)	16 (37)	55 (71)	19 (42)	47 (81)	23 (59)
Not reported	--	--	--	--	--	--	1 (2)	--
Tattoos in past 12 months (%)								
No	33 (77)	14 (88)	27 (79)	14 (88)	39 (71)	11 (58)	35 (74)	15 (65)
Yes	10 (23)	2 (13)	7 (21)	2 (13)	16 (29)	8 (42)	11 (23)	8 (35)
Not reported	--	--	--	--	--	--	1 (2)	--
Who did tattooing (%)*								
Prof tattooist	8 (80)	1 (50)	5 (71)	2 (100)	7 (44)	2 (25)	5 (45)	6 (75)
Friend	3 (30)	1 (50)	--	--	4 (25)	5 (63)	5 (45)	--
Prison inmate	2 (20)	--	1 (14)	--	3 (19)	--	1 (9)	1 (13)
Self	1 (10)	--	1 (14)	--	1 (6)	1 (13)	3 (27)	--
Family member	--	--	--	--	2 (13)	--	1 (9)	1 (13)
Other	--	--	--	--	--	--	--	--

* More than one option could be selected.

Table 387 Number (%) of respondents by sexual behaviour in the month (3 months) prior to survey by injector status and survey year

Sex behaviour	2004		2007		2010		2013	
	IDU N = 66	Non-IDU N = 47	IDU N = 55	Non-IDU N = 43	IDU N = 77	Non-IDU N = 45	IDU N = 58	Non-IDU N = 39
Sex last month / last 3 months (%)**								
No	24 (36)	14 (30)	15 (27)	11 (26)	5 (6)	9 (20)	4 (7)	10 (26)
Yes	41 (62)	32 (68)	40 (73)	32 (74)	71 (92)	36 (80)	54 (93)	28 (72)
Not reported	1 (2)	1 (2)	--	--	1 (1)	--	--	1 (3)
Male sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (1 – 8)	1 (0 – 2)	0 (0 – 3)	0 (0 – 2)
Female sex partners in last 3 months**								
Median (Range)	n/a	n/a	n/a	n/a	1 (0 – 12)	1 (0 – 6)	1 (0-12)	1 (0 – 6)
Condom use at last sex (%)								
No	46 (70)	36 (77)	42 (76)	26 (60)	n/a	n/a	n/a	n/a
Yes	20 (30)	11 (23)	13 (24)	17 (40)	n/a	n/a	n/a	n/a
Not reported	--	--	--	--	n/a	n/a	n/a	n/a
Condom use with regular sex partner(s) last month (%)*								
No	21 (75)	22 (88)	27 (84)	13 (54)	n/a	n/a	n/a	n/a
Sometimes	2 (7)	2 (8)	4 (13)	6 (25)	n/a	n/a	n/a	n/a
Always	5 (18)	1 (4)	1 (3)	5 (21)	n/a	n/a	n/a	n/a
Condom use with new sex partner(s) last month (%)*								
No	12 (71)	5 (63)	10 (50)	4 (33)	n/a	n/a	n/a	n/a
Sometimes	1 (6)	2 (25)	5 (25)	5 (42)	n/a	n/a	n/a	n/a
Always	4 (24)	1 (13)	5 (25)	3 (25)	n/a	n/a	n/a	n/a
Condom use with casual sex partner(s) last month (%)*								
No	9 (69)	7 (78)	10 (59)	2 (18)	n/a	n/a	n/a	n/a
Sometimes	1 (8)	2 (22)	5 (29)	5 (45)	n/a	n/a	n/a	n/a
Always	3 (23)	--	2 (12)	4 (36)	n/a	n/a	n/a	n/a
Condom use last sex - regular male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	4 (80)	2 (67)	--	1 (100)
Sometimes	n/a	n/a	n/a	n/a	1 (20)	--	9 (100)	--
Always	n/a	n/a	n/a	n/a	--	1 (33)	--	--
Condom use last sex - casual male partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	1 (50)	1 (100)	1 (33)	2 (67)
Sometimes	n/a	n/a	n/a	n/a	--	--	2 (67)	--
Always	n/a	n/a	n/a	n/a	1 (50)	--	--	1 (33)
Condom use last sex - regular female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	34 (79)	17 (61)	37 (84)	22 (96)
Sometimes	n/a	n/a	n/a	n/a	4 (9)	8 (29)	6 (14)	--
Always	n/a	n/a	n/a	n/a	5 (12)	3 (11)	1 (2)	1 (4)
Condom use last sex - casual female partners - last 3 months (%)**								
Never	n/a	n/a	n/a	n/a	18 (60)	4 (50)	7 (88)	3 (38)
Sometimes	n/a	n/a	n/a	n/a	6 (20)	1 (13)	1 (13)	1 (13)
Always	n/a	n/a	n/a	n/a	6 (20)	3 (38)	--	4 (50)
Sex work last month (%)								
No	66 (100)	46 (98)	52 (95)	43 (100)	76 (99)	44 (98)	57 (98)	39 (100)
Yes	--	1 (2)	3 (5)	--	1 (1)	--	1 (2)	--
Not reported	--	--	--	--	--	1 (2)	--	--
Condom used at last sex work last month (%)								
No	--	--	--	--	--	--	--	--
Yes	--	1 (100)	3 (100)	--	1 (100)	--	1 (100)	--
Not reported	--	--	--	--	--	--	--	--

* Percentages exclude participants reporting no regular, new or casual sex partner respectively in the previous month.

** Sexual health questions were changed in 2010 to reflect the past 3 months and to differentiate male / female partners. Shaded areas indicate previous survey items that were changed in 2010.

Table 388 Number (%) of respondents reporting previous testing for HIV, HBV and HCV infection, vaccinations for HBV and cervical cancer, and HCV treatment by injector status and survey year

Testing & treatment	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° surveyed	N = 66	N = 47	N = 55	N = 43	N = 77	N = 45	N = 58	N = 39
Previous HIV test (%)								
Last year	26 (39)	8 (7)	15 (27)	6 (14)	26 (34)	11 (24)	13 (22)	6 (15)
>1 year ago	17 (26)	11 (23)	25 (45)	11 (26)	21 (27)	9 (20)	26 (45)	13 (33)
Never tested	23 (35)	27 (57)	13 (24)	26 (60)	30 (39)	25 (56)	19 (33)	20 (51)
Not reported	--	1 (2)	2 (4)	--	--	--	--	--
HBV infection (%)								
No	52 (79)	41 (87)	38 (69)	37 (86)	71 (92)	44 (98)	50 (86)	37 (95)
Yes	5 (8)	1 (2)	10 (18)	1 (2)	4 (5)	--	5 (9)	--
Don't know	9 (14)	5 (11)	7 (13)	5 (12)	1 (1)	--	3 (5)	2 (5)
Not reported	--	--	--	--	1 (1)	1 (2)	--	--
HBV vaccination (%)*								
No	21 (32)	22 (47)	27 (49)	27 (63)	36 (47)	31 (69)	21 (36)	20 (51)
Yes	34 (52)	12 (26)	22 (40)	9 (21)	34 (44)	8 (18)	19 (33)	3 (8)
Don't know	11 (17)	12 (26)	6 (11)	7 (16)	7 (9)	6 (13)	18 (31)	15 (38)
Not reported	--	1 (2)	--	--	--	--	--	1 (3)
Ever had cervical cancer vaccine (women only)** (%)								
No	n/a	n/a	n/a	n/a	--	3 (100)	3 (60)	1 (25)
Yes	n/a	n/a	n/a	n/a	1 (100)	--	1 (20)	3 (75)
Unsure	n/a	n/a	n/a	n/a	--	--	1 (20)	--
Not reported	--	--	n/a	n/a	--	--	--	--
Previous HCV test (%)								
Last year	31 (47)	6 (13)	20 (36)	5 (12)	26 (34)	10 (22)	13 (22)	9 (23)
>1 year ago	12 (18)	7 (15)	25 (45)	10 (23)	27 (35)	9 (20)	28 (48)	7 (18)
Never tested	23 (35)	33 (72)	10 (18)	28 (65)	24 (31)	26 (58)	16 (28)	23 (59)
Unsure	--	--	--	--	--	--	--	--
Not reported	--	1 (<1)	--	--	--	--	1 (2)	--
Any HCV treatment (%)***								
	N = 16	N = 2	N = 16	N = 1	N = 22	N = 0	N = 11	N = 0
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	--	--	3 (27)	--
Int & Ribavirin & Boceprevir	--	--	--	--	--	--	--	--
Other	16 (100)	2 (100)	--	--	--	--	--	--
None	--	--	16 (100)	1 (100)	22 (100)	--	8 (73)	--
Not reported	--	--	--	--	--	--	--	--
Current HCV treatment								
Interferon (Int)	--	--	--	--	--	--	--	--
Int & Ribavirin	--	--	--	--	--	--	--	--
Other	--	--	--	--	--	--	--	--
Unsure	--	--	--	--	--	--	--	--

* Number (%) among participants with no history of HBV infection.

** Proportion of eligible women i.e. those under 27 years of age in 2007.

*** Number (%) of those reporting positive HCV test results.

Table 389 Number (%) of respondents reporting previous interest in treatment for HCV, willingness to receive treatment for HCV, and HCV treatment plans by injector status and survey year

Treatment willingness*	2004		2007		2010		2013	
	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU	IDU	Non-IDU
N° reporting previous positive HCV test not currently on treatment							N = 11	N = 0
Ever sought out HCV treatment?								
No	n/a	n/a	n/a	n/a	n/a	n/a	6 (64)	--
Yes	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--
Willingness to receive treatment for HCV								
Very unwilling	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--
Unwilling	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Neutral	n/a	n/a	n/a	n/a	n/a	n/a	1 (9)	--
Willing	n/a	n/a	n/a	n/a	n/a	n/a	3 (27)	--
Very willing	n/a	n/a	n/a	n/a	n/a	n/a	3 (27)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--
More willing to receive HCV treatment in prison than community								
Yes	n/a	n/a	n/a	n/a	n/a	n/a	4 (36)	--
No	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--
Unsure	n/a	n/a	n/a	n/a	n/a	n/a	5 (45)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Future treatment plans								
Within 1 year	n/a	n/a	n/a	n/a	n/a	n/a	5 (45)	--
Next 1-2 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
Next 2-5 years	n/a	n/a	n/a	n/a	n/a	n/a	--	--
>5 years	n/a	n/a	n/a	n/a	n/a	n/a	1 (9)	--
No plans	n/a	n/a	n/a	n/a	n/a	n/a	3 (27)	--
Not reported	n/a	n/a	n/a	n/a	n/a	n/a	2 (18)	--

* HCV Treatment willingness questions introduced in 2013.

HIV antibody prevalence

Table 390 HIV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)	N° tested	N° with HIV (%)
2004						
IDU	44	0 (0)	5	0 (0)	49	0 (0)
Non-IDU	36	0 (0)	7	0 (0)	43	0 (0)
p value		--		--		--
2007						
IDU	38	0 (0)	5	0 (0)	43	0 (0)
Non-IDU	36	0 (0)	2	0 (0)	38	0 (0)
p value		--		--		--
2010						
IDU	60	0 (0)	2	0 (0)	62	0 (0)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		--		--		--
2013						
IDU	39	0 (0)	7	0 (0)	46	0 (0)
Non-IDU	22	0 (0)	3	0 (0)	25	0 (0)
p value		--		--		--

† Excludes equivocal test results and missing values.

HCV antibody prevalence

Table 391 HCV antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
IDU	43	12 (28)	5	4 (80)	48	16 (33)
Non-IDU	36	2 (6)	7	0 (0)	43	2 (5)
p value		0.01		0.004		0.001
2007						
IDU	38	14 (37)	5	2 (40)	43	16 (37)
Non-IDU	37	1 (3)	2	0 (0)	39	1 (3)
p value		<0.001		0.3		<0.001
2010						
IDU	59	22 (37)	2	0 (0)	61	22 (36)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		<0.001		--		<0.001
2013						
IDU	40	11 (28)	8	5 (63)	48	16 (33)
Non-IDU	22	1 (5)	3	0 (0)	25	1 (4)
p value		0.03		0.06		0.005

† Excludes equivocal test results and missing values.

Table 392 HCV antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Heterosexual	79	14 (18)	12	4 (33)	91	18 (20)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	14 (19)	7	2 (29)	80	16 (20)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.3		--		0.3
2010						
Heterosexual	90	22 (24)	2	0 (0)	92	22 (24)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	0 (0)	1	0 (0)	2	0 (0)
Unsure	--	--	--	--	--	--
p value		0.6		--		0.6
2013						
Heterosexual	62	12 (19)	9	3 (33)	71	15 (21)
Bisexual	--	--	1	1 (100)	1	1 (100)
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		0.2		0.06

† Excludes equivocal test results and missing values.

Table 393 HCV antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
< 20 years	11	1 (9)	--	--	11	1 (9)
20 – 24	18	2 (11)	1	0 (0)	19	2 (11)
25 – 29	17	1 (6)	2	1 (50)	19	2 (11)
30 + years	36	10 (28)	7	1 (14)	43	11 (26)
p value		0.2		0.5		0.3
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	1 (8)	2	0 (0)	14	1 (7)
30 + years	38	13 (34)	5	2 (40)	43	15 (35)
p value		0.02		0.3		0.01
2010						
< 20 years	9	0 (0)	1	0 (0)	10	0 (0)
20 – 24	22	4 (18)	2	0 (0)	24	4 (17)
25 – 29	27	6 (22)	--	--	27	6 (22)
30 + years	34	12 (35)	1	0 (0)	35	12 (34)
p value		0.1		--		0.1
2013						
< 20 years	5	1 (20)	1	0 (0)	6	1 (17)
20 – 24	11	2 (18)	1	0 (0)	12	2 (17)
25 – 29	13	1 (8)	4	1 (25)	17	2 (12)
30 + years	32	8 (25)	5	4 (80)	37	12 (32)
p value		0.6		0.2		0.4

† Excludes equivocal test results and missing values.

Table 394 HCV antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
<3 years	9	0 (0)	--	--	9	0 (0)
3 to 5 years	5	3 (60)	--	--	5	3 (60)
6 to 10 years	12	2 (17)	1	1 (100)	13	3 (23)
10 + years	16	7 (44)	3	2 (67)	19	9 (47)
p value		0.03		0.6		0.02
2007						
<3 years	5	--	--	--	5	0 (0)
3 to 5 years	7	--	--	--	7	0 (0)
6 to 10 years	6	1 (17)	1	0 (0)	7	1 (14)
10 + years	19	12 (63)	4	2 (50)	23	14 (61)
p value		0.003		0.4		0.002
2010						
<3 years	10	1 (10)	1	0 (0)	11	1 (9)
3 to 5 years	4	2 (50)	--	--	4	2 (50)
6 to 10 years	16	7 (44)	1	0 (0)	17	7 (41)
10 + years	27	11 (41)	--	--	27	11 (41)
p value		0.3		--		0.2
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	4	0 (0)	0	0 (0)	4	0 (0)
6 to 10 years	4	1 (25)	3	1 (33)	7	2 (29)
10 + years	23	8 (35)	5	4 (80)	28	12 (43)
p value		0.4		0.2		0.2

† Excludes equivocal test results and missing values.

Table 395 HCV antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Amphetamine (Speed, Ice)	8	0 (0)	32	13 (41)	40	13 (33)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	3 (60)	6	3 (50)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5
2007						
Amphetamine (Speed, Ice)	5	0 (0)	34	12 (35)	39	12 (31)
Heroin	--	--	2	2 (100)	2	2 (100)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.09		0.07
2010						
Amphetamine (Speed, Ice)	9	0 (0)	37	14 (38)	46	14 (30)
Heroin	--	--	7	6 (86)	7	6 (86)
More than one	--	--	--	--	--	--
Other/not reported	2	1 (50)	4	0 (0)	6	1 (17)
p value		0.03		0.01		0.01
2013						
Amphetamine (Speed, Ice)	7	2 (29)	34	12 (35)	41	14 (34)
Heroin	--	--	3	2 (67)	3	2 (67)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	2	0 (0)	3	0 (0)
p value		0.5		0.3		0.2

† Excludes equivocal test results and missing values.

Table 396 HCV antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Less than daily	3	0 (0)	5	3 (60)	8	3 (38)
Daily or more	4	0 (0)	15	9 (60)	19	9 (47)
p value		--		0.06		0.6
2007						
Less than daily	--	--	11	2 (18)	11	2 (18)
Daily or more	2	0 (0)	11	9 (82)	13	9 (69)
p value		--		0.003		0.008
2010						
Less than daily	6	0 (0)	16	7 (44)	22	7 (32)
Daily or more	4	1 (25)	13	6 (46)	17	7 (41)
p value		0.2		0.9		0.6
2013						
Less than daily	4	1 (25)	14	6 (43)	18	7 (39)
Daily or more	2	1 (50)	12	4 (33)	14	5 (36)
p value		0.5		0.6		0.5

† Excludes equivocal test results and missing values.

Table 397 HCV antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	18	5 (28)	24	5 (21)
Yes	3	0 (0)	18	10 (56)	21	10 (48)
p value		--		0.09		0.06
2007						
No	2	0 (0)	11	6 (55)	13	6 (46)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.1		0.2
2010						
No	6	1 (17)	24	11 (46)	30	12 (40)
Yes	5	0 (0)	22	8 (36)	27	8 (30)
p value		0.4		0.5		0.4
2013						
No	--	--	--	--	--	--
Yes	2	2 (100)	6	2 (33)	8	4 (50)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 398 HCV antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
No	6	0 (0)	18	5 (28)	24	5 (21)
Yes	3	0 (0)	18	10 (56)	21	10 (48)
p value		--		0.09		0.06
2007						
No	2	0 (0)	11	6 (55)	13	6 (46)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		--		0.1		0.2
2010						
No	6	1 (17)	24	11 (46)	30	12 (40)
Yes	5	0 (0)	22	8 (36)	27	8 (30)
p value		0.4		0.5		0.4
2013						
No	1	0 (0)	15	6 (40)	16	6 (38)
Yes	2	1 (50)	14	6 (43)	16	7 (44)
p value		0.4		0.9		0.9

† Excludes equivocal test results and missing values.

Table 399 HCV antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
1	28	0 (0)	5	0 (0)	33	0 (0)
2 to 4	33	7 (21)	7	4 (57)	40	11 (28)
5 to 9	12	6 (50)	--	--	12	6 (50)
10 +	2	1 (50)	--	--	2	1 (50)
p value		0.001		0.04		0.001
2007						
1	28	2 (7)	2	1 (50)	30	3 (10)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	3 (30)	1	0 (0)	11	3 (27)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.03		0.7		0.07
2010						
1	55	7 (13)	2	0 (0)	57	7 (12)
2 to 4	19	9 (47)	2	0 (0)	21	9 (43)
5 to 9	13	3 (23)	--	--	13	3 (23)
10 +	5	3 (60)	--	--	5	3 (60)
p value		0.004		--		0.007
2013*						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

*Lifetime imprisonment questions not asked in 2013.

Table 400 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	51	6 (12)	6	2 (33)	57	8 (14)
Indigenous	31	8 (26)	6	2 (33)	37	10 (27)
p value		0.1		1.0		0.1
2007						
Non-Indigenous	49	12 (24)	2	1 (50)	51	13 (25)
Indigenous	25	3 (12)	5	1 (20)	30	4 (13)
p value		0.2		0.4		0.2
2010						
Non-Indigenous	60	13 (22)	1	0 (0)	61	13 (21)
Indigenous	32	9 (28)	3	0 (0)	35	9 (26)
p value		0.5		--		0.6
2013						
Non-Indigenous	38	6 (16)	7	5 (71)	45	11 (24)
Indigenous	24	6 (25)	4	0 (0)	28	6 (21)
p value		0.4		0.02		0.8

† Excludes equivocal test results and missing values.

Table 401 HCV antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Non-Indigenous	26	1 (4)	29	7 (24)	55	8 (15)
Indigenous	17	1 (6)	19	9 (47)	36	10 (28)
p value		0.8		0.1		0.1
2007						
Non-Indigenous	23	1 (4)	28	12 (43)	51	13 (25)
Indigenous	16	0 (0)	14	4 (29)	30	4 (13)
p value		0.4		0.4		0.2
2010						
Non-Indigenous	26	0 (0)	35	13 (37)	61	13 (21)
Indigenous	9	0 (0)	26	9 (35)	35	9 (26)
p value		--		0.8		0.6
2013						
Non-Indigenous	18	1 (6)	27	10 (37)	45	11 (24)
Indigenous	7	0 (0)	21	6 (29)	28	6 (21)
p value		0.5		0.5		0.8

† Excludes equivocal test results and missing values.

Table 402 HCV antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Highly accessible/accessible	62	13 (21)	8	3 (38)	70	16 (23)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	1 (8)	2	0 (0)	15	1 (7)
p value		0.3		0.5		0.2
2007						
Highly accessible/accessible	57	11 (19)	6	2 (33)	63	13 (21)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	9	1 (11)	1	0 (0)	10	1 (10)
p value		0.5		0.5		0.4
2010						
Highly accessible/accessible	84	19 (23)	3	0 (0)	87	19 (22)
Moderately accessible	3	2 (67)	--	--	3	2 (67)
Remote/very remote	5	1 (20)	1	0 (0)	6	1 (17)
p value		0.2		--		0.2
2013						
Highly accessible/accessible	54	11 (20)	11	5 (45)	65	16 (25)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	--	--	--	--	--	--
p value		0.5		--		0.4

† Excludes equivocal test results and missing values.

Table 403 HCV antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Australia	71	13 (18)	12	4 (33)	83	17 (20)
Other Oceania	1	0 (0)	--	--	1	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9
2007						
Australia	60	14 (23)	7	2 (29)	67	16 (24)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	1 (20)	--	--	5	1 (20)
p value		0.6		--		0.6
2010						
Australia	78	22 (78)	4	0 (0)	82	22 (27)
Other Oceania	4	0 (0)	--	--	4	0 (0)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	6	0 (0)	--	--	6	0 (0)
p value		0.3		--		0.3
2013						
Australia	51	11 (22)	10	4 (40)	61	15 (25)
Other Oceania	4	1 (25)	1	1 (100)	5	2 (40)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.8		0.3		0.6

† Excludes equivocal test results and missing values.

Table 404 HCV antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
English	76	14 (18)	11	3 (27)	87	17 (20)
Non-English	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.1		0.6
2007						
English	71	14 (20)	7	2 (29)	78	16 (21)
Non-English	4	1 (25)	--	--	4	1 (25)
p value		0.8		--		0.8
2010						
English	86	22 (26)	4	0 (0)	90	22 (24)
Non-English	6	0 (0)	--	--	6	0 (0)
p value		0.2		--		0.2
2013						
English	60	12 (20)	10	5 (50)	70	17 (24)
Non-English	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.5		0.3		0.3

† Excludes equivocal test results and missing values.

Table 405 Self-reported HCV status versus HCV serology by sex and survey year†

Self-report HCV	Male		Female		Total	
	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)	N° tested	N° with HCV (%)
2004						
Positive	6	6 (100)	2	2 (100)	8	8 (100)
Negative	25	6 (24)	3	0 (0)	28	6 (21)
Not sure	2	1 (50)	1	1 (100)	3	2 (67)
p value		0.003		0.05		<0.001
2007						
Positive	8	8 (100)	2	2 (100)	10	10 (100)
Negative	31	5 (16)	2	0 (0)	33	5 (15)
Not sure	7	1 (14)	--	--	7	1 (14)
p value		<0.001		0.05		<0.001
2010						
Positive	9	9 (100)	--	--	9	9 (100)
Negative	31	2 (6)	3	0 (0)	34	2 (6)
Not sure	8	3 (38)	--	--	8	3 (38)
p value		<0.001		--		<0.001
2013						
Positive	8	8 (100)	3	3 (100)	11	11 (100)
Negative	22	2 (9)	5	0 (0)	27	2 (7)
Not sure	2	0 (0)	3	2 (67)	5	2 (40)
p value		<0.001		0.02		<0.001

† Excludes equivocal test results and missing values.

HBV prevalence

Table 406 HBV surface-antigen prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	3 (7)	5	0 (0)	49	3 (6)
Non-IDU	35	0 (0)	7	0 (0)	42	0 (0)
p value		0.1		--		0.1
2007						
IDU	38	2 (5)	5	0 (0)	43	2 (5)
Non-IDU	37	0 (0)	2	0 (0)	39	0 (0)
p value		0.2		--		0.2
2010						
IDU	60	0 (0)	2	0 (0)	62	0 (0)
Non-IDU	33	0 (0)	2	0 (0)	35	0 (0)
p value		--		--		--
2013						
IDU	39	1 (3)	6	0 (0)	45	1 (2)
Non-IDU	22	1 (5)	3	0 (0)	25	1 (4)
p value		0.7		--		0.7

† Excludes equivocal test results and missing values.

Table 407 HBV core-antibody prevalence by sex, injector status and survey year†

Injector status	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
IDU	44	11 (25)	4	2 (50)	48	13 (27)
Non-IDU	35	3 (9)	5	0 (0)	40	3 (8)
p value		0.06		0.07		0.02
2007						
IDU	38	16 (42)	5	2 (40)	43	18 (42)
Non-IDU	37	4 (11)	2	1 (50)	39	5 (13)
p value		0.002		0.8		0.003
2010						
IDU	60	9 (15)	2	0 (0)	62	9 (15)
Non-IDU	33	7 (21)	2	0 (0)	35	7 (20)
p value		0.5		--		0.5
2013						
IDU	39	8 (21)	6	1 (17)	45	9 (20)
Non-IDU	22	5 (23)	3	0 (0)	25	5 (20)
p value		0.8		0.5		1.0

† Excludes equivocal test results and missing values.

Table 408 HBV core-antibody prevalence by sexual identity, sex and survey year†

Sexual identity	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Heterosexual	79	14 (18)	9	2 (22)	88	16 (18)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--
2007						
Heterosexual	73	19 (26)	7	3 (43)	80	22 (28)
Bisexual	--	--	--	--	--	--
Homosexual	2	1 (50)	--	--	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.5		--		0.5
2010						
Heterosexual	91	15 (16)	2	0 (0)	93	15 (16)
Bisexual	--	--	1	0 (0)	1	0 (0)
Homosexual	1	1 (100)	1	0 (0)	2	1 (50)
Unsure	--	--	--	--	--	--
p value		0.03		--		0.4
2013						
Heterosexual	61	13 (21)	8	1 (13)	69	14 (20)
Bisexual	--	--	--	--	--	--
Homosexual	--	--	--	--	--	--
Unsure	--	--	--	--	--	--
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 409 HBV core-antibody prevalence by age group, sex and survey year†

Age group	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
< 20 years	11	0 (0)	--	--	11	0 (0)
20 – 24	18	1 (6)	1	0 (0)	19	1 (5)
25 – 29	17	3 (18)	1	1 (100)	18	4 (22)
30 + years	36	10 (28)	6	1 (17)	42	11 (26)
p value		0.08		0.2		0.08
2007						
< 20 years	5	0 (0)	--	--	5	0 (0)
20 – 24	20	1 (5)	--	--	20	1 (5)
25 – 29	12	4 (33)	2	0 (0)	14	4 (29)
30 + years	38	15 (39)	5	3 (60)	43	18 (42)
p value		0.02		0.2		0.01
2010						
< 20 years	9	0 (0)	1	0 (0)	10	0 (0)
20 – 24	22	2 (9)	2	0 (0)	24	2 (8)
25 – 29	27	4 (15)	--	--	27	4 (15)
30 + years	35	10 (29)	1	0 (0)	36	10 (28)
p value		0.1		--		0.09
2013						
< 20 years	5	0 (0)	1	0 (0)	6	0 (0)
20 – 24	11	0 (0)	1	0 (0)	12	0 (0)
25 – 29	12	3 (25)	4	0 (0)	16	3 (19)
30 + years	32	10 (31)	3	1 (33)	35	11 (31)
p value		0.1		0.5		0.1

† Excludes equivocal test results and missing values.

Table 410 HBV core-antibody prevalence by duration of drug injection, sex and survey year†

Duration of drug injection	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
<3 years	9	1 (11)	--	--	9	1 (11)
3 to 5 years	5	0 (0)	--	--	5	0 (0)
6 to 10 years	13	3 (23)	1	1 (100)	14	4 (29)
10 + years	16	7 (44)	3	1 (33)	19	8 (42)
p value		0.1		0.3		0.2
2007						
<3 years	5	1 (20)	--	--	5	1 (20)
3 to 5 years	7	1 (14)	--	--	7	1 (14)
6 to 10 years	6	2 (33)	1	0 (0)	7	2 (29)
10 + years	19	11 (58)	4	2 (50)	23	13 (57)
p value		0.2		0.4		0.1
2010						
<3 years	10	0 (0)	1	0 (0)	11	0 (0)
3 to 5 years	4	1 (25)	--	--	4	1 (25)
6 to 10 years	16	2 (13)	1	0 (0)	17	2 (12)
10 + years	28	5 (18)	--	--	28	5 (18)
p value		0.5		--		0.4
2013						
<3 years	--	--	--	--	--	--
3 to 5 years	4	0 (0)	--	--	4	0 (0)
6 to 10 years	4	0 (0)	3	1 (33)	7	1 (14)
10 + years	22	8 (36)	--	--	25	8 (32)
p value		0.1		0.3		0.3

† Excludes equivocal test results and missing values.

Table 411 HBV core-antibody prevalence by last drug injected, duration of drug injection and survey year†

Last drug injected	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Amphetamine (Speed, Ice)	8	1 (13)	32	10 (31)	40	11 (28)
Heroin	--	--	--	--	--	--
More than one	1	0 (0)	5	2 (40)	6	2 (33)
Other/not reported	--	--	--	--	--	--
p value		0.7		0.7		0.7
2007						
Amphetamine (Speed, Ice)	5	1 (20)	34	14 (41)	39	15 (38)
Heroin	--	--	2	1 (50)	2	1 (50)
More than one	--	--	1	1 (100)	1	1 (100)
Other/not reported	--	--	--	--	--	--
p value		--		0.5		0.5
2010						
Amphetamine (Speed, Ice)	9	0 (0)	38	7 (18)	47	7 (15)
Heroin	--	--	7	1 (14)	7	1 (14)
More than one	--	--	--	--	--	--
Other/not reported	2	0 (0)	4	0 (0)	6	0 (0)
p value		--		0.6		0.6
2013						
Amphetamine (Speed, Ice)	7	0 (0)	30	7 (23)	37	7 (19)
Heroin	--	--	4	2 (50)	4	2 (50)
More than one	--	--	--	--	--	--
Other/not reported	1	0 (0)	2	0 (0)	3	0 (0)
p value		--		0.4		0.2

† Excludes equivocal test results and missing values.

Table 412 HBV core-antibody prevalence by frequency of injection last month, duration of drug injection and survey year†

Frequency of drug injection last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Less than daily	3	1 (33)	5	4 (80)	8	5 (63)
Daily or more	4	0 (0)	16	5 (31)	20	5 (25)
p value		0.2		0.06		0.06
2007						
Less than daily	--	--	11	4 (36)	11	4 (36)
Daily or more	2	0 (0)	11	7 (64)	13	7 (54)
p value		--		0.2		0.4
2010						
Less than daily	6	0 (0)	16	4 (25)	22	4 (18)
Daily or more	4	0 (0)	14	0 (0)	18	0 (0)
p value		--		0.04		0.06
2013						
Less than daily	4	0 (0)	13	4 (31)	17	4 (24)
Daily or more	2	0 (0)	12	3 (25)	14	3 (21)
p value		--		0.8		0.9

† Excludes equivocal test results and missing values.

Table 413 HBV core antibody prevalence by re-use of someone else's used needle and syringe last month, duration of drug injection and survey year†

Re-used someone else's used needle & syringe last month	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	1 (17)	15	8 (53)	21	9 (43)
Yes	1	0 (0)	5	1 (20)	6	1 (17)
p value		0.7		0.2		0.3
2007						
No	2	0 (0)	14	6 (43)	16	6 (38)
Yes	--	--	7	4 (57)	7	4 (57)
p value		--		0.5		0.4
2010						
No	8	0 (0)	24	3 (13)	32	3 (9)
Yes	1	0 (0)	4	0 (0)	5	0 (0)
p value		--		0.5		0.5
2013						
No	--	--	--	--	--	--
Yes	2	0 (0)	6	3 (50)	8	3 (38)
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 414 HBV core-antibody prevalence by imprisonment last year, duration of drug injection and survey year†

Imprisonment last year	<3 years IDU		3+ years IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
No	6	0 (0)	18	6 (33)	24	6 (25)
Yes	3	1 (33)	18	6 (33)	21	7 (33)
p value		0.1		0.6		0.9
2007						
No	2	1 (50)	11	6 (55)	13	7 (54)
Yes	1	0 (0)	13	3 (23)	14	3 (21)
p value		0.4		0.1		0.08
2010						
No	6	0 (0)	25	3 (12)	31	3 (10)
Yes	5	0 (0)	22	4 (18)	27	4 (15)
p value		--		0.6		0.6
2013						
No	1	0 (0)	15	5 (33)	16	5 (31)
Yes	2	0 (0)	11	2 (18)	13	2 (15)
p value		--		0.4		0.4

† Excludes equivocal test results and missing values.

Table 415 HBV core-antibody by number of previous imprisonments, sex and survey year†

Number of previous imprisonments	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
1	28	2 (7)	3	0 (0)	31	2 (6)
2 to 4	34	8 (24)	6	2 (23)	40	10 (25)
5 to 9	12	4 (33)	--	--	12	4 (33)
10 +	2	0 (0)	--	--	2	0 (0)
p value		0.2		0.3		0.1
2007						
1	28	5 (18)	2	1 (50)	30	6 (20)
2 to 4	22	3 (14)	3	1 (33)	25	4 (16)
5 to 9	10	5 (50)	1	0 (0)	11	5 (45)
10 +	3	2 (67)	--	--	3	2 (67)
p value		0.04		0.7		0.08
2010						
1	55	7 (13)	2	0 (0)	57	7 (12)
2 to 4	19	6 (32)	2	0 (0)	21	6 (29)
5 to 9	13	3 (23)	--	--	13	3 (23)
10 +	6	0 (0)	--	--	6	0 (0)
p value		0.2		--		0.2
2013						
1	n/a	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a	n/a
p value		--		--		--

† Excludes equivocal test results and missing values.

Table 416 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, sex and survey year†

Aboriginal and Torres Strait Islander origin	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	52	5 (10)	4	1 (25)	56	6 (11)
Indigenous	30	9 (30)	5	1 (20)	35	10 (29)
p value		0.2		0.9		0.03
2007						
Non-Indigenous	49	10 (20)	2	0 (0)	51	10 (20)
Indigenous	25	9 (36)	5	3 (60)	30	12 (40)
p value		0.1		0.2		0.05
2010						
Non-Indigenous	60	10 (17)	1	0 (0)	61	10 (16)
Indigenous	33	6 (18)	3	0 (0)	36	6 (17)
p value		0.9		--		1.0
2013						
Non-Indigenous	38	7 (18)	5	1 (20)	43	8 (19)
Indigenous	23	6 (26)	4	0 (0)	27	6 (22)
p value		0.5		0.3		0.7

† Excludes equivocal test results and missing values.

Table 417 HBV core-antibody prevalence by Aboriginal and Torres Strait Islander origin status, injector status and survey year†

Aboriginal and Torres Strait Islander origin	Non-IDU		IDU		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Non-Indigenous	25	0 (0)	29	6 (21)	54	6 (11)
Indigenous	15	3 (20)	19	7 (37)	34	10 (29)
p value		0.02		0.2		0.03
2007						
Non-Indigenous	23	1 (4)	28	9 (32)	51	10 (20)
Indigenous	16	4 (25)	14	8 (57)	30	12 (40)
p value		0.06		0.1		0.05
2010						
Non-Indigenous	26	4 (15)	35	6 (17)	61	10 (16)
Indigenous	9	3 (33)	27	3 (11)	36	6 (17)
p value		0.3		0.5		1.0
2013						
Non-Indigenous	18	3 (17)	25	5 (20)	43	8 (19)
Indigenous	7	2 (29)	20	4 (20)	27	6 (22)
p value		0.5		1.0		0.7

† Excludes equivocal test results and missing values.

Table 418 HBV core-antibody prevalence by sex, residential remoteness in the 12 months before prison and survey year†

Residential remoteness	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Highly accessible/accessible	62	9 (15)	5	1 (20)	67	10 (15)
Moderately accessible	4	0 (0)	1	0 (0)	5	0 (0)
Remote/very remote	13	5 (38)	2	0 (0)	15	5 (33)
p value		0.08		0.7		0.1
2007						
Highly accessible/accessible	57	13 (23)	6	2 (33)	63	15 (24)
Moderately accessible	2	0 (0)	--	--	2	0 (0)
Remote/very remote	9	5 (56)	1	1 (100)	10	6 (60)
p value		0.08		0.2		0.04
2010						
Highly accessible/accessible	85	15 (18)	3	0 (0)	88	15 (17)
Moderately accessible	3	0 (0)	--	--	3	0 (0)
Remote/very remote	5	1 (20)	1	0 (0)	6	1 (17)
p value		0.7		--		0.7
2013						
Highly accessible/accessible	53	9 (17)	9	1 (11)	62	10 (16)
Moderately accessible	2	1 (50)	--	--	2	1 (50)
Remote/very remote	--	--	--	--	--	--
p value		0.2		--		0.2

† Excludes equivocal test results and missing values.

Table 419 HBV core-antibody prevalence by region/country of birth, sex and survey year†

Region/Country of birth	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
Australia	71	13 (18)	9	2 (22)	80	15 (19)
Other Oceania	1	1 (100)	--	--	1	1 (100)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	1	0 (0)	--	--	1	0 (0)
Other	4	0 (0)	--	--	4	0 (0)
p value		0.2		--		0.2
2007						
Australia	60	19 (32)	7	3 (43)	67	22 (33)
Other Oceania	4	1 (25)	--	--	4	1 (25)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	5	0 (0)	--	--	5	0 (0)
Other	5	0 (0)	--	--	5	0 (0)
p value		0.3		--		0.3
2010						
Australia	79	11 (14)	4	0 (0)	83	11 (13)
Other Oceania	4	2 (50)	--	--	4	2 (50)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	3	0 (0)	--	--	3	0 (0)
Other	6	3 (50)	--	--	6	3 (50)
p value		0.06		--		0.05
2013						
Australia	50	10 (20)	8	1 (13)	58	11 (19)
Other Oceania	4	1 (25)	1	0 (0)	5	1 (20)
Asia	1	0 (0)	--	--	1	0 (0)
UK & Ireland	2	0 (0)	--	--	2	0 (0)
Other	4	2 (50)	--	--	4	2 (50)
p value		0.6		0.7		0.6

† Excludes equivocal test results and missing values.

Table 420 HBV core-antibody prevalence by main language spoken at home by parents, sex and survey year†

Main language spoken at home by parents	Male		Female		Total	
	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)	N° tested	N° with HBV (%)
2004						
English	76	14 (18)	8	1 (13)	84	15 (18)
Non-English	2	0 (0)	1	1 (100)	3	1 (33)
p value		0.5		0.05		0.5
2007						
English	71	19 (27)	7	3 (43)	78	22 (28)
Non-English	4	1 (25)	--	--	4	1 (25)
p value		0.9		--		0.9
2010						
English	87	15 (17)	4	0 (0)	91	15 (16)
Non-English	6	1 (17)	--	--	6	1 (17)
p value		1.0		--		1.0
2013						
English	59	13 (22)	8	1 (13)	67	14 (21)
Non-English	2	0 (0)	1	0 (0)	3	0 (0)
p value		0.5		0.7		0.4

† Excludes equivocal test results and missing values.

Table 421 Hepatitis B virus immune status by injector status and survey year†

Injector status	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
IDU	49	21 (43)	10 (20)	3 (6)	15 (31)
Non-IDU	42	29 (69)	3 (7)	0 (0)	10 (24)
p value					0.04
2007					
IDU	43	16 (27)	16 (37)	2 (5)	9 (21)
Non-IDU	39	29 (74)	5 (13)	0 (0)	5 (13)
p value					<0.01
2010					
IDU	62	28 (45)	9 (15)	0 (0)	25 (40)
Non-IDU	35	22 (63)	7 (20)	0 (0)	6 (17)
p value					0.06
2013					
IDU	46	20 (43)	8 (17)	1 (2)	17 (37)
Non-IDU	25	13 (52)	4 (16)	1 (4)	7 (28)
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 422 Hepatitis B virus immune status by sexual identity and survey year†

Sexual identity	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Heterosexual	90	50 (56)	13 (14)	3 (3)	24 (27)
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Homosexual	--	--	--	--	--
Unsure	--	--	--	--	--
p value					0.4
2007					
Heterosexual	80	44 (55)	20 (25)	2 (3)	14 (18)
Homosexual	--	--	--	--	--
Bisexual	2	1 (50)	1 (50)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.8
2010					
Heterosexual	93	48 (52)	15 (16)	0 (0)	30 (32)
Homosexual	1	1 (100)	0 (0)	0 (0)	0 (0)
Bisexual	2	1 (50)	1 (50)	0 (0)	0 (0)
Unsure	--	--	--	--	--
p value					0.6
2013					
Heterosexual	69	32 (46)	12 (17)	2 (3)	23 (33)
Homosexual	--	--	--	--	--
Bisexual	1	0 (0)	0 (0)	0 (0)	1 (100)
Unsure	--	--	--	--	--
p value					0.8

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 423 Hepatitis B virus immune status by age group and survey year†

Age group	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	No (%) vaccine conferred immunity*
2004					
< 20 years	11	6 (55)	0 (0)	0 (0)	5 (45)
20 – 24	19	13 (68)	0 (0)	1 (5)	5 (26)
25 – 29	20	12 (60)	3 (15)	1 (5)	4 (20)
30 + years	43	21 (49)	10 (23)	1 (2)	11 (26)
p value					0.3
2007					
< 20 years	5	3 (60)	0 (0)	0 (0)	2 (40)
20 – 24	20	16 (80)	1 (5)	0 (0)	3 (15)
25 – 29	14	8 (57)	3 (21)	1 (7)	2 (14)
30 + years	43	18 (42)	17 (40)	1 (2)	7 (16)
p value					0.09
2010					
< 20 years	10	4 (40)	0 (0)	0 (0)	6 (60)
20 – 24	24	13 (54)	2 (8)	0 (0)	9 (38)
25 – 29	27	18 (67)	4 (15)	0 (0)	5 (19)
30 + years	36	15 (42)	10 (28)	0 (0)	11 (31)
p value					0.07
2013					
< 20 years	6	4 (67)	0 (0)	0 (0)	2 (33)
20 – 24	12	5 (42)	0 (0)	0 (0)	7 (58)
25 – 29	16	8 (50)	3 (19)	0 (0)	5 (31)
30 + years	36	15 (42)	9 (25)	2 (6)	10 (28)
p value					0.4

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 424 Hepatitis B virus immune status by number of previous imprisonments and survey year†

Number of previous imprisonments	Hepatitis B Virus Immune Status				
	N° tested	N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
1	33	24 (73)	1 (3)	1 (3)	7 (21)
2 to 4	41	20 (49)	9 (22)	1 (2)	11 (27)
5 to 9	12	4 (33)	3 (25)	1 (8)	4 (33)
10 +	2	0 (0)	0 (0)	0 (0)	2 (100)
p value					0.08
2007					
1	30	20 (67)	5 (17)	1 (3)	4 (13)
2 to 4	25	15 (60)	4 (16)	0 (0)	6 (24)
5 to 9	11	4 (36)	4 (36)	1 (9)	2 (18)
10 +	3	1 (33)	2 (67)	0 (0)	0 (0)
p value					0.4
2010					
1	57	33 (58)	7 (12)	0 (0)	17 (30)
2 to 4	21	8 (38)	6 (29)	0 (0)	7 (33)
5 to 9	13	6 (46)	3 (23)	0 (0)	4 (31)
10 +	6	3 (50)	0 (0)	0 (0)	3 (50)
p value					0.5
2013					
1	n/a	n/a	n/a	n/a	n/a
2 to 4	n/a	n/a	n/a	n/a	n/a
5 to 9	n/a	n/a	n/a	n/a	n/a
10 +	n/a	n/a	n/a	n/a	n/a
p value					--

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 425 Hepatitis B virus immune status by Aboriginal and Torres Strait Islander origin and survey year†

Aboriginal and Torres Strait Islander origin	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Non-Indigenous	58	42 (72)	5 (9)	1 (2)	10 (17)
Indigenous	36	10 (28)	8 (22)	2 (6)	16 (44)
p value					<0.001
2007					
Non-Indigenous	51	32 (63)	9 (18)	1 (2)	9 (18)
Indigenous	30	13 (43)	11 (37)	1 (2)	5 (17)
p value					0.2
2010					
Non-Indigenous	61	40 (66)	10 (16)	0 (0)	11 (18)
Indigenous	36	10 (28)	6 (17)	0 (0)	20 (56)
p value					<0.001
2013					
Non-Indigenous	44	22 (50)	7 (16)	1 (2)	14 (32)
Indigenous	27	11 (41)	5 (19)	1 (4)	10 (37)
p value					0.6

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 426 Hepatitis B virus immune status by residential remoteness and survey year†

Residential remoteness	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
Highly accessible/accessible	70	42 (60)	7 (10)	3 (4)	18 (26)
Moderately accessible	5	2 (40)	0 (0)	0 (0)	3 (60)
Remote/very remote	15	6 (40)	5 (33)	0 (0)	4 (27)
p value					0.1
2007					
Highly accessible/accessible	63	38 (60)	13 (21)	2 (3)	10 (16)
Moderately accessible	2	2 (100)	0 (0)	0 (0)	0 (0)
Remote/very remote	10	2 (20)	6 (60)	0 (0)	2 (20)
p value					0.1
2010					
Highly accessible/accessible	88	47 (53)	15 (17)	0 (0)	26 (30)
Moderately accessible	3	1 (33)	0 (0)	0 (0)	2 (67)
Remote/very remote	6	2 (33)	1 (17)	0 (0)	3 (50)
p value					0.5
2013					
Highly accessible/accessible	63	31 (49)	9 (14)	1 (2)	22 (35)
Moderately accessible	2	1 (50)	1 (50)	0 (0)	0 (0)
Remote/very remote	--	--	--	--	--
p value					0.5

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 427 Hepatitis B virus immune status by main language spoken at home by parents and survey year†

Main language spoken at home by parents	N° tested	Hepatitis B Virus Immune Status			
		N° (%) with no evidence of HBV immunity	N° (%) immune through past exposure	N° (%) HBV carrier	N° (%) vaccine conferred immunity*
2004					
English	87	47 (54)	12 (14)	3 (3)	25 (29)
Non-English	3	2 (67)	1 (33)	0 (0)	0 (0)
p value					0.6
2007					
English	78	43 (55)	20 (26)	2 (3)	13 (17)
Non-English	4	2 (50)	1 (25)	0 (0)	1 (25)
p value					1.0
2010					
English	91	48 (53)	15 (16)	0 (0)	28 (31)
Non-English	6	2 (33)	1 (17)	0 (0)	3 (50)
p value					0.6
2013					
English	68	33 (49)	12 (18)	2 (3)	21 (31)
Non-English	3	0 (0)	0 (0)	0 (0)	3 (100)
p value					0.1

† Excludes equivocal test results and missing values.

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

Table 428 Self-reported hepatitis B immunisation versus serological testing and survey year*

Self-report HBV immunisation**	Male		Female		Total	
	N° tested	N° immune (%)	N° tested	N° immune (%)	N° tested	N° immune (%)
2004						
No	31	5 (16)	5	2 (40)	36	7 (19)
Yes	22	11 (50)	1	1 (100)	23	12 (52)
Not sure	11	5 (45)	4	1 (25)	15	6 (40)
p value		0.02		0.4		0.03
2007						
No	29	3 (10)	4	1 (25)	33	4 (12)
Yes	18	9 (50)	--	--	18	9 (50)
Not sure	8	1 (13)	--	--	8	1 (13)
p value		0.006		--		0.007
2010						
No	41	13 (32)	2	0 (0)	43	13 (30)
Yes	27	14 (52)	2	1 (50)	29	15 (52)
Not sure	9	3 (33)	--	--	9	3 (33)
p value		0.2		0.3		0.2
2013						
No	18	6 (33)	2	0 (0)	20	6 (30)
Yes	9	6 (67)	6	4 (67)	15	10 (67)
Not sure	20	6 (30)	1	1 (100)	21	7 (33)
p value		0.2		0.2		0.06

* HBV surface-antibody level of ≥ 10 mIU/ml signifies immunity. HBV core-antibody positive cases and HBV carriers are excluded.

** Yes to self-reported immunisation includes any immunisation shots against HBV.

Chlamydia

Table 429 Genital chlamydia prevalence by sex and survey year†

Sex	N° tested	N° with chlamydia (%)
2010		
Male	93	5 (5)
Female	5	1 (20)
p value		0.2
2013		
Male	65	2 (3)
Female	10	0 (0)
p value		0.6

† Excludes missing values.

Gonorrhoea

Table 430 Genital gonorrhoea prevalence by sex and survey year†

Sex	N° tested	N° with gonorrhoea (%)
2010		
Male	93	1 (1)
Female	5	0 (0)
p value		0.8
2013		
Male	65	0 (0)
Female	10	0 (0)
p value		--

† Excludes missing values.

Syphilis

Table 431 Syphilis markers by sex and survey year†

Sex	N° tested	N° with syphilis antibodies (%)	N° with syphilis RPR (%)	N° with any marker for syphilis (%)
2010				
Male	93	2 (2)	2 (2)	2 (2)
Female	4	0 (0)	0 (0)	0 (0)
p value		0.8	--	0.8
2013				
Male	60	0 (0)	0 (0)	0 (0)
Female	10	0 (0)	0 (0)	0 (0)
p value		--	--	--

† Excludes missing values.

Methodological Notes

- Percentages over 1 have been rounded up to the nearest whole number while those less than 1 are indicated as '<1'.
- The label 'n/a' ('not asked') indicates survey items that were added or removed from previous years.
- The Accessibility/Remoteness Index of Australia (ARIA)² classification was developed in 1997 and revised in 2011 as a continuous measure of remoteness developed by the National Key Centre for Social Applications of Geographical Information Systems (GISCA). In the version of this index used in this report (known as ARTIA+), geographic accessibility is indexed on a range from 0 (high accessibility) to 15 (high remoteness) as determined by road distance measurements. The index of accessibility can be organised into five primary classifications:
 1. Highly Accessible - relatively unrestricted accessibility to a wide range of goods and services and opportunities for social interaction.
 2. Accessible - some restrictions to accessibility of some goods, services and opportunities for social interaction.
 3. Moderately Accessible - significantly restricted accessibility of goods, services and opportunities for social interaction.
 4. Remote - very restricted accessibility of goods, services and opportunities for social interaction.
 5. Very Remote - very little accessibility of goods, services and opportunities for social interaction.

For the purpose of this report, 3 ARIA groupings were created: highly accessible + accessible, moderately accessible, and remote + very remote. Categories were allocated by using the postcode the individual had spent most time in during the 12 months before coming into prison and is based in self-report.

- Hepatitis B immune status was determined in accordance with CDC guidelines - <http://www.cdc.gov/hepatitis/hbv/PDFs/SerologicChartv8.pdf> Participants with surface antibody levels above 10mIU/mL were considered to be immune to hepatitis B infection. In a limited number of cases hepatitis B surface antibody levels were not reported, vaccination conferred immunity to hepatitis B was established through a combination of self-report of having received three doses of the hepatitis B vaccine and hepatitis B surface-antigen and hepatitis B core-antibody results. Analysis of self-reported hepatitis B vaccination and surface-antibody levels of above 10mIU/mL correlate reasonably well and so justified this approach.

Appendix 1 – Blood Tests, Test Kits and Testing Laboratories**Human Immunodeficiency Virus (HIV) Antibody & Antigen**

HIV Ag/Ab Combo Architect. ABBOTT (USA)

HIV Combi. ROCHE (USA)

ADVIA Centaur HIV Combo Assay. ROBION AG (Switzerland)

Hepatitis B Surface-Antibody

Anti-HBs Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B Surface-Antigen

HBsAg Qualitative Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis B (IgG & IgM) Core-Antibody

Anti-HBc II Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Hepatitis C Antibody

Anti-HCV Architect. ABBOTT (USA)

COBAS 6000. ROCHE (USA)

Murex THCV. ABBOTT (USA)

Chiron Riba HCV 3.0 Immunoblot. NOVARTIS (USA)

***Treponema pallidum* Antibody**

TPLA test 2.0. SEKISUI (Japan)

Syphilis TP Architect. ABBOTT (USA)

Serodia T. pallidum Hemagglutination Assay. FUJIREBIO (Japan)

Macrovue Rapid Plasma Reagin Assay. BECTON-DICKISON (USA)

TrepoSpot Immunofluorescent. BIOMÉRIEUX (France)

***Chlamydia trachomatis* DNA**

COBAS TaqMan CT test 2.0. ROCHE (USA)

COBAS 4800. ROCHE (USA)

***Neisseria gonorrhoea* DNA**

COBAS Amplicore NG test. ROCHE (USA)

COBAS 4800. ROCHE (USA)

Testing Centres:

ACT ACT Pathology, Canberra

NSW Institute of Clinical Pathology and Medical Research, New South Wales

NT NT Government Pathology Service, Northern Territory

Qld Pathology Queensland, Queensland

SA SA Pathology, South Australia

Tas Royal Hobart Hospital Pathology Services, Tasmania

Vic Healthscope Pathology, Victoria

Melbourne Pathology, Victoria

WA PathWest Laboratory Medicine, Western Australia

Appendix 2 – Questionnaire

2013 NATIONAL PRISON ENTRANTS BLOODBORNE VIRUS SURVEY

RESEARCH NURSE TO FILL IN ALL SECTIONS

State

Prison

MIN/ ID/ OTS/ JOIST/ 1800/ CRN/ UIS

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

D.O.B.

First two letters of LAST NAME

First two letters of FIRST NAME

1. Sex
 - Male
 - Female
 - Transgender

2. Are you Aboriginal or Torres Strait Islander?
 - Aboriginal
 - Torres Strait Islander
 - Both Aboriginal and Torres Strait Islander
 - Neither Aboriginal nor Torres Strait Islander

3. Is this your first ever time in prison?
 - Yes ➡ GO TO Q5
 - No

4. If not first time in prison, then how many times in prison in last 12 Months? *Exclude current episode*

5. Country of birth
 - Australia
 - Other (specify) _____

6. Main language spoken at home by parents
 - English
 - Other (specify) _____

- 6a. Legal marital status
 - Never married
 - Married
 - Divorced
 - Separated
 - Widowed

7. In the last 12 months before coming into prison, where did you spend the most time? *Complete all applicable boxes*

State or territory				
Suburb post code				
or Suburb/town				
or Town				
or Overseas country				

- 8a. Have you ever smoked a full cigarette?
 - Yes
 - No ➡ GO TO Q9a

- 8b. If yes, how old were you when you smoked your first full cigarette (yrs)

- 8c. Do you smoke now?
 - Yes
 - No ➡ GO TO Q9a

- 8d. If yes which of the following best describes your current use of tobacco? *Select one only*
 - I now smoke occasionally, but less than once a week
 - I now smoke occasionally, not everyday, but at least once a week
 - I now smoke regularly, every day or most days about:
 - 5 to 10 cigarettes a day
 - 11 to 20 cigarettes a day
 - 21 to 30 cigarettes a day
 - Over 30 cigarettes a day

- 9a. Do you have any body or ear piercings?
 - Yes
 - No ➡ GO TO Q10a

- 9b. Do you have any piercing other than an ear piercing?
 - Yes
 - No

- 9c. If yes, to 9a or 9b, were any of these piercings done in the last 12 months?
 - Yes
 - No ➡ GO TO Q10a

- 9d. If pierced in the last 12 months, who did them for you? *Select all that apply*
 - Chemist/hairdresser/ beauty salon
 - Professional piercer/studio
 - Tattooist / Parlour
 - Friend
 - Prison inmate
 - Self
 - Family member
 - Other (specify) _____

- 9e. If pierced by friend, inmate, self or family member in the last 12 months had anyone else used the needle before you?
 - Yes
 - No
 - Don't know

- 10a. Do you have any tattoos?
 - Yes
 - No ➡ GO TO Q10d

- 10b. If yes, were any done in the last 12 months?
 - Yes
 - No ➡ GO TO Q10d

- 10c. If tattooed in the last 12 months, who did your tattoo(s)? *Select all that apply*
 - Parlour / professional
 - Friend
 - Prison Inmate
 - Self
 - Family member
 - Other (specify) _____

- 10d. In the past 4 weeks which of the following drugs did you use? *Select all that apply*
 - No drugs taken in past 4 weeks
 - Cannabis
 - Heroin
 - Cocaine
 - Amphetamine (e.g. speed, ice, crystal)
 - Other's methadone
 - Other opiates (e.g. morphine, oxycontin)
 - Other's buprenorphine
 - Steroids
 - Hallucinogens (e.g. LSD, mushrooms)
 - Benzodiazepines
 - Ecstasy/MDA
 - Inhalant (e.g. petrol, solvents)
 - Other (specify) _____

11. Have you ever injected drugs?
 - Yes
 - No ➡ GO TO Q20

12. If yes, how old were you when you first injected drugs (years)?

13. What was the last drug you injected? *Select one only*
 - Heroin
 - Heroin + Cocaine together
 - Cocaine
 - Amphetamine (speed, ice, crystal)
 - Methadone
 - Morphine
 - Steroids
 - Suboxone / buprenorphine
 - Other (specify) _____

- 14a. How often did you inject in the last month?
 - More than 3 times most days
 - 2 to 3 times most days
 - Once a day
 - More than weekly, not daily
 - Less than weekly (1-4 times per month)
 - Did not inject in last month ➡ GO TO Q15

- 14b. Which places did you inject in the last month? *Select all that apply*
 - Prison
 - Own home
 - Friend's home
 - Dealer's home
 - Street, park or beach
 - Car
 - Public toilet
 - Commercial "shooting" room
 - MSIC (KX injecting centre in Sydney)
 - Squat
 - Other (specify) _____

- 14c. How often did you use a new sterile needle and syringe in the last month?
 - All injections
 - Most of the time
 - Half of the time
 - Some of the time
 - None of the time

Please contact Tony Butler (02) 9385 9257 or 041 111 4927 for enquires related to questionnaire.

14d. What equipment did you use after someone else in the last month?

- Spoon Tourniquet
 Water Drug solution / mix
 Filter Did not share any of above last month

14e. How many times last month did someone else inject you after injecting themselves or others?

- More than 5 times Once or twice
 3 to 5 times None

14f. How many times last month did you reuse a needle & syringe after someone else (including sex partner) had used it (even if it was cleaned)?

- More than 5 times Once
 3 to 5 times None **GO TO Q15**
 Twice

14g. How many different people (including your sex partner) have used a needle before you in the last month (even if cleaned)?

- More than 5 people 1 person
 3 to 5 people Don't know how many
 2 people

14h. Who were these people? *Select all that apply*

- Regular sex partner
 Other sex partners
 Close friend
 Acquaintance
 Other (specify) _____

15. How many times last month did you get needles & syringes from a needle exchange?

- Daily or almost daily
 A couple of times each week
 Less than weekly (1-4 times per month)
 Once last month
 Not in the last month

16. How many times last month did you get needles & syringes from a pharmacy?

- Daily or almost daily
 A couple of times each week
 Less than weekly (2 to 5 times)
 Once last month
 Not in the last month

17. When was the last time you re-used a needle after someone else?

- Last month
 In the last 2 to 6 months
 More than 6 months ago
 Never **GO TO Q19**

18. Where was the last place you re-used a needle or syringe after someone else? *Select one only*

- Prison
 Own home
 Friend's home
 Dealer's home
 Street, park or beach
 Car
 Public toilet
 Commercial "shooting" room
 MSIC (Kings Cross injecting centre Sydney)
 Squat
 Other (specify) _____

19. Have you ever participated in the yearly finger-prick survey at a needle exchange in the community?

- Yes No Don't remember

20. Have you ever been on a methadone program?

- Yes, on it now
 Yes, in the past
 No, never

21. Have you ever been on any other program (eg. naltrexone, buprenorphine or LAAM)?

- Yes, am on it now
 Yes, in the past
 No, never

22. Have you ever had any other therapies for drug use (e.g. detox, counselling, Narcotics Anonymous)?

- Yes No

23. Have you ever had hepatitis B infection?

- Yes No Unsure

24a. Have you ever had hepatitis B vaccination?

- Yes
 No **GO TO Q25a**
 Unsure **GO TO Q25a**

24b. If yes, how many injections have you had?

- One 3 or more
 Two Unsure

25a. Have you ever been tested for HIV?

- Yes, in the last year
 Yes, more than a year ago
 Never tested **GO TO Q26a**

25b. If yes, what was the result of your last HIV test?

- Did not have HIV
 I have HIV infection
 Don't know the result
 Declined to answer

26a. Have you been tested for hepatitis C?

- Yes, in the last year
 Yes, more than a year ago
 Never tested **GO TO Q27**

26b. If yes, what was the result of your last hepatitis C test?

- Did not have hepatitis C **GO TO Q27**
 I am hepatitis C antibody positive
 I am hepatitis C PCR positive
 Don't know result **GO TO Q27**

26c. How old were you when you first found out you had hepatitis C?

26d. Have you ever had treatment for hepatitis C?

- Select all that apply*
 No treatment **GO TO Q26f**
 Yes, Interferon
 Yes, Interferon + Ribavirin
 Yes, Interferon + Ribavirin + Boceprevir
 Yes, Interferon + Ribavirin + Telaprevir
 Other (specify) _____
 Don't know

26e. Are you having treatment for hepatitis C now?

- Yes, Interferon **GO TO Q27**
 Yes, Interferon + Ribavirin **GO TO Q27**
 Yes, Interferon + Ribavirin + Boceprevir **GO TO Q27**
 Yes, Interferon + Ribavirin + Telaprevir **GO TO Q27**
 No, not currently on treatment
 Other (specify) _____ **GO TO Q27**
 Don't know

26f. If you have not had treatment, have you ever sought treatment for hepatitis C?

- Yes **GO TO Q26i** No

26g. If no, what was the MAIN reason?

26h. Given that you are hepatitis C positive, how willing would you be in receiving treatment?

- Definitely unwilling
 Somewhat unwilling
 Neither unwilling or willing
 Somewhat willing
 Definitely willing

26i. Are you more likely to consider being treated for hepatitis C in prison rather than in the community?

- Yes No Unsure

Why? _____

26j. Do you plan to go on treatment in the future?

- Yes, in the next 12 months
 Yes, in the next 1 – 2 years
 Yes, in the next 2 – 5 years
 Yes, but not for at least another 5 years
 No, never

26k. If not in the next 12 months, what is the MAIN reason?

27. Have you had the cervical cancer vaccine?

- Women only*
 Yes No Unsure

28. Do you identify as:

- Heterosexual Bisexual
 Gay/lesbian Unsure

29a. How many female partners have you had sex with in the last 3 months?

29b. Did you use condoms with these partners?

	Regular	Casual
Never	<input type="checkbox"/>	<input type="checkbox"/>
Sometimes	<input type="checkbox"/>	<input type="checkbox"/>
Always	<input type="checkbox"/>	<input type="checkbox"/>

29c. How many male partners have you had sex with in the last 3 months?

29d. Did you use condoms with these partners?

	Regular	Casual
Never	<input type="checkbox"/>	<input type="checkbox"/>
Sometimes	<input type="checkbox"/>	<input type="checkbox"/>
Always	<input type="checkbox"/>	<input type="checkbox"/>

29e. Have you been paid for sex in the last 3 months? (include non-cash payments)


- Yes No **end of questionnaire**

29f. If yes to Q29e, did you use condoms (or dams) the last time you were paid for sex?

- Yes **end of questionnaire**
 No **end of questionnaire**

References

1. Australian Bureau of Statistics . *Prisoners in Australia, 2014*. 2014. Canberra, ACT: ABS. Available from: <http://www.abs.gov.au>
2. Australian Population and Migration Research Centre. *Measuring Remoteness: Accessibility/Remoteness Index of Australia (ARIA+)*. 2011. Adelaide, SA: University of Adelaide.
3. Butler T, Levy M, Dolan K, Kaldor J. Drug use and its correlates in an Australian prisoner population. *Addiction Research Theory*. 2003;11:89-101.
4. Gore S, Bird AG. Drugs in British prisons. *British Medical Journal*. 2000;316:1256-1257.
5. Butler T, Lim D, Callander D. *National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 and 2010*. 2011. Sydney, NSW: National Drug Research Institute (Curtin University) & National Centre in HIV Epidemiology and Clinical Research (University of New South Wales). ISBN: 1 74067 582 7. 2008.
6. Butler T, Spencer J, Cui J, Vickery K, Zou J, Kaldor J. Seroprevalence of markers for hepatitis B, C and G in male and female prisoners - NSW, 1996. *Australia & New Zealand Journal of Public Health*. 1999;23:377-384.
7. Butler T, Dolan K, Ferson M, McGuinness L, Brown P, Robertson P. Hepatitis B and C in New South Wales prisons: prevalence and risk factors. *Medical Journal of Australia*. 1997;166:127-130.
8. Crofts N, Stewart T, Hearne P. Spread of Blood borne viruses among Australian prison entrants. *British Medical Journal*. 1996;310:285-288.
9. Christensen P, Krarup H, Niesters H, Norder H, Georgsen J. Prevalence and incidence of bloodborne viral infections among Danish prisoners. *European Journal of Epidemiology*. 2000;16:1043-1049.
10. Vescio M, Longo B, Babudieri S, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. *Journal of Epidemiology and Community Health*. 2008;62:305-313.
11. Malliori M, Sypsa V, Psychogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. *Addiction*. 1998;92:243-251.
12. Haber P, Parsons S, Harper S, White P, Rawlinson W, Lloyd A. Transmission of hepatitis C within Australian prisons. *Medical Journal of Australia*. 1999;171:31-33.
13. Post J, Dolan K, Whybin R, Carter I, Haber P, Lloyd A. Acute hepatitis C virus infection in an Australian prison inmate: tattooing as a possible transmission route. *Medical Journal of Australia*. 2001;174:183-184.
14. Hellard ME, Aitken CK, Hocking JS. Tattooing in prisons - not such a pretty picture. *American Journal of Infection Control*. 2007;35:477-480.
15. Miller ER, Bi P, Ryan P. The prevalence of HCV antibody in South Australian prisoners. *Journal of Infection*. 2006;53:125-130.
16. National Centre in HIV Epidemiology and Clinical Research. *Annual Surveillance Report, 2010: HIV, Viral Hepatitis and Sexually Transmissible Infections in Australia*. 2010. Sydney, NSW: University of New South Wales. ISSN 1838-5559.
17. The Kirby Institute. *Australian NSP Survey. National Data Report 1995-2011*. Kirby Institute, University of New South Wales. ISSN 1448-5915. 2011.
18. Iversen J, Maher L. *Australian Needle and Syringe Program National Data Report 2009-2012*. 2013. Sydney, NSW: The Kirby Institute, UNSW Australia.



www.kirby.unsw.edu.au